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                                       ABSTRACT 
Health Technology Assessment (HTA) considers the therapeutic effectiveness of a 
health technology and may also evaluate cost-effectiveness. The aim of this study was 
to evaluate HTA agencies, their relationship to regulatory authorities and other 
decision-makers and to identify common appraisal practices with respect to the 
economic and therapeutic evaluation of new medicines. 
The national reimbursement pathways for 33 European jurisdictions were evaluated 
to identify two taxonomic sets that categorise HTA agencies by evaluating the 
relationship between the HTA, regulatory and decision-making functions within the 
reimbursement system (System taxonomy) and the processes for appraisal and 
conducting the clinical and economic evaluation (Process taxonomy).Ten distinct 
archetype groups were subsequently identified by comparing the two taxonomic sets.  
National HTA recommendations were identified for nine European jurisdictions with 
varied health care systems and approaches for HTA, to enable comparisons using the 
classification tool to assess correlation. HTA decisions were also identified from four 
countries that have generally similar approaches for HTA (Australia, Canada, England 
and Scotland) to understand the rationale for discordant HTA recommendations. The 
Canadian HTA environment was evaluated in greater detail to understand the impact 
of the national non-mandatory HTA recommendations for coverage decisions from 
four provinces (Alberta, British Columbia, Ontario and Quebec). Senior 
representatives and final decision-makers from these four provinces completed the 
study questionnaire and participated in semi-structured interviews to provide further 
insights regarding the impact of the national Canadian HTA agency. 
Comparisons of HTA recommendations from national HTA agencies with general 
similarities (Australia, Canada, England and Scotland) identified significant differences 
and a range of causes for discordant recommendations, such as: submission timing, 
comparator choice and willingness to accept risk. Results for comparing Canadian 
national HTA recommendations with coverage decisions from four provinces 
demonstrated much greater overall concordance (κ (kappa coefficient) =0.432 to 
κ=0.663) than comparing Canadian national HTA recommendations with Australia, 
England and Scotland (κ=0.129 to κ=0.336). Feedback from the semi-structured 
 
 
v 
interviews also indicated that participating provincial payers increasingly rely on the 
national HTA agency. 
The development of a novel classification tool, comparisons of HTA recommendations 
from very different and also generally similar HTA agencies and the evaluation of the 
Canadian HTA environment have ultimately led to the proposal of a progressive 
alignment approach which supports on-going efforts to create a more efficient 
European HTA environment.  
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 GLOSSARY OF TERMS 
Approval: Refers to a New Active Substance achieving licensing approval from a 
regulatory authority of a HTA agency granting a positive recommendation for the 
reimbursement of a new medicine. 
 
Company/Sponsor: The owner of the product that has initiated the submission.  
 
Comparator: A medicinal product or placebo used as a reference in clinical trials and 
HTA appraisals.  
 
Coverage: Refers to the extent to which medicines and/or healthcare costs rendered 
by a healthcare program are covered.  
 
Decision-maker: Determines the final decision to reimburse the new medicine by the 
coverage scheme for the system in question. 
 
Drug plans: Refers to multiple public Canadian drug plans that cover the cost for 
prescription medicines. 
 
Economic Value (EV): Refers to the determination of the cost-effectiveness, cost-
utility, cost-benefit, and/or budget impact of the new therapy. 
 
European Economic Area (EEA): Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, 
Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, 
UK. 
 
European Union (EU): Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, 
Slovenia, Spain, Sweden and UK. 
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Health Technology: May refer to a range of treatments (pharmaceutical, medical 
devices), vaccines, surgical procedures and preventative measures. 
 
Health Technology Assessment (HTA): Generally considers the clinical benefit and 
cost-effectiveness of a health technology in the appropriate context, but it also 
considers relevant social and ethical implications. 
 
Indication: The specific indication for which the active substance for the medicine is 
intended to cure, alleviate, treat, prevent or diagnose disease in humans. 
 
Payer: Refers to the entity that reimburses the costs for medicines and/or healthcare, 
other than the patient.   
 
Pharmacoeconomics: A scientific discipline that compares the value of medicines. 
 
Recommended: Refers to a positive recommendation issued by a Health Technology 
Assessment Agency. The recommendation may or may not include prescribing 
restrictions such as conditional clinical criteria. 
 
Recommended with restrictions: Refers to a recommendation that has been issued 
by a Health Technology Assessment with conditional criteria. This may include 
restrictions in the form of clinical criteria for prescribing, administrative or specialist 
approval, maximum quantity or limited reimbursement rate.   
 
Recommender: HTA appraisal results in a recommendation for reimbursement but 
the final decision is made elsewhere. 
 
Reviewer: Refers to persons trained in the scientific assessment of data to provide a 
recommendation for the reimbursement of new medicines. 
 
Risk: The possibility of harm or unfavourable effects caused by a medicine or 
treatment. 
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Marketing Authorisation: Refers to the legal approval granted to a company/sponsor 
by a national or regional authority to market a medicinal product in the appropriate 
market or region. 
 
Medicine: Pharmacological product for human use with intended medical intervention. 
 
Medicine-indication: Refers to medicine and the indication included in the 
submission to the Health Technology Assessment Agency. This may not reflect the 
full indication approved by the regulatory authority.  
 
New Active Substance (NAS): A chemical, biological, biotechnology or 
radiopharmaceutical substance that has not been previously available for therapeutic 
use in humans and is destined to be made available as a prescription only medicine, 
to be used for the cure, alleviation, treatment, prevention or in vivo diagnosis of 
diseases in humans. 
 
Not recommended: Refers to a negative reimbursement/coverage recommendation 
issued by a Health Technology Assessment agency. 
 
Patients’ Access: Refers to the new medicine being made available for patients by 
the public or private providers. 
 
Price Authority: Determines or controls the list price for a new medicine. This could 
be achieved by a voluntary price agreement of by imposing a ceiling price.  
 
Provider: Adopts the new medicine based on the outcome of the decision maker. 
 
Reimbursement: Payment by a third party to repay costs of medicines or healthcare 
on behalf of the patient. 
 
Scientific Advice (SA): Provision of scientific advice to the sponsor in relation to the 
drug development programme of the submission of evidence to that agency. 
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Submission: Is an application for review of a new medicine that has been submitted 
to the appropriate authority. This could refer to applications sent to a Health 
Technology Assessment agency for reimbursement of the proposed indications or an 
application submitted to a regulatory authority for market authorisation of the proposed 
indications. 
 
Therapeutic value (TV): The evaluation of the clinical evidence in order to determine 
if there is added therapeutic value in the new medicine. 
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General Introduction 
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BACKGROUND 
 
Life expectancy from birth has improved throughout the world since the 1950’s 
(Leon, 2011). Across the European member states, life expectancy increased 
by 5.1 years from 1990 to 2012 and continues to rise (Organisation for 
Economic Co-operation and Development (OECD), 2014a). Multiple factors 
can be attributed to these observed increases in life expectancy, such as: 
improved standards of living and increased access to quality healthcare. 
However, the costs for providing healthcare are also rising and often increasing 
faster than GDP. From 1990 to 2007 average healthcare expenditure increased 
by 80% in France, Germany, Italy, Spain, Switzerland and the United Kingdom 
while GDP only grew by 25% (Beyer et al., 2007).  Healthcare expenditure 
continues to increase and more countries throughout the world are spending a 
greater proportion of GDP on healthcare. In 2012, 58 countries spent more than 
6.1% of GDP on healthcare (Figure 1.1). An increased expenditure on 
healthcare is to be expected as more countries strive to provide universal health 
coverage but demand for access to innovative new treatments and improved 
standards of care is continuous.  
 
Figure 1.1: Total expenditure on health as a percentage of gross 
domestic product in 2012 
 
 
 
Source: Figure adapted from World Health Organisation (WHO) (2014b) 
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Beyer et al. (2007) describes the ever increasing demand for healthcare as a 
vortex with six key factors encouraging greater expenditure: greater wealth; 
consumerisation; changing demographics; innovation; specialisation and 
changing lifestyles. As societies become wealthier, citizens are usually more 
educated and are less accepting of disease and are more informed of treatment 
options. This increases patient demand and also drives consumerism, which 
encourages development of new innovative and more specialised treatments 
(Figure 1.2).  
 
Figure 1.2: Factors driving healthcare expenditure, figure reproduced 
from Beyer et al. (2007) 
 
 
 
Increased access to quality healthcare is a contributing factor towards 
increased life expectancy which is also producing a change in demographics. 
By 2050, an estimated two billion people will be aged 60 or older (World Health 
Organisation (WHO) 2014a).  A growing older population will further drive 
demand for new treatments as increased age is associated with chronic illness 
amongst other public health challenges. The sixth factor driving the healthcare 
vortex is changing lifestyles. Modern societies in many countries are 
experiencing greater prevalence of obesity in all age groups. Obesity is linked 
to many chronic diseases including type 2 diabetes which used to be known as 
adult-onset diabetes as it generally affected adults over 40 years of age 
(Diabetes UK, 2010). However, the increasing prevalence of childhood obesity  
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has resulted in more young people diagnosed with type 2 diabetes   In 2002, 
the first cases of juvenile type 2 diabetes in the UK were diagnosed in 
overweight girls aged 9 to 16 years old (Ehtisham et al., 2000). The rising costs 
associated with diabetes will provide many challenges for healthcare providers. 
Diabetes alone is expected to account for 17% of the total UK National Health 
Service (NHS) expenditure by 2035/36 (Hex et al., 2012). The continuously 
increasing costs of healthcare creates a challenging environment for policy 
makers and healthcare providers and emphasises the importance of using 
resources wisely. Yet, in 2010, the World Health Organisation (WHO) published 
a report that found 20 – 40% of health systems expenditure was wasted and 
concluded that every country could improve efficiency (World Health 
Organisation (WHO) 2010).  The sixty-seventh World Health Assembly 
resolution noted the results of this report and urges member states “to 
strengthen the link between health technology assessment and regulation and 
management, as appropriate” (World Health Organisation (WHO) 2014c).   
 
The definition for Health technology Assessment (HTA) can vary as the 
intended purpose and methodologies used to conduct HTA often differ, but a 
commonly used definition for HTA is: 
 
“A multidisciplinary process that summarises information about the medical, 
social, economic and ethical issues related to the use of a health technology in 
a systematic, transparent, unbiased, robust manner. Its aim is to inform the 
formulation of safe, effective, health policies that are patient focused and seek 
to achieve best value” (European Network for Health Technology Assessment 
(EUnetHTA) 2015b). 
 
The health technology to be assessed can include a range of treatments 
(pharmaceutical, medical devices), vaccines, surgical procedures and 
preventative measures. A HTA may focus on a single technology or consider a 
range of treatment options and preventative measures. Ultimately the scope of 
HTA depends on the mandate of each HTA agency and generally considers 
the clinical benefit and cost effectiveness of a health technology in the 
appropriate context, but it also considers relevant social and ethical 
5 
 
implications. Therefore, HTA is primarily concerned with the effectiveness of 
the health technology, whereas regulatory authorities consider safety and 
efficacy but there can still be areas of over-lap. HTA is currently utilised by many 
payers to inform pricing and reimbursement decisions and this additional step 
is commonly known as the fourth hurdle following the three hurdles for 
marketing approval: safety, efficacy and quality.  However, most healthcare 
systems already had some form of pricing controls prior to introduction of the 
fourth hurdle. For example, Australia and some Canadian provinces conducted 
comparative clinical assessments, the Netherlands grouped similar drugs and 
used therapeutic reference pricing and the UK routinely reimbursed new 
medicines but regulated prices through the Pharmaceutical Price Regulation 
Scheme (PPRS) which determined a maximum cap on profits for drugs sold to 
the UK National Health Service (Drummond, 2013). 
 
ORIGINS AND DEVELOPMENT OF TECHNOLOGY 
ASSESSMENT IN THE UNITED STATES 
 
Health Technology Assessment (HTA) is a relatively young field that was first 
introduced in the 1960’s but has rapidly grown over the last 30 years. In 1965, 
the term Technology Assessment (TA) was first used in the United States 
Congress by the committee of Science and Astronautics (Goodman, 2014). TA 
was intended to support policy and was defined as “a comprehensive form of 
policy research that examines the short- and long-term social consequences of 
the application or use of technology’’ (Office of Technology Assessment 1976, 
cited in (Banta, 2002). In 1972, Congress authorised the Office of Technology 
Assessment (OTA) and the OTA health programme was introduced in 1975 
(Figure 1.3) (Goodman, 2014).The OTA health programme released its first 
report in 1976 and activities included assessing health technologies and 
defining the methods for HTA such as cost effectiveness analysis and 
Randomised Controlled Trials (RCT) (Office of Technology Assessment, 1995).  
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Figure 1.3: First Health Technology Assessment agency or unit per country in Australasia, Europe and North America
1975 2007 1975 1978 1981 1984 1987 1990 1993 1996 1999 2002 2005 
 Office of Technology 
Assessment (OTA) 
Health Program, USA 
Comité d'Evaluation et de Diffusion 
des Innovations Technologiques 
Assistance Publique Hôpitaux de 
Paris (CEDIT), France 
The Netherlands 
Organization for Applied 
Scientific Research (TN), 
The Netherlands 
Institute of Technology 
Assessment, Austrian 
Academy of Sciences 
(ITA), Austria 
Medical Technology 
Unit Swiss Federal 
Office of Public Health 
(MTU-SFOPH), 
Switzerland 
Health Statistics and 
Medical Technology 
Agency (HSMTA), 
Latvia 
Danish Centre for 
Evaluation and 
Health Technology 
Assessment 
(DACEHTA), Denmark 
German Agency for 
Health Technology 
Assessment (DAHTA), 
Germany 
Unit of Health 
Economics and Health 
Technology 
Assessment 
(HunHTA), Hungary 
Agency for Health 
Technology 
Assessment in Poland 
(AHTAPol), Poland 
Health Services 
Assessment 
Collaboration 
(HSAC), New 
Zealand 
The National Health 
Technology Advisory 
Panel (NHTAP), 
Australia 
Centre for Medical 
Technology 
Assessment (CMT), 
Sweden 
Conseil d évaluation 
des Technologies de 
la Santé du Québec 
(CETS), Canada 
Catalan Agency for 
Health Technology 
Assessment and 
Research (CAHTA) 
(Formerly COHTA), 
Spain 
Finnish Office for 
Health Technology 
Assessment (FinOHTA), 
Finland 
National Coordinating 
Centre for Health 
Technology 
Assessment 
(NCCHTA), UK 
Norwegian Centre for 
Health Technology 
Assessment (SMM), 
Norway 
HTA Unit in A. 
Gemelli Teaching 
Hospital, Italy 
Belgian Health 
Care Knowledge 
Centre (KCE), 
Belgium 
Health 
Information and 
Quality Authority 
(HIQA), Ireland 
Data sources: from Velasco-Garrido and Busse (2005); Garrido et al. (2008); Goodman (2014); 
International Network of Agencies for Health Technology Assessment (INAHTA). (2015) 
Timeline is not intended to be exhaustive 
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After twenty three years, the OTA closed in 1995 due to budget cuts (Princeton 
University, 2015; Banta, 2002), but HTA was already becoming established in other 
countries facing similar challenges to the United States. The growth of HTA was also 
supported by developments in evidence-based medicine for supporting clinical 
practice and the establishment of the Cochrane Collaboration which generates 
evidence to inform clinical practice (Banta, 2002). 
 
ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN 
AUSTRALIA AND CANADA 
 
In 1982, the Commonwealth of Australia established The National Health Technology 
Advisory Panel (NHTAP) (Figure 1.3). NHTAP was a panel of experts with 
representatives from manufacturing, insurance and health professionals and provided 
suggestions for the appropriate use of devices or procedures in Australia (Hailey, 
2009). In 1990, NHTAP combined with a group for the development of guidelines for 
highly specialised procedures (Superspeciality Services Subcommittee) to become 
the Australian Health Technology Advisory Committee (AHTAC) and eventually 
AHTAC was replaced with the Medicare Services Advisory Committee (MSAC) 
(Hailey, 2009). MSAC is still active today and provides recommendations to the 
Minister for Health for the appropriate use and reimbursement of medical technologies 
or services (Australian Government Department of Health, 2014).  HTA is also utilised 
by the Australian public health system to guide reimbursement for the decisions for 
new medicines. The Pharmaceutical Benefits Advisory Committee (PBAC) provides 
recommendations to the Minister of Health for the inclusion of new medicines in the 
Pharmaceutical Benefits Scheme (PBS) (Australian Government Department of 
Health, 2015). In 1990, the PBAC produced guidelines for the use of economic 
evaluation and from 1993 the submission of an economic evaluation became a 
mandatory requirement for manufacturers (Hailey, 2009).  
 
In 1988, the first HTA body was established in Canada, the Conseil d évaluation des 
Technologies de la Santé du Québec (CETS) to support the Minister of Health and 
Social Services in Québec (Office of Technology Assessment, 1995) (Figure 1.3). A 
pan-Canadian HTA body was subsequently created in 1989 (Canadian Coordinating 
Office of Health Technology Assessment (CCOHTA)) to provide clinical and economic 
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guidance for participating drug plans (Menon and Stafinski, 2009). The CCOHTA has 
since become the Canadian agency for Drugs and Technologies in Health (CADTH) 
which includes the Common Drug Review (CDR) that conducts HTA for new medicines 
(excluding oncology products) and provides non-mandatory listing recommendations 
for 18 participating public drug plans. CADTH also includes the pan-Canadian 
Oncology Drug Review (pCODR), a HTA programme solely for the review of oncology 
medicines. Quebec does not participate in the national Canadian HTA programmes 
because it has maintained its own HTA agency: The Institut national d'excellence en 
santé et en services sociaux (INESSS) (International Network of Agencies for Health 
Technology Assessment (INAHTA), 2014). In 2000, CETS became the Agence 
d’évaluation des technologies et des modes d’intervention en santé (AETMIS) which 
merged with the Conseil du médicament in 2011 to become INESSS.  
 
ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN 
EUROPE 
 
Banta (2002) explains how the early work of the Office of Technology Assessment 
(OTA) was transferred to many European countries throughout the 1990’s and HTAs 
mainly focused on the clinical benefit and cost effectiveness of the health 
technology. The Comité d'Evaluation et de Diffusion des Innovations Technologiques 
Assistance Publique Hôpitaux de Paris (CEDIT) was established in 1982 to conduct 
HTA at the regional level and the Centre for Medical Technology Assessment (CMT) 
was formed in Sweden in 1984 to conduct ad hoc HTA (Garrido et al., 2008) (Figure 
1.3). In 1987, the first formal national European HTA agency was the Swedish 
Council on Technology Assessment in Health Care (SBU). The number of HTA 
agencies and organisations has grown rapidly since the mid-1990’s (Figure 1.4).  
 
Garrido et al. (2008) also observed that the organisations established to focus on 
conducting and disseminating were mostly established in the 1980’s and 1990’s and 
classified the HTA agencies into two difference groups: 1- organisations that primarily 
conduct and disseminate HTA reports (such as: CEMIT and SBU) and 2- organisations 
with broader mandates (Such as the Belgian Health Care Knowledge Centre (KCE) 
and the Agency for Health Technology Assessment in Poland (AHTAPol)). However, 
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these two categories are extremely broad and do not reflect the heterogeneity of the 
current European HTA environment. HTA agencies and units are established to 
assess health technologies within a specific context. This may be at the local level 
(e.g. Spain and Italy) or at the national level (e.g. UK and Germany). Healthcare 
systems also vary across Europe as they have originated from different welfare state 
ideologies and developed over time to meet different populations political and social 
needs (Bambra and Eikemo, 2008; Arts and Gelissen, 2002).  
 
Figure 1.4: European Health technology assessment (HTA) agencies and units 
established from 1982 to 2007 
 
Data source: Garrido 2008 
 
The current processes used to guide the pricing and reimbursement recommendations 
also differ between European countries. For example, the UK require a formal health 
economic analysis unlike Germany and France. Within the UK there are also different 
routes for gaining reimbursement approval for NHS England, NHS Scotland and NHS 
Wales. NICE appraises medicines to provide a reimbursement recommendation for 
NHS England and Wales, but NICE does not appraise all medicines. Only new 
medicines that are identified by horizon scanning and are requested by the secretary 
of state ((National Institute for Health and Care Excellence (NICE), 2013b) are 
appraised by NICE. NICE and the All Wales Medicines Strategy Group (AWMSG) have 
a memorandum of understanding to prevent duplication of work and the AWMSG will 
not appraise a new medicine if a NICE appraisal is expected to produce guidance 
within 12 months (All Wales Medicines Strategy Group (AWMSG), 2014). NHS 
Scotland has its own HTA agency to conduct HTA for new medicines, the Scottish 
Medicines Consortium (SMC). Unlike NICE, the SMC appraises all new medicines 
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prior to reimbursement by NHS Scotland and if the manufacturer does not provide a 
submission to the SMC within an appropriate timeframe the SMC will issue a negative 
reimbursement recommendation due to non-submission (Scottish Medicines 
Consortium (SMC), 2012).  Both NICE and SMC submissions require clinical and cost-
effectiveness data and prefer cost-utility analysis using Quality Adjusted Life Years 
(QALY) (Scottish Medicines Consortium (SMC) 2014; National Institute for Health and 
Care Excellence (NICE), 2013a).  
 
Prices for medicines sold in Germany have been considerably higher than the OECD 
average as a result of previous pricing mechanisms that enabled manufacturers to set 
their own prices (Organisation for Economic Co-operation and Development (OECD), 
2008). In 2011, the Act for Restructuring the Pharmaceutical Market in Statutory Health 
Insurance (AMNOG) was introduced to control the prices of patented medicines and 
generate savings of up to 2 billion Euros (Henschke et al., 2013). Since the introduction 
of AMNOG, manufacturers are required to submit evidence demonstrating a new 
medicine’s therapeutic benefit over an existing comparator. Medicines that 
demonstrate a therapeutic benefit are eligible for price negotiations to determine a 
price to reflect the level of additional benefit. If no additional benefit is found the 
medicine will be subject to reference pricing. Cost effectiveness evaluations are not 
explicitly required by AMNOG and Henschke et al. (2013) argues that this may 
overlook an important factor for evaluation and should at least be considered for long-
term policy.  Similar to Germany, the French National Authority for Health (HAS) 
assesses the clinical effectiveness and added therapeutic benefit of a new medicine 
without cost-effectiveness data to determine a reimbursement price. However, from 
October 2013, economic evaluation is now a required part of the submission for new 
medicines with a high clinical benefit and a significant impact on expenditure (more 
than 20 million Euros) (Rumeau-Pichon et al., 2014).  
 
COMPARATIVE STUDIES 
Previous work 
Many comparative studies have been published to describe and evaluate the 
differences between HTA agencies and several of these include more than one 
European HTA agency (Franken et al., 2012; Schwarzer and Siebert, 2009; Bending 
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et al., 2012; Kleijnen et al., 2012; Moharra et al., 2008; Sorenson and Chalkidou, 2012; 
Mathes et al., 2013; Levy et al., 2010; Nicod and Kanavos, 2012). However, projects 
such as the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR), Road Maps have compiled an online public database of descriptive profiles 
for the decision-making process of regulatory authorities, HTA agencies, healthcare 
providers for the reimbursement of pharmaceuticals and medical devices. The profiles 
are produced by local experts from each healthcare system which is particularly 
valuable for countries that are not transparent, but the profiles/road maps do not 
adhere to a uniform structure and many have not been updated since 2008 
(International Society For Pharmacoeconomics and Outcomes Research (ISPOR), 
2012). A report published by Charles River Associates has provided a descriptive 
overview of HTA agencies and the regulatory and reimbursement decision-making 
practices for pharmaceuticals at the national level for several countries (Wilsdon and 
Serota, 2011). These include uniform flow charts which are easier to compare but less 
detailed than the ISPOR Road Maps. This report has also produced a method for 
classifying HTA agencies but is limited to the timing of HTA. The WHO has also 
published country specific descriptive reports and posters for the pricing and 
reimbursement of pharmaceuticals (World Health Organisation Collaborating Centre 
for Pharmaceutical Pricing and Reimbursement Policies, 2015a; World Health 
Organisation Collaborating Centre for Pharmaceutical Pricing and Reimbursement 
Policies, 2015b). The WHO reports are comprehensive and produced by local experts 
but some countries only have reports produced in 2007. Similarly for the posters, they 
have been produced by local experts but once again they do not follow a uniform 
methodology so can be difficult to compare. Separate posters have been created to 
distinguish between the in-patient and out-patient pathways, but most of the posters 
were produced in 2010 and have not been directly updated, instead a separate 
document listing changes and future plans has been published to accompany the 
original poster. Straus and Jones (2004) noted that many studies from the previous 10 
years had focused on developing an evidence base and recommended future studies 
in the decade following 2004 should focus on outcomes. Many studies from 2004 have 
compared HTA recommendations across a range of countries, some have focused on 
process, approaches for cost-effectiveness evaluations, the clinical evidence and 
differences between therapeutic groups. 
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A descriptive study by Sorenson and Chalkidou (2012) compares evolution of HTA in 
England, France, Germany and Sweden and discusses potential future developments 
such as using HTA for disinvestment, methods for applying HTA to a localised context 
and increased interest in Value-Based Pricing (VBP) in the UK, but VBP was not part 
of the new Pharmaceutical Pricing and Reimbursement Scheme (PPRS) launched in 
2014. A  comparative study conducted by Bending et al. (2012) compares HTA 
processes and agreement of reimbursement recommendations for SMC and HAS. 
These two agencies were chosen as examples of HTA agencies that include or 
exclude cost effectiveness analysis, respectively. Bending et al. (2012) identified 
cases where SMC and HAS exhibited differences in dealing with clinical data 
uncertainties and concluded that France determines the reimbursement status based 
on a judgement of the therapeutic value which results in price as the main variable to 
be adjusted in negotiations for France. Whereas, Scotland receives a price submitted 
by the manufacturer and must determine the value of the product in relation to the 
submitted price, therefore the quantity/patient population is the main adjustable 
variable in Scotland.  The study provides an interesting comparison of two different 
systems to evaluate the contribution of formal health economic analysis. However, 
there are many variables between the two systems in addition to their processes 
regarding formal economic evaluation. For example, SMC provides a reimbursement 
recommendation for NHS Scotland which is funded by taxation and fully subsidises 
pharmaceuticals for all citizens. Whereas the HAS Transparency Committee (TC) 
determines the actual benefit of a new medicine which is used by the national health 
insurance to define the reimbursement rate (important-65%, moderate-30%, mild-
15%, insufficient-not included on the positive list) (Haute Autorité de Santé (HAS), 
2014) and the added therapeutic value is used to determine price. Therefore, there 
are many factors that could impact the reimbursement recommendation in addition to 
the utilisation of formal cost-effectiveness evaluations.  A larger study could be 
conducted to see if the differences observed occur in between groups of agencies 
categorised by their utilisation of clinical and cost-effectiveness evaluation. A study 
with more countries will still be comparing systems with multiple differences due to the 
varied nature of HTA and healthcare systems, but it might be able to identify trends. 
Mathes et al. (2013) compared a broader range of economic methods and processes 
for 14 HTA agencies and identified strong variation of the quantity and content of 
recommendations for HTA agencies and argued in favour of harmonisation of 
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economic evaluation processes which would aid generalisability and transferability of 
data.  
 
Comparative studies including Australia, Canada and the UK 
Of the many published comparative studies there are several that include HTA 
agencies from Australia, Canada, and the UK (Nicod and Kanavos, 2012; Mathes et 
al., 2013; Levy et al., 2010; Lexchin and Mintzes, 2008; Spinner et al., 2013; Clement 
et al., 2009; Mauskopf et al., 2011). This is not surprising as they are countries with 
an established history of HTA and although publications vary in detail, they are 
transparent enough to publish HTA recommendations online, in English and with a 
rationale for decisions. However, this should not imply that this area of research is 
saturated. The published studies compare various different country combinations and 
focus on a specific component of the HTA processes or recommendations. HTA 
agencies regularly adapt to meet the needs of the healthcare system and the patient 
population they serve, but are also subject to changes as a result of political reforms. 
Therefore, repeated evaluations are also needed throughout time to provide up-to-
date comparisons and to observe the evolution of HTA in these countries.   
 
Mauskopf et al. (2011) summarised evidence requirements for HTA agencies in 12 
countries (including Australia, Canada, England and Scotland) to evaluate how the 
differences could impact HTA recommendations and recommended that the impact 
caused by these differences could be used to guide future harmonisation of HTA. 
Numerous studies have also compared similarities and differences between HTA 
recommendations issued by Australian, Canadian and British HTA agencies. All of 
these studies identified disparities between the HTA recommendations, but the 
authors’ opinions regarding the primary reasons for discordant recommendations 
varied.  Lexchin and Mintzes (2008) compared the Canadian CDR recommendations 
issued up to 2006 with HTA recommendations from Australia (PBAC) and Scotland 
(SMC) and concluded that the CDR is ‘no different’ from PBAC and SMC in regard to 
the proportion of recommendations issued by each agency using three categories 
(recommended, recommended with restrictions and not recommended), but when 
they compared recommendations directly they identified poor concordance and 
suggested divergent recommendations were due to pharmacoeconomic reasons. A 
later study by Nicod and Kanavos (2012) compared HTA recommendations from 2007 
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to 2009 in Australia, Canada, England, Scotland and Sweden to identify divergent 
recommendations and the rationale behind recommendations for different therapeutic 
groups. This study concluded that there were significant differences between the HTA 
recommendations within therapeutic groups, for example Canada was found to be less 
likely to accept medicines with a marginal benefit for Central Nervous System (CNS) 
treatments (Nicod and Kanavos, 2012).  A study by Spinner et al. (2013) reviewed 
nine medicines that all received a HTA recommendation from Australia, Canada and 
England between 2007 and 2010. The medicines were reviewed in depth to assess 
whether different clinical evidence was a cause for divergent recommendations and 
the study did identify differences between the HTA agencies choice for comparator 
and inclusion of trials.  
 
Comparisons to provide learnings for the United States 
A few studies compared HTA agencies from Australia, Canada and the UK and used 
these countries as examples for including cost-effectiveness evaluation in the United 
States. Clement et al. (2009) compared HTA recommendations available up to 2008 
for Australia, Canada and England and argued that differences in listing decisions are 
more likely to be due to differences in willingness to accept risk. Clement et al. (2009) 
also used the results to discuss an update of comparative effectiveness research in 
the United States. Levy et al. (2010) reviewed the processes in HTA systems in 
Australia, Canada, the Netherlands, Scotland and Sweden to compare different 
approaches for comparative effectiveness research and also to provide discussion 
points for the United States.  Overall, Levy et al. (2010) found more similarities than 
differences for the processes across the five countries.  
 
Comparative studies for HTA in Canada 
Comparative studies evaluating medicines listed across Canadian provinces prior to 
the inception of the CDR generally identified low concordance across Canadian 
provincial listing decisions: (Anis et al., 2001; Gregoire et al., 2001; MacDonald and 
Potvin, 2004). The CDR was introduced to help standardise access to new medicines 
by maximising the use of resources, reducing duplication of assessments and 
providing timely and equal access to evidence (Allen et al., 2014), but Morgan et al. 
(2006) argued that decentralising decision-making to multiple provincial payers 
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reduces the impact of the CDR and Hollis and Law (2004) predicted that provinces will 
only become slightly more standardised without implementing a Canadian national 
formulary. The predictions by Hollis and Law (2004) and Morgan et al. (2006) were 
potentially supported by a more recent study by Attaran et al. (2011), which identifies 
concordance of listing decisions by some provincial payers with the CDR to be “no 
better than random chance”. However, McMahon et al. (2006) compared provincial 
listings with 25 new medicines, issued a CDR recommendation from inception (2003) 
to June 2005 and concluded that there was general concordance, but further studies 
are required to determine whether the CDR will harmonise provincial listings for new 
medicines. Similarly, Tierney et al. (2008) commented on the consistency of 
agreement between provincial listing decisions with CDR recommendations and 
refered to a presentation from CADTH that found CDR recommendations issued within 
the first three years of inception and provincial listing agreements matched 90 per cent 
of the time (Canadian Agency for Drugs and Technologies in Health (CADTH), 2007). 
These studies only evaluated the early years of the CDR and cannot inform us of the 
current impact of the CDR for provincial listing decisions. A more recent study by 
Gamble et al. (2011) compared provincial listing-decisions and CDR 
recommendations for new medicines granted marketing approval for sale in Canada 
up to May 2009 and identified greater concordance than Attaran et al. (2011) despite 
the fact that both studies evaluated CDR recommendations issued over a similar 
period of time. Subsequent research has evaluated CDR recommendations but has 
not compared a more recent cohort of CDR recommendations with provincial listing 
decisions (Rocchi et al., 2012; Iannazzo et al., 2013; Nicod and Kanavos, 2012; 
Spinner et al., 2013). Therefore, there is a need for further research comparing more 
recent CDR recommendations and provincial listing decisions to determine the impact 
of the non-mandatory CDR recommendations and to add more evidence to the 
existing body of research to help determine whether the CDR is increasing 
harmonisation of provincial listing decisions as recommended by McMahon et al. 
(2006).  
 
INTERNATIONAL HTA NETWORKS 
HTA has grown rapidly since the 1990’s and the growing number of HTA 
organisations, professionals and researchers has led to the establishment of societies 
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and networks. Health Technology Assessment international (HTAi), a society for the 
promotion of Health Technology Assessment, has members from over 65 countries 
and activities including hosting annual conferences, regional meetings, policy forums 
for senior representatives from private and public organisations to engage in strategic 
discussions and special interest sub-groups for all HTAi members to share 
experiences (Health Technology Assessment International (HTAi), 2015). The 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) was 
founded in 1995 and currently has more than 9500 members from 114 countries and 
its activities include annual meetings in North America, an annual European meeting 
and regional meetings in Asia and Latin America (International society For 
Pharmacoeconomics and Outcomes Research (ISPOR), 2015). ISPOR also has an 
official journal (Value in Health) and has published a range of research online including 
the ISPOR Road Maps (International Society For Pharmacoeconomics and Outcomes 
Research (ISPOR), 2012). The International Network of Agencies for Health 
Technology Assessment (INAHTA) was founded in 1993 and currently has 55 member 
agencies from 32 countries (International Network of Agencies for Health Technology 
Assessment (INAHTA), 2015). INAHTA’s mission is to provide a forum to identify and 
pursue member interests. Members meet each year adjunct to the HTAi annual 
meeting.  
 
The European Network for Health Technology Assessment (EUnetHTA) was 
established in 2006 to create a sustainable European network for HTA and to develop 
and implement tools to transfer information between members. EUnetHTA was based 
on previous collaborative projects such as EUR-ASSESS, HTA-EUROPE and the 
OECD Health Project (Banta et al., 1997; Jonsson, 2002; Organisation for Economic 
Co-operation and Development (OECD), 2005). EUnetHTA was initially granted three 
years funding from the European Commission, but continued to receive further funding 
and the European Commission has since supported the formation of a permanent 
European HTA network and the technical cooperation of the new network is expected 
to be conducted by EUnetHTA (Kristensen, 2012; European Network for Health 
Technology Assessment (EUnetHTA), 2014). EUnetHTA currently has over 80 
participant member organisations from more than 30 countries. According to 
Kristensen (2012) the most innovative scientific and practical output of EUnetHTA has 
been the development of a HTA Core Model. The HTA Core Model contains 9 domains 
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and each provide a framework for analysis (National Institute for Health and Welfare, 
2014): 
 Description and technical characteristics of technology 
 Health problem and current use of technology 
 Safety 
 Clinical Effectiveness 
 Cost and economic evaluation 
 Ethical aspects 
 Organisational aspects 
 Social aspects 
 Legal aspects 
The Core Model was designed to enable sharing of HTA information in a common 
format that can be transferred between members at the national and international 
level. However, Ascroft and Pichler (2014) question the practicalities of the quantity of 
information required for the Core Model as EUnetHTA members are unlikely to have 
the capacity to review all the medicines and technologies that were reviewed by the 
EMA. The EUnetHTA Core Model has also been modified for a rapid Relative 
Effectiveness Assessment (REA) process which only considers the effectiveness and 
safety data (European Network for Health Technology Assessment (EUnetHTA), 
2013) (Figure 1.5). Ascroft and Pichler (2014) have proposed that the rapid REA could 
provide value by developing a REA report to supplement the current European Public 
Assessment Reports (EPARs). 
 
Figure 1.5: Modification of the EUnetHTA Core Model, image reproduced from 
European Network for Health Technology Assessment (EUnetHTA), (2013) 
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HTA is also becoming more established in countries outside of Australasia, Europe 
and North America and regional networks have been created in Asia and the Americas 
that include members from countries with established HTA. The Pan-American Health 
Organisation (PAHO) recently established the HTA Network for the Americas 
(RedETSA) (Lemgruber, 2013). An agreement to create a regional network was 
determined at the regional 2010 HTAi meeting in Argentina. The network, chaired by 
PAHO currently has members from 25 institutions from 13 countries: Argentina, 
Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, Ecuador, Mexico, 
Paraguay, Peru, and Uruguay. RedETSA activities include mapping HTA activities 
throughout the region and opportunities for capacity building.  
 
HTA representatives from Thailand and South Korea met at the 2010 HTAi conference 
and identified the need for a regional collaboration network. In 2011 the first 
HTAsiaLink newsletter was produced and currently publishes three newsletters a year. 
A collaborative research project was also conducted for an Asian study on the value 
of the Quality Adjusted Life Year (QALY) (HTAsiaLink, 2015a). HTAsiaLink currently 
has 15 members including NICE International from the UK, HealthPact from Australia 
and the Australian Safety and Efficacy Register of New Interventional 
Procedures (HTAsiaLink, 2015b).  
 
MULTI-STAKEHOLDER INITIATIVES 
Regulatory authorities assess the quality, safety and efficacy of a new medicine to 
determine eligibility for marketing approval. Many countries now also require 
manufacturers to submit a dossier for a HTA reimbursement recommendation. The 
HTA will assess clinical effectiveness and usually will also consider the cost-
effectiveness evidence to determine a new medicine’s reimbursement status. Lumpkin 
et al. (2012) emphasised the need for regulatory authorities and reimbursement 
decision-makers to collaborate to reduce the duplication of work and generate data for 
both market access and reimbursement. Kendall et al. (2009) discussed the potential 
for including HTA with FDA to share information where they incorporate similar 
activities of HTA and regulatory to share data and reduce duplication. However, 
(Breckenridge et al., 2010) notes that merging regulatory and HTA could cause a 
conflict of interests as most regulatory authorities are partially funded by industry fees.  
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Some HTA agencies and regulatory authorities have been collaborating at the national 
and international level to enhance dialogue and to help create a more collaborative 
regulatory and HTA environment. In 2010, the European Medicines Agency (EMA) 
and EUnetHTA collaborated on a project to improve the EMA’s EPARs to be more 
supportive of the needs of HTA agencies (Berntgen et al., 2014). In 2010, the EMA 
and HTA agencies from the Austria, France, Germany, Italy, the Netherlands, Spain, 
Sweden and the UK also launched a pilot for providing joint scientific advice for 
manufacturers during the development stages. About 25 procedures were assessed 
using the joint EMA-HTA scientific advice by November 2013, when a joint EMA-HTA 
workshop was held to draft best-practice guidance for EMA-HTA (European Medicines 
Agency (EMA), 2015b). In 2010, the EMA and HTA agencies from Austria, France, 
Germany, Italy, the Netherlands, Spain, Sweden and the UK launched a pilot for 
providing joint scientific advice for manufacturers during the development stages. The 
Shaping European Early Dialogues (SEED) consortium is a pilot for early dialogue 
between health technology developers and HTA agencies during the development 
phase. SEED is currently led by HAS (France) and includes 14 participant HTA 
members (Shaping European Early Dialogues for Health Technologies, 2015).  
 
Joint regulatory and HTA scientific advice has also been piloted at the national level 
with varying success. In 2009, the Australian regulatory authority (Therapeutic Goods 
Administration (TGA)) and the PBAC conducted a pilot for offering joint scientific 
advice for manufacturers to identify the value and practicalities of the project (Wonder 
et al., 2013). Wonder et al. (2013) noted that the pilots provided an opportunity to 
discuss opposing views and work more closely but Fronsdal et al. (2012) also noted 
challenges with resource implications and limited manufacturer feedback. NICE has 
been offering a scientific advice programme since 2009 and first piloted parallel 
scientific advice with the MHRA in 2010 to determine interest in parallel scientific 
advice (National Institute for Health and Care Excellence (NICE), 2014; Methven, 
2010). MHRA and NICE have also recently announced a new collaboration. The Early 
Access to Medicines Scheme was launched in 2014 and provides manufacturers with 
the opportunity to participate in a voluntary scheme to collaborate with the MHRA and 
NICE to provide patients with life threatening or highly debilitating illnesses early 
access to medicines prior to marketing approval (Medicines and Healthcare Products 
Regulatory Agency (MHRA), 2014).   
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FRAMEWORKS AND BEST PRACTICES FOR HTA  
 
Studies have been conducted to develop general frameworks for HTA such as the 
EUnetHTA HTA Core Model that contains nine domains which each provide a 
framework for the development of information for sharing between members. 
Frameworks have also been developed to describe reimbursement processes (Hutton 
et al., 2006; Schwarzer and Siebert, 2009; Rogowski et al., 2008). The descriptive 
framework developed by Hutton et al. (2006) used information from the public domain 
(mainly official organisation websites) and included Canada and 13 European 
countries. Hutton noted that a “complete set of information on the systems in Europe, 
Canada and Australia would be a valuable resource for researchers and policy 
makers”. Schwarzer and Siebert (2009) produced a descriptive framework for 
comparison but it was only applied to five organisations in four European countries. 
The descriptive framework developed by Rogowski et al. (2008) is for both new 
medicines and procedures, but they also noted that the process is more formalised for 
new medicines. Producing a general framework for the reimbursement of procedures 
and medical devices will be more challenging as there is no formal national procedure 
for many countries and manufacturers often communicate directly with hospitals or 
regional buyers.  
 
Drummond et al. (2008) developed 15 key principles for the improved conduct of HTA 
for resource allocation decisions. The key principles cover a broad range of HTA 
activities and are organised into four categories: structure; methods; processes for 
conduct and use in decision-making. Drummond et al. (2008) emphasises the 
importance for unbiased and transparent HTA and argued that ‘the HTA process is 
best conducted independently of the body that ultimately will be responsible for 
adopting, paying and implementing the HTA decisions.’ The key principles were very 
well received and a study comparing the implementation of the key principles in 14 
organisations from nine countries was subsequently published in 2010 (Neumann et 
al., 2010). Neumann et al. (2010) identified great variation between the agencies and 
their uptake of the key principles and concluded that the HTA organisations have work 
to be done to meet the best practices for HTA outlined in the key principles and 
suggested using these for benchmarking, but a later publication that used these as a 
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benchmark received criticisms due to the ranking implications which may not provide 
fair comparisons when mandates vary greatly between HTA organisations 
(Drummond et al., 2012; Henshall, 2012). In order to benchmark an agency or 
organisation to compare performance or learn from similar agencies or organisations, 
suitable comparators must first be identified. A classification tool could enable 
identification of agencies with similar processes and facilitate benchmarking. Plus, if 
classifications are recorded over a period of time, the evolution of HTA agencies can 
also be evaluated.  
 
IMPACT ON STAKEHOLDERS  
The benefits of HTA have been acknowledged by many policy and decision-makers 
and this is reflected in the increasing international growth of HTA research and 
established organisations.  However, HTA has faced criticisms from patients and 
manufacturers. Patients need to understand why they are denied access to a new 
product and patient advocacy groups want to contribute towards the reimbursement 
decision-making process (Wyke, 2011; Canadian Diabetes Association, 2007). Baker 
(2011) also notes that patient groups may need guidance for preparing evidence and 
HTA should consider providing resources to enable patient input. 
The increasing growth of HTA can also provide an increasingly challenging 
environment for manufacturers that are required to produce submissions for a range 
of payers each with their own submission requirements and value judgements.  
 
 
POTENTIAL STUDIES FOR MOVING FORWARD 
A range of comparative studies have already been conducted for comparing HTA 
processes and recommendations for countries with established HTA agencies. 
However, HTA is a rapidly growing field and agencies are constantly evolving to meet 
healthcare system needs and in response to political changes. An up-to-date 
systematic comparison of a large group including countries with established HTA 
agencies and younger HTA organisations would expand the existing body of 
knowledge, but a broad range of approaches for HTA could also be used to identify 
key similarities and differences to generate a classification tool. The European 
Economic Area (EEA) consists of a diverse range of reimbursement systems including 
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countries with established HTA agencies to countries that do not conduct any HTA. 
Such a classification tool could be applied to regions beyond Europe, where HTA is 
already established but also for countries or regions that have recently introduced 
HTA, such as Asia and Latin America which have recently established regional HTA 
networks (HTAsiaLink and RedETSA). Development of such a classification tool with 
a large selection of countries also increases the potential number of HTA agencies 
that could be included to compare the classification tool with HTA recommendations. 
Several studies have been conducted comparing HTA recommendations issued by 
European HTA agencies and have identified many potential factors as causes for 
discordant recommendations that range from clinical evidence to pharmacoeconomic 
analysis. Comparing the classification tool with HTA recommendations will expand on 
existing research by evaluating a more recent cohort of HTA recommendations and 
calculating agreement between country pairs but may also identify correlations 
between country classification groups and reimbursement recommendations. 
 
Comparative studies for HTA recommendations issued by the national Canadian HTA 
agency (CDR) have produced conflicting conclusions regarding the impact of the non-
mandatory CDR recommendations for provincial listing decisions. Therefore, further 
research evaluating the impact of the CDR by calculating concordance of a more 
recent cohort of new medicines would build on the existing body of evidence, but 
combining HTA recommendations with opinions from representatives and decision-
makers across Canada would add more weight to the conclusions. A novel method for 
HTA comparisons would also include the cohort of medicines collected for the study 
to compare HTA recommendations and regional listing decisions within Canada to 
compare with HTA recommendations from similar international HTA agencies. This 
would provide three valuable outcomes:  
 Assess the impact of the CDR by calculating the level of agreement between 
national HTA recommendations and regional listing decisions compared with 
the level of agreement between the CDR and international HTA agencies that 
conduct their own full HTA. This also would provide evidence to support or 
oppose reports criticising the CDR for being more restrictive than other OECD 
countries.    
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 Investigate case studies to identify factors for discordant recommendations to 
add to the existing body of knowledge for factors that impact HTA 
recommendations. 
 Calculate the level of agreement for HTA recommendations between countries 
with existing similarities for which previously published studies have calculated 
the level of agreement, thus providing an opportunity for long-term comparisons 
to identify whether these countries are naturally becoming more harmonised as 
HTA evolves. 
 
Each national and regional reimbursement system should be profiled prior to 
conducting comparative studies for developing a classification tool for evaluating HTA 
recommendations. A novel HTA process mapping methodology should be used to 
produce these profiles and the resulting process maps may also provide value for 
persons with an interest in reimbursement pathways. Opinions from a selection of 
stakeholders could also identify the potential value of the HTA process maps.  
 
  
24 
 
AIM AND OBJECTIVES OF STUDY 
Aim 
The aim of this research is to review Health Technology Assessment agencies and 
their relationship to regulatory authorities and other decision-makers and to identify 
common appraisal practices with respect to economic and therapeutic evaluation.  
 
Objectives  
For this research the objectives are to: 
 
 Develop a classification tool to categorise systems and practices of Health 
Technology Assessment agencies in Europe. 
 
 Evaluate and compare HTA processes and reimbursement recommendations 
for nine European jurisdictions using the classification tool. 
 
 
 Identify similarities and differences with respect to national HTA 
recommendations in Canada, Australia, England and Scotland.  
 
 Evaluate the impact of the common drug review listing recommendations for 
provincial payers (Alberta, British Columbia and Ontario) and Quebec.  
 
 
 Assess the value of the HTA process maps for the pharmaceutical industry 
and Health Technology Assessment agency stakeholders. 
 
 Discuss the feasibility of a pan-European Health Technology Assessment 
agency.  
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CHAPTER 2 
 
 
 
 
 
 
Study Rationale and Methodological 
Framework 
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STUDY RATIONALE  
Health technology assessment (HTA) is a relatively young field but also one that has 
been readily adopted to help guide reimbursement recommendations for new 
medicines at both the national and regional levels.  HTA agencies and practices vary 
between countries and within regions due to differences in healthcare systems, 
budgets, politics and social expectations, which can result in discordant 
reimbursement recommendations for the same medicine. The European commission 
provides funding for the European Network of Health Technology Assessment 
(EUnetHTA) to harmonise scientific criteria to reduce patient access inequalities, 
reduce duplication of workload and shared learning. A comprehensive literature review 
identified the need for a non-ranking method of comparison for HTA agencies and 
reimbursement systems, greater understanding of the factors influencing 
reimbursement recommendations and the impact of non-mandatory HTA 
recommendations. Therefore, this research aims to assess the international HTA 
environment in Canada, Australia and Europe to develop a classification tool, review 
rationale for discordant recommendations and compare the non-mandatory 
recommendations of the Canadian common drug review with provincial listing 
decisions. 
 
METHODOLOGICAL FRAMEWORK  
Study Design 
An appropriate study design must first be selected to facilitate data collection and 
analysis that will enable the research question to be answered. The purpose of 
research can be classified as exploratory, descriptive or explanatory (Yin, 2003). 
Exploratory studies generate new insights, are suitable when the problem or key 
variables are difficult to determine and often lead to further research (Zikmund et al., 
2009). Descriptive studies seek to provide an accurate profile and can follow 
exploratory studies or lead to explanatory or exploratory studies, but explanatory 
research investigates the cause and effect relationship and is suitable when variables 
and relationships are already defined (Saunders et al., 2009).   
 
Methodological approaches to research can broadly be classed as qualitative or 
quantitative. However, as Dabbs (1982) observed, “Qualitative and quantitative are 
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not distinct.”  (as cited in Berg, 2009). Creswell (2003) argues that “Mixed methods 
research has come of age” and thus describes three categories for approaches to 
research: quantitative, qualitative and mixed methods.  
 Quantitative approaches: these generate objective and quantifiable data using 
surveys or experimental methods. The data is usually statistically analysed to 
test hypotheses.  
 Qualitative approaches: qualitative research seeks to generate hypotheses 
and methods include interviews and observations to generate text-based data, 
collect opinions or describe the complexity or range of events (Curry et al., 
2009). 
 Mixed methods approaches: these combine quantitative and qualitative 
research approaches that can be conducted sequentially or in parallel. 
Combining quantitative and qualitative approaches can utilise the benefits of 
both methods, generate a more complete data set, confirm results and provide 
deeper insights (Curry et al., 2009; Creswell, 2003). 
 
The main purpose of this research will be exploratory and will also include supportive 
descriptive studies. To achieve the aims of this research a range of studies will be 
conducted utilising mostly qualitative and mixed methods approaches. Therefore, 
hypothesis testing will be discussed in individual chapters where appropriate.  
 
Data Sources  
Information will be sourced from official agency websites, peer-reviewed journals, HTA 
agency representatives and pharmaceutical industry representatives.  
 
Literature search strategy  
Published literature will be systematically searched to provide an overview of the 
development and current HTA environment in Europe, North America and Australia. 
Scopus and PubMed will be the primary repositories searched for peer-reviewed 
publications that should ideally have been published within the last five years to ensure 
information is up-to-date. However, older publications will also be included where 
these are expected to provide value to the study. The following key words and terms 
will be included in the search strings for the literature search: 
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 Health Technology Assessment 
 HTA 
 HTA recommendations 
 HTA networks 
 Reimbursement recommendations 
 Reimbursement pharmaceuticals 
 Coverage decisions 
 Payers 
 Fourth Hurdle 
 Affordability 
 
Official agency websites and public databases  
Public databases will be used to construct databases of reimbursement 
recommendations for new medicines. The European Medicines Agency (EMA) online 
database for human medicines will be the initial source for identifying new medicines 
for sale in Europe and the list of medicines recorded from the EMA will be used to 
identify medicine reimbursement recommendations from various official European 
HTA websites. The Canadian Agency for Drugs and Technologies in Health (CADTH) 
and Common Drug Review (CDR) online database will be searched to identify new 
medicines granted a reimbursement recommendation from the CDR and this will 
generate a list of medicines that will be used to identify reimbursement 
recommendations and rationale from regional Canadian payers and from Australia and 
the UK. The inclusion criteria, exclusion criteria and date to be recorded are specific 
to each study and will be discussed in the appropriate chapters.    
 
Advantages 
 By collecting data from official agency websites public databases the data will 
be obtained directly from the primary source and is expected to be the most 
recently published data available for each agency   
 The information sources are published online which enables instant access to 
the most recently published data 
 Data is already published in the public domain and therefore will not require any 
confidentiality considerations 
29 
 
 The information available should be standardised for each medicine within each 
agency website or database. 
 
Disadvantages 
 The official agency websites or databases may not all be regularly updated. 
 The information available may not be standardised between the different 
agency websites and public databases and is restricted to the data published. 
 The published information may not be a true representation of practices. 
 Confidentiality agreements may require information to be omitted prior to 
publication.  
 
HTA agency, pharmaceutical industry and payer representatives 
Representatives from HTA agencies, the pharmaceutical industry and payer agencies 
will be contacted to provide opinions, insights and validate information obtained from 
the public domain. For example, process maps are developed using information 
primarily sourced from the public domain (official agency websites and peer reviewed 
publications) and agency or pharmaceutical representatives that have working 
experience of expert knowledge of the agencies included in the process map will be 
asked to review and provide feedback.  
 
Advantages 
 Information available in the public domain may not be the most up-to-date and 
different sources can provide conflicting information. Therefore, it is very 
valuable to have direct feedback. 
 Provides opportunity to obtain information not available in the public domain. 
 
Disadvantages 
 Opinions are subjective by nature. 
 The representative may not have knowledge or experience in all the areas 
investigated. 
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Data Collection Techniques  
Several studies will be conducted in order to answer the research questions and these 
will require various data collection techniques. This will include the primary researcher 
collecting information from the public domain to be recorded in a database using 
Microsoft Excel and subsequently validated and analysed.  Data will also be collected 
directly from HTA agencies and pharmaceutical industry representatives using a 
questionnaire technique. There are generally two approaches for administering a 
questionnaire: a self-administered questionnaire to be completed by the study 
participants or the questionnaire is administered by an interviewer (a semi-structured 
interview).    
 
Questionnaires  
The questionnaire provides a structured method for collecting primary data using 
carefully designed questions. A self-administered questionnaire with no interviewer 
present is the most common and reliable form but its advantages and disadvantages 
must be considered to determine whether it is appropriate for the study (Allsop, 2006; 
Evans, 1995; Dillman, 2013; Trochim, 2006b): 
 
Advantages 
 Inexpensive as a questionnaire can be distributed electronically by 
email/website to a large sample or can be posted for a small cost if a paper 
version is required. There are also no travel or time costs as an interviewer 
does not need to be present 
 Less time consuming as a self-administered questionnaire does not require an 
interviewer to be present for completing it and therefore information can be 
collected from a large sample in a shorter period of time 
 Convenient as respondent can complete at any chosen time, stop and start 
 Greater consistency as all recipients respond to exactly the same set of 
questions 
 It can be anonymised if required 
 Versatile as questionnaires can be sent to the study sample electronically or by 
post 
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Disadvantages 
 No opportunity for respondents to ask interviewer to clarify questions or 
terminology for e-mail or postal versions. If required this can be remedied by 
employing an interviewer delivered self-administered questionnaire where an 
interviewer delivers the questionnaire with short verbal instruction to the study 
participants and is present during the completion of the questionnaire to answer 
any queries from the study participants 
 Response rates can be low and recipients may not be willing to e-mail or post 
their completed questionnaire 
 Open ended or long free text questions are not usually practical 
 Closed questions could be too restrictive and not provide an option that 
accurately reflects the respondents’ answer 
 Difficult to judge the quality of the response or to be certain who has completed 
the questionnaire 
 Require follow-ups to improve the response rate 
 
Questionnaire data collection methods 
There is range of options for collecting data using both the self-administered and 
interviewer-administered questionnaire approaches. The most appropriate method is 
the one that would facilitate collection of the desired data, which is relevant to the study 
population and achieved with the available resources (Evans, 1995).   
 
Paper-based questionnaire delivered by Post - the simplest form of questionnaire 
technique is paper-based as it only requires the respondent to have access to a pen 
or pencil to complete. There are no software or internet access barriers to completion 
but the respondent is required to return the completed questionnaire by post. This 
would require additional time for postal delivery. There is also usually only one copy 
which could get lost or damaged in transit. 
 
Electronic questionnaire delivered by email - data only needs to be entered once for 
electronic questionnaires and can be saved in multiple locations to reduce risk of 
losing data. The electronic questionnaire can also be easily duplicated in cases where 
a respondent needing to send a section of the questionnaire to another colleague or 
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department for completion. This method requires access to the internet for retrieving 
and completing the questionnaire. There is, however, a risk that emails may get lost 
in spam folders. There may also be software limitations depending on the format of 
the questionnaire.  
 
Web-based electronic questionnaire - as with the electronic questionnaires sent by 
email, data only needs to be entered once for a web based questionnaires and will 
require internet access. Depending on the software used to create the questionnaire, 
it can potentially be accessed from any computer and optimised for completion by 
smart phone or tablet. A web-based questionnaire can also enable access by more 
than one person if the questions cannot all be answered by a single respondent. 
The completed questionnaire can be saved to a location chosen during the design 
stage of the web-based questionnaire which enables instant response. 
 
 
Interviewer administered questionnaire by telephone or conference call - administering 
the questionnaire remotely reduces expenses and saves time by removing need for 
interviewer to travel to meet respondents but time-zones may need to be considered. 
Telephone interviews can be conducted spontaneously or arranged in advance. 
However, conference or video calls will require a pre-arranged time slot and access to 
the appropriate software and internet. The interviewer records the respondents 
answers in real-time therefore, there is a spontaneous response but the respondent 
also has a limited time to prepare their answer. The interviewer may record their 
conversion with the respondents, but would require their consent and additional time 
and resources to transcribe and analyse the recorded interviews. 
 
Interviewer questionnaire administered in person - interviews conducted face-to-face 
are the most personable option and this can enhance the interviewers rapport with the 
respondent, help the respondent feel more at ease and provides opportunity for the 
interviewer to consider the respondents facial expressions and body language. 
Interviewer time and travel costs can be lengthy and expensive depending on the 
location of the respondents in relation to the interviewer.   Similar to the questionnaires 
administered by an interviewer remotely, the respondents will have a limited time to 
formulate their response to questions but answers would be of spontaneous nature. If 
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the respondent gives permission for the interview to be recorded, additional time and 
resources will be needed to transcribe and analyse the audio data.  
 
Interviewer questionnaire administered to groups - an interviewer may administer a 
questionnaire to an individual or to a group. Group interviews can be conducted 
remotely using conference and video calls and may also be conducted face-to-face. 
In addition to the previously discussed strengths and limitations associated with 
interviewer administered questionnaires, a group interview can save time as a single 
interviewer can collect responses from more than one respondent. Time and expenses 
associated with travel may also be reduced, but additional planning is likely to be 
required to organise an appropriate time that satisfies all the respondents and 
interviewer needs.  
 
Semi-structured interviews  
Semi-structured interviews are similar to self-administered questionnaires as they both 
utilise predefined list of structured questions. However, semi-structured interviews are 
administered by an interviewer and the respondents provide their answers verbally for 
the interviewer to record. The interview format is more flexible and can be conducted 
face-to-face, by telephone, video conferencing etc. However, the interviewer is also 
considered to be part of the method instrument (Trochim, 2006b). The interview 
technique provides additional advantages to that of the questionnaires which must be 
carefully considered (Evans, 1995; Trochim, 2006b; Weinberg, 2013): 
 
Advantages 
 Interviewer has opportunity to ask probing or follow-up questions. 
 Respondent can ask the interviewer clarifying questions. 
 Often easier for the respondent as they can talk freely and particularly beneficial 
for questionnaires that require opinions or more open ended questions. 
 The more personal nature of the interview makes it easier to judge the quality 
of the response.  
 Higher response rate. 
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Disadvantages 
 Travel and time costs for the interviewer may need to be considered.  
 More resource intensive and time consuming to conduct and analyse. 
 Greater variance as the interviewer becomes part of the method instrument and 
the interviewer’s style for delivery of questions and interactions with the 
respondent will vary to a certain degree, which can cause difficulties for 
comparison (e.g. Variability between different interviewers). 
 Risk of the interviewer asking leading questions resulting in biased answers. 
 
Both self-administered questionnaires and semi-structured interview techniques will 
be used to collect data. The self-administered electronic questionnaire delivered by 
email is more appropriate for collecting HTA agency and pharmaceutical industry 
representative’s opinions regarding the value of the process map methodology as the 
target respondents are located in various European and American cities.  A 
combination of self-administered electronic questionnaires and semi-structured 
interviews will be conducted for the study of regional Canadian payers.  The self-
administered questionnaires are more appropriate for collecting factual data which is 
likely to require the respondent to conduct some research. The chosen payer 
representatives are based in four Canadian provinces which would be resource 
intensive requiring additional time and travel expenses for the interviewer. However, 
face-to-face semi-structured interviews enable the interviewer to ask more open ended 
questions and provide opportunities for the Canadian payers to ask clarifying 
questions for the questions in both the interview and self-administered questionnaire.    
 
Questionnaire Development 
The self-administered questionnaires for the Canadian payers study and the study 
evaluating the value of the process maps will be designed with consultations with 
experts and piloted prior to the full studies. Evans (1995) advises piloting  
questionnaires with a small sample to identify issues such as misleading instructions, 
vague or leading questions, limited or incomplete response options and choice of 
terminology. The questionnaire for the Canadian payers study will be created in 
consultation with representatives from CADTH and Alberta services. The 
questionnaire will initially be piloted with a regional payer prior to full distribution. The 
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questionnaire for evaluating the value of the process maps will be created in 
consultation with experts to design the questionnaire structure and content prior to 
piloting the survey with representatives from both the HTA agencies and 
pharmaceutical industry.  
 
Questionnaire validation 
It is important to determine the validity of a questionnaire. Use of a valid questionnaire 
will improve the quality and comparability of the data and confidence in the conclusions 
(Kazi and Khalid, 2012). According to Jary and Jary (1995) validity is “the extent to 
which a measure, indicator or method of data collection possesses the quality of being 
sound or true as far as can be judged” (as cited in(Pierce, 2008), in other words 
‘measuring what it purports to measure’. There are multiple types of validity to be 
measured in questionnaire development (Block, 2006; Phelan and Wren, 2006; 
Trochim, 2006a). 
 
Face validity 
For a questionnaire to have face validity, the meaning of the questions should be clear 
and obvious (Block, 2006). This is a simple measure and can be easily determined by 
stakeholders (Phelan and Wren, 2006).  
 
Content validity 
Content validity assesses whether the questions in the questionnaire, in terms of their 
emphasis and focus, are relevant and suitable for their intended purpose/population 
(Block, 2006). This can be measured by checking the content of the questionnaire 
against a defined list of criteria that should be met (Trochim, 2006a). A panel of experts 
and a panel selected from the intended population can be brought together to 
determine the content validity by assessing emphasis and focus of each question 
against the objectives (Phelan and Wren, 2006). 
 
Criterion validity 
Criterion validity checks the performance of the questionnaire by determining whether 
it will generate results that will correlate with existing criterion if available (i.e. gold 
standard) (Block, 2006; Phelan and Wren, 2006).  
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Construct validity 
The construct validity determines the questionnaires ability to assess its intended 
purpose or support hypotheses (Block, 2006). It should exhibit strong correlation with 
closely related measures (i.e. convergent construct validity) and exhibit poor 
correlation with distantly related measures (i.e. divergent construct validity). 
 
These concepts for questionnaire development will be examined in relation to the 
questionnaire that will be developed for Chapter 7 to assess the impact of HTA process 
maps for pharmaceutical industry and HTA agency stakeholders. 
 
Data validation 
Various methods will also be employed to validate the data collected from the range 
of studies to be conducted: 
 Data will be retrieved from primary sources and reputable published material. 
 Draft process maps and the information sources used to produce the process 
maps will be audited by a second researcher to clarify that the map is an 
appropriate representation of the available sources. The two researchers will 
discuss any discrepancies and if a consensus cannot be reached a third 
researcher or expert in the field will be consulted. 
 The final process maps will be sent to HTA representatives or experts for 
review. This will be particularly useful when sources are conflicting or do not 
accurately reflect current practices. 
  Data collected from the public domain will be sourced and recorded by the 
primary researcher. A second researcher will then audit the completed 
database against the public domain sources for accuracy or the primary 
researcher will conduct the audit after a reasonable period of time has passed 
from completion of the initial database. The audit technique will include 
checking data points at defined intervals and if errors are found the audit will 
include every data point.  
 The face-to-face interviews provide opportunity to the respondents in the 
Canadian payers study to ask clarifying questions for the self-administered 
questionnaire. 
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Data Processing and Analysis 
The information to be collected will include a combination of quantitative and 
qualitative data. The quantitative data will be analysed using Microsoft Excel, SPSS 
and EpiTools (Sergeant, 2015) to conduct descriptive statistics and test hypotheses. 
The qualitative data will include responses from the questionnaire, semi-structured 
interview recordings and descriptive data to produce HTA process maps.  
 
HTA recommendation categories 
To facilitate analysis, the HTA recommendation categories must be compared across 
the agencies to find comparable categories. Both binomial and multinomial 
classification methods have been published and offer different strengths and 
weaknesses. The binomial classification is the simplest option as medicines are either 
positively recommended or receive a negative recommendation (not recommended). 
This classification approach is more appropriate when the available information is 
unclear or not available for restrictions. In addition, the two category classification 
approach is also more appropriate for conducting descriptive statistics that require two 
categories.  However, as stated by Fischer (2012), omitting the restrictions may 
oversimplify the effects of the recommendations. Multinomial classifications of varying 
complexity have also been published (Clement et al., 2009; Gamble et al., 2011; Nicod 
and Kanavos, 2012). These commonly include three recommendation categories 
(recommended, recommended with restrictions and not recommended). More detailed 
classifications include categories for different types of restrictions but these usually 
focus on a single HTA agency rather than comparing across agencies (Raftery, 2006; 
Mason and Drummond, 2009; O'Neill and Devlin, 2010).  
   
Three different databases of HTA recommendations will be conducted for this 
research. The first will collect HTA recommendations from 9 European HTA agencies 
for new medicines approved in Europe, the second will collect HTA recommendations 
for national HTA recommendations for new medicines in Australia, Canada and the 
UK and the third will collect national and regional HTA recommendations for new 
medicines in Canada. HTA recommendations will be collected directly from the 
primary source. However, the level of transparency varies between agencies and a 
language translation tool will be required for information that is not available in English. 
The reimbursement recommendation will be recorded as categorised by the HTA 
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agency that issued the decision. The types of HTA recommendations recorded in each 
database will be compared across the included agencies (or payers) to determine 
comparable groups. Both multinomial and binomial classifications will be used in these 
studies where appropriate.   
 
Percentage agreement 
Using Microsoft Excel, HTA recommendations classified in binomial or multinomial 
categories can be numerically coded to calculate the quantity of concordant 
recommendations for each medicine between jurisdictional pairs. Not all HTA 
agencies will have reviewed the same medicines. Thus, reporting the total number of 
concordant recommendations alone could be misleading and, therefore the 
percentage agreement will be calculated between jurisdiction pairs to report the 
proportion of concordant recommendations.   
 
Inter-rater reliability 
Statistical methods are available for calculating the degree of reliability between raters. 
Cohen’s Kappa is a method for calculating reliability (degree of error) between two 
raters that can be considered to be more reliable than percentage agreement alone 
as it considers the proportion of agreements expected due to chance (Feinstein and 
Cicchetti, 1990). Fleiss’s kappa is similar to Cohen’s kappa but enables comparison 
of more than two raters. However, according to Hallgren (2012) Fleiss’s Kappa is not 
suitable for studies where data is fully-crossed (rated by the same raters/coders).   
 
Cohen’s kappa will be used to calculate inter-rater reliability for HTA recommendations 
but according to Gwet (2014) “If categories can be ordered (or ranked) from the “Low” 
to the “High” ends, then the Kappa coefficient could dramatically understate the extent 
of agreement among raters.”  Therefore, the kappa coefficient can be calculated for 
HTA recommendations using the binomial classification (nominal groupings) but a 
weighted kappa is required for the multinomial classification (ordinal groupings). 
Cohen (1968) emphasises the importance of these weightings and recommends 
consulting a committee of “substantive experts” to reach a consensus.  
 
Limitations of the kappa coefficient include two paradoxes that must be considered 
when interpreting the results (Feinstein and Cicchetti, 1990; Cicchetti and Feinstein, 
39 
 
1990; Viera and Garrett, 2005). These paradoxes occur as kappa is affected by the 
prevalence of results and the distribution of marginal proportions. The effect of 
prevalence can result in a low kappa value for rare findings (Viera and Garrett, 2005). 
(Feinstein and Cicchetti, 1990) also state that the kappa paradox can result in a low 
kappa value for two observers that appear to have a high level of agreement. Various 
methods have been published to account for these paradoxes and support the 
interpretation of results and these include reporting the proportion of both positive and 
negative agreements and calculating confidence intervals (Feinstein and Cicchetti, 
1990; Cicchetti and Feinstein, 1990; Sim and Wright, 2005; Viera and Garrett, 2005). 
 
Confidence intervals  
Understanding uncertainty is important for inferential statistics and, therefore 
calculating confidence interval (CI) can quantify the level of uncertainty. The CI can be 
defined as “a range of values for a variable of interest constructed so that this range 
has a specified probability of including the true value of the variable.” (Gillam et al., 
2012). A 95% confidence interval is commonly stated and will be used for this study 
(Porta, 2014). 
 
Methods for calculating a confidence interval for binomial proportions include the 
standard Wald, adjusted Wald, Wilson Score, Clopper-Pearson and Jeffrey’s (Brown 
et al., 2001). The standard Wald method is commonly used but also has important 
limitations to consider. If the proportion has a value close to 0 or 1 the standard Wald 
may produce an interval with a percentages that are negative or larger than 100% and 
is also not suitable for small n values and (Brown et al., 2001) recommends either the 
Wilson score and equal-tailed Jeffrey’s for dataset with an n<40. This study has 
chosen to use the Wilson score method because it is suitable for small n values and 
will not produce confidence intervals with negative or larger than 100% value.  
 
 
Semi-structured interviews 
The semi-structured interviews will be conducted with a predefined checklist of 
questions to be used during all interviews for consistency. The interviewer will request 
permission to record the interview and the resulting audio files will be transcribed to 
facilitate identification of themes.  
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STUDY PLAN  
A systematic literature review for the production of HTA process maps will provide an 
overview of the current regulatory to reimbursement systems included in this research 
and form the basis of the studies to be conducted (Figure 2.1). The uniform 
methodology of the HTA process maps facilitate comparison for the development of a 
classification tool and to help understand the process for determining the 
reimbursement recommendations to be collected and compared. Finally, a study will 
be conducted to identify how the HTA process maps can provide value to 
stakeholders.  
 
Study 1 (Chapter 3): Development of a classification tool 
The initial research to be conducted for this study will be the production of HTA process 
maps using a novel mapping methodology (see chapter 3) to provide an overview of 
33 European national reimbursement systems. Therefore, the research for the HTA 
process maps will have a descriptive purpose but this will then lead to exploratory 
research through the identification of key variables between the HTA processes and 
reimbursement systems. The uniform aspect of the mapping methodology provides 
comparable profiles that will be used to develop a classification tool. 
 
Study 2 (Chapter 4): Comparison of European HTA recommendations and 
classification tool 
The second study will compare HTA recommendations from nine European national 
agencies for comparison with the classification tool to identify potential relationships 
between the classification categories and reimbursement recommendations. This 
study will include the collection of HTA recommendations that will be coded to enable 
basic descriptive analysis for hypotheses testing.  
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Figure 2.1: The Study flowchart 
 
Key: AB- Alberta; BC- British Columbia; CDR: Common Drug Review; EEA- European Economic Area; 
EMA- European Medicines agency; HTA; Health Technology Assessment;  ON- Ontario; QC- Quebec; 
PBAC- Pharmaceutical Benefits Assessment Committee; NICE- National Institute for Health and Care 
Excellence; SMC- Scottish Medicines Consortium  
 
Study 3 (Chapter 5): Evaluation of divergent national HTA recommendations in 
Australia, Canada and UK 
Study 3 will begin with descriptive research through the production of HTA process 
maps for the national regulatory to reimbursement systems for new medicines in 
Australia, Canada, England and Scotland. The study will then include exploratory 
•Process maps to be produced for 33 
EEA jurisdictions
•Identif ication of  key similarities and 
dif ferences to develop a taxonomy for 
HTA processes and the position of  
HTA within the health care system
•Comparison of  taxonomic groups to 
yield classif ication archetypes 
•Process maps to be produced for 
Australia, Canada, England and 
Scotland
•CDR recommendations to be 
identif ied for medicine-indication 
combinations f rom 2009 to 2013 and 
compared with recommendations f rom 
PBAC, NICE and SMC 
Study 1:
Development of classification tool 
Study 3:
Evaluation of divergent national 
HTA recommendations in Australia, 
Canada and UK
•HTA recommendations to be collected 
for 9 European jurisdictions for  new 
medicines approved by the EMA f rom 
2008 to 2012
• Assess the relationship between HTA 
Process taxonomic sets with HTA 
recommendations
•Evaluate HTA recommendations by 
therapeutic area
Study 2:
Comparison of European HTA 
recommendations and classification 
tool
•Process maps to be produced for the 
national CDR and provincial payers 
(AB, BC, ON, QC)
• CDR recommendations and regional 
drug plan decisions to be compared for 
Medicine-indication combinations 
issued f rom 2009 to 2013
• Questionnaires and semi-structured 
interviews to be conducted with four 
provincial payers 
Study 4:
Evaluation of national HTA 
recommendations and regional 
payers in Canada 
Study 5:
Assessing the impact of HTA process maps for pharmaceutical industry and 
HTA agency stakeholders
Questionnaire to be distributed to representatives f rom  pharmaceutical industry and 
HTA agencies to: 
•Identify availability of information sources for industry and agency stakeholders
•Assess the value of the process maps for industry and agency stakeholders
•Evaluate how the systematic process maps could impact company strategy  or decision -
making
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research through the collection of HTA recommendations from the national HTA 
agencies for each jurisdiction for comparison with descriptive statistics. The 
distribution of positive and negative recommendations will be compared across 
jurisdictions to identify case studies to compare rationale for medicines reimbursement 
recommendations.   
 
Study 4 (Chapter 6): Evaluation of national HTA recommendations and regional 
payers in Canada 
Study 4 will expand on the research conducted for study 3 by using the same initial 
cohort of new medicines but these will be used to compare CDR recommendations 
against local payer decisions rather than comparing CDR recommendations 
internationally (study 3). This study will be exploratory using a mixed methods 
approach through the construction of a database of reimbursement recommendations 
and the utilisation of a questionnaire followed by semi-structured interviews.  
 
Study 5 (Chapter 7): Assessing the impact of process maps for pharmaceutical 
industry and HTA agency stakeholders 
The electronic questionnaire approach will be used to source feedback and comments 
for the HTA process mapping methodology from HTA agency and pharmaceutical 
industry stakeholders. This study will also be exploratory as it seeks to identify how 
the HTA process maps can provide value for stakeholders and could formulate 
suggestions for future improvements and developments of the methodology.   
 
 
SUMMARY 
 This chapter provides the rationale for the studies to be conducted on the 
Australian, Canadian and European HTA environment. 
 
 The advantages and disadvantages for the different methods for administering 
and delivering a questionnaire have been described and methods for analysing 
the information obtained has been discussed. 
 
 The chosen approaches for data validation, data processing and data analysis 
have been described  
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 A study plan has been developed to describe the various studies to be 
conducted for this research and demonstrate how the studies are connected 
and ordered.   
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CHAPTER 3 
 
 
 
 
 
 
 
 
Development of archetypes to facilitate 
comparative analysis of 
reimbursement and decision-making 
processes 
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INTRODUCTION 
Healthcare expenditure in Europe, as with much of the world, is rising faster than 
national gross domestic product (GDP) (Beyer et al., 2007). Healthcare resources face 
an increasing demand from consumers resulting in a greater gap between public 
expectations and affordability (Pammolli et al., 2012). With limited options for 
additional healthcare funding, policy/coverage decision-makers are turning to Health 
Technology Assessment (HTA) in order to ensure healthcare resources are used 
efficiently. In general, HTA for coverage decision-making evaluates the added 
therapeutic benefits, the risks and the uncertainties of applying the new technology to 
the coverage population in the context of the local standard of care. In addition, HTA 
may also include economic assessment of the new technology. A typical output from 
HTA is a recommendation as to the use and/or relative value of the technology to the 
decision-maker and payer (Henshall et al., 2011; Drummond et al., 2008; Facey, 
2006). 
 
One particularly impactful aspect of decision-making with regard to healthcare 
resource allocation occurs when HTA recommendations result in highly publicised 
negative decisions for non-coverage of new pharmaceuticals (Littlejohns et al., 2009). 
Pharmaceuticals only form about a fifth of most total healthcare budgets (Organisation 
for Economic Co-operation and Development (OECD), 2011). However, they can have 
an immediate budget impact and are a component of healthcare expenditure that, from 
a political perspective, are measurable and relatively easy to regulate in comparison 
to, for example, salaries of healthcare professionals, costs incurred from clinical errors 
or finding a consensus for general expenditure cuts in healthcare services (British 
Medical Association (BMA), 2010; Reynard et al., 2009; Myllykangas et al., 1997). The 
impact of HTA on new pharmaceutical coverage decision-making in Europe has 
caused concern amongst patient groups over access to medicines and rationing by 
the pharmaceutical industry in relation to curbing innovation and the impact on pricing 
of new pharmaceuticals (Baker, 2011; Wyke, 2011; Pammolli et al., 2011). A key 
concern shared by these and other healthcare stakeholders is the degree of variation 
by which HTA is conducted and applied across Europe (European Network for Health 
Technology Assessment (EUnetHTA), 2007). 
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The variation in philosophies and techniques across national and regional HTA bodies 
in Europe is a product of political, social and financial differences. European 
healthcare systems can be classified according to many different typologies of varying 
indicators (Eikemo and Bambra, 2008; Arts and Gelissen, 2002). However, they are 
generally based upon 3 different ideologies of social welfare (Arts and Gelissen, 2002): 
 Liberal/ Beveridge  
A model that provides modest benefits according to strict eligibility criteria and 
means testing 
 Conservative/ Bismark  
Regime of social insurance coverage that provides benefits proportional to 
earnings  
 Social Democratic/ Scandinavian  
A model of high universalism for the distribution of benefits  
 
Within the context of these different healthcare ideologies, HTA has developed as 
standalone agencies or as units within existing healthcare agencies and their remit 
and context varies considerably by country or region. The different systems have 
spawned different approaches to HTA, resulting in a diversity of organisational 
architectures and processes for HTA assessment (Hutton et al., 2006). Key aspects 
of the variation between European HTA systems are (i) the extent of information that 
is applied to the assessment of the new technology, especially the use of economic 
information (ii) the level of independence between the processes for assessment, 
appraisal and decision-making and (iii) the variation in methodologies used in the 
evaluations (Sculpher and Drummond, 2006). 
Although some factors are unique to each nation and therefore cannot be aligned, 
such as the political milieu and a country’s ability to fund national healthcare schemes, 
the fundamental scientific criteria used for the HTA evaluation should have their basis 
in consistently applied, scientifically rigorous methodologies that encourage 
transparency of quality decision-making. The European Commission has recognised 
the need for a more efficient European HTA environment to help overcome inequalities 
in patient access to therapies (European Network for Health Technology Assessment 
(EUnetHTA), 2008). Accordingly, this organisation has recently amended the 
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Transparency Directive to ensure timely coverage decision-making and provided 
grants to support the European Network of Health Technology Assessment 
(EUnetHTA), which recently implemented the EUnetHTA Joint Action project 2 
(EUnetHTA JA2) to establish sustainable cross-border HTA collaboration in Europe 
with the development of a core HTA model (European Commission, 2012; European 
Network for Health Technology Assessment (EUnetHTA), 2012). 
 
Table 3.1: Key Principles for the improved conduct of Health Technology 
Assessment  
Key Principles 
Structure of HTA programmes 
1. The goal and scope of the HTA should be explicit and relevant to its use 
2. HTA should be an unbiased and transparent exercise 
3. HTA should include all relevant technologies 
Methods of HTA 
5. HTA should incorporate appropriate methods for assessing costs and benefits 
6. HTAs should consider a wide range of evidence and outcomes 
7. A full societal perspective should be considered when undertaking HTAs 
8. HTAs should explicitly characterize uncertainty surrounding estimates 
9. HTAs should consider and address issues of generalisability and transferability 
Processes for conducting HTA 
10. Those conducting HTAs should actively engage all key stakeholder groups 
11. Those undertaking HTAs should actively seek all available data 
12. The implementation of HTA findings needs to be monitored 
Use of HTA in decision-making 
13. HTA should be timely 
14. HTA findings need to be communicated appropriately to different decision 
makers 
15. The link between HTA findings and decision-making processes needs to be 
transparent and clearly defined 
Source: Drummond et al., (2008) 
Drummond et al. (2008) proposed 15 Key Principles to be used as a measure to 
benchmark HTA agencies by applying a score to each principle (Table 3.1). The 15 
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Key Principles cover a range of HTA practices, but not all of the Key Principles may 
be relevant to the mandates of individual agencies. Therefore, scoring HTA agencies 
according to a criterion that is not applicable to their practices will result in these 
agencies unfairly achieving a lower overall score. Henshall (2012) responded to this 
publication by expressing a need for an “objective approach to describing health 
system decision-making systems”. Resources are currently available that offer flow 
diagrams and pictorial representations of coverage systems (International Society For 
Pharmacoeconomics and Outcomes Research (ISPOR), 2012; Eldessouki and Dix 
Smith, 2012; World Health Organisation Collaborating Centre for Pharmaceutical 
Pricing and Reimbursement Policies.). However, this study aims to provide additional 
value to the currently available resources through the application of a novel mapping 
process that ensures all maps conform to a uniform methodology, a common graphical 
representation and standardised descriptors focused on reimbursement. 
 
OBJECTIVES 
The main objectives of this study are to:  
1. Characterise the review and decision-making systems for new pharmaceuticals 
for 33 European jurisdictions and to categorise these according to a standard 
taxonomy. 
2. Categorise the diversity of the different HTA systems by identifying sub-groups 
with common elements of process (ie, archetypes) that could be used to 
describe general characteristics common to the different systems within each 
archetype, and provide a method of non-ranking classification. 
3. Examine the relationship of the subgroups to determine how these archetypes 
could be useful in practice, for example by the identification of groups of 
countries where work sharing could be adopted. 
 
METHODOLOGY 
The scope of this research was limited to the national pathway and processes for 
regulatory, HTA and coverage decisions for New Active Substances. For the purpose 
of this research a New Active Substance (NAS) was defined as a chemical, biological, 
biotechnology or radiopharmaceutical substance that has not been previously 
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available for therapeutic use in humans and is destined to be made available as a 
prescription only medicine, to be used for the cure, alleviation, treatment, prevention 
or in vivo diagnosis of diseases in humans. This research was also limited to the 
creation of process maps, using a systematic mapping methodology, for the following 
33 European jurisdictions from the European Economic Area (EEA): 
 Austria 
 Belgium 
 Bulgaria 
 Cyprus 
 Czech Republic 
 Denmark 
 England 
 Estonia 
 Finland 
 France 
 Germany 
 Greece 
 Hungary 
 Iceland 
 Ireland 
 Italy 
 Latvia 
 Liechtenstein 
 Lithuania 
 Luxembourg 
 Malta 
 Netherlands 
 Norway 
 Poland 
 Portugal 
 Romania 
 Scotland 
 Slovakia 
 Slovenia 
 Spain 
 Sweden 
 Switzerland 
 Wales 
 
Some European nations have decentralised decision-making to the regional level and, 
in such cases, the presence of multiple regional decision-makers are indicated within 
the map for the overall national pathway. Information used to create the process maps 
was primarily sourced from the most up to date information in the public domain. This 
included the official agency or Ministry of Health websites (Appendix A) International 
Drug Regulatory Affairs Compendium (IDRAC©) expert reports (Thomson Reuters, 
2015), ISPOR Roadmaps and the WHO Collaboration Centre Country Reports. This 
information was applied to a refined systematic mapping methodology (Allen et al., 
2010a; Allen et al., 2010b; Patel et al., 2011; Pichler et al., 2010). 
The novel mapping methodology used to create the process maps displays 
information in three tiers. The first information tier identifies the interaction between 
the NASs sponsor and agencies involved in the national process (Figure 3.1). The 
interactions are indicated by coloured arrows; red arrows for sponsor and agency 
interactions, and blue arrows for agency to agency interaction. Dashed arrows are 
used to show interactions that are not mandatory but often occur. The Sponsor (red) 
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arrows are also numbered to help indicate the order of these interactions. A pale blue 
shaded area is added to highlight which agencies operate within government.  
Figure 3.1: Mapping methodology information tier 1  
 
 
Interactions between the NASs sponsor (red box) and key agencies (dark blue box) are visually 
represented for the first information tier. Sponsor to agency interactions are numbered and indicate 
the order of steps involved in the system. Dashed lines have also been included to represent non-
mandatory interactions.  A pale blue shaded area highlights agencies that are within government. 
The second information tier examines the roles performed by the agencies within the 
system. The most significant components of the system are chosen and defined to 
create seven core functions. A colour-coded tab is produced for each of these seven 
core functions and is added to the agency, or agencies, that perform the defined 
function (figure 3.2) (Pichler and Wang, 2012): 
 Regulator  
Scientific evaluation based on safety, quality and efficacy is conducted to 
determine if market authorisation should be recommended.  
 Market Authorisation 
Decision to grant market authorisation to the new medicine is made. 
 HTA 
The assessment of the new medicine is conducted in relation to the therapeutic 
value and/or economic value of the new medicine to the healthcare system. 
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Figure 3.2: Mapping methodology information tier 2 
 
 
 
 
 
 
 
 
 
 
Seven agency core functions are identified for the second information tier: Regulator, Market Access, 
HTA, Price Authority, Recommender, Decision Maker and Provider. Each core function is allocated a 
colour-coded label and added to agency that performs the function. 
 Price Authority 
 Determines or controls the list price for a new medicine. This could be 
 achieved by a voluntary price agreement of by imposing a ceiling price.  
 Recommender 
HTA appraisal results in a recommendation for reimbursement but the final 
decision is made elsewhere. 
 Decision Maker 
 Decision to reimburse the new medicine is made in relation to the coverage 
 scheme for the system in question. 
 Provider 
The new medicine is adopted based on the outcome of the decision maker. 
The HTA core function tab includes a task bar to display additional information about 
the agencies HTA processes. Six key activities are chosen as the defining elements 
to characterise the agency. A colour-coded icon is produced for each key activity, and 
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added to the HTA task bar for agencies that routinely partake in a particular activity 
(Figure 3.3): 
Figure 3.3: Mapping methodology information tier 3 
 
    
The core function label for ‘HTA’ includes a toolbar to display the key functions performed by the HTA 
agency. The mapping methodology pilot indentifies 6 key HTA activities: Scientific Advice (SA), 
Therapeutic Value (TV), Economic Value (EV), Reimbursement Rate Setting ($), Public Consultation 
and Coverage with Evidence Development (CED).   
 Scientific Advice (SA) 
Provision of scientific advice to the sponsor in relation to the drug development 
programme of the submission of evidence to that agency. 
 Therapeutic value (TV) 
Evaluation of the clinical evidence in order to determine if there is added 
therapeutic value in the new medicine. 
 Economic value (EV)  
Determination of the cost-effectiveness, cost-utility, cost-benefit, and/or budget 
impact of the new therapy. 
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 Reimbursement rate ($) 
Determination of the rate of reimbursement for the new medicine, usually into 
pre-defined categories. 
 Public consultation 
Involvement of patients, patient advocates and/or public representatives, to 
include both formal and informal forms of consultation. 
 Coverage with Evidence Development (CED) 
Provision of release of the new medicine where data is limited with the condition 
of further evidence development. 
 
All three information tiers are consolidated to produce the final process map.  The 
different system processes were determined by interpreting sources available from 
official HTA agency or Ministry of Health websites (Appendix A), journal publications 
and the International Drug Regulatory Affairs Compendium (IDRAC©; Thomson 
Reuters) expert reports. An Internet translation tool (Google Translate) was used to 
translate online information sources unavailable in English. This included all official 
HTA agency or Ministry of health webstes for jurisdictions except where English is the 
primary language (England, Ireland, Scotland and Wales). Several agency websites 
do provide some information in English (e.g. G-BA (Germany), HAS (France) and TLV 
(Sweden)), but more detailed information is often included in the primary language 
and was therefore translated for completeness. Each process map was reviewed by 
a second in-house researcher to confirm the primary researcher’s interpretation of the 
information sources. If consensus could not be agreed, a third opinion from a 
researcher with previous experience as director of a European HTA agency was 
consulted. Where possible, the process maps were reviewed by a country expert. 
Usually this included a representative from the national HTA agency (AHTAPol; HAS; 
INAMI; IQWIG; NICE; SMC; TLV; ZIN (formerly CVZ), but feedback from presentations 
provided at meetings of a not-for-profit organisation to members of the pharmaceutical 
industry were also incorporated as the process maps provide an overview of the 
reimbursement system from regulatory approval to the healthcare provider from the 
perspective of the sponsor. The sourced information is used to generate an 
information hierarchy displayed within 3 tiers in the resulting process maps. These 
information tiers allow all stakeholders, including those with no prior knowledge of 
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HTA, to understand the reimbursement process. All process maps also conform to a 
specification of defined colour-coded functions and icons to enable efficient 
intersystem comparison. Following the completion of all 33 process maps, common 
similarities and differences were identified and used to create 2 groups of taxonomies 
for the healthcare systems.  
RESULTS 
The results for this chapter will be presented in six parts:  
 Part I- Process maps for 33 European jurisdictions  
 Part II- Categorising the ‘System taxonomy’ 
 PART III- Categorising the ‘HTA Process taxonomy’  
 Part IV- Convergence of taxonomies to establish archetypes  
 Part V- Relationships between taxonomies and archetype groups 
 Part VI- Geographical locations of classifications  
 
PART I- Process maps for 33 European jurisdictions 
Process maps were developed for each of the 33 European nations to illustrate the 
steps involved in regulatory, HTA, and coverage processes for NASs. Process maps 
for Austria, Denmark, Liechtenstein, Portugal, Spain and Switzerland are provided in 
Figures 3.4 – 3.9 to demonstrate the variation in processes included in this study. For 
example, the process map for Spain represents a system with greater decentralised 
decision-making compared to the majority of European reimbursement systems 
(Figure 3.8). The system shown in the process map for Liechtenstein is even more 
unique because Liechtenstein will accept drugs that have been granted marketing 
authorisation in Austria and Switzerland and may also choose to adopt the prices set 
by the Swiss Federal Office of Public Health.    
The full set of process maps for the 33 European jurisdictions included in this study is 
available in Appendix B. The maps identified notable differences in the extent to which 
agencies conducted a defined set of core functions, the number of decision–making 
bodies, their sequence within the overall process and the key HTA tasks that they 
undertake.  
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Figure 3.4: Process map for Austria (January 2012) 
 
 
 
 
Figure 3.5: Process map for Denmark (June 2014) 
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Figure 3.6: Process map for Liechtenstein (February 2012) 
 
 
 
 
Figure 3.7: Process map for Portugal (June 2014) 
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Figure 3.8: Process map for Spain (May 2014) 
 
 
 
 
Figure 3.9: Process map for Switzerland (June 2014) 
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PART II- Categorising the ‘System taxonomy’ 
The 33 European process maps were compared to identify similarities and differences 
between the regulatory to reimbursement systems. The comparisons focused on high-
level similarities and differences to ensure that the observed diversity could be 
represented by a small number of categories that could each be assigned to multiple 
systems.  
The first taxonomy produced by this research is the ‘System taxonomy’. This shows 
the position of the national HTA agency with regards to the regulatory and decision-
making coverage body (Figure 3.10). This ‘System taxonomy’ set contains 4 groups 
including HTA and an additional fifth group for systems that use external HTA:  
Figure 3.10: System taxonomy 
 
The System taxonomic set is based on the position of a national HTA agency, if present, in relation to 
the position of the regulatory (REG) and the decision-making coverage body (CB). 
 
 S1 - Regulatory, HTA and decision-making coverage body functions are 
performed by separate agencies. This is the most fragmented category of the 
‘System taxonomy’ and could be perceived to offer the most independent option 
for HTA and decision-making. More independent systems could be perceived 
to be less susceptible to bias. However, sustaining multiple agencies could be 
more costly than a single agency performing multiple functions.  
 S2 - Regulatory and HTA functions are performed by a single agency and the 
decision-making coverage body functions are independent. A single agency 
performing HTA and regulatory functions could enable resource sharing and 
therefore require fewer resources than two independent agencies. A single 
agency may also offer greater opportunities for HTA and regulatory to share 
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learnings and expertise. There may also be improved communication and 
therefore more timely processes between HTA and regulatory. 
 S3 - HTA and decision-making coverage body functions are performed by a 
single agency with the regulatory function performed independently. The 
combined HTA and decision-making function may provide more opportunities 
for communication and more timely decisions. However, HTA may be perceived 
to be susceptible to bias if conducted by the same agency responsible for the 
final funding decision.  
 S4 - Regulatory, HTA and decision-making coverage body functions are all 
performed within a single agency. This is the most integrated of the four HTA 
containing categories. This integrated approach could provide the best 
opportunities for shared learnings and increase cost-effectiveness due to more 
opportunities for resource sharing. However, HTA may be perceived to be 
susceptible to bias if conducted by the same agency responsible for the final 
funding decision. 
 S5- No HTA is performed within the national regulatory to reimbursement 
system. This group has been created to enable the categorisation of systems 
that do not conduct their own HTA.  
 
PART III- Categorising the HTA ‘Process taxonomy’  
The second categorisation outcome of this research is the ‘HTA process taxonomy’ 
(Figure 3.11). This focuses on the relationship between the HTA appraisal, therapeutic 
assessment and the economic evaluation if present. The HTA process taxonomic set 
also includes a group for systems that utilise external HTA:  
 H1 - Therapeutic value assessment, economic evaluation and appraisal are 
performed within the same agency. Combining multiple aspects of the HTA 
process could be more susceptible to bias. 
 H2 - Therapeutic value assessment is conducted within the same agency as 
economic evaluation but the appraisal is performed independently, usually by 
healthcare professionals rather than civil servants. It could perceived that 
including an independent appraisal is less susceptible to bias.  
 H3 - Therapeutic value is assessed prior to independent appraisal. This is the 
most fragmented of the three HTA containing categories of the ‘HTA process 
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taxonomy’. Conducting an independent assessment of therapeutic value could 
be perceived to be less susceptible to bias, especially for high cost drugs.  
 H4 - Appraisal is conducted using information from an external HTA report or by 
considering the coverage decisions of reference countries. This group has been 
created to enable the categorisation of systems that do not conduct their own 
HTA. 
 
Figure 3.11: HTA process taxonomy 
 
The HTA process taxonomic set, focuses on the key tasks performed by the HTA agency. Each group 
shows the relative positions of 3 key tasks, if performed, within the HTA agency: therapeutic value 
(TV); economic value (EV); and appraisal (AP). 
PART IV- Convergence of taxonomies to establish archetypes 
Each of the national HTA agencies were categorised by the convergence of their two 
taxonomic sets (this excluded the external HTA options), which were determined by 
the primary researchers interpretation of the system structure and HTA activities 
presented in the 33 EU HTA process maps (Figure 3.12). The nations with HTA-
performing agencies or committees were classified using this grid; the two nations that 
do not conduct HTA were listed by the name of their jurisdiction only. By comparing 
the confluence of the two taxonomies, the 33 national agencies were classified into 
different archetype groups. For example, the National Centre for Pharmacoeconomics 
(NCPE) is part of the Irish public healthcare system and has been assigned to group 
H1S1 because the regulator, HTA agency and the coverage decision-making body are 
positioned independently within the system (System taxonomy S1) and the NCPE 
review considers both cost effectiveness and clinical evidence and conducts the 
appraisal (‘HTA process taxonomy’ H1).  
 
The archetype group S5H4 is derived from the System taxonomic set S5 that does not 
include HTA in the national healthcare system and HTA Process taxonomic set H4 
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which utilises evidence from external HTA. The inclusion of this group enables this 
research to classify national healthcare systems that do not conduct their own HTA. 
Overall, this study has yielded ten distinct HTA archetype groups which enables 
representation of all 33 European nations assessed in this study (Figure 3.12). 
 
Figure 3.12: Archetype grid 
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agency, and its respective national system, have been allocated. The ten archetype groups are listed 
by their abbreviations in the archetype key and each group’s position is represented on the grid by 
colour. Boxes with no agencies have been left blank.  
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Nine jurisdictions were allocated to the largest archetype grouping S3H1: Bulgaria; 
Iceland; Latvia; Lithuania; Luxembourg; Slovakia; Scotland; Sweden and Wales 
(Figure 3.12). The S3H1 group includes systems with an agency that performs both 
HTA and decision-making with an independent regulatory authority and for the HTA 
process, the therapeutic value assessment, economic evaluation and appraisal are 
performed within a single agency. The second most common archetype observed in 
Europe was S1H2 and includes five jurisdictions: Austria; Belgium; Germany; Hungary 
and Poland. Unlike group S3H1, the systems allocated to group S1H2  have separated 
agencies or bodies to perform the HTA and decision-making. The S1H2 jurisdictions 
also include an independent appraisal within their HTA process.  
 
PART V- Relationships between taxonomies and archetype groups 
 
The relationships between the subgroups of the two taxonomic sets and archetype 
groups were examined to evaluate whether the differences could theoretically impact 
utilisation of the groups for information sharing. The potential for collaboration between 
different archetype groups was considered by initially evaluating the possible 
obstacles for HTA information flow between the two taxonomic sets (Figure 3.13).  
 
Figure 3.13: Information sharing flow diagrams 
A: Information sharing flow for system taxonomy 
 
B: Information sharing flow for HTA process taxonomy
 
This pictorial diagram shows the optimal direction for information flow. The numerically labelled 
dashed arrows indicate different opportunities for conflicts of interests.  
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Five key obstacles were identified for the HTA process and System taxonomies and 
their positions are indicated by numbered arrows in Figure 3.13: 
1- Potential conflict of interests when information provided by a system containing 
an agency with combined HTA and coverage body (S3 and S4) to a system that 
conducts HTA separately from the decision-making coverage body (S1 and S2). 
2- Need to consider the potential impact of agencies collaborating with agencies 
from less integrated systems (S1, S2 and S3) as this may affect timeliness. More 
integrated systems (S4) that include multiple functions performed by a single 
agency could have increased opportunity for communication and pooling 
resources.  
3- The countries allocated to groups S5 and H4 use information from external HTA. 
Therefore they could receive information provided by any of the other groups 
within their taxonomies but they are unable to provide HTA.  
4- Agencies allocated to group H3 perform an exclusively clinical HTA. Therefore 
collaborating with agencies that combine their therapeutic and economical 
assessments (H1 and H2) is unlikely to provide optimal results due to a 
potentially perceived conflict of interest. 
5- The potential conflict of interests (or additional workload) when the recipient 
group (H2 and H3) that routinely conducts external appraisal receives 
information from a group that does not conduct an external appraisal (H1). 
 
The key difference between the System taxonomic sets S1 and S2 is whether the 
Regulator and HTA functions are performed in a single agency or independently. 
These have been combined in Figure 3.13 because the differences in positioning 
these two core functions are not considered to be a potential conflict of interest. In fact, 
the combination of these two core functions in a single agency could provide increased 
opportunities for communicating, sharing resources and learnings.  These potential 
conflicts were then applied to the archetype groups and added to a grid to show 
potential for sharing HTA assessment information between different archetype groups 
and where conflicts of interest may need consideration (Figure 3.14).   
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Figure 3.14: Information sharing schematic for archetypes 
 
 
Symbol  Description  
✓ Information generated by provider group should be suitable for recipients needs.  
? Consider potential conflict of interests. Information provided by an agency with combined 
HTA and coverage body.  
?? Consider potential conflict of interests. Recipient group may need an additional external 
appraisal.  
X Information from provider is unlikely to be appropriate for the requirements of agencies within 
this group.  
 
This pictorial representation shows how agencies allocated to archetype groups could provide and 
receive information from HTA assessments for optimal value. The ‘?’ symbol is used to highlight 
sharing scenarios which have potential but may have potential conflicts of interest.  
 
Potential for sharing HTA assessment information between archetype groups are 
catergorised as one of the following: 
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✓- Information generated by provider group should be suitable for recipients 
needs. For example agencies within the same archetype group should be ideal 
candidates for information sharing as they should not be subject to the conflict of 
interests proposed for agencies sharing between different archetype groups. 
Sharing between different archetype groups could also be more preferable 
between certain pairs of archetype groups. For example, information generated by 
agencies allocated to group S1H3 (France (HAS), Netherlands (WAR) and 
Switzerland (FDC)) has the potential to share information with all other archetype 
groups because S1H3 is derived from the most independent System and HTA 
Process taxonomic groups and its processes could be perceived to be less subject 
to bias.  
?- Consider potential conflict of interests. Information provided by an agency with 
combined HTA and coverage body. For example an agency allocated to archetype 
group S3H1, such as the Dental and Pharmaceutical Benefits agency (TLV) in 
Sweden, will perform both HTA and coverage decision-making. This could be a 
perceived conflict of interest for agencies allocated to groups S1H1 or S2H1 as 
their coverage decision-making body is independent.  
?? - Consider potential conflict of interests. Recipient group may need an additional 
external appraisal. For example, agencies allocated to groups S1H1 (e.g. Spain 
(DGFPS)), S2H1 (e.g. Portugal (INFARMED)), S3H1 (e.g. Wales (AWMG) and 
S4H1 (e.g. Italy) could provide information that may not have been externally 
appraised.  
X - Information from provider is unlikely to be appropriate for the requirements of 
agencies within this group. For example, healthcare systems allocated to group 
S5H4 (Greece and Lichtenstein) are not recommended for sharing information with 
any other archetype group and S5H4 members do not conduct their own HTA.  
PART VI- Geographical locations of classifications 
Colour-coded maps were created to display the geographical locations of the two 
taxonomic groups (Figures 3.15 – 3.17). 
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Figure 3.15: System taxonomy geographical location map 
  
 
Figure 3.16: HTA process taxonomy geographical 
location map 
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The ‘System taxonomy’ demonstrates some clustering of the S1 across central Europe 
with more variation for the ‘System taxonomy’ allocations for the peripheral 
jurisdictions. However, the reverse is observed for the HTA process taxonomy that 
demonstrates more variation for the HTA processes adopted in central Europe and 
preference for a single ‘HTA process taxonomy’ subset (H1) for peripheral jurisdictions. 
A colour-coded map was also produced for the HTA archetype groupings (Figure 
3.17). The 33 jurisdictions are not distributed evenly to the 10 distinct archetype groups 
and the largest group (S3H1) is the most dispersed. However, the second largest group 
(S1H2) exhibits the greatest amount of clustering of all the archetypes. 
Figure 3.17: Archetype geographical location map  
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DISCUSSION 
The European Medicines Agency (EMA) has provided a centralised regulatory review 
process for European member states since 1995 (European Medicines Agency 
(EMA), 2015c). However, post-marketing authorisation pathways for reimbursement 
remain unique to each member state. Most European jurisdictions utilise HTA 
methodologies to guide reimbursement decision-making but similarities between HTA 
practices can result in duplication of workload and inefficient use of resources when 
multiple jurisdictions assess the same health technology. There are also many 
differences between European HTA agency mandates, HTA processes, existing 
formularies, best care pathways, budget limitations and national political and social 
expectations. This can result in duplication of effect, different reimbursement decisions 
for the same health technology and cause patient access inequalities throughout 
Europe. These inefficiencies are recognised and the European Network of HTA 
(EUnetHTA) has already begun initiatives for European HTA collaboration (European 
network for Health Technology Assessment (EUnetHTA), 2015a). 
Various efforts have also been conducted to explain the many different reimbursement 
pathways across Europe (Table 3.2)  
The International Society For Pharmacoeconomics and Outcomes Research (ISPOR), 
(2012) Roadmaps are produced by local experts or agency representatives and many 
have not been updated for several years. Local experts and agency representatives 
provide the data in a format of their choosing resulting in mostly text-base descriptions 
accompanied by diagrams produced by various different methodologies. The 
reimbursement systems can also change quickly and the most current practices may 
no longer be represented by some of the ISPOR Roadmap profiles.  
The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement 
Policies has published a collection of posters that provide flow diagrams of the 
reimbursement process for in-patient and out-patient pathways. These posters provide 
a more visual representation of the systems compared to the ISPOR Roadmaps but 
they do not follow a uniform methodology and many were produced more than five 
years ago.  
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Table 3.2: Comparison of this research and resources available in the public domain 
Resource Similarities to 
process maps 
Differences to process maps 
International Society 
For 
Pharmacoeconomics 
and Outcomes 
Research (ISPOR), 
(2012) 
 The published 
Roadmaps including a 
visual representation of 
the national 
reimbursement 
pathways  
 Roadmaps available for 
15 European countries 
included in this study 
 Process maps are created using a 
uniform methodology unlike the 
Roadmaps which are created by local 
experts who use a format of their choice 
 Process maps are accompanied by a 
table of information that is more concise 
than the more detailed text description 
included in the Roadmaps 
 Process maps produced for an 
additional 18 European jurisdictions 
than ISPOR  
 The Roadmaps are created by local 
experts and the process maps are sent 
for validation by local experts  
 Developed a method to categorise the 
reimbursement systems 
 Many of the Roadmaps have not been 
updated since 2008.  
World Health 
Organisation 
Collaborating Centre 
for Pharmaceutical 
Pricing and 
Reimbursement 
Policies. (2015a) 
 Published posters of the 
reimbursement 
pathways for 27 
European jurisdictions 
included in this study  
 The process maps and 
WHO posters both 
provide visual 
representations of the 
systems with supportive 
text to explain the roles 
of the agencies or 
committees 
 The WHO have produces separate flow 
diagrams for the in-patient and out-
patient pathways 
 The explanatory text is included in the 
flow charts of the WHO posters but is 
provided as an accompanying table for 
the process maps 
 Process maps are created using a 
uniform colour-coded methodology 
unlike the WHO Roadmaps  
 The individual WHO in-patient and 
outpatient pathway posters were mostly 
created in 2010 and have not been 
updated. However a separate poster 
has been produced to list more recent 
changes to the systems  
Charles River 
Associates  (Wilsdon 
and Serota, 2011; 
Wilsdon et al., 2014) 
 The Charles River 
Associates (CRA) 
reports provide an 
overview of the national 
pathway for 8 European 
jurisdictions included in 
this research 
 The CRA flow diagrams are uniform but 
very basic and do not include colour-
coded tabs or icons to enable quick 
identification of agency roles or the HTA 
processes conducted 
Charles River Associates have published reports to compare international HTA 
practices including eight European jurisdictions included in this study. The reports also 
included basic flow diagrams of the reimbursement systems and other analyses 
(Wilsdon and Serota, 2011; Wilsdon et al., 2014).  
However, none of these sources have utilised a systematic mapping methodology to 
produce uniform visual representations of the regulatory to reimbursement systems 
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for all member states of the European Union (EU) in 2012. A total of 33 process maps 
were created according to predetermined specifications to ensure uniformity. The 
diversity of these 33 systems was evaluated to produce two taxonomic sets to classify 
agencies according to their positions within the national system and also by the HTA 
processes the agency performs.  
The similarities and differences of the 33 European national regulatory and 
reimbursement systems have been reviewed to produce a taxonomy that focuses on 
the external environment of the HTA agency by classifying organisational architecture 
of each system according to the interactions between 3 core functions, namely 
regulator, HTA, and the coverage body that contribute to the final decision. The 
interactions between these 3 core functions can ultimately affect overall system 
performance and Drummond et al. (2008) has also stressed the importance of 
conducting HTA independently of the decision-making body to reduce bias.  
The ‘System taxonomy’ could be used to suggest potential collaborations to develop 
core HTA tools and methodologies. The ‘System taxonomy’ indicates which agencies 
may have more similar opportunities for communication and resource sharing due to 
multiple functions being performed by the same agency. However, it could also be 
perceived that a less integrated system is less susceptible to bias due to the greater 
level of independence of the decision-making coverage body from the agency 
responsible for conducting HTA.  
The second resulting classification group is the ‘HTA process taxonomy’. The 
subgroups of the ‘HTA process taxonomy’ distinguish between the HTA agency’s 
approach for conducting the therapeutic value and economic value assessments and 
their relationship to the overall appraisal. The process maps display six different key 
HTA activity icons, but only therapeutic value and economic value were chosen for the 
HTA process taxonomic set as these are the most frequently utilised to assist 
reimbursement decisions (Henshall et al., 1997). The position of the HTA appraisal 
has also been added to the HTA process taxonomic set as this indicates a key 
difference between the different agencies approaches for conducting HTA. The 
incorporation of an independent appraisal can reduce the perception of bias 
(Drummond et al. 2008) and is therefore an important factor that should be considered 
for classification. Each taxonomic set also contains a subgroup for nations that adopt 
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external HTA to ensure the taxonomies were representative of all 33 national systems. 
Although many European nations still do not have a formal HTA system (e.g. Bulgaria 
and Cyprus), 31 of the 33 systems profiled for this study required therapeutic 
assessment as a minimum requirement for coverage decision-making (Moharra et al., 
2008). Greece and Liechtenstein were the only two national systems that did not 
perform their own HTA at the time of this study. However, this does not imply that 
medicines are reimbursed by these two nations without any additional considerations 
following market access approval, as the coverage decisions of these countries are 
formed using information from external HTA reports.  
The ‘HTA process taxonomy’ could suggest appropriate working collaborations by 
distinguishing how different HTA agencies utilise the therapeutic evaluation in relation 
to the economic assessment and appraisal. This would enable HTA agencies to 
collaborate and share information that would be of optimal value to the agencies within 
each archetype group and between appropriate groups. Group H3 agencies, that 
perform their therapeutic evaluation independent of economic data such as the French 
National Authority for Health (HAS), and The Scientific Advisory Board (WAR) of the 
National Health Care Institute (ZIN; Netherlands), would be more natural partners for 
collaboration as compared to agencies from the highly integrated set H1 which perform 
the therapeutic and economic evaluation together (Italian Medicines Agency (AIFA) 
and Norwegian Medicines Agency (NOMA)). 
This study has subsequently achieved its second objective: to categorise the diversity 
of the different HTA systems by identifying sub-groups with common elements of 
process (ie, archetypes) that could be used to describe general characteristics 
common to the different systems within each archetype and provide a method of non-
ranking classification. Ten distinct HTA archetype groups were created by evaluating 
the confluence of the ‘HTA process taxonomy’ and the ‘System taxonomy’. The 
archetypes and the two taxonomies provide a non-ranking method of categorising the 
diversity of HTA systems. This addresses a need for an “objective approach to 
describing healthcare decision-making systems” (Henshall, 2012). Henshall (2012) 
raised this need in response to a suggested methodology for benchmarking agencies 
using Drummonds Key Principles (Drummond et al., 2008; Drummond et al., 2012). 
Charles River Associates have suggested a simpler method to categorise HTA by the 
timing of the assessment (Wilsdon and Serota, 2011).   
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A geographical colour-coded set of maps was produced to identify trends between 
geographical location and a jurisdiction’s allocated taxonomic subsets or archetype 
group. These maps demonstrated a preference for one ‘System taxonomy’ subset for 
some countries across central Europe but overall the maps did not demonstrate any 
strong correlation.  This could be due to the various different welfare state ideologies 
that developed throughout Europe (Bambra and Eikemo, 2008; Arts and Gelissen, 
2002). The effects of these ideologies can help explain why some welfare states such 
as Germany and France are funded by compulsory health insurance (Bismark) rather 
than through taxation as in the UK (Beveridge). However, even neighbouring countries 
with the same underpinning welfare state origins do not necessarily fall within the 
same groupings. It was concluded from the results that classifications based primarily 
on geographical location, ability to pay, or welfare state design may not be the 
optimum solution for determining groups for collaborations that require agencies with 
similar processes. Instead, identifying factors more closely related to the current HTA 
processes and their position within the reimbursement system could produce a more 
productive collaboration. Identifying groups with similar processes in Europe could be 
used to create collaborative groups as a stepping-stone for greater alignment. This 
progressive alignment approach would deliver the benefits of collaboration: reduced 
duplication of work, more efficient use of resources, more timely HTA and potentially 
less patient access inequalities. HTA is also a young field and it may be premature to 
suggest a one-size-fits-all approach for conducting HTA. A non-ranking classification 
can also help to characterise HTA agencies objectively without implying a particular 
HTA model as gold standard. A universally accepted classification method that implies 
rank could encourage an unnatural convergence of HTA practices towards the more 
positively ranked model. Therefore, an objective method of classification that does not 
suggest a gold standard could help maintain key differences in HTA practices. This 
approach could also be used as a basis for progressive alignment that would also 
provide an environment in which the key differences observed in the present HTA can 
be maintained while encouraging the development of more efficient HTA practices in 
the future. 
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Assessing the national pathways for NASs in order to test this conceptual approach 
was the main focus of this research. The taxonomies, and therefore archetypes, were 
developed to identify the main common and high-level factors that can be directly 
compared to produce a limited number of groups with a sizeable subset. 
 
The process maps can provide an overview of the regulatory and reimbursement 
systems to help explain the complexity of the reimbursement process and provide 
value for a variety of stakeholders. This can be a useful tool to assist healthcare 
professionals explain to patients why they may have to wait to gain access to 
medicines following marketing approval, or why a patient in another European 
jurisdiction has access to different medicines. The process maps and subsequent 
archetypes can provide value to HTA agencies who wish to explain their role and 
processes to external parties and to gain increased knowledge of other systems and 
HTA processes to facilitate comparison with their peers. The process maps may also 
help regulators to compare the multiple HTA processes and will be increasingly useful 
as HTA and regulatory agencies continue to work more closely to provide shared 
scientific advice (European Medicines Agency (EMA), 2015b). Finally, this approach 
can provide value to the pharmaceutical industry by enabling a comparison of multiple 
regulatory and reimbursement systems and identifying groupings with key similarities 
and differences that could assist market access strategies.  
 
Future research should investigate more detailed HTA activities and comparisons with 
HTA recommendations to identify whether HTA processes correlate with HTA 
outcomes. It is acknowledged that information sharing in practice would require a more 
detailed comparison of HTA methodologies. The taxonomic sets and archetype 
groups that have created are deliberately high-level to enable the exploration of new 
concepts.    
 
SUMMARY  
 A novel mapping methodology has produced process maps of the regulatory, HTA 
and reimbursement systems for New Active Substances in 33 European jurisdictions. 
These process maps can provide value for patients who wish to understand how their 
health service provider decides which drugs to reimburse. 
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 The diversity observed in the 33 process maps was summarised to form two 
taxonomic sets. The ‘System taxonomy’ represents the variation of the regulatory, 
HTA and reimbursement systems organisational architecture. The ‘HTA process 
taxonomy’ displays the relationship between the three key elements of the HTA 
process: therapeutic value assessment, economic value assessment and the 
appraisal. 
 
 The confluence of the System and HTA process taxonomies identified 10 individual 
archetype groups to classify all 33 jurisdictions.  
 
 The taxonomic sets and archetype groups provide value to agencies by enabling a 
comparison of processes with their peers and to industry by enabling a comparison of 
multiple regulatory and reimbursement systems and identifying groupings with key 
similarities and differences that could assist market access strategies. 
 
 Colour-coded maps of the 33 European jurisdictions were created for the ‘System 
taxonomy’, ‘HTA process taxonomy’ and the 10 archetype groups.  Some regional 
clustering was observed, but overall the colour-coded maps suggest other factors, 
such as political and social, may impact the diversity observed in the current European 
HTA environment. 
 
 The archetypes are labeled by combining the alpha-numeric code given to the 
taxonomic subgroups from which they are derived. This coding provides an objective 
form of characterising HTA agencies and the regulatory to reimbursement system. An 
objective form of classification is desirable as it enables comparison of systems that 
often have vastly different mandates and avoids scoring on aspects that may be 
irrelevant for a particular system.  
 
 The differences between the taxonomic groups were evaluated to examine how these 
archetypes could be useful in practice. The potential impact these differences could 
have upon information exchange was used to investigate alternative methods for 
choosing work sharing groups for HTA. 
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CHAPTER 4 
 
 
 
 
 
Comparisons of HTA Processes and 
Reimbursement Recommendations for 
nine European Jurisdictions using the 
classification tool 
 
 
 
 
 76 
 
INTRODUCTION 
Patients in the developed world are becoming increasingly involved in many stages of 
their healthcare system from actively engaging in the treatment decision-making 
process with their physician, to joining patient advocacy groups and providing the 
patients’ perspective for funding decisions. The advent of the internet has provided 
patients with a wealth of knowledge and increased opportunities for communication 
and collaboration. However, increased knowledge of treatment options drives 
consumerism and feeds into the healthcare vortex that drives expectations and 
demands of the healthcare system (Beyer et al., 2007).  
More informed patients are aware of patient access inequalities. Patients living within 
one jurisdiction may experience delays, or be denied access to the same medicine 
that was approved for reimbursement in another jurisdiction due to different processes 
and requirements of the reimbursement system. The need to reduce inefficiencies for 
access to new medicines in Europe is recognised and the European Commission 
funded permanent network for HTA will expand on the work conducted by the 
European Network for Health Technology Assessment (EUnetHTA), (2014) to 
produce a more collaborative and efficient European HTA environment.  
As a result of the research described in Chapter 3 it is proposed that there should be 
a progressive approach to support moving towards a more aligned HTA environment 
in Europe. Therefore, two taxonomic sets were developed to classify agencies 
according to the organisation of the system and the relationship between key HTA 
processes. The confluence of these two taxonomies produced 10 archetype groups 
that were developed as a theoretical exercise for categorising HTA processes. This 
theoretical method of categorisation by the two taxonomic sets will be compared with 
real world HTA recommendations to identify potential congruence and to highlight 
areas for refinement.  
OBJECTIVES 
The main objectives of this study are to: 
1- Assess the relationship between System taxonomic sets with HTA 
recommendations for New Active Substances granted EMA approval from 2008 
to 2012 
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2- Assess the relationship between HTA Process taxonomic sets with HTA 
recommendations for NASs granted EMA approval from 2008 to 2012 
3- Evaluate HTA recommendations for NASs granted EMA approval from 2008 to 
2012 by therapeutic area groups 
 
METHODOLOGY 
The European Medicines Agency (EMA) online database was searched for New 
Active Substances granted EMA marketing approval from January 1st 2008 to 
December 31st 2012. A NAS was defined as: 
A chemical, biological, biotechnology or radiopharmaceutical substance that has not 
been previously available for therapeutic use in humans and is destined to be made 
available as a prescription only medicine, to be used for the cure, alleviation, 
treatment, prevention or in vivo diagnosis of diseases in humans. 
Generics, vaccines and products previously licensed for sale in any European 
jurisdiction were excluded from this study. 
Health Technology Assessment recommendations were subsequently identified for 
each NAS and approved indication(s) from the official national agency websites for 
the following agencies (Appendix A): The Belgium Health Insurance Agency (INAMI); 
National Centre for Health and Care Excellence (NICE) in England; French National 
Authority for Health (HAS); Federal Joint Committee (G-BA) in Germany; National 
Centre for Pharmacoeconomics (NCPE) in Ireland; Italian Medicines Agency (AIFA); 
Dutch National Health Care Institute (ZIN); Scottish Medicines Agency (SMC) and The 
Dental and Pharmaceutical Benefits Agency (TLV) in Sweden. The nine agencies 
were chosen on the basis of the availability of published recommendations in English 
or because the agency allows data for HTA recommendations to be available in the 
public domain. The final selection of agencies also required a selection of jurisdictions 
that could be allocated to a range of taxonomic sets for comparison. An online 
translation tool (Google Translate) was also used to aid data collection when agency 
recommendations were not available in English, such as: AIFA; INAMI; TLV and ZIN. 
When more than one review was published, the first HTA recommendation or listing 
was recorded and the completed dataset was also validated. Each HTA 
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recommendation or listing was then allocated to one of the following three categories: 
recommended; recommended with restrictions or not recommended.  
The three HTA recommendation categories were subsequently numerically coded for 
direct comparison between agency pairs to enable the identification of the total number 
of recommendations with congruent outcomes. The percentage of total congruent 
outcomes were calculated for each pair of agencies and presented in two colour-coded 
cross-tabulation tables.  The two tables grouped each jurisdiction according to the two 
taxonomies (‘System taxonomy’ and ‘HTA process taxonomy’) developed in chapter 
3. These tables facilitated testing of the following hypotheses: 
1- There is a correlation between HTA recommendations and System taxonomic 
sets 
2- There is a correlation between HTA recommendations and HTA Process 
taxonomic sets 
The NASs identified for this study were also classified according to the British National 
Formulary categories to enable a comparison of HTA recommendations by therapeutic 
areas.  
 
RESULTS 
Results are presented in three parts:  
PART I- reimbursement recommendations by nine EU jurisdictions for NASs approved 
by EMA 
PART II- a comparison of nine HTA agencies for congruence with respect to 
taxonomic groupings following EMA regulatory approvals 
PART III- a comparison of nine HTA agencies reimbursement recommendation with 
respect to therapeutic area 
 
PART I- Reimbursement recommendations by nine EU jurisdictions 
for NASs approved by EMA 
A total of 102 NASs were approved by the EMA from January 1st 2008 to December 
31st 2012. The online databases for the nine European jurisdictions were  
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subsequently searched for reimbursement recommendations for each of the NASs 
and their approved indication(s). The quantity of information available varied between 
jurisdictions, as the only data obtained was that in the public domain. Published 
reimbursement recommendations were recorded and classified into three categories: 
recommended, recommended with restrictions and not recommended (Table 4.1).  
The INAMI (Belgium) online database reported the reimbursement status of 69% of 
the total 102 NASs approved by the EMA. NASs approved for reimbursement by 
INAMI are categorised into one of three classes: “Class 1” are NASs of added 
therapeutic value; “Class 2” is for NASs with comparable therapeutic value and “Class 
3” is for Generics .(Belgium Health care Knowledge Centre (KCE), 2013) Class 3 has 
been excluded from table 4.1 as only recommendations for NASs have been recorded.  
 
Reimbursement recommendations for NICE (England) were only available for 39% of 
the NASs because NICE only conduct an appraisal for NASs expected to have a 
‘significant impact’ and excludes generics, biosimilars, antibiotics, vaccines and HIV 
drugs (National Institute for Health and Care Excellence (NICE), 2015a).  
 
HAS (France) reviewed the largest proportion of the 102 EMA NASs (91%). NASs 
recommended for reimbursement by HAS include an Improvement in Medical Benefit 
(ASMR) score of I to V.  
 
Recommendations from the G-BA (Germany) early benefit assessment are published 
online as a requirement of the Act on the Reform of the Market for Medicinal 
Products (AMNOG), However, AMNOG only came into effect from January 1st 2011 
so older NASs would not have been reviewed by the AMNOG process. Therefore, the 
G-BA produced the lowest number of recommendations (30%) as G-BA early benefit 
assessment recommendations are only available for products approved by the EMA 
from 2010 onwards. All recommendations issued by the G-BA have been allocated to 
the universal reimbursed category because the G-BA recommendation gives a score 
for the added therapeutic benefit.   
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Table 4.1: Multinomial classification for HTA recommendations 
Jurisdiction 
(Agency) 
Reimbursed 
Reimbursed with 
restrictions 
Not reimbursed 
Total 
recommendations 
for 102 NASs 
approved by EMA 
Belgium (Belgium 
Health Insurance 
Agency (INAMI)) 
Insured (Class 1) 
Orphan drugs Not Reimbursed 69% 
Insured (Class 2) 
England  (National 
Institute for Health 
and Care Excellence 
(NICE)) 
Recommended Optimised Not recommended 39% 
France (French 
National Authority for 
Health (HAS)) 
Approved 
Approved with 
restriction 
Not recommended 91% 
Germany (Federal 
Joint Committee (G-
BA)) 
Indication of a 
considerable 
additional benefit 
N/A N/A 30% 
Hint of considerable 
additional benefit 
Proof of a significant 
additional benefit 
Minor additional 
benefit 
Additional benefit has 
not been proved 
Ireland (National 
Centre for 
Pharmacoeconomics 
(NCPE) 
 
Reimbursement 
Recommended N/A 
Reimbursement not 
recommended 
56% Reimbursement not 
recommended at 
submitted price 
Italy (Italian Medicines 
Agency (AIFA))** 
Reimbursed Class A 
Not available Not available 67% 
 Reimbursed class H 
Netherlands (National 
Health Care Institute 
(ZIN)) 
Insured (Annex 1A) 
Insured with 
restrictions 
Not recommended 75% 
Insured (Annex 1B) 
Expensive drugs 
policy 
Orphan drugs 
Scotland  (Scottish 
Medicines Consortium 
(SMC)) 
Accepted Restricted Not recommended 77% 
Sweden  (Dental and 
Pharmaceutical 
Benefits Agency 
(TLV)) 
General Limitations Not recommended 61% 
The NCPE (Ireland) publishes the recommendations from the initial Rapid Review and 
the Full Pharmacoeconomic Review. No recommendation is recorded when there is 
only a recommendation to conduct a Full Pharmacoeconomic review, but the outcome 
of the Full Pharmacoeconomic Review recommendation is not available.   
New Active Substances are reviewed by AIFA for inclusion in the national formulary 
that consists of three lists: ‘list A’ for products fully reimbursed by the NHS; ‘list H’ for 
products only reimbursed in hospitals and ‘list C’ for products not reimbursed (Italian 
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Medicines Agency (AIFA), 2015). Only lists A and H are published online and neither 
list includes approved indications of criteria for prescribing. Therefore, the negative 
recommendations are unknown and it is unclear whether the recommended drugs are 
reimbursed with any restrictions. Due to the ambiguity of these recommendations, Italy 
has been excluded from the final comparisons. 
Positive recommendations for reimbursement by ZIN (Netherlands) can be 
categorised into two groups: ‘Annex 1a’ for NASs that have a similar therapeutic value 
and are interchangeable and ‘Annex 1b’ for NASs that have added therapeutic value.  
The SMC (Scotland) reviewed the second highest number of EMA approved NASs 
(77%) during the study period. The SMC is the only agency that issued a negative 
recommendation when sponsors of a NAS had failed to submit a dossier for review. 
These recommendations are not a true negative and have been excluded from this 
study. Therefore only the first recommendation issued following a complete 
submission has been recorded.               
The TLV (Sweden) published recommendations for 61% of the EMA approved NASs 
and the online database categorised recommendations under three categories:  
general, limitations and not recommended. 
The HTA recommendations and outcomes for nine European jurisdictions classified 
according to three categories are presented in Figure 4.1. HAS (France) reviewed the 
largest number of NASs (n=93) and also had the largest proportion of positive 
recommendations (n=82). AIFA (Italy) issued the second largest quantity of positive 
recommendations but AIFA is also the only agency that did not publish information for 
indications and restrictions. INAMI (Belgium) issued the third largest number of 
positive recommendations (n=55) and also recommended 15 NASs for reimbursement 
with restriction. ZIN (Netherlands) reviewed more NASs than Belgium but issued a 
larger proportion of negative recommendations (n=16). The outcomes of the NCPE 
(Ireland) assessment did not include a category that could be classified as restricted. 
Therefore there are no NASs allocated a restricted recommendations by the NCPE 
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Figure 4.1: HTA recommendations and listing outcomes for 9 European 
jurisdictions classified according to three categories. 
 
 
The G-BA (Germany) early benefit assessment recommendations are only available 
for 31 of the NASs reviewed by the EMA. The G-BA only issues a recommendation 
for the level of added therapeutic benefit to be used in price negotiations. Therefore, 
there are no recommendations classified as ‘restricted’ or ‘not recommended’. The 
TLV (Sweden) reviewed more than half (n=62) of the NASs approved by the EMA but 
only 10 of the reviewed NASs were not recommended for reimbursement.  The SMC 
(Scotland) issued the largest number of negative reimbursement recommendations 
(n=17) and the fewest positive recommendations (n=34). 
 
The reimbursement pathway for NASs is outlined for all nine European jurisdictions in 
figures 4.2 to 4.10.  
 
Belgium 
Once a NAS has been granted marketing approval by the EMA or the Federal Agency 
for Medicines and Health Products (AFMPS), the sponsor (manufacturer) can apply 
for reimbursement by INAMI (Figure 4.2). The cost-effectiveness and added 
therapeutic value of the NAS is evaluated by the Medicines Reimbursement 
Commission (CTG) and the maximum price is then determined by the Federal Public 
Service Economy (FPSE). Finally, the reimbursement level is decided by the Federal 
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Public Service Social Security (FPSSS). NASs allocated to Class 1 are fully 
reimbursed and can be priced according to the level of added therapeutic value, but 
NASs allocated to Class 2 have a comparable therapeutic value and the maximum 
reimbursement price is set according to the price of other drugs in the same category 
(Belgium Health care Knowledge Centre (KCE), 2013).  
 
Figure 4.2: Process map for Belgium (May 2014)
 
 
England 
The English national HTA agency (NICE) only review NASs that are expected to have 
a ‘significant impact’ and excludes generics, biosimilars, antibiotics, vaccines and HIV 
drugs (National Institute for Health and Care Excellence (NICE). 2015a). NICE 
conducts horizon scanning and receives requests from the Department of Health to 
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identify potential NASs for review. Manufacturers can submit information about their 
upcoming products to be included in NHS horizon scanning via UK PharmaScan 
online. Once a NAS receives a positive recommendation by NICE, it is legally required 
to be made available to all eligible NHS England patients (Figure 4.3). Therefore, 
antibiotics are excluded from NICE appraisals due to regional differences in antibiotic 
resistance. NICE does not review HIV drugs or prepare treatment guidelines for HIV 
because these are prepared by the British HIV Association (BHIVA) and clinicians 
prescribe HIV treatment inline with the BHIVA guidance (British HIV Association 
(BHIVA), 2015). 
Figure 4.3: Process map for England (August 2014) 
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France 
The French national HTA agency (HAS) accepts applications to review NASs granted 
marketing approval by the EMA for reimbursement by the French Social Security 
System (Figure 4.4). The Transparency Committee reviews the medical benefit (SMR) 
and improvement in medical benefit (ASMR) and forwards the recommendation to the 
Economic Committee on Health Care Products (CEPS) to determine price and to the 
National Union of Health Insurance Funds (UNCAM) to decide on the reimbursement 
rate. 
 
Figure 4.4: Process map for France (July 2014) 
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Germany 
When a NAS is granted marketing approval in Germany the sponsor (manufacturer) 
is free to set the initial price (valid for 12 months) but also required to submit a dossier 
to the Federal Joint Committee (G-BA) (Figure 4.5). The added therapeutic benefit of 
the NAS is assessed either by the G-BA or the Institute for Quality and Efficiency in 
Healthcare (IQWIG) on behalf of the G-BA.  
 
Figure 4.5: Process map for Germany (May 2014) 
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reimbursement price. NASs that score one of the four levels of added therapeutic 
benefit will be priced according to the comparators and the level of added therapeutic 
benefit. NASs deemed to have no added therapeutic benefit will be priced inline with 
comparators. The final reimbursement price will be effective after the first year of 
launch (Federal Joint Committee (G-BA), 2015b).  
 
Figure 4.6: Process map for Ireland (May 2014) 
 
Ireland 
The National Centre for Pharmacoeconomics (NCPE) conducts a review of all NASs 
granted marketing approval for sale in Ireland. The sponsor (manufacturer) must 
submit a dossier to the NCPE for a Rapid Review (Figure 4.6). NASs that are ‘high-
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2014). The NCPE recommendation is then sent to the Health Service Executive (HSE) 
to determine the final reimbursement decision. 
 
Italy 
Once a NAS has been granted marketing approval by the EMA or the Italian Medicines 
Agency (AIFA), the sponsor (manufacturer) can apply for the NAS to be included in 
the national pharmaceutical formulary (Figure 4.7). 
 
Figure 4.7: Process map for Italy (May 2014) 
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Reimbursement Committee (CPR) will negotiate the final reimbursement price with the 
manufacturer. However, the level of co-payment is determined at the regional level.  
 
Figure 4.8: Process map for the Netherlands (May 2014) 
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1b’). The NASs allocated to ‘Annex 1b’ are priced in relation to other drugs in the same 
group.  
Scotland 
Sponsors (manufacturers) of NASs granted marketing approval by the EMA or the 
MHRA, are required to submit a dossier to the SMC at the time of launch (Figure 4.9). 
The SMC will review the data submitted by the sponsor to determine the added 
therapeutic benefit and cost-effectiveness of the NAS.  
 
Figure 4.9: Process map for Scotland (May 2014) 
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a PASAG approved patient access scheme the SMC will disseminate details of the 
scheme to the NHS boards (Scottish Medicines Consortium (SMC), 2015a). Positive 
recommendations of the SMC are included in the regional formularies and reimbursed 
by NHS Scotland. 
 
Sweden 
When a NAS has been granted marketing approval in Sweden by the EMA or the 
Medicines Products Agency (MPA) the sponsor (manufacturer) can apply to the 
national HTA agency (TLV) for a decision for reimbursement by the Pharmaceutical 
Benefits Scheme (Figure 4.10).  
Figure 4.10: Process map for Sweden (September 2014) 
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the speed and contextualisation of the recommendation will vary between regions. 
The TLV will not negotiate price, and will therefore base the final reimbursement 
decision on the price submitted by the manufacturer.  
 
PART II- A comparison of nine HTA agencies for congruence with 
respect to taxonomic groupings following EMA regulatory 
approvals 
Each national agency was directly compared with the other eight national agencies to 
determine the percentage of congruent HTA recommendations. A total of 36 unique 
pair combinations and their congruence percentage were evaluated and displayed in 
a cross tabulation format (Table 4.2). The congruence percentages have been 
classified into three grades: high congruence (≥ 75%); medium congruence (≥ 50%) 
and low congruence (<50%). An official consensus for acceptable level of agreement 
using percentage agreement could not be identified, but ranges from 75% or higher 
have been considered acceptable (Graham et al. 20012). The lowest end of this range 
was used to identify high correlation as this enabled two pair wise agreements to be 
considered as ‘high’ agreement compared to the majority of results. Each jurisdiction 
has also been colour coded and grouped according to its allocated System taxonomic 
set (Figure 3.10). 
 
The largest taxonomic set is S1 (Germany, Ireland, France, Netherlands and Belgium) 
that represents a system that has separate agencies or organisations to perform the 
regulatory, HTA and decision-making functions.  The second group is S3 (England, 
Scotland and Sweden) and includes systems that have an independent regulatory 
agency or an agency that performs both the HTA and decision-making functions. 
Jurisdictional pairs grouped in the same taxonomic set have been highlighted by 
yellow boxes to aid comparison (Table 4.2). Out of all the countries compared, there 
were only two pairs that displayed high level congruence (Belgium, France and 
Germany) and both pairs are located within a single taxonomic group and have been 
circled in red (Table 4.2). All pairs within the S1 taxonomic group had a 50% or higher 
agreement for HTA recommendations and therefore scored either high or medium 
congruence with the implication that these classifications could provide a basis for 
collaboration and work sharing.  
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Table 4.2: Congruence of HTA recommendations and listings allocated to three categories and colour-coded by System 
taxonomy 
 
 
Congruence Key 
High 
congruence ≥ 
75% 
Medium 
congruence < 
75% to ≥ 50% 
Low 
congruence 
<50% 
 
 N\A- Not Applicable
Congruent outcomes
by 3 categories (total 
number of products 
reviewed) 
Germany Ireland France Netherlands Belgium England Scotland Sweden
Germany N/A 54% (24) 93% (30) 68% (25) 79% (24) 60% (15) 33% (21) 31% (16)
Ireland N/A N/A 54% (50) 51% (47) 64% (42) 55% (29) 51% (49) 33% (42)
France N/A N/A N/A 71% (72) 68% (68) 58% (38) 26% (74) 46% (57)
Netherlands N/A N/A N/A N/A 60% (57) 60% (35) 44% (63) 52% (54)
Belgium N/A N/A N/A N/A N/A 65% (31) 27% (60) 54% (46)
England N/A N/A N/A N/A N/A N/A 45% (38) 53% (30)
Scotland N/A N/A N/A N/A N/A N/A N/A 50% (56)
Sweden N/A N/A N/A N/A N/A N/A N/A N/A
System taxonomy Key 
S1 S2 S3 S4 S5
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Taxonomic set S3 (England, Scotland and Sweden) did not include any high 
congruence pairs and only included two medium and one low congruence pair.  
Overall, this has demonstrated that there were two pairs with high congruence (≥ 
75%), 18 pairs scored medium congruence (≥ 50%), and 8 pairs scored low 
congruence (<50%).  
 
The same 36 congruence percentage pairs have been arranged in a second cross 
tabulation to compare with the HTA Process taxonomic sets (Table 4.3) (Figure 3.11). 
The nine European jurisdictions have been arranged into three HTA process 
taxonomic sets. The taxonomic group H1 (Scotland, Ireland and Sweden) includes 
HTA agencies that perform the economic evaluations, therapeutic value and appraisal 
together. The second taxonomic group H2 (Germany, Belgium and England) perform 
the therapeutic value and economic value assessment with an independent appraisal 
and taxonomic set H3 (France and Netherlands) includes agencies that perform a 
separate therapeutic value with an independent appraisal. The jurisdictions have also 
been colour-coded by taxonomic group and jurisdictional pairs grouped in the same 
taxonomic set have been highlighted with yellow boxes to aid comparison (Table 4.3). 
 
The jurisdictional pairs for countries in HTA process taxonomic group H2 (Germany, 
England and Belgium) scored one high congruent pair (Belgium and Germany) and 
two medium congruent pairs. Group H1 (Scotland, Ireland and Sweden) scored two 
medium congruent pairs and one low congruent pair (Sweden and Ireland). 
Taxonomic group H3 only included France and Netherlands, with a percentage 
agreement of 71%.   
 
The distribution of high, medium and low congruence pairs does not suggest any 
clustering around HTA process taxonomic groupings. The two high congruence pairs  
have been circled in red but only one appears in a pair allocated to the same taxonomic 
set (Table 4.3). Equally, only five of the 18 pairs displaying medium congruence are 
located in the same taxonomic set: England and Germany; England and Belgium; 
Ireland and Scotland; Sweden and Scotland; France and Netherlands.  
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Table 4.3: Congruence of HTA recommendations and listings allocated to three categories and colour-coded by HTA 
Process taxonomy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Congruence Key 
High 
congruence 
≥ 75% 
Medium 
congruence < 
75% to ≥ 50% 
Low 
congruence 
<50% 
 
      N/A- Not Applicable 
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The first taxonomic group (‘System taxonomy’) is more likely to be useful in practice 
as the HTA recommendations for NAS approved by the EMA demonstrate greater 
correlation with the ‘System taxonomy’ than the HTA process taxonomy.  
 
PART III- A comparison of nine HTA agencies reimbursement 
recommendation with respect to therapeutic area 
 
HTA recommendations by therapeutic area were compared by allocating the 102 
NASs to BNF categories (Table 4.4). The category for malignant disease contains the 
largest group of NASs (n=28) but the second largest category (Cardiovascular system) 
only contained 11 NASs. Only five of the Cardiovascular NASs had been reviewed by 
eight or more agencies and three of the NASs had been reviewed by less than half of 
the nine national agencies in this study. Therefore, only the NASs for malignant 
disease will be compared as the other categories do not contain enough NASs for a 
meaningful comparison.  
 
Table 4.4: NASs classified by British National Formulary categories 
 
BNF Category Total NASs 
1- Gastro-intestinal system 3 
2-Cardiovascular system 11 
3- Respiratory system 7 
4- Central nervous system 7 
5- Infection 10 
6- Endocrine system 9 
7- Obstetrics, gynaecology, and urinary-tract disorders 2 
8- Malignant disease and immunosuppression 28 
9- Nutrition and blood 6 
10- Musculoskeletal and joint diseases 10 
11- Eye 1 
12- Ear, nose, and oropharynx 1 
13- Skin 1 
14- Immunological products and vaccines 0 
15- Anaesthesia 1 
Unclassified 5 
 
 
The HTA recommendations for NASs for malignant disease from nine jurisdictions are 
compared in Figure 4.11. 
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The French national agency (HAS) was the only agency to review all 28 of the NASs 
for malignant disease. The 28 recommendations from HAS included 25 positive and 
three negative decisions. 
 
AIFA (Italy) issued the second largest number of positive recommendations but this 
may not be a true representation as information for restrictions and negative 
recommendations was not publicly available. 
 
INAMI (Belgium) recommended positive reimbursement for 20 NASs for malignant 
disease and of these restricted reimbursement for four NASs.  
 
Figure 4.11: HTA recommendations for NASs for malignant disease 
 
 
The German G-BA reviewed the fewest number of NASs for malignant disease (n=11) 
but the G-BA early benefit assessment recommendations only became a legal 
requirement since 2011 (Figure 4.11). 
 
ZIN (Netherlands) reviewed 20 of the NASs for malignant disease and issued positive 
recommendations for 10 NASs, four were recommended with restrictions and six were 
issued a negative reimbursement recommendation.  
 
0
5
10
15
20
25
30
To
ta
l H
TA
 R
e
co
m
m
e
n
d
at
io
n
s 
Jurisdiction (n= total number of  HTA recommendations 
Total recommended
Total resitrictions
Total not recommended
 98 
 
NICE (England) did not recommend reimbursement for seven of the NASs for 
malignant disease, recommended one drug with restrictions and recommended nine 
drugs for full reimbursement.  
 
The TLV only reviewed 15 of the 28 NASs for malignant disease approved by the 
EMA, of which eight were granted full recommendation for reimbursement, three were 
recommended with restrictions and four were not recommended.  
 
The SMC (Scotland) and NCPE (Ireland) issued the two highest quantities of negative 
recommendations for NASs for malignant disease with 20 and 10 negative 
recommendations respectively (Figure 4.11). A possible explanation for these results 
could be a higher weighting on cost-effectiveness but the implications of these 
decisions are that patients in Scotland and Ireland are denied access to treatments 
approved in other European jurisdictions.  
 
Overall, the percentage congruence of jurisdictional pair recommendations for NASs 
to treat malignant disease (Table 4.5) was much lower compared to the percentage 
agreements for all other therapeutic areas (Tables 4.2 and 4.3). The Belgian (INAMI), 
French (HAS) and German (G-BA) national agencies were the only three to have high 
congruence for their issued recommendations (Table 4.5). These three national 
agencies also issued the greatest number of positive recommendations (excluding 
Italy). This is inline with the previous tables for all therapeutic area congruence pairs 
(Table 4.2 and 4.3) and the highest observed percentage agreement was 100% for 
the 11 NASs reviewed by Germany and France. However, the majority of jurisdictional 
pairings (n=19) had a congruence of less than 50% for recommendations for NASs for 
malignant disease.  The two national agencies with the highest number of negative 
recommendations (Scotland and Ireland) both had 0% agreement with the German 
national agency (G-BA). This is likely to be due to the recommendations from the G-
BA not including an option for no reimbursement. Instead, the G-BA issues a 
recommendation of unproven or minimal added therapeutic benefit to guide price 
negotiations.  
 99 
 
 
 
Table 4.5: Congruence for HTA recommendations by jurisdictional pairs for NASs for malignant disease  
 
BNF 8  Germany England Scotland Ireland France Netherlands Sweden Belgium 
Germany N/A 38% (8) 0% (6) 0% (7) 100% (11) 63% (8) 0% (4) 78% (9) 
England N/A N/A 47% (15) 44% (9) 41% (17) 46% (13) 44% (9) 54% (13) 
Scotland N/A N/A N/A 69% (13) 9% (23) 24% (17) 29% (14) 6% (17) 
Ireland N/A N/A N/A N/A 21% (14) 17% (12) 30% (10) 31% (13) 
France N/A N/A N/A N/A N/A 55% (20) 33% (15) 70% (20) 
Netherlands N/A N/A N/A N/A N/A N/A 42% (12) 56% (16) 
Sweden N/A N/A N/A N/A N/A N/A N/A 50% (12) 
Belgium N/A N/A N/A N/A N/A N/A N/A N/A 
 
 
Congruence Key 
High 
congruence 
≥ 75% 
Medium 
congruence < 
75% to ≥ 50% 
Low 
congruence 
<50% 
 
N/A- Not Applicable 
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DISCUSSION  
Healthcare systems vary greatly between European jurisdictions. However, the 
processes and requirements for approving new medicines for reimbursement 
have been established to meet unique population needs and budget limitations. 
Two taxonomic sets and archetype groups for characterising the diversity of 
processes observed in 33 national European healthcare systems have been 
developed (Chapter 3) and these have been compared with HTA 
recommendations from nine European national agencies that have been 
included based on transparency and language limitations. 
The depth of information published varied between agency websites, as does 
the rationale for the HTA recommendation and this provides some difficulties 
for the comparisons carried out. For example, SMC (Scotland) publishes 
recommendations for the reimbursement and criteria for use of NASs, but the 
G-BA (Germany) publishes a recommendation with a score for the level of 
added therapeutic benefit compared to existing treatment options, which will be 
used to guide pricing. Therefore, the SMC recommendations can be easily 
allocated into all three of the reimbursement recommendation categories used 
in this study: recommended, recommended with restrictions and not 
recommended (Federal Joint Committee (G-BA), 2015a; Scottish Medicines 
Consortium (SMC), 2015b). Conversely, the German G-BA recommendation 
only provides a score for the level of added therapeutic benefit and can only be 
categorised into a single category: ‘recommended’.  Both the G-BA and SMC 
publish recommendations including the indications under review and it is clear 
when the SMC has issued any negative recommendations or recommendations 
with restrictions.  
Despite the difficulties for comparing G-BA recommendations, Germany has 
been included in this study because it is a very important market. Germany has 
the largest pharmaceutical sector in Europe with the highest value and greatest 
number of employees (European Commission. 2013). Additionally, the AMNOG 
law only came into effect from 2011 and has been met with resistance since 
(Research-Based Pharmaceutical Companies, 2012). Therefore, it was of 
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interest to include the G-BA early benefit assessment recommendations in this 
comparative study of European HTA recommendations and processes.  
 
HTA recommendations were compared with the two taxonomic sets rather than 
the archetype groups as the archetype groups were developed from the 
confluence of the two taxonomies. Therefore, if HTA recommendations were 
congruent with both the taxonomic sets, this should also be evident in the 
archetype groupings. It would not be possible to have a range of jurisdictional 
pairs for the majority of the ten archetype groups as HTA recommendations 
were only collected for nine European jurisdictions. The HTA process archetype 
contains jurisdictional pairs for all three HTA performing taxonomic sets. 
However, the ‘System taxonomy’ does not contain pairs for two of the four 
taxonomic sets: S2 and S4. The S2 taxonomic set is unusual as only two 
agencies were allocated to this set for the full European study. The S4 
taxonomic group included more jurisdictions in the full study (Chapter 3) than 
the S2 set but is only represented by Italy in this study. 
The congruence between HTA recommendations and taxonomic sets was 
calculated by percentage agreement for all 36 possible combinations of 
jurisdictional pairs. The percentage agreement results support the first 
hypothesis that there is a correlation between HTA recommendations and 
System taxonomic sets. This could imply that there is a relationship between 
the regulatory, HTA and decision-making functions in the healthcare system 
and the final HTA recommendations. A relationship between the process and 
HTA recommendations could support the conclusions of chapter three that 
suggests identifying working groups based on process could be useful for a 
progressive alignment approach. However, the lack of correlation between the 
‘HTA process taxonomy’ and HTA recommendations does imply that further 
research is required to refine the archetypes for real life application.  
The second hypothesis, that there are correlations between HTA 
recommendations and HTA process taxonomic sets is not supported by the 
results of this study. It is more difficult to allocate agencies to HTA process 
taxonomic sets because it is not always clear how independent the clinical 
evaluation will be from the economic evaluation.  For example, HAS (France) 
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now requires a submission of an economic dossier in parallel with the clinical 
submission but only for NASs that have a high rating for improvement in 
medical benefit (ASMR I, II or III) and a estimated annual cost of more than €20 
million  (Rumeau-Pichon et al., 2014). Therefore, the HAS evaluation could be 
allocated to a different HTA process taxonomic set depending on the NAS 
evaluated.  
One hundred and two NASs were allocated to therapeutic areas using the BNF 
categories. However, only the category for NASs for malignant disease 
contained a large enough group for comparison (n=28). Only one of the 28 
NASs was reviewed by all nine jurisdictions. Vemurafenib, was granted 
marketing approval by the EMA in 2012 as ‘monotherapy for the treatment of 
adult patients with BRAF-V600-mutation-positive unresectable or metastatic 
melanoma.’ (European Medicines Agency (EMA), 2014). Six jurisidictions 
approved vemurafenib for reimbursement (Belgium, England, Germany, 
France, Italy and Netherlands) but three jurisdictions did not recommend 
vemurafenib due to cost (Ireland, Scotland and Sweden). Five NASs were 
reviewed by eight of the nine jurisdications: ipilimumab, fingolimod 
hydrochloride, gefitinib, abiraterone acetate and cabazitaxel. Notably, all five of 
these NASs were not recommended for reimbursement by the NCPE (Ireland) 
or the SMC (Scotland).  
The G-BA early benefit assessment does not issue negative reimbursement 
recommendations but it does classify NASs according to the added therapeutic 
benefit. Two NASs for malignant disease (pixantrone dimaleate and 
vandetanib) were allocated to the G-BA’s lowest classification group for NASs 
that have not proven any therapeutic benefit. Pixantrone dimaleate was also 
reviewed by HAS (France) and NICE (England). HAS also assigned pixantrone 
dimaleate to the lowest classification for added therapeutic value (V-absence) 
but has approved pixantrone dimaleate for as third or fourth-line treatment for 
multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 
NICE granted optimised reimbursement status for pixantrone dimaleate as a 
third or fourth-line treatment at the discounted price agreed with the 
manufacturer for the patient access scheme. Vandetanib was classified as no 
proven benefit as the G-BA did not receive full documentation for review. 
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Belgium, France, Italy and Netherlands approved vandetanib for 
reimbursement but HAS (France) only found a minor therapeutic benefit and 
Netherlands recommended vandetanib for reimbursement with only a 
comparative therapeutic benefit (‘Annex 1a’).  
Overall, the comparison of the 28 NASs for malignant disease revealed a larger 
proportion of low congruent percentage agreements (n=19) compared to the 
comparison of 102 NASs for all therapeutic areas (n=8). Both comparisons 
produced only two jurisdictional pairs with a high congruence percentage. 
Therefore, the larger quantity of jurisdictional pairs with a medium congruence 
agreement for the comparison with all therapeutic areas would suggest that 
NASs in therapeutic areas other than malignant disease could have much 
greater agreement for HTA recommendations and should be investigated 
further.  
 
Overall, the comparison of HTA recommendations for EMA approved NASs 
with the two taxonomic groups has provided value by identifying a correlation 
between the organisation of the healthcare reimbursement system (‘System 
taxonomy’) and HTA recommendations. The case study comparison of 28 EMA 
approved NAS for malignant disease between nine European jurisdictions also 
provides value by demonstrating potential variation between HTA 
recommendations and therapeutic area.     
 
SUMMARY 
 HTA recommendations for nine national agencies were obtained from 
the public domain for 102 NASs approved by the EMA from January 1st 
2008 to December 31st 2012.  
 
 HTA recommendations were included from nine national agencies: The 
Belgium Health Insurance Agency (INAMI); National Centre for Health 
and Care Excellence (NICE) in England; French National Authority for 
Health (HAS); Federal Joint Committee (G-BA) in Germany; National 
Centre for Pharmacoeconomics (NCPE) in Ireland; Italian Medicines 
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Agency (AIFA); Dutch National Health Care Institute (ZIN); Scottish 
Medicines Agency (SMC) and The Dental and Pharmaceutical Benefits 
Agency (TLV) in Sweden. 
 
 Potential congruence between the ‘System taxonomy’ and HTA 
recommendations was identified. A relationship between system 
organisation and HTA recommendations supported the conclusion 
(Chapter 3) that suggest identifying working groups based on system 
organisation.  
 
 Agreement between the ‘HTA process taxonomy’ and HTA 
recommendations was not identified. This does imply that further 
research is required to refine ‘HTA process taxonomy’ and this would 
subsequently influence the archetype groups derived from the 
confluence of the two taxonomies.   
 
 
 HTA recommendations for malignant disease demonstrated a larger 
number of jurisdictional pairs with low congruence compared to the 
comparisons that included NASs from all therapeutic areas. Further 
research should evaluate more therapeutic areas to identify whether 
certain therapeutic areas impact HTA recommendations. 
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CHAPTER 5 
 
 
 
 
 
 
A Comparison of HTA Processes 
and Reimbursement 
Recommendations in Australia, 
Canada and the UK 
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INTRODUCTION 
An estimated $103 billion was lost in global pharmaceutical sales following 
patent expiry during the period of 2009 to 2012 (Deloitte, 2012), with the result 
that generics rapidly replaced multiple top blockbuster branded medicines 
(Jimenez, 2012; Thakur and Ramacha, 2012). Competition from generics is 
increasing, and the global generics market is predicted to reach over $400 
billion by 2016 (IMS Institute for Healthcare Informatics, 2012; Vernaz et al., 
2013). The growing availability of less expensive generics plus the rising costs 
for new medicines and limited healthcare budgets increases the need for the 
rationalised allocation of public resources (Pammolli et al., 2011; Stuckler et al., 
2010). As a result, most public health providers require manufacturers to 
demonstrate the benefits of their new drug technology over existing treatments 
prior to reimbursement approval. The evaluations of treatments to guide health 
policy and reimbursement decisions is usually performed by Health Technology 
Assessment (HTA) agencies. HTA can minimise patient access inequalities, 
support evidence-based medicine and promote the efficient use of resources 
(European Network for Health Technology Assessment (EUnetHTA), 2008). 
However, HTA can require additional time following post-marketing 
authorisation and may deny reimbursement for licensed treatments that fail to 
display sufficient added benefit or that are deemed too costly. Thus, HTA is 
often cited as the fourth hurdle to patients’ access to medicines (Jackson, 2007; 
Packer et al., 2006; Hutton et al., 2006). Generally, HTA will evaluate the 
therapeutic value and cost effectiveness of a health technology. However, the 
scope and methodologies utilised to conduct HTA can vary greatly between 
agencies, as affordability, and social and political factors are unique to each 
coverage population (Allen et al., 2013). 
Reimbursement recommendations from HTA have to meet a variety of 
stakeholder needs: manufacturers require their product to be reimbursed to 
cover the costs of research and development and fund future research for 
innovative treatments; healthcare providers and payers seek to maximise 
utilisation of limited resources to provide the best possible healthcare for the 
population; patients and physicians need access to the most efficacious and 
innovative treatments.  
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The methodologies informing the final HTA recommendation  
vary between agencies. For example, to determine the value of a new 
pharmaceutical product, France and Germany consider an added therapeutic 
value assessment (Drummond et al., 2014). Alternatively, Australia, Canada, 
England and Scotland consider the value of a new pharmaceutical product in 
terms of health gains expressed in Quality-Adjusted Life-Years (QALY) 
(Cleemput et al., 2011; Drummond et al., 2014). An Incremental Cost-
effectiveness Ratio (ICER) can also be calculated to determine the additional 
cost per QALY and agencies may have an implicit (e.g., Canada and Australia) 
or explicit (e.g., England and Scotland) ICER thresholds for determining 
reasonable cost-effectiveness (Cleemput et al., 2011).   
 
This study focuses on the HTA environment in Australia, Canada, England and 
Scotland as these 4 nations have an entwined history and are often classified 
as sharing a common liberal/ basic security welfare state ideology (Eikemo and 
Bambra, 2008; Arts and Gelissen, 2002). The classification of the welfare state 
can help explain why these jurisdictions all provide a basic universal healthcare 
coverage that is funded through taxation and often means tested.  
 
OBJECTIVES 
 Evaluate the national regulatory, HTA and reimbursement pathways for 
public healthcare in Australia, Canada, England and Scotland 
 Compare initial Canadian national HTA recommendations from January 
2009 to May 2013 with the initial HTA decisions by Australian, English 
and Scottish HTA agencies   
 Identify factors for differing national HTA recommendations between 
Australian, Canadian, English and Scottish HTA agencies 
 
METHODOLOGY  
Information from the public domain was evaluated to identify the key agencies 
involved in the national regulatory, HTA and reimbursement process for 
Australia, Canada, England and Scotland. This information enables the 
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development of a process map for each jurisdiction using a previously 
developed mapping methodology (Allen et al., 2010a). The process maps 
display the regulatory, HTA and reimbursement pathways through a uniform 
methodology for visual comparison. These maps enable the identification and 
relationships between the agencies conducting HTA and the body responsible 
for the final reimbursement decision. 
 
The reimbursement outcomes for Australia, Canada, England and Scotland 
have also been chosen for comparison due to several common factors: 
recommendations and rationale are publicly available online, regularly updated, 
published in English and are transparent (Neumann et al., 2010). Data for the 
reimbursement recommendations, although not the final coverage decision, 
were identified for the responsible agency. The Canadian Agency for Drugs and 
Technologies in Health (CADTH) Common Drug Review (CDR) programme 
was selected as the primary agency for this study as the intention is to compare 
the national non-mandatory recommendations with Canadian provincial payer 
listing decisions (chapter 6). For this study, the list of drug products that meet 
the following inclusion criteria were identified, namely: initial submission to the 
CDR with a listing recommendation issued from January 2009 to May 2013. 
New indication submissions were also included if the initial submission meets 
the inclusion criteria. The proprietary name, generic name, indication and 
recommendation were recorded from the online CDR database (Canadian 
Agency for Drugs and Technologies in Health (CADTH), 2015b). 
 
The published HTA agency recommendations for the Pharmaceutical Benefits 
Advisory Committee (PBAC) of the Pharmaceutical Benefits Scheme (PBS), 
(2015) (Australia), the National Institute for Health and Care Excellence (NICE), 
(2015b) (England) and the Scottish Medicines Consortium (SMC), (2015b) 
(Scotland) were also obtained for the medicine-indication pairs recorded from 
the CDR database. The HTA recommendations for Australia, England and 
Scotland were identified by generic name and indication and included 
medicines if marketed under a different brand name for the Australian or 
European market provided they were listed for the same indications as the initial 
CDR recommendation. Where an agency has reviewed indications separately 
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or issued different recommendations per indication within a single review, this 
was recorded as a medicine-indication pair for all four agencies.   
 
The data for HTA recommendations included a range of different outcomes that 
were specific for each jurisdiction. All potential outcomes were reviewed to 
enable a cross comparison of the recommendations according to multinomial 
categories (recommended, recommended with restrictions or not 
recommended). The proportion of medicines allocated to each category was 
identified for each jurisdiction. Using these multinomial categories, the 
recommendations for each medicine were then compared with the drug product 
listing from each of the other three jurisdictions and coded accordingly.  
 
The rationale for the HTA recommendations for the medicine case studies were 
collected from the four HTA agency websites (Canadian Agency for Drugs and 
Technologies in Health (CADTH), 2015b; Pharmaceutical Benefits Scheme 
(PBS), 2015; National Institute for Health and Care Excellence (NICE), 2015b; 
Scottish Medicines Consortium (SMC), 2015b). The dates for regulatory 
approval were also identified from the Australian, Canadian and European 
regulatory authorities’ online databases (Therapeutic Goods Administration 
(TGA), 2015; Health Canada, 2015; European Medicines Agency (EMA), 
2015a). 
 
RESULTS 
For the purpose of clarity the results will be presented in four parts 
PART I- a review of HTA agencies and their characteristics and role in the 
healthcare systems for Australia, Canada, England and Scotland 
PART II- identification of HTA recommendations for new medicines-indication 
combinations for Australia, Canada England and Scotland  
PART III- an evaluation of the factors influencing concordant HTA 
recommendations for Australia, Canada, England and Scotland 
PART IV- an evaluation of factors influencing discordant HTA 
recommendations for Australia, Canada, England and Scotland 
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PART I- a review of HTA agencies and their characteristics and 
role in the healthcare systems for Australia, Canada, England 
and Scotland 
Characteristics of the healthcare system and HTA agencies of the four chosen 
countries were recorded for comparison (Table 5.1). Australia, Canada, 
England and Scotland all provide universal healthcare funded by taxation and 
share a long history of HTA. The first HTA organisations were established in 
the eighties in Australia and Canada followed by the UK in 1996. Currently all 
four countries have a national HTA agency and they all consider clinical 
effectiveness and cost effectiveness to guide reimbursement 
recommendations, but their activities vary due to different mandates and their 
unique political, social and population needs. For example, NICE does not 
routinely evaluate every medicine for reimbursement by NHS England and 
Wales. Only medicines that are expected to meet an unmet need or a high cost 
are considered for a NICE evaluation and some medications are exempt 
(antibiotics and HIV therapies). However, the SMC conducts a review of all new 
medicines, formulations and indications to provide a reimbursement 
recommendation to NHS Scotland. The PBAC also reviews all new medicines 
to be reimbursed by the PBS. No medicines can be accepted for reimbursement 
by the PBS without a positive recommendation from the PBAC.  
    
The CDR also reviews all new medicines (excluding oncology products) to 
provide a listing recommendation to guide the final listing decisions of the 
participating drug plans.  Stakeholder involvement also varies between the four 
HTA agencies. For example, NICE is currently the only HTA agency that offers 
scientific advice, but the CDR has recently started to accept applications for its 
new scientific advice programme.  
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Table 5.1: Comparison of Canadian, Australian, English and Scottish Healthcare Coverage 
Data Sources: *Organisation for Economic Co-operation and Development (OECD), (2014b), **Office for National Statistics (2013), ***Menon and Stafinski 
(2009), + Office of Technology Assessment (1995), ++ Drummond and Sorenson (2009), +++ historical conversion rate from January 1st 2015  (XE, 2015)
Characteristics 
Jurisdictions 
Canada  Australia England Scotland 
Population 2012 34,880,500*  22,684,000* 53,500,000 5,300,000 
Year of first HTA 
organisation 
1988 (Conseil d’Evaluation des 
Technologies de la Santé du 
Québec (CETS))***  
1982 (The National Health 
Technology 
Advisory Panel (NHTAP))+ 
1996 (National Coordinating Centre for Health Technology 
Assessment (NCCHTA)) ++ 
Current HTA agency 
Canadian Agency for Drugs and 
Technologies in Health (CADTH) 
Common Drug Review (CDR) 
Pharmaceutical Benefits 
Advisory Committee (PBAC) of 
the Pharmaceutical Benefits 
Scheme (PBS)   
National Institute for Care 
and Health Excellence 
(NICE) 
Scottish Medicines 
Consortium (SMC) 
Products reviewed 
The CDR process assesses out 
patient pharmaceuticals 
excluding all oncology products 
as these are reviewed by the 
pan-Canadian Oncology Drug 
Review   
The PBAC provides a listing 
recommendation for 
reimbursement of outpatient 
pharmaceuticals by the PBS 
NICE only assesses 
pharmaceuticals that are 
expected to have a high 
impact or address an unmet 
need. Nice does not review 
antibiotics or HIV medication 
SMC assesses all new 
outpatient and inpatient 
pharmaceuticals 
Scientific Advice 
(SA) programme 
Not currently: in 2014 CADTH 
announced plans for a SA 
programme and is accepting 
applications from January 2015 
Yes: Manufacturers can submit 
a request for advice from the 
Pharmaceutical Evaluation 
Branch (PEB) 
Yes: SA is offered 
independently and NICE 
also offers parallel SA with 
the Medicines and 
Healthcare Products 
Regulatory Agency (MHRA) 
and the European Medicines 
Agency (EMA) 
 
No 
Cost per QALY 
Threshold (USD+++) 
CAD $20,000 to $100,000  (USD 
$17,214 to $86,072 
AUD $69,900 (USD $57,095)   
GBP £20,000 to £30,000 
(USD $ 31,156 to £46,735) 
GBP £20,000 to £30,000  
(USD $ 31,156 to £46,735)  
Implicit or explicit 
QALY threshold 
Implicit Implicit Explicit Explicit 
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Table 5.1 (continued): Comparison of Canadian, Australian, English and Scottish Healthcare Coverage 
Characteristics 
Jurisdictions 
Canada   Australia England Scotland 
Impact of 
recommendations 
Recommendations are sent to 
the decision-maker of 18 
participating public drug plans to 
guide listing decisions in the 
local context  
Recommendations are sent to 
the government to determine 
the final listing decision for 
inclusion in the PBS. 
Pharmaceuticals cannot be 
included in the PBS without a 
PBAC recommendation 
Pharmaceuticals 
recommended by NICE 
should be available within 3-
months to eligible patients  
Scottish NHS Boards 
should ensure that 
pharmaceuticals 
recommended by the 
SMC are available 
Transparency  
Submission progress report and 
rationale for final 
recommendation published on 
CADTH website  
Public summary documents 
published online include 
recommendations and 
rationale 
A summary of the NICE 
appraisal committee 
conclusions published online 
Summary of SMC 
recommendations 
published online 
Formal patient input  
The CDR sends a formal 
request to patient input groups 
and allows 15 working days for 
response  
The agenda for PBAC 
meetings are published 6 
weeks in advance. Patients 
and citizens can submit 
comments online 
Patient access scheme 
expert panel includes two 
patients/ lay persons 
Bimonthly Public and 
Patient Involvement 
Group (PAPIG) meetings 
Universal healthcare 
coverage 
A government-funded national 
healthcare system for 
permanent residents. Each 
province and territory is 
responsible for its own 
healthcare plan and provides 
cover for all necessary medical 
services. Coverage for 
prescription drugs is highly 
subsidised and varies by region.     
Medicare provides free 
hospital treatment and highly 
subsidised prescription 
medicines through the PBS for 
all Australian permanent 
residents 
The National Health Service 
(NHS) provides free 
healthcare for permanent 
residents of the UK and EU 
nationals. NHS prescriptions 
incur a highly subsidised flat-
rate charge in England, but 
about 90% of prescriptions 
are dispensed for free due to 
various exemption criteria.  
 
The National Health 
Service provides free 
healthcare for permanent 
residents of the UK and 
EU nationals. All NHS 
prescriptions in Scotland 
and dispensed free of 
charge. 
Funding source  Taxation Taxation Taxation 
Total health expenditure 
as percentage of GDP 
2012 (World Bank, 2015) 
10.9% GDP 9.1% GDP 9.4% GDP 
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All four HTA agencies have a system to formally include patient input to guide 
their HTA recommendations. These systems vary from accepting online 
comments from patients and citizens (PBAC), sending a formal request to 
patient input groups for comments (CDR), including patients and lay persons at 
meetings (NICE) and hosting bimonthly Public and Patient Involvement Group 
(PAPIG) meetings (SMC). Process maps were produced to show the 
regulatory, HTA and reimbursement pathways for: Canada (CDR), Australia 
(PBAC), England (NICE) and Scotland (SMC) (Table 5.1) (Figures 5.1 – 5.4).  
 
Common Drug Review (CDR) 
The CDR is the centralised Canadian HTA agency recognized by all federal, 
provincial and territorial public drug plans except that of Quebec.  
Figure 5.1: Process map for the Canadian Common Drug Review (March 
2014) 
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The Canadian Agency for Drugs and Technologies in Health (CADTH) 
established the CDR to standardise the Canadian HTA environment, reduce 
the duplication of HTA and ultimately to decrease the time taken for patients to 
access new and innovative medicines (Spitz, 2013). For a new medicine or 
indication to be eligible for review the following steps are required (Figure 5.1): 
Step 1: The manufacturer (sponsor) must first apply for marketing approval 
from Health Canada. Medicines approved by Health Canada (or expecting 
approval within 90 days) can be submitted to CADTH for review by the CDR. 
Step 2: Once a submission is received, the CDR notifies patient advocacy 
groups of the upcoming review and provides for patient input. The CDR 
evaluates the therapeutic benefit and cost-effectiveness of the submitted 
medicine and prepares a report to send to the Canadian Drug Experts 
Committee (CDEC) with any received patient input. The CDEC is an 
independent advisory committee that reviews the CDR reports and determines 
a listing decision for participating provincial, territorial and federal plans.  
Step 3: The CDR sends the CDEC recommendation to the manufacturer for 
comments prior to notifying the participating drug plans of the final listing 
recommendation.  
Step 4: Manufacturers are required to submit prices to the Patented Medicines 
Price Review Board (PMPRB) from introduction to the Canadian market and 
then twice a year until patent expiry.  
 
Pharmaceutical Benefits Scheme (PBS) 
The PBS provides subsidised prescription drugs for all Australian citizens. For 
a new drug to be eligible for inclusion in the PBS schedule the following steps 
a required: 
Step 1: The manufacturer (Sponsor) must first apply for the new medicine to 
be registered in the Australian Register of Therapeutic Goods (Figure 5.2).  
Step 2: The manufacturer can then submit an application for review by the 
Pharmaceutical Benefits Advisory Committee (PBAC). The Drug Utilisation 
Sub-Committee (DUSC) estimates usage and expected costs of the new 
medicine and the Economics Sub-Committee reviews the pharmacoeconomic 
data in the manufacturer’s submission to advise the PBAC.    
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Step 3: The PBAC provides written advice to the manufacturer following the 
PBAC decision and provides an opportunity for the manufacturer to comment 
on the Public Summary Document (PSD) prior to publication. 
Step 4: The PBAC provides a listing recommendation for the Minister of Health 
who is responsible for the final listing decision following consultation with the 
manufacturer (Sponsor) and the PBAC. The Minister of Health can only 
approve medicines if they have first received a listing recommendation from the 
PBAC, but any medicine with an expected annual cost greater than AUD$10 
million must be determined at Cabinet level.  
 
Figure 5.2: Process map for Australia (December 2014) 
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The Scottish Medicines Consortium (SMC) 
The SMC was established to review all new medicines for sale in Scotland to 
provide a recommendation for reimbursement by NHS Scotland. The following 
steps are required for a new medicine to be considered for reimbursement 
(Figure 5.3): 
Step 1a or 1b: The manufacturer (sponsor) can apply for marketing 
authorisation for new medicines to be sold in Scotland from either the European 
Medicines Agency (EMA) (Step 1a) or the Medicines and Healthcare Products 
Regulatory Agency (MHRA) (Step 1b).  
 
Figure 5.3: Process map for Scotland (May 2014)
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Step 2a: The manufacturer (Sponsor) must provide a submission to the SMC 
for review otherwise the SMC will be unable to review the medicine and a 
negative non-submission status will be assigned until a full submission is 
received. Submissions to the SMC will first be reviewed by the New Drug 
Committee who will prepare a draft for manufacturer comments prior to 
submission to the SMC for the final decision.  
Step 2b: The manufacturer may also submit an application for a patient access 
scheme to the Patient Access Scheme Assessment Group (PASAG) for review. 
A Public and Patient Involvement Group (PAPIG) also meets bimonthly to 
promote the patient/carer view and to present a summary of patient advocacy 
group submissions prior to SMC meetings (Scottish medicines Consortium, 
2013a). Once the SMC has determined a final reimbursement 
recommendation, the Scottish National Health Service (NHS) Regional Health 
Boards (RHB) and Area Drug and Therapeutic Committees (ADTCs) are 
notified of the recommendation and prescribing advice. (Scottish Medicines 
Consortium, 2013b). 
Step 3: The Pharmaceutical Price Regulation Scheme (PPRS) regulates 
pharmaceutical prices indirectly by controlling the profit of member 
pharmaceutical companies. The PPRS is a voluntary scheme that is generally 
renewed every five years and the current PPRS scheme started January 2014.  
 
National Institute for Health and Care Excellence (NICE) 
Unlike the public healthcare systems in Canada, Australia and Scotland, not all 
new medicines are required to be reviewed for reimbursement in England. The 
national HTA agency in England is NICE which conducts a Single Technology 
Appraisal (STA) for medical products that are formally requested by the 
Secretary of State for Health. Each request is considered against a list of 
elimination criteria to ensure technology appraisals are not conducted if NICE 
has already published guidance or considered a similar or identical product for 
review (National Institute for Health and Care Excellence, 2013). The following 
steps are required for new medicines to be reviewed by NICE (Figure 5.4): 
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Figure 5.4: Process map for England
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clinical and cost effectiveness of the medicine and sends the report to the 
manufacturers to confirm accuracy. 
Step 4: The ERG sends the final report to the NICE appraisal Committee for 
the Final Appraisal Determination (FAD). The NHS in England and Wales is 
required to provide funding for drug products recommended by NICE within 
three months of a positive recommendation. SMC guidance is also 
recommended for use by NHS England and Wales when a NICE appraisal has 
not been conducted. 
Step 5: Manufacturers are invited to participate in a voluntary government 
scheme to regulate prices for the NHS.   
 
PART II- identification of HTA recommendations for new 
medicine-indication combinations for Australia, Canada 
England and Scotland 
 
Eighty-nine initial submissions were identified for medicine-indication pairs that 
met the inclusion criteria for an initial submission to the CDR that issued a listing 
recommendation from January 2009 to May 2013. New indication submissions 
were also included if the initial submission met the inclusion criteria. Sixteen 
different HTA recommendation outcomes were recorded from across the four 
HTA agencies (Table 5.2). These HTA recommendations have been classified 
into three multinomial categories for comparison (recommended, 
recommended with restrictions and not recommended). Five of the sixteen 
different HTA recommendations types were identified from the CDR 
recommendations. The ‘list’ and ‘list in a similar manner’ were categorised 
according to the universal ‘recommended’ category. 
 
The ‘list in a similar manner’ recommendation advises participating drug plans 
to list the product in the same manner as other drugs in its class. The ‘list with 
criteria/condition’ recommendation includes CDR recommended restrictions 
and is therefore allocated to the multinomial ‘recommend with restrictions’ 
category. The CDR issues two distinct negative recommendation categories 
‘Do not list’ and ‘Do not list at the submitted price’. The latter was introduced by 
the CDR to indicate, to participating drug plans, where a negotiated price could 
have produced a positive recommendation.  
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Table 5.2: Comparison of HTA recommendations options for Canada 
Australia, England and Scotland 
 
 HTA 
Agency 
Binomial classification: 
Positive recommendation 
Negative 
recommendation 
Multinomial classification: 
Recommended 
Recommended with 
restrictions Not Recommended 
CDR 
(Canada) list 
list with 
criteria/condition do not list 
  list in a similar manner   
do not list at the 
submitted price 
PBAC 
(Australia) unrestricted benefit restricted benefit rejected 
    
authority required 
(streamlined)   
    authority required   
NICE 
(England) recommended optimised  not recommended  
SMC 
(Scotland)  accepted  restricted use  not recommended 
 
Five different recommendations were identified from the PBAC published 
summary documents. The ‘unrestricted benefit’ recommendation was allocated 
to the universal recommended category and the ‘rejected’ recommendation 
was included in the universal ‘Not recommended’ category. The ‘authority 
required’ and ‘authority required (streamlined)’ ‘authority required (streamlined) 
recommendations were both allocated to the universal recommended with 
restrictions category as these both include barriers to access. The ‘authority 
required’ recommendation requires written or telephone approval from 
Department of Human Services (DHS) or the Department of Veterans’ Affairs 
(DVA) prior to prescribing (Pharmaceutical Benefits Scheme (PBS), 2014). The 
‘authority required (streamlined)’ recommendation is less restrictive as 
physicians are only required to include a streamlined authority code on the 
prescription. However, any prescriptions for quantity or repeats greater than 
approved PBS listing will be treated as an ‘authority required’ item and will need 
written or telephone approval from the DHS or DVA.  
 
NICE and the SMC both issued reimbursement recommendations under three 
main categories. NICE recommendations are categorised as either 
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‘recommended’, ‘optimised’ or ‘not recommended’ and these were allocated to 
the universal recommended, recommended with restrictions and not 
recommended categories respectively. NICE ‘optimised’ recommendations 
include criteria to restrict reimbursement. Similarly, the three different SMC 
recommendations were ‘accepted’, ‘restricted use’ and ‘not recommended’ and 
these three recommendation types were allocated to the universal 
recommended, recommended with restrictions and not recommended 
categories respectively. Binomial categories for comparison were created by 
combining the recommended and recommended with restrictions categories to 
produce a group for positive recommendations to enable comparisons between 
positive or negative listings (Table 5.2). The not recommended category for the 
multinomial classification has been relabeled negative recommendations to 
distinguish between the two classification systems. 
 
All of the 89 medicine-indication pairs were reviewed by the CDR because the 
CDR recommendations were the initial source for identifying drug products for 
inclusion in this comparative study. The SMC reviewed the largest proportion 
of the CDR drug product and indication combinations (n=71), followed by 
Australia (n=61) and England (n=29) (Figure 5.5). 
 
Figure 5.5: Medicine-indication pairs HTA recommendations for Canada, 
Australia, England and Scotland 
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The proportion of recommendation types issued by each HTA agency for the 
89 medicine-indication pairs was calculated for the multinomial category and 
binomial category classifications (Table 5.3 - 5.4). The multinomial categories 
enables inclusion of the restricted criteria, but restrictions can vary by each drug 
and agency remit and this variation is difficult to capture with a single restriction 
category. Therefore, the binomial categories are also included to compare 
recommendations as either positive or negative.  The 95% confidence interval 
was also calculated for each recommendation type using the Wilson score 
method (Brown et al., 2001). 
Table 5.3: Proportion of Medicine-indication pairs by multinomial 
categories of recommendations 
 
Agency 
Recommended  
(95% CI) 
Recommended 
with restriction 
(95% CI) 
Not recommended 
(95% CI) 
CADTH CDR 
(Canada) n= 89 
19.1%  
(12.3%; 28.5%) 
28.1%  
(19.8%; 38.2%) 
52.8%  
(42.5%; 62.8%)  
PBS PBAC 
(Australia) n=61 
3.3%  
(0.9%; 11.2%)  
59%  
(46.5%; 70.5%)  
37.7%  
(26.6%; 50.3%) 
NICE (England) 
n=29 
65.5%  
(47.3%; 80.1%)  
27.6%  
(14.7%; 45.7%)  
6.9%  
(1.9%; 22%)  
SMC  
(Scotland) n= 71 
33.8%  
(23.9%; 45.4%)   
40.8%  
(30.2%; 52.5%)  
25.4%  
(16.7%; 36.6%) 
 
Table 5.4: Proportion of Medicine-indication pairs by binomial 
categories of recommendations 
 
Agency 
Positive 
recommendation 
(95% CI) 
Negative 
recommendation 
(95% CI) 
CADTH CDR 
(Canada) n= 89 
47.2%  
(37.2%; 57.5%) 
52.8%  
(42.5%; 62.8%)  
PBS PBAC 
(Australia) n=61 
 62.3%  
(49.7%; 73.4%) 
37.7%  
(26.6%; 50.3%)  
NICE (England) 
n=29 
93.1%  
(78%; 98.1%) 
6.9%  
(1.9%; 22%) 
SMC  
(Scotland) n= 71 
74.6%  
(63.4%; 83.3%) 
25.4%  
(16.7%; 36.6%)  
 
The PBAC issued the greatest number of ‘recommendations with restrictions’ 
(59%) however, when calculated using the binomial category classification, 
which combines the ‘recommended’ and ‘recommended with restrictions’ 
groups, the PBAC issued the third most positive recommendations (62.3%) 
followed by the CDR (47.2%). NICE issued the greatest proportion of positive 
recommendations (93.1%), but also issued the lowest number of total 
 123 
 
recommendations (n=29) as NICE does not review all new medicines and 
indications. The SMC issued the second highest proportion of positive 
recommendations (74.6%) and also reviewed the second largest number of 
medicine-indication pairs (n=71).  
 
The three HTA recommendation classification categories (recommended, 
recommended with restriction and not recommended) were coded for direct 
comparison between each of the four HTA agencies. The percentage 
agreement was calculated for each agency pair and all scored lower than 50% 
(Table 5.5). The percentage agreement was also calculated for the binomial 
category classification and all agency pairs scored greater than 50%, but none 
higher than 80% (Table 5.6). Greater concordance in expected for the binomial 
classification as there are fewer categories for comparison. However, the 
percentage agreement for the binomial categories still suggests a sizeable 
proportion of discordant recommendations have been issued.   
 
Table 5.5: Percentage agreement of national HTA recommendations in 
Australia, Canada, England and Scotland (multinomial category 
classification) 
Percentage 
agreement CADTH CDR PBS PBAC NICE SMC 
CADTH CDR  N/A 49% 24% 38% 
PBS PBAC N/A N/A 21% 32% 
NICE N/A N/A N/A 45% 
SMC N/A N/A N/A N/A 
N/A = Not Applicable 
 
Table 5.6: Percentage agreement of national HTA recommendations for 
medicine–indication combinations in Australia, Canada, England and 
Scotland (binomial category classification) 
Percentage 
agreement 
(n= total 
reviewed) CDR PBAC NICE SMC 
CDR  N/A 67% (n=61) 55% (n=29) 61% (n=71)  
PBAC N/A N/A 63% (n=24) 62% (n=53) 
NICE N/A N/A N/A 72% (n=29) 
SMC N/A N/A N/A N/A 
N/A = Not Applicable 
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Table 5.7: Kappa agreement of national HTA recommendations for 
medicine–indication combinations in Australia, Canada, England and 
Scotland (binomial category classification) 
 
Kappa 
agreement 
(n= total 
reviewed) CDR PBAC NICE SMC 
CDR  N/A 
κ=0.336 
(n=61) 
κ=0.129 
(n=29) 
κ=0.194 
(n=71) 
PBAC N/A N/A 
κ=0.115 
(n=24) 
κ=0.156 
(n=53) 
NICE N/A N/A N/A 
κ=0.101 
(n=29) 
SMC N/A N/A N/A N/A 
N/A = Not Applicable 
 
The level of agreement between HTA agency recommendations using the 
binomial category classification was calculated for jurisdictional pairs using 
kappa scores. The CDR and PBAC achieved the greatest kappa score 
(κ=0.336), but this is only considered to be a fair level of agreement (Viera and 
Garrett, 2005). All other jurisdictional pairs achieved kappa scores within the 
slight agreement range despite the overall percentage agreement for one of 
these jurisdictional pairs being greater than the percentage agreement for the 
CDR and PBAC. However, this is likely to be due to a documented kappa 
paradox that has been discussed in chapter 2. Clement et al. (2009) and Nicod 
and Kanavos (2012) both published kappa scores for comparing agreement 
between HTA recommendations issued by the CDR, NICE and PBAC, but only 
Nicod and Kanavos (2012) also included recommendations from the SMC. 
However, both of these studies included oncology medicines which are 
excluded from this study due to the inclusion criteria for drugs reviewed by the 
CDR. Nicod and Kanavos (2012) reviewed drug indication pairs appraised 
between 2007 to 2009 and identified the largest kappa score for 
recommendations issued by NICE and PBAC (κ=0.287), followed by the CDR 
and PBAC (κ=0.250). Clement et al. (2009) identified HTA recommendations 
for the CDR, NICE and PBAC that were publicly available from December 2008 
which included varying start dates for datasets (2001 for NICE, 2004 for the 
CDR and 2005 for PBAC). The largest kappa coefficient identified by Clement 
et al. (2009) was for recommendations issued by the CDR and NICE of κ=0.55 
 125 
 
followed by the CDR and PBAC κ=0.27. Therefore, comparing the results of 
this study with the larger kappa scores identified in previous studies could imply 
that HTA recommendations are becoming more divergent. However, these 
differences may also be explained by the varying agency criteria that include 
oncology medicines and resubmissions.   
 
Eighty-nine medicine-indications were evaluated in this study and these were 
categorised by the number of agencies that reviewed each medicine-indication 
pair (Figure 5.6): 
 
 Twenty-four medicine-indications were reviewed by all four HTA 
agencies and seven of these were granted a positive recommendation 
from all four HTA agencies (Figure 5.6A). No medicines were issued a 
negative recommendation from all four agencies.  
 Thirty-five medicines were reviewed by three of the four HTA agencies 
and 14 of these were granted a positive listing recommendation by all 
three HTA agencies (Figure 5.6B). Eight medicines received a positive 
recommendation from 2 agencies and another eight medicines received 
a positive recommendation from only one of the three agencies. Five 
medicines were issued a negative recommendation by all three 
agencies. 
 Five medicine-indication pairs were also issued all negative 
recommendations for the group reviewed by only two HTA agencies. 
However, this group only included 21 medicine-indication pairs (Figure 
5.6C). Nine of the medicine-indication pairs were issued positive 
recommendations by both reviewing agencies and seven medicine-
indication pairs were granted a single positive recommendation. 
 The smallest group includes medicines reviewed by only one agency 
(n=9) (Figure 5.6D). All of these medicines were reviewed by the CDR 
as the inclusion criteria for the list of medicine-indication pairs required 
a CDR review. Only two of the nine medicine-indication pairs reviewed 
by a single agency (CDR) were granted a positive recommendation. 
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The group of medicines reviewed by all four HTA agencies was evaluated to 
select medicine-indication pairs for case studies. The seven medicines to 
receive all positive recommendations were chosen as examples for positive 
recommendation case studies. 
 
Figure 5.6: Positive HTA recommendations for medicine-indication pairs  
 
 
*0 positive recommendations represents the proportion of medicines that received all 
negative recommendations  
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receive a submission for reimbursement. This can have negative implications 
for patient access as fewer submissions reduces potential opportunities for a 
positive reimbursement recommendations for patients to access the new 
medicine. However, if the manufacturer has anticipated that the medicine is 
unlikely to be reimbursed by HTA agencies with similar criteria then the decision 
to not submit saves time and resources for the manufacturer and HTA 
agencies.  
 
Figure 5.7: Proportion of medicines were all issued a negative 
recommendations  
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Figure 5.8: Medicine and indication combinations classified by 
therapeutic area  
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regulatory approval and HTA recommendations was collected from the public 
domain directly from the following regulatory authorities or HTA agency 
websites:  
 European Medicines Agency (www.ema.europa.eu) 
 Canadian Agency for Drugs and Technologies in Health Common Drug 
Review (www.cadth.ca) 
 Health Canada (www.hc-sc.gc.ca) 
 National Institute for Care and Health Excellence (www.nice.org.uk) 
 Pharmaceutical Benefits Scheme Pharmaceutical Benefits Advisory 
Committee  (www.pbs.gov.au) 
 Scottish Medicines Consortium (www.scottishmedicines.org.uk) 
 Therapeutic Goods Administration (www.tga.gov.au) 
 
The dates of regulatory approval from the EMA, Health Canada and the TGA 
were recorded with the publication dates for each initial HTA recommendation 
to produce a timeline of events for each case study. The time from first HTA 
recommendation to the fourth HTA recommendation varied greatly across the 
seven positive case studies from 5 months to 20 months (Table 5.8). 
 
Case study 1: Apixaban (Eliquis) for prevention of venous 
thromboembolic events (VTE) 
 
Apixaban (Eliquis) was granted marketing approval by the EMA (May 2011), 
the TGA (July 2011) and Health Canada (December 2011) for the prevention 
of Venous Thromboembolic Events (VTE) in patients that have undergone 
elective knee or hip replacement surgery. The first HTA approval was for an 
‘authority required’ recommendation issued by the PBAC in July 2011, shortly 
after marketing authorisation was granted by the TGA (Figure 5.9). Apixaban 
was subsequently recommended as ‘accepted’ for reimbursement by the SMC 
in December 2011 and NICE ‘recommended’ apixaban in January 2012. The 
CDR subsequently issued a ‘list with criteria/condition’ recommendation in June 
2012. The final HTA recommendation from the CDR was issued eleven months 
after the first HTA recommendation from the PBAC.  
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Figure 5.9: Timeline for apixiban (Eliquis) for prevention of venous 
thromboembolic events (VTE) 
 
 
 
 
All four HTA agencies considered subcutaneous enoxaparin as a comparator 
for the orally administered apixaban. Enoxaparin was considered the 
appropriate comparator by NICE as it is the most widely used low molecular 
weight heparin in the UK. The PBAC noted that they accepted the 
manufacturer’s submission with rivaroxaban as the primary comparator and 
enoxaparin as the secondary comparator. However, the trials submitted for 
rivaroxaban were indirect comparisons using enoxaparin as the common 
comparator. 
 
The PBAC and SMC both accepted that apixaban is non-inferior/similar to 
enoxaparin, but NICE concluded that there was insufficient clinical evidence to 
determine the efficacy of apixaban and rivaroxaban. The CDR, NICE and SMC 
all concluded that apixaban was clinically superior to enoxaparin and more cost-
effective. The final PBAC recommendation was also based on a cost 
minimisation basis of apixaban compared with rivaroxaban.
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Table 5.8: Summary table of case studies that received positive recommendations from four agencies   
Case Study 
Generic 
Name 
Proprietary 
name Indication  
CDR 
(Canada) 
PBAC 
(Australia 
NICE 
(England) 
SMC 
(Scotland) 
Time from 
H1 to H4 
(Months) 
Case study 1 Apixaban  Eliquis 
Prevention of 
venous 
thromboembolic 
events (VTE) RR RR R R 11 
Case study 2 Denosumab  Prolia 
Osteoporosis in 
postmenopausal 
women RR RR RR RR 9 
Case study 3 Golimumab  Simponi 
Rheumatoid 
Arthritis R RR RR RR 18 
Case study 4 Golimumab  Simponi 
Ankylosing 
spondylitis R RR R RR 20 
Case study 5 Telaprevir  Incivek 
Hepatitis C 
infection 
(genotype 1), 
Chronic 
(treatment naïve) RR RR R R 5 
Case study 6 Tocilizumab  Actemra 
 Rheumatoid 
Arthritis RR RR RR RR 16 
Case study 7 Ustekinumab  Stelara Psoriasis RR RR R RR 19 
 
Key: H1- first HTA recommendation, H4- fourth HTA recommendation, R- Recommended, RR- Recommended with restrictions 
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Case study 2: Denosumab (Prolia) for Osteoporosis in postmenopausal 
women 
 
In May 2010 the EMA was the first regulatory authority to grant marketing 
approval for denosumab (Prolia) for the treatment of osteoporosis in 
postmenopausal women. The TGA and the CDR also granted marketing 
approval for the treatment of osteoporosis in postmenopausal women in June 
2010 and August 2010, respectively (Figure 5.10).  
 
Figure 5.10: Timeline for denosumab (Prolia) for Osteoporosis in 
postmenopausal women  
 
 
 
 
The PBAC issued the first HTA recommendation for denosumab on a price 
minimisation basis with zolendronic acid, which was considered to be of similar 
effectiveness. This recommendation approved denosumab for the patient 
population suggested in the manufacturers submission. However, The 
manufacturer had originally requested denosumab to be listed under the 
‘Authority required (streamlined)’, but the PBAC decided to recommend 
denosumab for the more restricted ‘Authority required’ option due to the 
medicine’s novel method of action and limited safety data that would require 
ongoing surveillance.  
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NICE issued the second HTA recommendation (October 2010), shortly followed 
by SMC (December 2010) and the CDR (March 2011). 
The manufacturer’s submission to NICE and SMC requested review of 
denosumab for patients that were contraindicated or intolerant to oral 
bisphosphonates and this is reflected in the restrictions included in the NICE 
and SMC recommendation.  The CDR listing recommendation also included 
these restrictions. The CDR, NICE and SMC all accepted that trials 
demonstrate denosumab to be clinically superior to placebo and could be 
considered more cost effective for patients that are contraindicated or intolerant 
to oral bisphosphonates.  
 
Case study 3: Golimumab (Simponi) for rheumatoid arthritis 
 
In April 2009, Health Canada granted marketing authorisation for golimumab 
(Simponi) as combination therapy with methotrexate for the treatment of 
moderate to severe active rheumatoid arthritis, including eligible patients that 
had not been treated previously with methotrexate (Figure 5.11).  
 
Figure 5.11: Timeline for golimumab (Simponi) for rheumatoid arthritis  
 
 
 
Golimumab was also approved for the same indication by the EMA (October 
2009).  In November 2009, the TGA subsequently approved golimumab as a 
combination therapy with methotrexate for the treatment of moderate to severe 
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active rheumatoid arthritis, but only for patients that had not responded to 
treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) including 
methotrexate. The CDR and PBAC both provided a listing recommendation for 
golimumab (50mg monthly dose) for the treatment of rheumatoid arthritis in 
March 2010.  The PBAC recommended an ‘authority required’ listing and cost 
minimisation with comparators (adalimumab and etanercept), which were 
deemed to be of a comparable efficacy. Golimumab would also be listed with 
the same restrictions and price reductions the PBAC has applied to 
comparators.  
 
The CDR determined golimumab as clinically superior to placebo and issued a 
‘list in similar manner to other drugs in class’ recommendation. The CDR 
recommendation was also restricted to a maximum of 50mg monthly dose, as 
the annual cost was expected to be more cost-effective than other TNF-alpha 
inhibitors if administered once a month and only a limited benefit for identified 
doses higher than 50mg. NICE issued an ‘optimised’ recommended golimumab 
as combination therapy with methotrexate when previous treatments have 
failed. NICE was the only HTA agency to recommend the higher 100mg dose, 
but only if the manufacturer provided it at the same price as the 50mg option. 
SMC agreed that golimumab is superior to methotrexate alone and also cost 
effective at the 50mg dose. The SMC ‘restricted’ recommendation requires 
golimumab to be used in line with the existing British Society for Rheumatology 
prescribing guidelines for TNF-alpha inhibitors and only recommends the 
monthly 50mg dose.  
Four HTA agencies recommended the 50mg dose as the cost effective option, 
unless the manufacturer provided the 100mg dose at the same cost (NICE). 
The four HTA agencies also noted the absence of direct trial comparisons with 
other TNF-alpha inhibitors.  
 
Case study 4: Golimumab (Simponi) for ankylosing spondylitis 
 
In April 2009, Health Canada approved golimumab (Simponi) for the treatment 
of active Ankylosing Spondylitis (AS) for patients who had not responded to 
conventional therapy and the EMA approved golimumab for the same indication 
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in October 2009 (Figure 5.12). The marketing authorisation granted by the TGA 
approved golimumab for the treatment of active AS.  
 
Figure 5.12: Timeline for golimumab (Simponi) for ankylosing 
spondylitis  
 
 
 
 
The PBAC and the CDR both issued recommendations for golimumab for the 
treatment of AS in March 2010, the same time as the recommendations issued 
for golimumab for the treatment of rheumatoid arthritis. The PBAC, CDR and 
SMC all issued the same HTA recommendation classification for both of the 
reviewed indications: ‘authority required’ and ‘list in a similar manner’ and 
‘restricted’ respectively. NICE issued a ‘recommended’ recommendation for 
golimumab for the treatment of AS in line with clinical practice, which is less 
restrictive than the NICE ‘optimised ‘recommendation for golimumab for the 
treatment of rheumatoid arthritis. 
 
Once again, all four HTA agency recommendations were for the 50mg dose as 
the cost effective option, unless the manufacturer provided the 100mg dose at 
the same cost (NICE). All HTA agencies noted the absence of direct trial 
comparisons with other TNF-alpha inhibitors.  
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Case study 5: Telaprevir (Incivek) for Hepatitis C infection (genotype 1), 
Chronic (treatment naïve) 
 
Telaprevir for the treatment of Hepatitis C infections in treatment naïve and 
treatment experienced patients were included in a single submission to all HTA 
agencies except for the initial submission to the PBAC. The initial submission 
received a negative recommendation and is reviewed in more detail in case 
study 13. The resubmission to the PBAC also included the indication for 
treatment naïve patients and was recorded as the first PBAC recommendation 
for telaprevir for hepatitis C infection and therefore meets the inclusion criteria 
for the positive case studies (Figure 5.13).     
 
Figure 5.13: Timeline for Telaprevir (Incivek) for Hepatitis C infection 
(genotype 1), Chronic (treatment naïve) 
 
 
 
Case study 6: Tocilizumab (Actemra) for rheumatoid arthritis 
 
Tocilizumab (Actemra/RoActemra) was granted market authorisation for the 
treatment of moderate to severe active rheumatoid arthritis in combination with 
methotrexate, or as monotherapy if methotrexate is inappropriate, by the EMA 
(January 2009), the TGA (May 2009) and Health Canada (April 2010) within a 
15-month period. The market authorisation from the TGA and Health Canada 
also approved tocilizumab for the treatment of rheumatoid arthritis in 
combination with other Disease-Modifying Antirheumatic Drugs (DMARDs) and 
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this treatment combination is also considered for the HTA recommendations 
issued by the PBAC and the CDR (Figure 5.14).  
 
Figure 5.14: Timeline for tocilizumab (Actemra) for rheumatoid arthritis 
 
 
 
The PBAC issued the first HTA listing recommendation for tocilizumab (July 
2009) and recommended the PBS provide tocilizumab with the ‘authority 
required’ restriction as part of the Highly Specialised Drugs Program. The 
indications approved include tocilizumab in combination with methotrexate in 
eligible patients that have not responded to TNF-alpha treatment on a cost-
minimisation basis with abatacept, which was considered to be of comparative 
efficacy.  The PBAC did not approve tocilizumab for combination therapy with 
other DMARDs due to uncertain efficacy and cost.  
 
In January 2010, the SMC determined tocilizumab to be clinically superior 
compared to placebo and cost-effectiveness analysis indicated that tocilizumab 
was unlikely to exceed the threshold of £30,000/QALY. The SMC issued a 
‘restricted use’ recommendation for tocilizumab, which only recommended 
tocilizumab for combination therapy with methotrexate, when one or more 
previous treatments (TNF-alpha inhibitors and DMARDs) had failed, as the 
economic case for monotherapy was not proven. NICE issued an ‘optimised’ 
recommendation (August 2010) which approved the use of tocilizumab as 
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combination therapy, but this did not include a recommendation for 
monotherapy due to lack of data, similar to the SMC recommendation.  
 
The CDR issued a HTA recommendation 16months after the first HTA 
recommendation from the PBAC. The CDR recommended tocolizumab should 
be ‘listed with criteria/condition’ as combination therapy with methotrexate or 
other DMARDs for eligible patients that have not responded to previous 
treatment (TNF-alpha inhibitors and DMARDs).  The CDR recommendation 
noted that tocilizumab was not licensed for general use for patients that had 
failed to respond to DMARDs alone and this is therefore reflected in the listing 
recommendation.  
 
Case study 7: Ustekinumab (Stelara) for psoriasis  
 
Ustekinumab (Stelera) was granted marketing approval for the treatment of 
moderate to severe plaque psoriasis in adult patients who are eligible for 
phototherapy or systemic therapy by Health Canada in December 2008 and the 
TGA in July 2009 (Figure 5.15).  
 
Figure 5.15: Timeline for ustekinumab (Stelera) for psoriasis  
 
 
 
 
Ustekinumab was also granted marketing approval by the EMA in January 2009 
for the treatment of moderate to severe plague psoriasis in adult patients. 
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contraindicated, intolerant or failed to respond to phototherapy or other 
systemic therapy as the benefit/risk ratio was positive for the restricted 
population (EMA, 2009). 
 
All four HTA agencies reviewed ustekinumab within seven months of the first 
HTA assessment. The CDR granted the first HTA approval for ustekinumab in 
June 2009 as ‘list with criteria/conditions’, followed by a ‘recommended’ 
recommendation from NICE (September 2009), an ‘authority required’ 
recommendation from PBAC (November 2009) and an approval for ‘restricted 
use’ from the SMC (February 2010).  All four HTA agencies used etanercept as 
a comparator and noted a significant therapeutic benefit for ustekinumab. All 
four HTA agencies determined the cost effectiveness of ustekinumab to be 
comparable to competitors (etanercept and adalimumab). Cost effectiveness 
was determined by comparing the equivalent annual cost of treatments (CDR) 
or by incremental cost per QALY (PBAC, NICE and SMC). NICE and SMC both 
noted that an acceptable level of cost-effectiveness was achieved with the 
inclusion of a patient access scheme. 
 
The Canadian CDR and Australian PBAC recommendation both included 
criteria/conditions that include the EMA marketing restriction to patients that 
had failed to respond, contraindicated or intolerant to phototherapy and other 
systemic therapies. The published CDEC reasons for the recommendation 
noted that the committee had concerns over the associated risks of 
ustekinumab and needed to balance the benefits and harms.  
 
PART IV- an evaluation of factors influencing discordant HTA 
recommendations for Australia, Canada, England and 
Scotland 
 
The final results section will focus on case studies of medicine-indication pairs 
reviewed by all four HTA agencies that include a negative recommendation 
from only one HTA agency (Table 5.9).  
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Table 5.9: Summary table of case studies that received a negative recommendation from one of the four agencies  
Case 
Study 
Generic 
Name 
Proprietary 
name Indication  
CDR 
(Canada) 
PBAC 
(Australia 
NICE  
(England) 
SMC 
(Scotland) 
Time 
from H1 
to H4 
(Months) 
Case 
study 8 
Dabigatran 
etexilate Pradaxa 
Thromboembolism (venous), 
prevention DR RR R R 14 
Case 
study 9 Fingolimod Gilenya Multiple Sclerosis RR RR R DR 13 
Case 
study 10 Golimumab Simponi Arthritis, psoriatic R RR R DR 13 
Case 
study 11 
Prasugrel 
hydrochloride Effient Acute Coronary Syndrome DR RR R RR 18 
Case 
study 12a 
Ranibizumab 
injection Lucentis 
Macular oedema, secondary to 
retinal vein occlusion, (branch 
retinal vein occlusion) RR DR RR DR 19 
Case 
study 12b 
Ranibizumab 
injection Lucentis 
Macular oedema, secondary to 
retinal vein occlusion, (central 
retinal vein occlusion) RR DR R RR 19 
Case 
study 13 Telaprevir Incivek 
Hepatitis C infection (genotype 
1), Chronic (treatment 
experienced) RR DR R R 5 
 Case 
study 14 Ticagrelor Brilinta 
Thrombotic events in Acute 
Coronary Syndromes, 
Prevention DR RR R R 19 
 
 
Key: H1- first HTA recommendation, H4-  fourth HTA recommendation, R- Recommended, RR- Recommended with restrictions, DR- Not recommended
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Seven medicine-indication pairs met this inclusion criteria, but the case study 
for ranibizumab also discusses two indications (cast 12a and 12b) despite only 
one indication meeting the inclusion criteria as both indications were reviewed 
in the same submissions on most occasions. Each case study is accompanied 
by a timeline that outlines the sequence of regulatory approvals and HTA 
recommendations using multinomial categories.  
 
Case study 8: Dabigatran (Pradaxa) for prevention of venous thrombo 
emobolism following a total hip replacement or total knee replacement 
surgery 
 
Dabigatran was first granted marketing authorisation by the EMA (March 2008) 
for the prevention of venous thromboembolism (figure 5.16) and was positively 
approved by the SMC (June 2008) and NICE (September 2008) within six 
months. The PBAC was the third HTA agency to issue a positive 
recommendation in November 2009. The CDR was the only HTA agency to 
issue a negative recommendation (January 2009) as the CDEC committee 
found the evidence submitted for dabigatran was not sufficient to prove non-
inferiority to enoxaparin.  
 
Figure 5.16: Timeline for dabigatran (Pradaxa) for prevention of venous 
thromboembolism 
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The CDEC committee also noted concerns that dabigatran could be used for 
indications outside of the marketing authorisation. The SMC, NICE and PBAC 
all included enoxaparin as a comparator and the SMC agreed that dabigatran 
was non-inferior to enoxaparin and NICE  determined dabigatran was likely to 
have an equivalent clinical and cost effectiveness. The SMC, NICE and PBAC 
all noted cost-saving benefits of orally administering dabigatran compared to 
sub-cutaneous comparators as part of their recommendation rationale.  
 
For this cases study, the CDR was the only agency to issue a negative 
recommendation despite other HTA agencies also expressing concerns over 
evidence supporting non-inferiority with comparator (Figure 5.16). The CDR 
was also the only HTA agency that did not explicitly refer to the cost-saving 
benefits of dabigatran’s oral route of administration. 
 
Case study 9: Fingolimod (Gilenya) for multiple sclerosis 
 
Fingolimod (Gilenya) was granted marketing authorisation for the treatment of 
active, relapsing multiple sclerosis by the TGA (February 2011), the EMA 
(February 2011) and Health Canada (March 2011) within a two-month period 
(Figure 5.17). Fingolimod is the first oral medicine available for the treatment of 
multiple sclerosis and this provides benefits for patients by removing the need 
for injections. All four HTA agencies concluded that fingolimod treatment 
produced a significant reduction in annualised relapsed rates, but generally 
accepted that its efficacy was comparable to Interferon beta-1a. 
 
All of the HTA submissions included Interferon beta-1a as the main comparator, 
which received a varied response from the agencies. The PBAC accepted 
Interferon beta-1a as the main comparator and considered the additional 
comparator (natalizumab) as informative. However, NICE and SMC both noted 
concerns regarding the manufacturers choice of Interferon beta-1a as the only 
comparator as the marketing authorisation from the EMA specifies fingolimod 
is to be used by patients with high disease activity despite treatment with at 
least one disease modifying therapy. Health Canada also recommended that 
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fingolimod is generally recommended for patients that have had an inadequate 
response or are intolerant to one of more therapies for multiple sclerosis. 
 
Figure 5.17: Timeline for fingolimod (Gilenya) for multiple sclerosis 
 
 
 
The PBAC issued the first HTA recommendation in March 2011, which was a 
restricted ‘authority required’ recommendation. However, the published public 
summary document states that the PBAC initially refused to recommend 
fingolimod due to uncertain cost effectiveness and an exceptionally high price, 
but the manufacturer submitted a lower price prior to the meeting and this was 
then considered to be cost-effective. The restricted recommendation from the 
PBAC requires a diagnosis confirmed by MRI, at least two relapses in 2 years 
and specifies criteria to discontinue treatment if patients demonstrate 
continuing disability progression.  
 
The CDR ‘list with criteria/condition’ recommendation also specifies criteria for 
identifying patients where fingolimod treatment should be stopped as the 
reasons for recommendation state that the use of a high-cost agent is 
unwarranted without substantial and sustained clinical benefit.  
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submission in March 2012.  The resubmission contained an additional 
comparator (natalizumab) and fingolimod was subsequently granted ‘restricted 
use’ in September 2012. 
 
Fingolimod was eventually issued a positive listing recommendation by all four 
HTA agencies within 14 months of first regulatory approval, but received an 
initial negative recommendation from the SMC due to comparator choice. This 
case-study is an example of a high cost medicine that achieved positive listing 
recommendations from HTA agencies that consider cost-effectiveness 
because the agencies recognised the innovative value.  
 
Case study 10: Golimumab (Simponi) for psoriatic arthritis 
 
Golimumab (Simponi) was granted market authorisation for the treatment of 
moderate to severe psoriatic arthritis, alone or in combination with methotrexate 
for patients that have not responded adequately to disease-modifying anti-
rheumatic drugs (DMARDs) by Health Canada (April 2009), the EMA (October 
2009) and the TGA (November 2009). A HTA recommendation for the 
treatment of psoriatic arthritis was issued by all four agencies within 12 months 
of the first recommendation by the CDR (March 2010) (Figure 5.18).  
 
Figure 5.18: Timeline for golimumab (Simponi) for psoriatic arthritis 
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All four HTA recommendations noted a lack of trials with direct comparisons, 
but accepted that golimumab was clinically superior to placebo (CDR, NICE 
and SMC) and/or suggests similar efficacy to other TNF-alpha inhibitors (PBAC, 
NICE). The CDR, NICE and SMC accepted adalimumab, infliximab and 
etanercept as comparators and the PBAC also used adalimumab and 
etanercept. 
 
The CDR accepted the cost of golimumab to be less than comparators when 
administered 12 times a year. NICE also noted that the ICER for golimumab 
compared with infliximab would result in a savings per QALY lost due to the 
lower price and less QALYs gained. The CDR, NICE and PBAC all 
recommended golimumab for reimbursement, but the SMC issued a negative 
recommendation due to an insufficiently robust economic analysis. However, 
following a resubmission in June 2012, golimumab was granted a 
recommendation for ‘restricted’ use as the economic case was demonstrated. 
The SMC restricted golimumab to only the 50mg dose as the 100mg was not 
considered cost-effective. The recommendations from the CDR and PBAC 
were also only for the 50mg dose, but NICE accepted the 100mg dose for use 
only with a patient access scheme that acquires the 100mg dose at the same 
cost as the 50mg dose. 
 
 
Following the successful resubmission to the SMC, golimumab was eventually 
granted a positive listing recommendation by all four HTA agencies. Golimumab 
has also been reviewed in case study 3 for rheumatoid arthritis and case study 
4 for ankylosing spondylitis and both indication submissions received positive 
initial recommendations from the SMC and were submitted after the initial 
golimumab submission to the SMC for psoriatic arthritis. It could be concluded 
that the manufacturers’ experience from this case study provided useful insights 
for future submissions. 
 
Case study 11: Prasugrel (Effient) for acute coronary syndrome 
 
Case study 11 identified for medicines issued a negative recommendation by a 
single agency is for prasugrel (Effient) for the treatment of acute coronary 
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syndromes. Prasugrel was initially granted marketing authorisation by the EMA 
(February 2009), shortly followed by the TGA (June 2009) and finally approved 
by Health Canada a year later. The PBAC issued the first HTA recommendation 
for a restricted (authority required (streamlined)) listing, followed by a restricted 
listing from the SMC in September 2009 and a ‘recommended’ 
recommendation from NICE in October 2009. The CDR issued the last HTA 
recommendation in February 2011 with a negative ‘do not list’ recommendation 
(Figure 5.19).  
 
Figure 5.19: Timeline for prasugrel (Effient) for acute coronary 
syndromes 
 
 
The incremental cost per QALY considered by all four HTA agencies were all 
within the explicit or implicit QALY thresholds (Table 5.1). All four HTA agencies 
accepted clopidogrel as the main comparator and either accepted the superior 
clinical benefit of prasugrel (PBAC and SMC) or raised concerns over the 
transferability of the clinical trials for national clinical practice (CDR and NICE). 
NICE was uncertain about the comparative efficacy, but believed prasugrel 
could be beneficial for certain patient populations. Both the NICE 
‘recommended’ and SMC ‘restricted’ recommendations only recommended the 
10mg dose of prasugrel.  
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The negative recommendation from the CDR cited uncertainty over the 
applicability of the trial design to Canadian clinical practice and also raised 
concerns over safety due to trial results indicating a statistically significant 
increase of major bleeding events for prasugrel over clopidogrel. The CDR also 
noted that they expect prasugrel could offer benefits for some patients, but did 
not have data to support these assumptions. In June 2012, the CDR issued 
another ‘do not list’ recommendation in response to the manufacturer’s 
resubmission. The resubmission included a lower price, but the comparator 
(clopidogrel) was then available as a generic. Additional data were also 
included, but no new randomised controlled trials met CDR requirements and 
the CDR still expressed concerns over the generalisability of trial data in the 
Canadian context. However, the resubmission recommendation also stated 
that a positive listing could be achieved at a lower price for prasugrel.  
 
The CDR does not negotiate price as the final listing decision and price 
negotiations are determined by participating drug plans but the CDR states that 
a positive listing recommendation could be achieved at a lower price. The CDR 
has indicated to participating plans that prasugrel could be a viable option and 
demonstrated that the CDR recommendation is partially similar to the other 
three HTA agencies but differences in agency remit have resulted in a different 
recommendation classification.   
 
Case studies 12a and 12b: Ranibizumab injection (Lucentis) for Macular 
oedema, secondary to retinal vein occlusion (Branch Retinal Vein 
Occlusion (BRVO) (case study 12a) and Central Retinal Vein Occlusion 
(CRVO) (case study 12b) 
 
Case studies 12a and 12b are for medicines issued a negative recommendation 
by a single HTA agency and are both for ranibizumab (Lucentis) for the 
treatment of macular oedema, secondary Branch Retinal Vein Occlusion 
(BRVO) (case study 12a) (figure 5.20) or to Central Retinal Vein Occlusion 
(CRVO) (case study 12b) (Figure 5.21).   
 
The EMA issued the first marketing authorisation for ranibizumab (March 2011) 
followed by Health Canada (July 2011) and the TGA (December 2011). The 
SMC issued the first HTA assessment recommendation for ranibizumab 
 148 
 
(November 2011) a year before the next HTA recommendation was issued by 
the CDR (October 2012) and the PBAC (November 2012) and 18 months prior 
to a HTA recommendation from NICE (May 2013).  
 
Figure 5.20: Timeline for ranibizumab injection (Lucentis) for Macular 
oedema, secondary to retinal vein occlusion (Branch Retinal Vein 
Occlusion (BRVO)  
 
 
 
Figure 5.21: Timeline for ranibizumab injection (Lucentis) for Macular 
oedema, secondary to Central Retinal Vein Occlusion (CRVO) 
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 All four HTA agencies accepted laser photocoagulation as the comparator for 
macular oedema, secondary to BRVO (Figure 5.20). However, macular 
oedema, secondary to CRVO does not respond to laser photocoagulation and 
therefore three HTA agencies (CDR, PBAC and SMC) accepted ‘observation’ 
as the main comparator and one agency used ‘best supportive care’ for 
comparison. Patients with macular oedema, secondary to BRVO may 
experience spontaneous improvement in their condition, but spontaneous 
improvement is not expected for patients with macular oedema, secondary to 
CRVO. Therefore, there is a greater need for treatment options for patients with 
macular oedema, secondary to CRVO and HTA agencies issued different 
recommendations for the different indications.  
 
The PBAC was the only HTA agency to issue a negative recommendation for 
ranibizumab for the treatment of macular oedema, secondary to CRVO and 
BRVO due to its high cost and uncertain cost-effectiveness (Figure 5.21 and 
5.20). The ICERs across BRVO and CRVO were considered to be between 
AUS$45,000 to $75,000 and likely to be even higher as the PBAC found the 
benefits to be overestimated in the manufacturers submission. Therefore the 
ICERS are expected to exceed the implicit QALY threshold of AUD $69,900. 
The PBAC also expressed concerns over laser photocoagulation as a 
comparator and noted that bevacizumab is widely used to treat macular 
oedema secondary to BRVO and CRVO despite not being TGA approved for 
these indications or formulated for intravitreal use. The manufacturer 
resubmitted ranibizumab for consideration by the PBAC. However, the first 
resubmission (November 2013) was deferred due to ongoing concerns over 
comparator and another resubmission (March 2014) was also deferred as the 
price reduction was still not low enough to outweigh the uncertainties around 
cost effectiveness. 
 
The SMC issued a ‘restricted’ recommendation for ranibizumab, which only 
recommends ranibizumab for the treatment of macular oedema, secondary to 
CRVO as ranibizumab can provide benefits to patients that lack alternative 
treatment options and the manufacturer agreed to a patient access scheme. 
The SMC did not recommend ranibizumab for the treatment of BRVO due to 
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uncertainties over cost effectiveness and a high ICER. However, the 
manufacturer submitted a resubmission for ranibizumab to treat BRVO and the 
SMC issued a positive recommendation in May 2013 as a result of a patient 
access scheme. 
 
The CDR issued a ‘list with criteria/condition’ recommendation for ranibizumab 
for the treatment of macular oedema, secondary to CRVO and BRVO. The 
BRVO recommendation is to offer ranibizumab to patients not previously 
treated with a Vascular Endothelial Growth Factor (VEG-F) inhibitor and 
coverage limited to 24 months. 
 
In May 2013 NICE issued two different recommendations for ranibizumab to 
treat retinal vein occlusion. NICE issued a ‘recommended’ recommendation for 
the treatment of macular oedema, secondary to CRVO in line with market 
authorisation and a patient access scheme with a price reduction from the 
manufacturer.  However, an ‘optimised’ recommendation was issued for 
ranibizumab with a patient access scheme for the treatment of macular 
oedema, secondary to BRVO only when laser photocoagulation therapy was 
unsuccessful or not appropriate.  
 
Ranibizumab received positive recommendations from the CDR, SMC and 
NICE for both BRVO and CRVO indications. The SMC recommendation for 
ranibizumab to treat CRVO was initially negative but a resubmission with a 
patient access scheme has since resulted in a positive recommendation. All 
three of these HTA agencies issued more restrictive positive recommendations 
for ranibizumab to treat BRVO as this indication has potential treatment options 
and patients can spontaneously improve unlike CRVO. The manufacturers 
submission to the PBAC has been deferred due to ongoing concerns for 
comparator choice. PBAC and NICE both considered bevacizumab to be an 
appropriate comparator choice despite no marketing authorisation to treat 
CRVO or available intravitreal formulation. However, the varying willingness to 
accept alternative comparators has resulted in different reimbursement 
recommendations. 
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Case study 13: Telaprevir (Incivek) for Hepatitis C infection (genotype 1) 
in treatment experienced patients 
 
Telaprevir (Incivek) for the treatment of Hepatitis C infection (genotype 1) with 
compensated liver disease was given two different initial reimbursement 
recommendations by the PBAC due to the initial manufacturers submission 
(November 2011) only requesting a review of telaprevir for patients that are 
treatment experienced. This initial submission was rejected by the PBAC 
because final product information from the TGA was not available at the time 
of the review (Figure 5.22). 
 
Figure 5.22: Timeline for telaprevir (Incivek) for Hepatitis C infection 
(genotype 1) in treatment experienced patients 
 
 
 
In March 2012, the TGA approved marketing authorisation for telaprevir for the 
treatment of chronic Hepatitis C infection (genotype 1) with compensated liver 
disease in patients who are either treatment naïve or are treatment experienced 
(interferon alpha with or without ribavirin). The manufacturer’s resubmission to 
the PBAC (March 2012) also included a request to review telaprevir for the 
treatment of naïve patients. 
 
The PBAC approved both indications (treatment naïve and treatment 
experienced), with separate restrictions, for ‘authority required (streamlined)’ 
Health 
Canada
August 
2011
EMA
September 
2011
PBAC
November 
2011
SMC 
December 
2011
TGA 
March 
2012
CDR 
February 
2012
NICE 
April 
2012
Regulatory 
Approval: 
HTA 
Recommended: 
HTA 
Restricted: 
HTA Not 
Recommended: 
 152 
 
listing to be only available in specialised treatment centres. The 
recommendation was based on acceptable cost-effectiveness when the price 
of the telaprivir treatment course was equal to the cost of boceprevir. The PBAC 
also recommended the manufacturer provides a 100% rebate for treatment 
costs above the provided estimates. However, sponsor comments stated that 
they did not believe in a 100% rebate for a risk share agreement. The 
resubmission for treatment of experienced patients was also the initial PBAC 
consideration for the treatment naïve indication. All four HTA agencies provided 
a positive initial recommendation for telaprevir for this indication. Therefore, 
telaprevir also meets the inclusion criteria for the positive case studies.  
 
The SMC was the second HTA agency to review telaprevir for patients with 
chronic hepatitis C and published two separate recommendations for treatment 
naïve and treatment experienced patients in December 2011. Both indications 
were determined to have a statistically significant clinical benefit and cost 
effectiveness compared to peginterferon alpha and ribavirin. However, the 
ICER for telaprevir/peginterferon alpha and ribavirin for treatment experienced 
patients that were null responders was calculated to be as high as £73,600 per 
QALY, but this was sensitive to many variables (e.g. age) and overall, cost 
effectiveness was accepted. 
 
In February 2012, the CDR issued a final recommendation for telaprevir for the 
treatment of hepatitis C, including both treatment naïve and treatment 
experienced patients. A recommendation for ‘list with criteria/condition’ at a 
reduced price with clinical criteria that eligible patients are not co-infected with 
HIV. The CDR published recommendation noted that patients with HIV were 
excluded from the trial and the benefits are unclear for this subgroup of patients. 
The SMC and NICE published recommendations also noted that HIV patients 
were excluded from the trial, but no restrictions for HIV patients were included 
in the recommendations from NICE, SMC or the accepted PBAC resubmission.   
 
Ultimately, telaprevir for hepatitis C infection in treatment experience patients 
achieved positive recommendations from the four HTA agencies. The initial 
negative recommendation from the PBAC was due to the timing of the 
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submission as the TGA final product information was not available at the time 
of the meeting.  
 
Case Study 14: Ticagrelor (Brilinta/Brillique) for acute coronary syndrome  
 
The fnal case study for medicines issued a negative recommendation by a 
single HTA agency is for ticagrelor, sold as Brillique in Europe and Brillinta in 
Canada and Australia. In December 2010 the EMA issued the first marketing 
approval for ticagrelor for the treatment of acute coronary syndromes. 
Marketing authorisation for ticagrelor was issued more than a year later in 
Canada (May 2011) and Australia (June 2011) (Figure 5.23).  
 
Figure 5.23: Timeline for ticagrelor (Brilinta/Brillique) for acute coronary 
syndrome 
 
 
The SMC issued the first HTA recommendation in May 2011 as ‘accepted’ 
followed by an ‘authority required (streamlined)’ recommendation from the TGA 
in July 2011 and a ‘recommended’ recommendation from NICE in October 
2011. All three HTA reviews accepted ticagrelor as clinically superior to 
clopidogrel, but uncertainties were raised over comparative safety (PBAC). 
 
However NICE decided the potential benefits outweighed the risks and the 
SMC found the increase in adverse events were not significant. The PBAC, 
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NICE and SMC review all accepted the increased cost per QALY to clopidrogrel 
to be below the implicit or explicit thresholds. 
 
The CDR issued a ‘Do not list’ recommendation in December 2011 as a 
regional analysis did not provide evidence that ticagrelor would provide 
significant benefits over clopidogrel for the North American population and the 
CDR could therefore not justify the increased cost of ticagrelor. However, the 
CDR recommendation summary also stated that a positive recommendation 
would be more likely if the price was reduced. The CDR issued a similar 
recommendation for prasugrel (case study 1) which also noted that a reduced 
price could result in a positive recommendation. Once again, this is a divergent 
recommendation issued by the CDR as negotiating price is not part of the 
CDR’s remit.  
 
DISCUSSION 
This chapter describes a comparison of HTA in Canada, Australia, England and 
Scotland. These four jurisdictions were selected due to transparency and 
availability of data in English, as these all provide online summaries with 
rationale for reimbursement recommendations. The comparisons of the full 
HTA recommendations dataset provides a useful overview of 
recommendations for non-cancer medicines issued over a period greater than 
three years and has demonstrated that the more negative HTA 
recommendations a medicine receives, the fewer markets will receive a 
submission for reimbursement (Figure 5.7). The four HTA agencies selected 
for inclusion in this study share common factors, such as: considering clinical 
and cost-effectiveness of new medicines and have an implicit or explicit QALY 
threshold. When one or more of these HTA agencies issue a negative 
recommendation it is possible that the manufacturer may decide against further 
submissions to similar agencies. This could be perceived negatively for patients 
as they will be unable to access medicines that have not been reviewed and 
recommended for their jurisdiction. This is also negative for the manufacturer 
as it reduces the opportunity to achieve a return on the initial research and 
development expenditure. However, it may also require the time and costs 
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spent on rejected submissions for the manufacturer and HTA agencies. This 
could produce a more innovative and efficient environment if manufacturers are 
deterred from allocated resources for the research and development of 
products that are unlikely to satisfy HTA requirements and therefore have 
reduced chances of reimbursement. 
 
The case studies provide further insights into the rationale behind the HTA 
recommendations. The fourteen case studies were selected from the 25 
medicine-indication pairs that were reviewed by all four HTA agencies. No 
medicine-indication pairs received all ‘recommended’ using the multinomial 
classification, but seven medicine-indication pairs were all positive 
recommendations using the binomial classification (Figure 5.6) (Table 5.4). 
These were selected to provide further insights into the similarities and 
differences behind positive recommendations. Another seven medicine-
indication pairs were issued a negative recommendation by only one of the four 
agencies. These seven medicine-indication pairs were chosen as case studies 
to identify reasons for the divergent recommendations as the other three 
agencies were in general agreement and issued a positive recommendation. 
These were of value for identifying similarities and differences between the four 
agencies.  
 
The most common factor associated with the divergent case studies was 
uncertainties around cost-effectiveness and the justification for a high cost 
product. For example, golimumab for psoriatic arthritis (case study 10) was 
initially rejected by the SMC due to submission of an insufficient economic 
analysis. The initial submission to SMC included a cost-utility analysis that 
demonstrated that a comparator (etanercept) had a lower cost per incremental 
QALY so that SMC concluded that the comparator would be preferred by 
decision-makers. The resubmission included a cost-minimisation comparison 
of the drug costs over a year with the same three comparators and 
demonstrated etanercept to be more cost-effective than two comparators 
(etancercept and infliximab) and cost-neutral with adalimumab. Interestingly, a 
cost minimization analysis was also included in the initial submissions to the 
CDR and PBAC which were submitted up to a year before the initial submission 
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to the SMC. This might imply that the cost-minimisation analysis was a key 
factor for positive recommendations. Therefore, if the manufacturer’s 
submission to the SMC had originally included this, then golimumab may have 
had a positive recommendation for the initial submission and patients in 
Scotland would have had earlier access to golimumab.  
 
Case studies eleven and twelve for ranibizumab for the treatment of macular 
oedema secondary to Branch Retinal Vein Occlusion (BRVO) (case study 12a) 
and CRVO (case study 12b) also included divergent recommendations due to 
uncertainties for cost-effectiveness of the product. The PBAC was the only HTA 
agency to issue a negative recommendation for both indications due to these 
uncertainties. Ranibizumab is a high cost product and the calculated 
Incremental Cost Effectiveness Ratios (ICERs) exceeded the implicit QALY 
threshold for the PBAC. However, the PBAC also expressed concerns 
surrounding the choice of comparator. The same comparators were included in 
the submissions to the four agencies and all agencies generally accepted 
observation or best supportive care as a comparator for CRVO and laser 
photocoagulation for BRVO. However, the PBAC noted that in clinical practice 
bevacizumab was often used to treat both CRVO and BRVO despite 
bevacizumab not having TGA approval for these indications and not formulated 
for intravitreal use. The NICE appraisal also concluded bevacizumab to be an 
appropriate comparator despite having no marketing authorisation from the 
EMA, as this is not a prerequisite to be considered as a comparator. NICE 
considered the safety and efficacy of bevacizumab for the treatment of CRVO 
and BRVO, but ultimately did not include bevacizumab in the cost-effectiveness 
analysis due to a lack of evidence.    
 
Fingolimod for the treatment of MS (case study 9) also resulted in a divergent 
recommendation due to concerns regarding the cost-effectiveness of the 
product as a result of comparator choice. The SMC rejected the initial 
submission in March 2012 due to the economic case not being demonstrated, 
but subsequently approved fingolimod for restricted use in September 2012 
when the manufacturer resubmitted with a new comparator (natalizumab). 
Natalizumab was also submitted as a secondary comparator in the PBAC 
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submission a year earlier (March 2011). Fingolimod is also an example of a 
high cost product that exceeds implicit QALY threshholds, but still gains 
approval: CDR calculated that the cost per QALY could be as high as 
CAN$337,381 and PBAC calculated the incremental cost per QALY up to 
AUD$200,000. The four agencies all acknowledged the therapeutic benefits of 
fingolimod and its innovative value as the first oral treatment for MS and the 
need for new treatment option in this area.  
 
The CDR issued negative recommendations for two medicines for the treatment 
of acute coronary syndromes. The CDR first rejected prasugrel in February 
2011 due to concerns surrounding the trial design which they believed may not 
be generalisable to Canadian clinical practice and also expressed safety 
concerns for the product. NICE also noted that the trial submitted may not be 
generalisable to English clinical practice and PBAC, NICE and SMC all noted 
concerns over safety. The CDR also rejected ticagrelor in December 2011 
(case study 14) due to uncertain therapeutic benefit for the North American 
patient population, but recommendations for both ticagrelor and prasugrel 
noted that a reduced price could result in a positive decision. These are 
examples where a divergent recommendation from the CDR is likely to be due 
to the remit of the CDR as the CDR does not negotiate price. The participating 
drug plans are responsible for price negotiations and therefore the CDR has 
acknowledged in its recommendation that this medicine may be a viable option 
and manufacturers are granted the opportunity to resubmit at a reduced price 
during the embargo period if the CDEC recommendation states that a reduced 
price will be considered. However, the manufacturer can only submit a reduced 
price once and the CDR does not consider price listing agreements, price caps, 
rebates or changes to the indication population (CDR, 2014). The results of 
these case studies support the results of Clement et al. (2009) who also 
concluded that recommendations from the CDR, NICE and PBAC can vary due 
to agencies ability to negotiate price.  
The rationale for the divergent decision issued by the PBAC for incivek for the 
treatment of hepatitis C (case study 13) was very different to the other 6 case 
studies. This case study provides an example where the timing of the process 
was the cause of uncertainties that led to a negative recommendation. The four 
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agencies all accepted that incivek demonstrated a clinical benefit, but the 
submission to the PBAC (November 2011) was prior to TGA approval (March 
2012) and therefore the PBAC did not have the final TGA product information 
at the time of the appraisal and the submission was rejected. The resubmission 
was subsequently approved in July 2012 after TGA approval.  
 
The seven divergent case studies demonstrate examples where new medicine-
indication pairs have been rejected due to uncertainties surrounding a range of 
factors such as: cost-effectiveness, comparator choice, clinical benefit, safety, 
trial design, and submission timing. In several of the case studies with divergent 
recommendations, the rationale for the negative recommendation was also 
considered by the other three agencies yet they issued a positive 
recommendation. Therefore, the differences in recommendations could be 
considered to be due to agencies approaches to risk perception. This supports 
an observation by Clement et al. (2009) where observed differences in listing 
decisions from the CDR, PBAC and NICE were more likely due to agency 
processes and different attitudes to risk than the interpretation of clinical and 
economic evidence. Two case studies provide examples where the SMC 
initially rejected a submission, but later accepted a resubmission that contained 
a cost-minimisation comparison or a comparator choice that was not included 
in the original submission, but was included in submissions to other agencies a 
year prior to the initial SMC submission. This could suggest that manufacturers 
may require more specific guidance for submissions and more transparency 
regarding how the agency considers different types of evidence to determine a 
listing decision. Increasing consistency of the HTA process and evidence 
requirements could reduce discordant recommendations that are a result of 
initial submissions that misjudged the evidence requirements. Discordant 
recommendations that are due to differences in agency risk perception or 
agency mandate to negotiate price are more difficult to overcome.  
 
This study expands upon prior work by Clement et al. (2009), Nicod and 
Kanavos (2012) and Spinner et al. (2013) that reviewed similarities and 
differences between HTA recommendations from all, or three, of the four 
jurisdictions examined in this study. The HTA recommendations reviewed in 
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this study are for a more recent selection of medicine-indication pairs and have 
a unique inclusion criteria by requiring all medicines to be reviewed by the CDR. 
This enables this study to draw comparisons with the Canadian regional payers 
reviewed in chapter 6 in addition to this international comparison. The HTA 
recommendations for the 89 medicine-indication pairs has identified substantial 
variation between recommendations issued by the CDR, PBAC, NICE and 
SMC and, unlike the comparative studies by Clement et al. (2009) and Nicod 
and Kanavos (2012), this study excluded resubmissions. This focused on the 
first recommendation issued by agencies and provided insights into how 
successful the manufacturers initial submissions are for these four established 
and transparent HTA agencies (Neumann et al., 2010). The case studies have 
included resubmissions as this can help identify the impact of the updates for 
the resubmissions.  The results of this research includes case studies where 
submissions were for trials that did not appropriately follow clinical practice for 
the country of submission (case study 11) and uncertainties surrounding 
comparator choice (case studies 9, 12a and 12b). This supports the findings by 
Spinner et al. (2013), which included comparator choice and agency reasons 
for rejecting trials as a result of varying clinical evidence. Unlike the study by 
Skinner et al. this did not focus on clinical evidence and also identified other 
factors for divergent decisions, such as an agency’s ability to negotiate price or 
product listing agreements (case studies 11 and 14) which supports the findings 
of Clement et al. (2009) and Nicod and Kanavos (2012). The prevalence and 
impact of the factors identified in the full set of divergent case studies could be 
investigated in further work with a larger dataset and more detailed insights 
could be obtained if data can be sourced directly from agencies where 
information is not available in detail in the public domain.  
 
SUMMARY 
 Process maps for the regulatory to reimbursement pathways of new 
medicines and indications were produced for the CDR (Canada), PBAC 
(Australia), NICE (England) and SMC (Scotland).  
  
 160 
 
 The comparison of HTA recommendations for new medicine-indication 
pairs issued from January 2009 to May 2013 builds on previous work 
comparing recommendations from the CDR, PBAC and NICE (Clement 
et al. 2009; Nicod and Kanavos 2012; Spinner et al. 2013). 
 
 Percentage agreement using a binomial category classification enabled 
the calculation of percentage agreement and kappa coefficients. NICE 
and SMC had the greatest percentage agreement for recommendations, 
but the CDR and PBAC demonstrated the greatest interrater reliability 
with a kappa coefficient of 0.336.  
 
  Using the CDR recommendations as inclusion criteria produces a 
unique dataset that enables comparisons to be drawn with a study 
evaluating the impact of CDR recommendations on regional payer 
decision-making (Chapter 6).   
 
 Seven case studies compared the rationale for medicine-indication pairs 
that received a positive recommendation from four agencies and seven 
case studies investigated the rationale for divergent negative HTA 
recommendations by a single agency for medicine-indication pairs that 
received a positive recommendation by the other three agencies. 
 
 Overall, the four HTA agencies reviewed for this study are all established 
agencies with expertise, experience and generally similar approaches 
for conducting HTA, but their recommendations still have substantial 
differences. 
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CHAPTER 6 
 
 
 
 
 
 
 
An Evaluation of the Impact of 
Canadian National HTA 
Recommendations for Provincial 
Payers 
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INTRODUCTION 
Canada’s publicly funded national healthcare system has been providing 
medical care for residents for nearly half a century. In accordance with the 
Canada Health Act of 1984, provinces are required to provide all medically 
necessary hospital and physician services, although this mandate only included 
prescription medicines when administered within hospital. Multiple payers 
provide coverage for outpatient medicines, including 19 publicly funded federal, 
provincial and territorial drug plans, each with varying eligible groups and 
formularies. In 2013, the total annual expenditure for prescription medications 
in Canada was an estimated $29.3 billion, of which $12.2 billion was funded 
through the public sector (Canadian Institute for Health Information (CIHI), 
2014) which is similar to many European publicly funded healthcare systems. 
Canada’s public drug plans utilise health technology assessment (HTA) to 
inform reimbursement decision-making. Canada has a long history of HTA and 
created its first HTA body in 1988 with the establishment of Conseil d'Évaluation 
des Technologies de la Santé du Québec (CETS) to promote, support and 
produce assessments of health technologies to advise the Ministère de la Santé 
et des Services sociaux (Minister of Health and Social Services) (Office of 
Technology Assessment, 1995). In 1989, the Canadian Coordinating Office of 
Health Technology Assessment (CCOHTA) was created as a pan-Canadian 
HTA body to provide clinical and economic guidance for the reimbursement of 
health technologies to 18 public drug plans (Menon and Stafinski, 2009). In 
1991, the British Columbia Office of Health Technology Assessment (BCOHTA) 
was created within the University of British Columbia as HTA was also 
becoming established within Alberta and Saskatchewan (Office of Technology 
Assessment, 1995).  
 
Health Technology Assessment has evolved in Canada and throughout the 
world as healthcare policy and decision-makers are increasingly utilising HTA 
to ensure healthcare resources are used efficiently (Allen et al., 2013). The 
Canadian Agency for Drugs and Technologies in Health (CADTH) provides the 
Common Drug Review (CDR) programme to conduct a centralised national 
HTA review recognised by all federal, provincial and territorial public drug plans 
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except that of Quebec. Prior to the inception of the CDR in 2002, multiple 
provincial, territorial and federal drug plans performed their own HTAs to 
determine coverage for a new drug product. CADTH established the CDR to 
standardise the Canadian HTA environment, reduce the duplication of HTA and 
ultimately to decrease the time taken for patients to access innovative 
medicines (Spitz, 2013). The more recently established European Network of 
HTA (EUnetHTA) was also created to develop a more timely and efficient use 
of HTA resources for participating members (European Network for Health 
Technology Assessment (EUnetHTA), 2008). However, EUnetHTA aims to 
create a sustainable network of European HTA agencies that share information 
and methodologies, rather than creating a single European HTA agency to 
provide reimbursement recommendations. EUnetHTA participants will 
ultimately need to provide a reimbursement recommendation that considers 
their unique population needs, budget and existing treatment options. The 
patient populations, healthcare systems, budgets, political and cultural 
differences of EUnetHTA members are more heterogeneous than the 
participating plans of the CDR, but the Canadian HTA environment is an 
example of a working model for sharing HTA information that is contextualized 
at the local level and this can provide useful insights for the European HTA 
environment.  
 
The CDR has been subjected to criticism from various stakeholders. In 2007, 
the Canadian Diabetes Association prepared a written submission to the House 
of Commons Standing Committee on Health that questions whether the CDR 
has created duplication of work and delays for patient access to new medicines 
(Canadian Diabetes Association, 2007). The written submission states that 
participating drug plans were to dismantle their existing drug review processes 
and focus on budget impact and regional health priorities, but refers to the 
expansion of Ontario’s expert committee for reviewing medicines to now include 
patient representatives and British Columbia’s review of its provincial drug 
review. In 2011 the Atlantic Institute for Market Studies (AIMS) published a 
report evaluating the alignment of a sample of provincial listing decisions and 
CDR recommendations (Attaran et al., 2011). Attaran et al. (2011) calculated 
percentage agreement between the CDR and three provinces (Ontario, Prince 
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Edward Island and Newfoundland and Labrador) to be as low as 50% which is 
described as ‘no better than random chance’. However the findings of Attaran 
et al. (2011) conflict with a study that also compared CDR recommendations 
from inception to 2009 with provincial listing decisions and identified greater 
agreement between the CDR and provincial listing decisions (Gamble et al., 
2011).  
 
No studies have subsequently been published comparing post-2009 CDR 
recommendations with provincial listing decisions. Therefore, there is a gap in 
the existing body of knowledge and a more recent comparison of CDR 
recommendations and with provincial listing decisions will provide data that is 
more up-to-date and relevant for the current HTA environment. Building upon 
existing studies is also recommended by McMahon et al. (2006) to identify 
whether the CDR is creating more standardised coverage for medicines across 
Canada.  This will also provide more evidence to either support or oppose 
Morgan et al. (2006) who argues that multiple provincial decision-makers 
reduces the impact of the CDR and similarly, Hollis and Law (2004) who predict 
that, without a national Canadian formulary, the CDR will only slightly improve 
standardization of medicines coverage across provinces. Therefore, this 
research focuses on the Canadian HTA environment to compare the non-
mandatory HTA recommendations from the national CDR and the final listing 
decisions from provincial drug plans and HTA. For this study, the 4 largest 
provinces have been chosen for comparison with the CDR: Alberta, British 
Columbia, Ontario and Quebec. Quebec has its own HTA agency and, 
therefore, does not officially use the CDR report as a guide for their final 
reimbursement decision. 
 
OBJECTIVES  
This study aims to evaluate the impact of the CDR recommendations for 
participating payers. This will be achieved by: 
 Comparing CDR recommendations issued from January 2009 to May 
2013 with listing decisions from three participating provincial public 
payers (Alberta, British Columbia and Ontario) and Quebec 
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 Identifying HTA resources for Alberta, British Columbia, Ontario and 
Quebec 
 Understanding how these four decisions-makers use CDR assessments 
 Identifying additional assessments that are not considered for the CDR 
recommendation, but are required by the three provincial payers 
 Comparing how the patient-voice is included in the listing decision-
making process in Alberta, British Columbia, Ontario and Quebec 
 
METHODOLOGY  
Information from the public domain was evaluated to identify the key agencies 
involved in the regulatory, HTA and reimbursement process for the CDR and 
new medicines in 4 jurisdictions: Alberta, British Columbia, Ontario and 
Quebec. This information was collected to produce a process map for each 
jurisdiction using the novel mapping methodology described in chapter 3 (Allen 
et al., 2010a). The process maps display the regulatory, HTA and 
reimbursement pathways through a uniform methodology for visual 
comparison. Data for the reimbursement recommendations and final listing 
decisions were identified for the responsible agency or organisation. The first 
agency to be reviewed was CADTH, to identify the list of drug products that 
meet the following inclusion criteria: initial submission to the CDR and issued a 
recommendation from January 2009 to May 2013. Data collected from the CDR 
section of the CADTH website included the following for each medicine-
indication pair: Generic name; proprietary name; indication; date final CDR 
recommendation issued (dd/mm/yyyy) and final recommendation. The online 
websites for Alberta, British Columbia, Ontario and Quebec were subsequently 
searched for the initial listing decision of the same medicine-indication 
combinations identified from the CDR. The listing decisions for each province 
were also sent to each provincial drug plan for verification. The data collected 
for HTA recommendations and payer listing decisions included a range of 
different reimbursement outcomes for each jurisdiction. All potential outcomes 
were reviewed to enable an appropriate cross comparison of the 
recommendations and listings to create multinomial categories for comparison, 
namely: recommended, recommended with restrictions and not recommended. 
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These multinomial categories were reviewed with the CDR and provincial 
payers/agencies to ensure comparability.   
 
Using the multinomial categories, the CDR recommendation for each drug 
product was then compared with the medicine listing from each of the four 
provincial payers/agencies and numerically coded for comparison and to 
identify where there were divergent outcomes. The percentage of listings that 
agreed with the CDR recommendations was subsequently calculated. From 
this list five case studies were selected on the basis of at least one 
agency/payer issuing a listing decision that differs from the CDR 
recommendations and each case study was further investigated by 
questionnaire and interview. Alberta Health, INESSS and CADTH reviewed the 
questionnaire during its development to ensure the scope was feasible and the 
lexicon was not misleading. This was particularly important for the Quebec 
agency where French is the predominantly spoken language. The 
questionnaire contained two parts: the first part includes agency/payer profile 
information, and the second part was drug-specific data. The agency profile 
section included: year HTA activities began; total annual spend; total number 
of full time employees; review committee membership composition; and budget 
impact considerations. Each questionnaire was prefilled with the chosen 
medicine and indication. When possible, additional sections were completed 
with information from the public domain and this was verified by the regional 
payers. The data requested in the drug specific section of the questionnaire 
included: consultation with patient advocacy groups; consultation with 
manufacturer; date of final HTA recommendation and date of final listing 
decision. Following distribution of the questionnaire, semi-structured interviews 
were conducted by the primary researcher with representatives from the 
provincial drug plans or HTA agency in Alberta, British Columbia, Ontario and 
Quebec.  
  
 167 
 
Table 6.1: General agency and survey specific discussion points for 
interview 
 
Main question Additional questions 
 Can you tell me about the 
resources available to your 
agency? 
 How many staff?  
 How many staff are allocated to HTA/assessment of 
pharmaceuticals? 
 Annual Budget?  
 Proportion of budget allocated to HTA? 
 Can you provide an 
overview of the process for 
reviewing a new drug for 
reimbursement? 
 Target time for drug review? 
 Average time for drug review? 
 How do you communicate with the manufacturer during the 
review process? 
 How is the final recommendation deliberated? 
 What happens if you can't reach consensus? 
 How is the final result disseminated? 
 What initiatives does you agency undertake to promote 
transparency? 
 What is the key driver for transparency? 
 Can your agency negotiate price with the manufacturer? 
 Can you tell me how 
patient input is included in 
the decision-making 
process? 
 Can you tell me if your agency provides guidance or financial 
support for patient input? 
 How does your agency view input from patient groups 
sponsored by industry? 
 Can you think of an example when patient input has been the 
primary reason for a positive reimbursement decision? 
 Can you tell me how your 
agency uses the CDR 
recommendation and 
report? 
 How does your agency receive applications for a new drug to 
be reimbursed? 
 Can you tell me if your agency conducts any assessments in 
addition from the common drug review? 
 How useful is the common drug review report for 
reimbursement decision-making at your agency?  
 How often do you think your agency complies with the CDR 
recommendation?  
 In your experience, which 
factors often have the 
most impact on the final 
reimbursement decision? 
 What are the most common reasons for a change in 
reimbursement status? 
 What are the most common causes for a drug to be 
reassessed? 
 Can you tell me how your 
agency reviews medical 
devices? 
 How do you communicate with stakeholders during the review 
process? 
 How is the final recommendation deliberated? 
 What happens if you can't reach consensus? 
 Can you review the 
classification table and tell 
me if you think the listing 
recommendations from 
your agency are 
appropriately classified?  
 Show table of drug recommendation classifications 
 Can you tell me about your 
experience completing the 
questionnaire? 
 Were there any questions in the questionnaires that need 
clarification? 
 Was any of the prefilled information incorrect? 
Drug specific questions 
(personalized for agency) 
 Were any of the drugs subject to a pricing agreement? 
 Was patient input provided? 
 How was patient input requested? 
 Can you tell me which group provided the patient input? 
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Representatives were chosen from a very small population of Canadian 
provincial payers, based on relationships established from previous research 
and introductions by senior staff at the Canadian Common Drug Review. The 
interviews were supported by a list of core and additional questions to ensure 
each interview covered all the required topics (Table 6.1). The primary 
researcher also transcribed and manually coded the individual transcripts to 
compare and identify common themes.  
 
RESULTS 
The results are presented in the following three parts: 
PART I- Process maps for the regulatory to reimbursement pathways for the 
Canadian national HTA review and four provincial pathways 
PART II- Comparison of CDR recommendations and provincial reimbursement 
decisions 
PART III- A description of provincial payers and HTA structure, resources and 
medicine case studies 
 
PART I- Process maps for the regulatory to reimbursement 
pathways for the Canadian national HTA review and four 
provincial pathways 
 
HTA process maps were produced for the CDR and the four provinces using 
information primarily sourced from the public domain (Appendix A), and from 
the semi-structured interviews.  
 
Common Drug Review (CDR)  
Although outlined previously, this chapter will include a more detailed 
description of the CDR as it is pivotal for this study, which is solely focused on 
Canada. The CDR process is driven by manufacturer submissions, but 
applications for new medicines, medicines with new indications and new 
combination products are required to have obtained a Notice of Compliance 
(NOC) from Health Canada or are expected to obtain an NOC from Health 
Canada within 90 days of submission (pre-NOC submission) (figure 6.1, Step 
1) (Canadian Agency for Drugs and Technologies in Health (CADTH), 2013).  
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Generally, submissions are reviewed as they are received on a first-come, first-
served basis. Once an application has been received, the name of the medicine 
under review is posted on the CADTH patient input website with a 15-day 
deadline for response (Figure 6.1 Step 2). Patient input is then forwarded to the 
review team, which includes clinical experts, clinical and economic reviewers 
and information specialists. The review team conducts an independent 
literature search to be reviewed with the manufacturer’s submission and patient 
input to produce a CDR Clinical Review Report. The review team then uses the 
information in the CDR Clinical Review Report to assess the manufacturer-
submitted pharmacoeconomic data to produce the CDR Pharmacoeconomic 
Review Report.  
 
Figure 6.1: Process map for the Common Drug Review (March 2014)  
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The final reviewers’ reports are sent to the manufacturer for comment and 
reviewers’ responses to manufacturers’ comments are included in the brief 
prepared for use by the Canadian Drug Expert Committee (CDEC) (Canadian 
Agency for Drugs and Technologies in Health (CADTH), 2015a) (Figure 6.1, 
step 3). CDEC is an advisory body composed of healthcare professionals and 
public members which reviews the information in the reviewers’ reports and a 
reimbursement recommendation is decided by a majority vote at the scheduled 
CDEC meeting after a period of deliberation (Canadian Agency for Drugs and 
Technologies in Health (CADTH), 2014).  Manufacturers are given ten business 
days from receipt of the CDEC recommendation to file a request for 
reconsideration. In accordance with Canada’s decentralised healthcare 
system, the final notice of CDEC recommendation is sent to the federal, 
provincial and territorial drug plans, where each plan will review the submission 
and the CDEC recommendation in their own local context. The Patented 
Medicines Price Review Board (PMPRB) regulates the prices of patented 
medicines sold in Canada and manufacturers are required to submit prices from 
inception to patent expiry (Figure 6.1, step 4).  
 
CDR Participating provincial payers  
Alberta, British Columbia and Ontario are three of the eighteen CDR 
participating provincial, territorial and federal public payers and have been 
evaluated for this study. These three provincial payers have been reviewed to 
produce three process maps to show the relationship between the CDR and 
the provincial specific process. The HTA process maps for provinces that are 
participants of the CDR, initially follows the process for submission to the CDR 
outlined in chapter 5. The process following the final CDR review 
recommendation are province specific and are outlined below.  
 
Alberta 
The Alberta Minister of Health and Wellness determines the final listing decision 
for new medicines and indications (Figure 6.2). The CEDEC recommendation 
and CDR clinical and economic dossiers are considered with additional regional 
specific data to form a listing decision that accounts for the local context. 
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Alberta’s Expert Committee on Drug Evaluation and Therapeutics (ECDET) is 
required to review all new medicines and indications that do not meet the CDR 
requirements (Figure 6.2). Alberta also offers a Price Listing Agreement (PLA) 
option for medicines that have not been listed through the CDR or the ECDET 
process (Alberta Health, 2015).  
 
Figure 6.2: Process map for the regulatory to reimbursement pathway 
for new medicines in Alberta (September 2013) 
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6.3). The CDR dossiers are sent to the Drug Review Resource Committee 
(DRRC) to determine the review requirements and assemble a Drug Review 
Resource Team (DRRT) that will prepare a report of the medicine to be 
reviewed for the manufacturer to comment (British Columbia Ministry of Health, 
2015a). The Ministry of Health also publishes a list of medicines under review 
online on ‘Your Voice’ website which enables patients and carers to submit their 
comments for consideration by an independent committee of 12 professional 
and public members (Drug Benefit Council (DBC)) (British Columbia Ministry of 
Health, 2015b). Patient input from ‘Your Voice’ website is sent with the DRRT 
report and manufacturer’s comments for the DBC to review and provide a listing 
recommendation for the Minister of Health. 
 
Figure 6.3: Process map for the regulatory to reimbursement pathway 
for new medicines in British Columbia (March 2013) 
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Ontario 
Manufacturers seeking listing approval for the Ontario Drugs Benefit Program 
(ODBP) for new medicines and indications can submit an application to the 
ODBP following completion of the CDR process (Figure 6.4). The submission 
is reviewed by the Committee to Evaluate Drugs (CED), which consists of 16 
members including two patient representatives (Ministry of Health and long-
term care, 2013) (Figure 6.4). The CED provides a listing recommendation to 
the executive officer of the ODBP and they determine the final listing decision. 
 
Figure 6.4: Process map for the regulatory to reimbursement pathway 
for new medicines in Ontario (March 2013) 
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Québec: Institut national d’excellence en santé et en services sociaux 
(INESSS) 
In 2000, CETS became the Agence d’évaluation des technologies et des 
modes d’intervention en santé (AETMIS) (Battista et al., 2009). Eleven years 
later, AETMIS merged with the Conseil du médicament and was renamed 
INESSS. Amongst other roles, INESSS is responsible for assessing the clinical 
advantages and cost effectiveness for drugs, devices and interventions to 
provide a recommendation for their use and coverage by the Québec public 
insurance plan, the Régie de l'assurance maladie du Québec (RAMQ).  
 
The INESSS review process for medicines takes about 6 months from 
submission to completion and the public announcement of the decision by the 
Minister (Institut national d’excellence en santé et en services sociaux 
(INESSS), 2013). INESSS considers applications from the 
manufacturer/sponsor for medicines that have been granted a NOC from Health 
Canada and the reviews concern medicines to be added to Québec’s drug 
insurance plan (Liste des medicaments) as well as for medicines to be 
dispensed in hospitals (Liste des medicaments-Établissements), including 
innovative medicines, as well as generics (Figure 6.5, Step 1).  When a 
completed submission is received, the medicines are added to a work schedule 
and are posted online once the deadline for applications has passed (figure 6.5, 
Step 2).  
 
As soon as the work plan is published online, patient advocacy groups and 
professional bodies are invited to provide feedback. INESSS also accepts 
patients’ comments from individuals that are not part of a patient group 
organisation. The manufacturer’s submission and any feedback from 
stakeholders is reviewed by professionals at INESSS and the Comité 
scientifique de l’évaluation des médicaments aux fins d’inscription (CSEMI) 
(Institut national d’excellence en santé et en services sociaux (INESSS), 2014). 
CSEMI consists of healthcare professionals, economists, ethicists, managers, 
experts and public members. The submitted medicine first undergoes a clinical 
review to assess effectiveness in terms of the therapeutic benefit compared to 
current reimbursed treatment options. If the therapeutic benefit cannot be 
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established, the review goes no further and the Ministère de la Santé et des 
Services sociaux (Minister of Health and Social Services) is notified. If a 
satisfactory therapeutic benefit is determined, the value of the medicine product 
is considered in the dimensions of price, cost effectiveness, the advisability of 
adding the medicine to the list and its impact on the health and social services 
system. After the review is complete, CSEMI produces a report to be sent to 
the INESSS Board of Directors, who ratify the CSEMI recommendation to be 
passed to the Ministère de la Santé et des Services sociaux (Minister of Health 
and Social Services), who determines the final reimbursement decision for the 
Québec public insurance plan. 
 
Figure 6.5: Process map for the regulatory to reimbursement pathway 
for new medicines in Quebec (September 2013)  
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The assessment report is available to the public on INESSS website when the 
announcement is made (Institut national d’excellence en santé et en services 
sociaux (INESSS), 2013). The manufacturer is also required to provide pricing 
details of all patented medicines sold in Canada from initial sale to patent expiry 
(Figure 6.5, step 3). 
 
PART II- Comparison of CDR recommendations and provincial 
reimbursement decisions 
Two methods have been used to classify the HTA and payer recommendation 
in this study. The binomial classification contains two categories: positive and 
negative recommendations. The positive recommendation category combines 
the multinomial recommended and recommended with restriction categories 
and the negative recommendation category is the equivalent of the ‘do not 
recommend’ category (Table 6.2).  
Table 6.2: Comparison of options for HTA recommendations and 
formulary listing outcomes. 
 
Payer or HTA 
agency 
Binomial classification: 
Positive recommendation 
Negative 
recommendation 
Multinomial classification: 
Recommended 
Recommended 
with restrictions Not recommended 
CDR List 
List with 
criteria/condition Do not list 
 
List in a similar 
manner  
Do not list at the 
submitted price 
Alberta Health Regular benefit 
Rare disease drug 
program Not a benefit 
 
Regular benefit/ 
restricted benefit 
Multiple Sclerosis 
(MS) Drug  
  
Step Therapy/ 
Special 
Authorisation  
  Restricted benefit  
British Columbia 
Pharmacare General benefit Special Authority Non-benefit 
Ontario Drug 
Benefit Program Regular benefit Limited use 
Funding not 
available 
  
Exceptional access 
program 
Funding not 
considered 
INESSS (Quebec) 
Ajout aux listes de 
médicaments 
Medicament 
d'Exception Avis de refus 
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Recommendations recorded from the CDR were one of five different outcomes:’ 
list’; ‘list in a similar manner’; ‘list with criteria/condition’; ‘do not list’ and ‘do not 
list at the submitted price’. For the multinomial classification with three universal 
categories, the ‘list’ and ‘list in a similar manner’ recommendations were 
categorised as ‘recommended’. 
 
The ‘list with criteria/condition’ recommendations were allocated to the 
‘recommended with restrictions’ category and the ‘do not list’ and ‘do not list at 
the submitted price’ were categorised as ‘not recommended’. Medicines issued 
a ‘regular benefit’ or ‘regular benefit/restricted benefit’ were grouped in the 
universal ‘recommended’ category. Medicines issued a ‘restricted benefit’, 
‘Step Therapy/ Special Authorisation’ or allocated to the ‘rare disease program’ 
or ‘Multiple Sclerosis Drug’ were grouped in the recommended with restrictions 
category and medicines that were deemed ‘not a benefit’ were allocated to the 
not recommended category. For British Columbia, ‘General benefit’ medicines 
were grouped in the recommended category and the ‘special authority’ and ‘not 
a benefit’ medicines were allocated to the recommended with restrictions and 
not recommended categories respectively. Similarly, the ‘regular benefit’ 
medicines for Ontario were grouped in the recommended category, ‘limited use’ 
and ‘Exceptional access’ medicines were grouped in the recommended with 
restrictions category and medicines that were granted a ‘funding not available’ 
or ‘funding not considered’ recommendation were grouped in the not 
recommended category. Medicines with an ‘Ajout aux listes de médicaments’ 
recommendation from INESSS were grouped in the recommendation category, 
‘Medicament d'Exception’ medicines were added to the recommended with 
restrictions group and medicines with an ‘Avis de refus’ recommendation were 
allocated to the do not recommend category. 
 
The original 86 medicine-indication pairs that were identified for CDR 
recommendations issued from January 2009 to May 2013 (chapter 5) were also 
used in this study. However, the total number of medicine-indications evaluated 
in chapter 5 was 89 because other national HTA agencies included in the study 
had split some indications to issue multiple recommendations. To ensure the 
study was a like-for-like comparison, the indications were subsequently split 
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and the total number of medicine-indications reviewed in chapter 5 was 89. The 
86 medicine-indication pairs evaluated in this study were grouped according to 
the BNF therapeutic categories to provide an overview of the therapeutic areas 
and the proportion of recommendations using the multinomial categories 
(Figure 6.6). The largest therapeutic area is the central nervous system (n=19) 
followed by the cardiovascular system (n=12) and the Endocrine system 
(n=11). The least common therapeutic areas were the gastro-intestinal system 
(n=3), skin (n=3) and malignant disease and immunosuppression (n=2). The 
latter is a direct result of the inclusion criteria because the CDR does not review 
oncology medicines. 
 
Figure 6.6: Medicines approved by the CDR from January 2009 to May 
2013 grouped by therapeutic area  
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An overview of the total number of medicine-indication pairs reviewed by the 
CDR and the four provincial payers/ agencies and their allocation to the 
multinomial categories is provided in Figure 6.7. Alberta health reviewed the 
smallest number of medicine-indication pairs (n=76), Ontario and Quebec both 
reviewed 81 and British Columbia reviewed 84 medicine-indication pairs. 
 
Figure 6.7: Overview of medicine recommendations issued from January 
2009 to May 2013 by the CDR with provincial payers and HTA 
recommendations 
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Table 6.3: Proportion of medicine-indication pair recommendations by 
multinomial categories 
 
HTA agencies and 
payers 
Recommended 
(95% CI) 
Recommended 
with restrictions 
(95% CI) 
Not 
recommended 
(95% CI) 
CDR (n=86) 
19.8%  
(12.7%; 29.4%) 
26.7%  
(18.5%; 36.9%) 
53.5%  
(43.0%; 63.7%) 
Alberta (n=76) 
18.4%  
(11.3%; 28.6%) 
34.2%  
(24.5%; 45.4%) 
47.4%  
(36.5%; 58.4%) 
British Columbia 
(n=84) 
4.8%  
(1.9%; 11.6%) 
51.2%  
(40.7%; 61.6%) 
44.0%  
(33.9%; 54.7%) 
Ontario (n=81) 
18.5%  
(11.6%; 28.3%) 
44.4%  
(34.1%; 55.3%) 
37.0%  
(27.3%; 47.9%) 
Quebec (n=81) 
17.3%  
(10.6%; 26.9%) 
33.3%  
(24.0%; 44.1%) 
49.4% 
(38.8%; 6.0%) 
 
 
Table 6.4: Proportion of medicine-indication pair recommendations by 
binomial categories 
 
HTA agencies and 
payers 
Positive 
recommendation 
(95% CI) 
Negative 
recommendation 
(95% CI) 
CDR (n=86) 
46.5%  
(36.3%; 57.0%) 
53.5%  
(43.0%; 63.7%) 
Alberta (n=76) 
52.6%  
(41.6%; 63.5%) 
47.4%  
(36.5%; 58.4%) 
British Columbia 
(n=84) 
56.0%  
(45.3%; 66.1%) 
44.0%  
(33.9%; 54.7%) 
Ontario (n=81) 
63.0%  
(52.1%; 72.7%) 
37.0%  
(27.3%; 47.9%) 
Quebec (n=81) 
50.6%  
(40.0%; 61.2%) 
49.4% 
(38.8%; 6.0%) 
 
The binomial and multinomial categories were also used to calculate the 
percentage agreement between the CDR recommendations and regional payer 
decisions or regional HTA (INESSS). For the multinomial categories the 
percentage agreements ranges from 63% (Ontario) to 74% (Alberta) (Figure 
6.8). The binomial categories increased the percentage agreements to 72% 
agreement with Quebec, 78% with Ontario, 82% with British Columbia and 83% 
with Alberta (Figure 6.9).  
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Figure 6.8: Percentage agreement CDR recommendations with 
provincial payer and HTA recommendations using multinomial 
categories 
 
 
 
 
Figure 6.9: Percentage agreement of provincial payer and HTA 
recommendations and CDR recommendations using binomial 
categories 
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(0.647) demonstrated substantial levels of agreement with the CDR and Ontario 
(0.560) and Quebec (0.432) scored moderate agreement with the CDR 
recommendations (Viera and Garrett, 2005). 
 
PART III- A description of provincial payers and HTA structure, 
resources and medicine case studies  
 
The four provincial payers/agencies were surveyed using a combination of 
questionnaires and semi-structured interviews. Invitations to interview were 
sent to the four provinces and interviews were scheduled with seven 
representatives (Alberta n=1, British Columbi n=1, Ontario n=2 and Quebec 
n=3) with decision-making or advisory roles. The semi-structured interviews 
were conducted, transcribed and analysed by the primary researcher. Answers 
were manually coded for each transcript and then compared to identify the 
following common themes for discussion: 
  Payer/agency resources 
 Provincial review processes for new medicines  
 Utilisation of the CDR recommendation and report 
 Manufacturers role in the provincial review 
 Opportunities for patient input 
 Factors that impact listing decisions 
 Opportunities for price negotiations  
 
The first part of the survey and semi-structured interviews requested 
information about the payer organisation/HTA agency and the results indicated 
a very varied payer environment. For example, the total number of full time 
employees ranged from twenty (Alberta) to one hundred and thirty (Quebec) 
and total number of full time employees allocated to HTA or reimbursement 
review activities ranged from four (Ontario) to twenty-five (Quebec). All four 
provincial payers/agencies include a review committee to provide a listing 
decision. The majority of members on these review committees were 
physicians for all provinces except for British Columbia, which had a marginally 
greater number of pharmacists (Table 6.5). Alberta was the only province that 
did not include a health economist whereas other member professions included 
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ethicists, bioethicists and statisticians. Only two provincial expert committees 
included patient members (Quebec and Ontario) but British Columbia included 
three public members. The CDR, British Columbia, Ontario and Quebec 
provided an opportunity for patient input online and all accepted submissions 
from patient advocacy groups but only British Columbia and Quebec accepted 
an input from individuals (Table 6.6). Alberta, British Columbia and Ontario also 
use patient input from the CDR process.   
 
The second part of the survey and semi-structured interviews requested 
information about five specific case studies. These were identified for medicine-
indication pairs that received discordant provincial listing decisions. Only one 
of the case studies (Olmesartan) received an initial positive recommendation 
(binomial categories) from all four provinces (Figure 6.10). Three case studies 
(aztreonam, calcitriol and golimumab) received an initial positive 
recommendation from three provinces and one case study (Saxagliptin) 
received a single positive recommendation.  
 
Figure 6.10: Provincial listing decision agreement with CDR  
recommendations for 5 case studies with binomial categories 
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Table 6.5: Provincial expert committee composition 
Payer or HTA 
Agency 
Committee Composition 
Physicians Pharmacists Health Economists Patient representatives Other total 
Alberta Health 4 4 0 0 0 8 
British Columbia 
Ministry of Health 
3 4 1 0 
3 public, 1 
bioethicist 
12 
INESSS 7 4 1 2 
2 ethicists, 1 
statistician expert 
17 
Ontario Drug 
Benefit Program 
12 2 1 2 1 Chair 17 
 
 
Table 6.6: Patient input opportunities at the national and regional HTA agencies and payers
 
N/A – Not Applicable
Payer or HTA 
Agency 
Patient 
members on 
expert 
committee 
Public 
members on 
expert 
committee 
Call for patient 
input online 
Input accepted 
from patient 
groups 
Input accepted 
from individuals  
preferred 
template for 
input provided 
Uses patient 
input from 
centralised 
review  
Alberta Health ─ ─ ─ ─ ─ ─ + 
British Columbia 
Pharmacare ─ + + + + + + 
CADTH ─ + + + ─ + N/A 
INESSS + ─ + + + ─ N/A 
Ontario Drug 
Benefit Program + ─ + + ─ + + 
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Only one province consulted the manufacturer during the assessment period (British 
Columbia) (Figure 6.11). However, other provinces indicated that they communicated 
with the manufacturer at different stages of their review process, usually prior to the 
review to confirm submission meets requirements or post review to clarify questions for 
the expert committee.  
 
Fig 6.11: Manufacturer consultations during assessment period 
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participating plans was consistent ranging from 180 days to 228 days (Figure 6.12). The 
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Figure 6.12: Days taken for CDR process and provincial review 
 
 
*Data not provided for provincial listing date 
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listing decisions in Alberta, British Columbia, Ontario and Quebec.  Multinomial and 
binomial category classification were used to group the recommendations for 
comparison and calculate the percentage agreement and kappa coefficients for each 
province and the CDR. These results expand on previous work and provide interesting 
insights when compared with results of previous studies. Gamble et al. (2011) 
calculated agreement between the CDR and 11 public drug plans for all CDR 
recommendations issued from CDR inception to May 2009. The data set included in 
this study has a slight overlap with the data set for Gamble et al. as data was collected 
from January 2009, but the majority of this data set is for more recent recommendations. 
A comparison of the percentage agreements and kappa coefficients that were 
calculated using binomial classifications (listed or not listed) suggests that provincial 
payers are increasingly aligning with CDR recommendations. The study by Gamble et 
al. (2011) identified Ontario as the province with the lowest percentage agreement 
(64.2%) and kappa coefficient (k=0.28) with the CDR. However, the more recent data 
set used in this study calculated the CDR and Ontario percentage agreement to be 
77.8% and the kappa coefficient doubled to k=0.56 (Table 6.7).  
 
Table 6.7: Comparison of percentage agreement and kappa coefficients with 
previous study 
 
 Alberta 
British 
Columbia 
Ontario Quebec 
Percentage agreement 
from Gamble et al. 
(2011) 
86.8% 67.9% 64.2% 71.7% 
Percentage agreement 
from this study 
82.1% 82.9% 77.8% 71.6% 
Kappa coefficients from 
Gamble et al. (2011) 
K=0.73 K=0.33 K=0.28 K=0.45 
Kappa coefficients from 
this study 
K=0.663 K=0.647 K=0.560 K=0.432 
 
The kappa coefficient is arguably a more robust measurement of agreement as it 
considers the proportion of agreement that could be due to chance (chapter 2). 
Therefore, these results suggest a substantial increase in alignment between Ontario’s 
more recent listing decisions and the CDR recommendations. The results of this study 
also produced an increase in percentage agreement for the CDR and British Columbia 
from 67.9% to 82.1% and an increase in kappa score from k=0.33 to k=0.647 (Table 
6.7). The percentage agreement and kappa coefficients calculated for Quebec and the 
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CDR are consistent with the results previously published by Gamble et al. (2011), but 
the percentage agreement and kappa coefficients for Alberta and the CDR decreased 
slightly. However, this still demonstrates a substantial level of agreement (Viera and 
Garrett, 2005). Overall the percentage agreements and kappa coefficients from this 
study show greater alignment between the CDR and recent provincial listing decisions. 
Seven public drug plans were reviewed by Gamble et al. (2011), but were not included 
in this study. Five of these public drug plans (Saskatchewan, New Brunswick, Nova 
Scotia, Newfoundland and Labrador and the Non-insured Health Benefits (NIHB)) all 
scored percentage agreement values from 83% to 96.2% and the remaining two plans 
had percentage agreement values of 73.6% (Manitoba) and 67.9% (Prince Edward 
Island) (Gamble et al., 2011). In addition, all seven have high percentage agreements 
and kappa coefficients from k=0.31 to 0.88 (Gamble et al., 2011). Therefore, if we 
assume that the listing decisions for these seven public plans have increased or 
decreased in alignment with the CDR in proportion to the changes observed for the four 
provincial plans in this study, then there will still be substantial alignment.  
 
The kappa coefficients from this study can also suggest that there is greater provincial 
alignment for listing decisions by comparing with the results of a study conducted prior 
to inception of the CDR. Anis et al. (2001) also calculated kappa coefficients for 
provincial listing decisions using binomial categories (positive and negative) and for the 
10 provinces the results ranged from k=-0.11 to k= 0.64. For the four provinces included 
in this study (Alberta, British Columbia, Ontario and Quebec), Anis et al. (2001) 
calculated the pair wise kappa coefficients ranging from k=0.06 to k=0.39. The results 
from this study calculated kappa coefficients for the four provinces (Alberta, British 
Columbia, Ontario and Quebec) compared with recommendations from the CDR and 
results ranged from k=0.432 to k=0.663.   Anis et al. (2001) directly compared provincial 
pairs as there was no CDR at the time of the study. However, comparing the provinces 
with the CDR to indirectly compare between provinces, these values suggest provincial 
listing decisions are becoming more aligned. The results from MacDonald and Potvin 
(2004) are more difficult to compare as they used ‘full’ and ‘restricted’ as the two 
categories for comparison, unlike this study which used positive and negative listing 
recommendations for binomial comparisons which enables comparison with previous 
studies such as Gamble et al. (2011) and (Anis et al., 2001).  
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The questionnaires and semi-structured interviews provided insights into the provincial 
review and decision-making process, but the interviews were also conducted with senior 
representatives and decision-makers and these provide valuable insights, especially 
regarding the use of CDR reports and recommendations. The responses from the three 
CDR participating provinces (Alberta, British Columbia and Ontario) indicated that they 
only conduct a partial-HTA on an ad hoc basis. This is consistent with the information 
provided for total number of full time employees and full time employees allocated to 
HTA or reimbursement activities. For example, the number of full time employees 
allocated to HTA or reimbursement activities for all three CDR participating provinces 
was much smaller compared to Quebec which conducts a full HTA.   
 
The CDR participating provinces also indicated that there are occasions when they may 
conduct a local review, but these are generally the exception. Alberta, British Columbia 
and Ontario have all maintained expert committees post inception of the CDR to provide 
a provincial listing recommendation that considers the CDR recommendation and 
evidence for providing local context. Alberta outlined three key components that are 
generally used to evaluate new medicines in the Alberta context: Alberta specific budget 
impact; alternative treatments available through the Alberta Drug Benefit List and the 
position in therapy. These three components are broadly similar to additional criteria 
used to contextualise the CDR recommendation for British Columbia and Ontario, but 
these two provincial payers also have opportunities for patient input to be submitted for 
consideration in the provincial review. The 2008 Alberta pharmaceutical strategy 
proposed the creation of a public committee for a more accountable and transparent 
provincial review process (Alberta Health and Wellness, 2009). However, a public 
committee had not been implemented at the time of the interview but was still under 
consideration.  
 
The three CDR participating provinces will receive patient input provided to the CDR 
with the CDR reports and final recommendation. British Columbia have the ‘Your Voice’ 
website for patients to subscribe and receive alerts for upcoming reviews. Any patient 
input is summarised by the public members of the Drug Benefit Council and presented 
to all members of the Drug Benefit Council. Ontario also has an online submission 
process for patient groups to register interest and provide patient input submissions. 
Neither British Columbia nor Ontario provide formal training, but they do provide a 
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template of key questions for guidance and generally allow about 30 days for 
submissions.  Both agencies accept patient input that received support from the 
pharmaceutical industry, but payers noted that they do not want a repeat of the 
manufacturer’s submission and conflicts of interest should be disclosed. One provincial 
payer also noted that manufacturer supported patient input can help facilitate and speed 
up the patient input process. Quebec does not participate in the CDR so does not 
receive the patient input from the CDR, but has its own process for including patient 
input. A list of drugs to be evaluated is published on the INESSS (Quebec) website and 
patients’ are generally given 30 days to provide submissions. Patient input is accepted 
from individuals and organisations and no formal structure is required, so submissions 
will be accepted in any format including those using templates from other agencies. 
    
The semi-structured interviews also discussed the impact of patient input and the 
general consensus was that patient input was a main consideration but not a driving 
factor for the final listing decision. Ontario provided an example where a patient group 
for Attention Deficit Hyperactivity Disorder (ADHD) produced a very detailed submission 
to outline concerns regarding short-acting treatments for ADHD and eventually this led 
to broader access to long-acting treatments for ADHD in Ontario. Quebec also provided 
examples where patient input had been an important factor for determining listing 
decisions for the treatment of rare diseases in children. In two of these cases an 
additional meeting was organised for a family member to meet with a sub-group of the 
committee so they can provide their experiences in a less intimidating environment.  
 
Therapeutic benefit was generally considered the most important factor for influencing 
a listing-decision. Ontario and Quebec both stated that if a product cannot demonstrate 
a therapeutic benefit then the review will not proceed to discuss other factors. Quebec 
requires a benefit over existing treatments otherwise a negative listing-decision is 
issued. Safety and the absence of alternative treatments were also discussed as 
secondary considerations if therapeutic benefit had first been determined. British 
Columbia also referred to the CDR evidence report as a driving factor for the Drug 
Benefit Council recommendation.  
 
Comments and opinions regarding the CDR were unanimously positive from all 
provinces. The participating drug plans receive two dossiers from the CDR (one clinical 
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and once economic) to guide their recommendations. Quebec does not receive the CDR 
dossiers, but they noted that they conduct a systematic review as part of the HTA 
process and if a review from the CDR was published they would consider it along with 
other published HTA reports. However, due to the CDR first-come-first-serve queuing 
system for submissions, INESSS often issues a listing recommendation and final 
decision prior to the CDR recommendation. Ontario emphasised the value of the CDR 
by stating that without the CDR evidence they would be reanalysing exactly the same 
information. Alberta expressed similar views by noting that they are very supported by 
the CDR and they do their best to align with the CDR recommendations.  British 
Columbia also said that they rely a great deal on the CDR and described it as ‘a 
cornerstone in our review process’. British Columbia also discussed upcoming changes 
to their review process that demonstrate an increasing reliance on the CDR and 
upcoming medicines issued a ‘do not list’ recommendation from the CDR will no longer 
be considered for provincial review in British Columbia.   
 
The three CDR participating drug plans all agreed that their recommendations are 
generally congruent with the CDR, but price negotiations often impact the final decision. 
British Columbia explained that they may negotiate on the following three CDR 
recommendations: ‘list’; ‘list with condition/criteria’ and ‘do not list at the submitted price’. 
However, they rarely negotiate for ‘do not list’ recommendations. The review process in 
Alberta only allows price negotiation with manufacturers after the formal review decision 
is determined, so price negotiations can occur following irrespective of positive or 
negative listing decisions. Quebec was the only province in this study that does not 
negotiate on price because it is not within the INESSS mandate.  
 
Two provincial payers also discussed the more recently established Pan-Canadian 
Pharmaceutical Alliance (PCPA) (formerly the Pan-Canadian Pricing Alliance) that is 
part of The Council of the Federation’s Health Care Innovation Working Group (HCIWG) 
(Council of the Federation, 2015). The PCPA aims to combine the purchasing power of 
participating provinces (excluding Quebec and Nunavut) to benefit price negotiations 
and all medicines reviewed by the CDR and the pan-Canadian Oncology Drug Review 
(pCODR) are eligible.  The PCPA could lead to more consistent reimbursement 
decisions across Canada.  However, the participating provinces will still have varying 
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budgets and the prices negotiated by the PCPA may still be more affordable for 
wealthier provinces.  
 
Overall, this study has demonstrated increasing alignment between provincial payers 
and the CDR by expanding upon previous work by Gamble et al., (2011). This study 
also suggests greater alignment between recent provincial listing decisions compared 
to provincial listing decisions issued prior to the inception of the CDR by drawing 
comparisons with Anis et al., (2001). The results of this study disagreed with the 
conclusions drawn in the report published by AIMS (Attaran et. al., 2011). The data set 
in this study is more recent than the AIMS dataset, which selected the first 25 and last 
25 drug reviews published on the Common Drug Review in February 2009.  The AIMS 
study calculated percentage agreements using a multinomial classification category that 
the authors acknowledged was ‘not necessarily accurate’ and grouped 
recommendations as: ‘province agrees with CDR’; ‘province disagrees with CDR and 
has a drug benefit less than CDR’s recommendation’ or ‘Province disagrees with CDR 
and has a drug benefit exceeding CDR’s recommendation’. The use of multinomial 
categories has been criticised due to the difficulty of accurately comparing restrictions 
(Fischer, 2012). Binomial categories provide mutually exclusive categories for 
comparison but it is also argued that these can also be too simplistic. Therefore, this 
study used both multinomial and binomial classifications for comparison. The AIMS 
study has also only published percentage agreement values, which, unlike kappa 
coefficients, do not take into consideration the proportion of agreement which is likely 
to be due to chance (chapter 2).  
 
This study also evaluated the impact of the CDR on three participating plans and has 
drawn comparisons with the listing decisions and review processes of the Quebec HTA 
agency, INESSS. A written submission from the Canadian Diabetes Association 
regarded the provinces decisions to maintain their provincial review processes post 
inception of the CDR as an indication that the CDR and provinces are duplicating work. 
However, the results of this study comparing the resources of CDR participating drug 
plans demonstrate fewer employees compared to Quebec’s INESSS which conducts a 
full HTA. The three participating drug plans have also described how their expert 
committees review the CDR reports with province specific information (budget impact, 
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existing treatment options and position in therapy) to formulate a listing decision in the 
local context.  
 
The report from Canada's Research-Based Pharmaceutical Companies (Rx&D), (2011) 
found the listing rate from the CDR to be below the average for OECD countries, but 
this listing rate is close to the listing rate for Austria (<60%) and Finland (60%) and New 
Zealand (60%). The report also compares the listing rate of CDR recommendations 
(54%) with public drug plan listing average (46%) from 2004 to 2010. These results 
indicate that the public drug plans are generally more restrictive than the CDR, but the 
results from this study show the four listing rates for the four provinces to either be 
equivalent (Alberta) or higher (British Columbia, Ontario and Quebec) than the CDR. A 
more recent report from Canada's Research-Based Pharmaceutical Companies 
(Rx&D), (2012) also found the total number of positive listings for new medicines to be 
below average (23rd) for the 32 jurisdictions included in the study. 
 
In conclusion, this study has evaluated the impact of the CDR on provincial listing 
decisions by comparing the CDR recommendations for 86 medicine-indication pairs 
with the listing decisions of four provincial public plans. Surveys and semi-structured 
interviews with payer/agency representatives and decision-makers provide unique 
insights into the processes and opinions of experts. A review of published literature 
identified criticisms of the CDR process, but these were not supported by the results of 
this study. The provincial listing decisions and CDR recommendations demonstrate 
moderate to substantial agreement, which, combined with the results of the survey and 
semi-structured interviews, shows the CDR does influence provincial listing decisions 
and therefore provides value for participating plans. These observed increases in 
alignment could be a result of provinces becoming more reliant on the CDR over time, 
but may also indicate that the CDR continues to improve and develop to meet payers’ 
needs. However, a proportion of divergent outcomes can also demonstrate the flexibility 
of the CDR process. The ability for provincial payers to incorporate local context, and 
issue recommendations accordingly, is a valuable characteristic of the CDR process, 
which supports public plans with varying budgets and patient populations. European 
countries are much more heterogeneous than Canadian provinces, but CDR does 
provide an example of a centralised review process that provides evidence to support 
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the common requirements of participating plans with the added flexibility of 
incorporating evidence and budget impact that is context specific.  
 
SUMMARY 
 This study adds to the existing body of knowledge by providing novel research 
to fill an identified gap in previously published research. No studies have been 
published comparing the impact of post-2009 CDR recommendations on 
provincial listing decisions and previously published studies reached conflicting 
conclusions for the concordance of provincial listing decisions with CDR 
recommendations.   
 
 The evaluation of the concordance of CDR recommendations with provincial 
listing decisions builds on previous studies (Gamble et al., 2011; Anis et al., 2001; 
Gregoire et al., 2001; MacDonald and Potvin, 2004), which also meets a need 
for additional research to identify whether the CDR is helping to standardise 
coverage decisions  across provinces (McMahon et al., 2006). 
 
 The reimbursement processes have been described and represented using a 
novel, uniform HTA process mapping methodology for the Canadian centralised 
HTA process (CDR), three CDR participating provincial payers (Alberta, British 
Columbia and Ontario) and for provincial HTA agency (Quebec).  
 
 Reimbursement recommendations issued by the CDR for 86 medicine-indication 
pairs from January 2009 to May 2013 were compared and demonstrated 
moderate to substantial alignment with listing decisions in Alberta, British 
Columbia, Ontario and Quebec. 
 
 Comparing the results of this study with previously published studies 
demonstrates that participating provinces are generally becoming increasingly 
aligned with CDR recommendations (Gamble et al., 2011; Anis et al., 2001; 
Gregoire et al., 2001; MacDonald and Potvin, 2004).  
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 The results of the data generated from the questionnaires and semi-structured 
interviews demonstrated strong support for the CDR from provincial payers and 
describes how they utilise the CDR evidence and listing recommendations. 
 
 Canada has established various mechanisms to include patient input at the 
national and regional levels. The CDR, British Columbia, Ontario and Quebec 
have all established their own approaches for including patient input, and Alberta 
currently uses patient input provided to the CDR but is considering establishing 
its own public committee.  
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CHAPTER 7 
 
 
 
 
 
 
 
Assessing the Value of HTA Process 
Maps and their Impact on the 
Pharmaceutical Industry and Health 
Technology Assessment Agencies 
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INTRODUCTION 
Health Technology Assessment (HTA) and reimbursement decision-making processes 
can vary greatly between jurisdictions at both the national and regional level. HTA 
activities and their role within the regulatory and reimbursement (R&R) system can 
evolve quickly in response to political, social and economic developments. This can 
create a challenging environment for stakeholders as HTA is increasingly utilised to 
guide reimbursement decisions. For example, patients may wish to understand why 
they are unable to access funding for a new medicine that is has already been approved 
for reimbursement in a different jurisdiction. A systematic mapping methodology 
(Chapter 3) was previously created to provide a uniform visual representation of the 
regulatory, HTA and reimbursement systems. The uniform methodology facilitates 
comparisons between multiple jurisdictions and a visual format can enable quick 
identification of key aspects and improve usability. The process mapping methodology 
has also been applied to produce more than 70 process maps for New Active 
Substances (NASs), oncology products and medical devices at the national and 
regional level. The process maps have also facilitated the development of a tool for non-
ranking classification of HTA agencies and reimbursement systems (Chapter 4).  
Industry and agency representatives have been consulted to help understand how the 
compilation of process maps (Regulatory and Reimbursement Atlas) can provide value 
to stakeholders and guide future research.  
 
The aim of this study was to assess the value of HTA process maps and their impact 
on the pharmaceutical industry and HTA agencies with the following objectives: 
OBJECTIVES 
 Identify general availability of HTA process maps for HTA agencies and 
pharmaceutical companies 
 Assess the value of the systematic process mapping methodology for HTA 
agencies and pharmaceutical companies 
 Evaluate how the process maps could impact agency activities 
 Determine how the process maps could impact pharmaceutical company 
strategy 
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 Assess how the process maps may inform decision-making for pharmaceutical 
companies 
 
METHODOLOGY 
Two study questionnaires were designed to collect information from pharmaceutical 
industry and HTA agency representatives, which were primarily selected due to 
membership of the Centre for Innovation in Regulatory Science (CIRS) HTA program. 
CIRS is a not-for-profit organisation that provides a neutral, professional forum to 
facilitate dialogue and productive discussions between members from the 
pharmaceutical industry, regulatory authorities and HTA agencies. The G-BA 
(Germany) is not a member of CIRS but was included in the scope of this study as 
Germany is the largest pharmaceutical market in Europe. CIRS membership was 
chosen as the primary selection criteria because this potentially provided access to a 
range of senior industry and agency representatives. The HTA process maps have also 
been presented at previous CIRS workshops and this increased the likelihood that more 
responders will be familiar with the process maps and may be able to draw upon 
previous experiences to determine their value. However, this selection criteria may also 
introduce bias which should be considered when interpreting the results.  
 
The HTA agency questionnaire contained multiple tick box response options and free 
text questions within three distinct sections: 
Part I – Identify availability of HTA process maps for HTA agencies  
Part II – Assess the value of the systematic HTA process mapping methodology for HTA 
agencies  
Part III – Evaluate how the systematic process maps could impact HTA agency activities 
 
The pharmaceutical industry study was divided in four sections and also included two 
additional industry specific items: 
Part I – Identify availability of the HTA process maps for pharmaceutical companies 
Part II – Assess the value of the systematic HTA process mapping methodology for 
pharmaceutical companies 
Part III – Evaluate how the systematic process maps could impact company strategy 
PART IV – Assess how the systematic process maps may inform decision-making for 
pharmaceutical companies 
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The two study questionnaires were reviewed by an expert panel of senior staff members 
from CIRS with experience developing and questionnaires for conducting research with 
agency and industry representatives. The expert panel reviewed the study 
questionnaires to determine their content validity using four criteria: clarity of 
instructions; language clarity; sentence structure completeness and relevance. 
Feedback from the expert panel was incorporated prior to the pilot study. Two 
pharmaceutical industry representatives and two HTA agency representatives were 
subsequently contacted to complete the study questionnaire and participate in a 
discussion to review the study questionnaire and to provide feedback. The pilot study 
identified areas for improvement, such as the inclusion of an additional free-text 
question to enable respondents to specify why they might decide to use the 
consolidated collection of process maps (Regulatory and Reimbursement Atlas) over 
other sources and to include an additional response option (‘Sometimes’) to describe 
respondents experiences using a range of information resources.  
 
The agency questionnaire was updated in line with the pilot recommendations and 
distributed to ten agencies (Figure 7.1): 
 AIFA (Italy) 
 CADTH 
(Canada) 
 GBA (Germany) 
 HAS (France) 
 INAMI (Belgium) 
 INESSS 
(Canada) 
 NICE (England) 
 SMC (Scotland) 
 TLV (Sweden) 
 ZIN (Netherlands
 
 
The final version of the industry questionnaire was distributed to eight pharmaceutical 
companies (Figure 7.2): 
 Bayer 
 Daiichi-Sankyo 
 Eli Lilly  
 GlaxoSmithKline 
 Johnson & Johnson 
 Pfizer 
 Roche 
 Sanofi 
 
Respondents provided electronic and hand completed versions of the questionnaire 
or completed the study via telephone.  
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Figure 7.1: Agency questionnaire 
 
1. Identifying availability of process maps 
1.1) Have you seen the HTA process maps prior to completing this survey? Please put a cross 
in one box.  
 Yes   No 
1.2) Have you used any of the following sources to find information on regulatory and 
reimbursement (R&R) systems? Please put a cross in all relevant boxes 
 
 Other agency websites   ISPOR Roadmaps  R&R Atlas  Internal reference 
source 
 Thomson Reuters Cortellis™    Consultants   Other*   
*Please provide name of ‘other’ source(s). 
_____________________________________________________________________________ 
1.3) Please put a number in the boxes to rank the following factors of an R&R source in order 
of importance according to your opinion (from 1 being most important to 4 as least important): 
 
 up-to-date information  user-friendly  standardised format       
 link to sources 
 
For questions 1.4 to 1.10, please put a cross either the Yes, Sometimes (SO), No or Don’t Know 
(DK) box to indicate if, in your opinion, the source complies with each of the following factors: 
  Up-to-date 
information 
 User-friendly Standardised 
format 
Link to sources 
 Yes SO No DK Yes SO No DK Yes SO No DK Yes SO No DK 
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 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.10) Other 
(please name) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* SO- Sometimes, DK– Don’t Know 
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Figure 7.1 (continued): Agency questionnaire  
 
 
2. Assessing the value of systematic process mapping methodology  
Please review the systematic process map methodology (pages 3-4), then for each statement 
2.1) to 2.11) please put a cross in one box that describes how far you agree with each 
statement.  
 Strongly 
Agree 
Agree Disagree Strongly 
disagree 
No 
opinion 
2.1) It is of value to know how the 
sponsor interacts with agencies 
within the R&R system  
     
2.2) It is of value to know how 
agencies interact with each other 
within the R&R system  
     
2.3) Process maps are easy to 
understand for a person with NO 
prior knowledge of R&R systems 
     
2.4) Process maps are easy to 
understand for a person with some 
prior knowledge of R&R systems 
     
2.5) Process maps are valuable for 
a person who wishes to expand 
their knowledge of R&R systems to 
include new jurisdictions 
     
2.6) The 7 core functions identify 
important roles within the R&R 
system 
     
2.7) The 7 core functions aid 
comparability between R&R 
systems 
     
2.8) The 6 HTA key icons identify 
valuable aspects of HTA activities 
     
2.9) The 6 HTA key icons aid 
comparability between R&R 
systems 
     
2.10) The uniform methodology 
enables quick visual comparison 
between R&R systems 
     
2.11) Please provide reasons or examples to explain, in your opinion, why you would choose to use 
the R&R Atlas instead of other sources: 
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Figure 7.1(continued): Agency questionnaire  
 
3. Evaluate how the HTA process maps could impact agency activities  
Please review the systematic process map methodology (pages 3-4), then for each statement 
3.1) to 3.7), please put a cross in one box that describes how far you agree with each 
statement. 
I see the value of the HTA process 
maps as a… 
 
Strongly 
Agree 
Agree Disagree Strongly 
disagree 
No 
opinion 
3.1) Presentation aid      
3.2) Training tool to introduce 
employees to new R&R systems 
     
3.3) Reference source to 
understand new R&R systems 
     
3.4) Reference source to update 
knowledge of R&R systems 
     
3.5) Source to identify how other 
R&R systems and HTA processes 
compare  
     
3.6) Source to identify how other 
R&R systems and HTA processes 
compare to your own practices 
     
3.7) Demonstrating your agencies 
role in the R&R system to 
stakeholders 
     
3.8) Please provide comments for 
any additional factors _________________________________ 
 
3.9) How important is it for your agency to obtain up-to-date information for reimbursement 
systems in the following countries? 
Please put a cross in one box (high, medium or low) for each country  
 
 
Country  
Level of importance 
High Medium Low 
Brazil    
Canada      
China    
Denmark     
France    
Germany     
Greece    
Italy     
Japan      
Latvia     
Country 
Level of importance 
High Medium Low 
Luxembourg    
Netherlands    
Poland    
Portugal    
Russia    
Spain    
Switzerland    
South Korea    
UK    
USA    
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Figure 7.1(continued): Agency questionnaire  
 
3.10) Please provide details of any high-importance countries not included in the above tables: 
 
 
3.11) The R&R Atlas is available in multiple formats. Which of the following formats would you 
or team be likely to use? Please put a cross in all relevant boxes 
 Website   interactive PDF   iPad® application  Android® application 
 
To be completed by the respondent:   
Name: 
_____________________________________________________________________________ 
Position: 
___________________________________________________________________________  
Agency: 
__________________________________________________________________________ 
Signature: ________________________________________________ 
Date:_____________________ 
 
 
 
 
Please provide any comments regarding this survey and the R&R Atlas below: 
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Figure 7.2: Industry questionnaire 
1. Identifying availability of process maps 
1.1) Have you seen the HTA process maps prior to completing this survey? Please put a cross 
in one box.  
 Yes   No 
1.2) Have you used any of the following sources to collect information on regulatory and 
reimbursement (R&R) systems? Please put a cross in all relevant boxes 
 
 Agency Websites   ISPOR Roadmaps  R&R Atlas  Internal reference source 
 Thomson Reuters Cortellis™   Consultants   Other*   
*Please provide name of ‘other’ source(s). 
_____________________________________________________________________________ 
1.3) Please put a number in the boxes to rank the following factors of an R&R source in order 
of importance according to your opinion (from 1 being most important to 4 as least important): 
 
 up-to-date information  user-friendly   standardised format      
 link to sources 
For questions 1.4 to 1.10, please put a cross either the Yes, Sometimes (SO), No or Don’t Know 
(DK) box to indicate if, in your opinion, the following information source complies with each of 
the following factors: 
Information source Up-to-date 
information 
User-friendly Standardised 
format 
Link to sources 
 Yes SO No DK Yes SO No DK Yes SO No DK Yes SO No DK 
 
1.4) Agency 
Websites 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5) ISPOR 
Roadmaps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6) R&R Atlas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7) Internal 
reference source 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.8) Thomson 
Reuters Cortellis™   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9) Consultants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.10) Other (please 
name) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* SO- Sometimes, DK– Don’t Know   
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Figure 7.2 (continued): Industry questionnaire  
 
2. Assessing the value of systematic process mapping methodology  
Please review the systematic process map methodology (pages 3-4), then for each statement 
2.1) to 2.11) please put a cross in one box that describes how far you agree with each 
statement.  
 Strongly 
Agree 
Agree Disagree Strongly 
disagree 
No 
opinion 
2.1) It is of value to know how the 
sponsor interacts with agencies 
within the R&R system  
     
2.2) It is of value to know how 
agencies interact with each other 
within the R&R system  
     
2.3) Process maps are easy to 
understand for a person with NO 
prior knowledge of R&R systems 
     
2.4) Process maps are easy to 
understand for a person with some 
prior knowledge of R&R systems 
     
2.5) Process maps are valuable for 
a person who wishes to expand 
their knowledge of R&R systems to 
include new markets 
     
2.6) The 7 core functions identify 
important roles within the R&R 
system 
     
2.7) The 7 core functions aid 
comparability between R&R 
systems 
     
2.8) The 6 HTA key icons identify 
valuable aspects of HTA activities 
     
2.9) The 6 HTA key icons aid 
comparability between R&R 
systems 
     
2.10) The uniform methodology 
enables quick visual comparison 
between R&R systems 
     
 
 
  
2.11) Please provide comments to explain why you would chose to use the R&R Atlas instead of 
other sources: 
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Figure 7.2 (continued): Industry questionnaire  
 
 
3. Evaluate how the HTA process maps could impact company strategy  
Please review the systematic process map methodology (pages 3-4), then for each statement 
3.1) to 3.7), please put a cross in one box that describes how far you agree with each 
statement. 
I see the value of the HTA process 
maps as a… 
 
Strongly 
Agree 
Agree Disagree Strongly 
disagree 
No 
opinion 
3.1) Presentation aid      
3.2) Training tool to introduce 
employees to new R&R systems 
     
3.3) Reference source to 
understand new R&R systems 
     
3.4) Reference source to update 
knowledge of R&R systems 
     
3.5) Source to identify which 
agencies to engage with 
     
3.6) Tool to support research 
projects to aid market access 
strategies 
     
3.7) Tool to aid planning of market 
access strategies 
     
3.8) Please provide comments for 
any additional factors  
 
 
 
3.9) How important are the following markets for your company’s market access teams? 
Please put a cross in one box (high, medium or low) for each country  
 
3.10) Please provide details of any high-importance markets not included in the above tables: 
 
Market  
Level of importance 
High Medium Low 
Brazil    
Canada      
China    
Denmark     
France    
Germany     
Greece    
Italy     
Japan      
Latvia     
Market 
Level of importance 
High Medium Low 
Luxembourg    
Netherlands    
Poland    
Portugal    
Russia    
Spain    
Switzerland    
South Korea    
UK    
USA    
 
 
207 
 
Figure 7.2 (continued): Industry questionnaire  
 
 
4. Assessing how the HTA process maps may inform decision-making  
Please review the systematic process map methodology (pages 3-4), then for each statement 
4.1) to 4.7), put a cross in one box that describes how far you agree with each statement. 
 
I see the value of the HTA process 
maps influencing decision-making for… 
 
Strongly 
Agree 
Agree Disagree Strongly 
disagree 
No 
opinion 
4.1) Determining which parts of your 
organisation should be involved  
     
4.2) Identifying which agencies to 
approach 
     
4.3) Determining order of agencies to 
approach   
     
4.4) Acquiring better knowledge of R&R 
system market access requirements 
     
4.5) Identifying which R&R systems are 
similar/dissimilar 
     
4.6) Determining which agencies drive 
access 
     
4.7) Determining which agencies drive 
price 
     
4.8) Please provide comments for any 
additional factors  
 
4.9) The R&R Atlas is available in multiple formats. Which of the following formats would you 
or team be likely to use? Please put a cross in all relevant boxes 
 Website   interactive PDF   iPad® application  Android® application 
 
Name: 
_____________________________________________________________________________ 
Position: ____________________________________ Company: 
______________________________ 
Signature: ___________________________________ Date: _____________________ 
 
 
 
 
Please provide any comments regarding this survey and the R&R Atlas below: 
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RESULTS 
 
For the purpose of clarity the results are presented in the following seven parts: 
PART I - Availability of the HTA process maps for HTA agencies 
PART II - Value of the systematic HTA process mapping methodology for HTA 
agencies  
PART III - How the systematic process maps could impact HTA agency activities 
PART IV - Availability of the HTA process maps for pharmaceutical companies 
PART V- Value of the systematic HTA process mapping methodology for 
pharmaceutical companies 
PART VI - How the process maps could impact company strategy 
PART VII - How the process maps may inform decision-making for pharmaceutical 
companies 
 
HTA Agency  
  
PART I – Availability of the HTA Process Maps for HTA agencies 
The agency study questionnaire was distributed to ten HTA agencies and five of these 
HTA agencies provided a completed questionnaire (50% response rate) following 
either one or two reminders for completion. Four of the agencies did not respond and 
one explained that they were too busy to take part in the study. The five HTA 
responders that completed the questionnaire held senior positions (Director, Chief 
pharmacist, or advisor). Three of the five agency respondents had seen the process 
maps prior to completion of the questionnaire. 
 
Agency representatives used only three of the six regulatory and reimbursement 
information sources included in the questionnaire and did not provide any information 
for ‘Other’ information sources (Figure 7.3). This would suggest that no other 
information sources are utilised to collect information for reimbursement systems by 
the responding HTA agency representatives. The most commonly used source was 
other agency websites (n=5) and the second most common source was the Regulatory 
and Reimbursement Atlas (n=3). Only one agency representative selected the option 
for the ISPOR Roadmaps (Figure 7.3). 
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Figure 7.3: Sources used by HTA agencies to collect information for regulatory 
and reimbursement systems 
 
 
 
The study required respondents to rank regulatory and reimbursement factors by order 
of importance (Figure 7.4). This question was answered by four agency respondents 
and three of the four agency respondents ranked ‘up-to-date information’ as the most 
important factor. Overall, ‘user-friendly’ was the second most important factor by rank 
and one of the four HTA agency respondents ranked ‘user-friendly’ as the most 
important factor.  
  
Agency respondents completed the study questionnaire to indicate whether, in their 
opinion, sources they have used to collect information for reimbursement systems 
have up-to-date information, are user friendly, link to sources and have a standardised 
format (Figure 7.5). The most commonly used information source was other agency 
website but the most positively scored information resource was the Regulatory and 
Reimbursement Atlas (Figure 7.5). The Regulatory and Reimbursement Atlas was the 
only information resource that had at least one responder agree that it provided up-to-
date information, is user friendly, links to sources and has a standardised format 
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Figure 7.4: Information source factors ranked by agencies (n=4)  
(from 1 being most important to 4 as least important) 
 
 
 
The HTA agency respondents all answered ‘sometimes’ for whether other agency 
websites were user-friendly and only one respondent selected ‘yes’ for providing up-
to-date information. Some HTA respondents indicated that they mostly selected the 
‘sometimes’ option due to the large diversity of content demonstrated across different 
HTA agency websites. Only one agency respondent indicated that they use the ISPOR 
Roadmaps as an information resource and this responder agreed that the ISPOR 
Roadmaps complied with three of the four ranked factors:  (Figure 7.5).  
 
PART II -Value of the systematic HTA process mapping methodology 
for HTA agencies 
Respondents were asked to indicate whether they agreed with 10 statements as to 
how the process mapping methodology and information provided by the systematic 
process maps could provide value as an educational or comparative tool. 
Respondents were given a five point Likert scale to indicate the degree they agreed 
with each statement (strongly agree, agree, no opinion, disagree and strongly 
disagree). Overall, respondents agreed with the ten statements. All of the statements 
were scored ‘agree’ or ‘strongly agree’ by the agency respondents. 
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Figure 7.5: Factors exhibited by information sources according to HTA agency 
respondents 
 
Only one of the nine questions did not receive any ‘strongly agree’ scores from the 
agency respondents: ‘process maps are easy to understand for a person with NO prior 
knowledge of R&R systems’ (Figure 7.6). However, respondents also reviewed a 
similar statement ‘process maps are easy to understand for a person with some prior 
knowledge of R&R systems’ which was assigned two ‘strongly agree’ scores. This 
could imply that additional support materials might be needed to enable individuals 
with no knowledge of reimbursement systems to gain maximum benefit from the 
systematic process maps included in the Regulatory and Reimbursement Atlas.  
Agency respondents also provided scores for statements about the systematic 
mapping methodology. Each HTA process map is created in a three-step process to 
display three tiers of information (Chapter 3). The second tier of information identifies 
core functions (Regulatory, Market Access, HTA, pricing, recommender, decision-
maker and provider) performed by the agencies in the system and the third information 
tier focuses on the HTA component of the system by including six icons for key HTA 
activities (Scientific advice, Therapeutic value, Economic value, Reimbursement rate, 
Public consultation and Coverage with evidence development). 
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Figure 7.6: Value of systematic HTA process mapping methodology according to agency respondents  
 
0 1 2 3 4 5
The uniform methodology enables quick visual
comparison between R&R systems (n=5)
The 6 HTA key icons aid comparability between R&R
systems (n=5)
The 6 HTA key icons identify valuable aspects of HTA
activities (n=5)
The 7 core functions aid comparability between R&R
systems (n=5)
The 7 core functions identify important roles within the
R&R system (n=5)
The CIRS process maps are valuable for a person who
wishes to expand their knowledge of R&R systems  to
include new jurisdictions (n=5)
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CIRS process maps are easy to understand for a person
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The agency respondents scored mostly agreed or strongly agreed that the core 
functions and key HTA activity icons represented important aspects of the system and 
aided comparability (Figure 7.6).  A free text question was included in part II of the 
agency study to enable agency respondents the opportunity to suggest reasons why 
they would chose to use the systematic process maps (Regulatory and 
Reimbursement Atlas). Two of the five respondents (holding a director or advisor 
position) provided comments for this question. Both comments referred favourably to 
the usability of the process maps: 
 “One-stop shop, easy to use, comparability” 
 “The flow chart kind of illustration is most helpful in terms of user friendliness 
etc. I guess you might come to a point where the flow chart will get too 
complicated but so far it works for these purposes” 
 
PART III - How the systematic process maps could impact HTA 
agency activities 
 
HTA agency respondents were also asked to indicate whether they agreed with 
statements that suggest how the systematic process maps could be used to support 
agency activities (Figure 7.7). The overall HTA agency respondent scores for these 
statements were all positive with no statements were scored negatively. The most 
popular statement was scored ‘strongly agree’ by four of the five agency respondents 
and one respondent scored ‘agree’:  
 ‘Demonstrating your agencies role in the R&R System to stakeholders’. 
The second most popular option was allocated three ‘strongly agree’ and two ‘agree’ 
scores:  
 ‘Source to identify how other Regulatory & Reimbursement (R&R) systems 
compare’.  
Only two statements received a ‘no opinion’ score from an agency respondent:  
 ‘Training tool to introduce employees to new R&R systems’  
 ‘Reference source to understand new R&S systems’  
Agency respondents were also asked to rank 20 countries as ‘high’, ‘medium’ or ‘low’ 
importance to their organisation (Figure 7.8).   Five jurisdictions with established and 
active HTA agencies were ranked high by all five agency respondents (Canada, 
France, Germany, Netherlands and UK). 
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Figure 7.7: Potential process map impact on HTA activities (n=5) 
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Switzerland was the only jurisdiction to achieve rankings of ‘High’, ‘Medium’ and ‘Low’. 
Poland was the only jurisdiction ranked ‘Medium’ by all agency responders and no 
jurisdictions were assigned all ‘Low’ rankings. The low scoring jurisdictions included 
those without HTA agencies such as China and Japan. 
 
Figure 7.8: Importance of jurisdictions to HTA agency respondents (n=4) 
 
  
Finally, the agency study included a question to identify how HTA agencies would 
access the compilation of process maps. Four format options were provided (Website, 
Interactive PDF, iPad® application and Android® application) and all were selected by 
at least one responder (Figure 7.9).  The website option was the most favoured with 
all agency respondents selecting this option. Two agencies indicated that they would 
use the Interactive PDF and iPad© application and only one respondent indicated that 
they would use the Android© format. 
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A box for general comments was included in the study and captured very supportive 
statements from agency representatives: 
 “Great job. I think this work fills an important gap in the resources and tools 
available for industry, HTA bodies, payers and academics. This is a fast 
growing field and getting increasingly complex with time and this tool (Atlas) 
provides a one stop experience for people who are keen to understand the 
Regulatory-HTA-Payer landscape, different interaction points and similarities 
and differences across different systems. Finally, the methodology and 
standardised format is quite sophisticated yet simple and user-friendly.” 
 “Great tool. The HTA Key Activity value would benefit from 2 additional icons:-
One that relates to other factors like for instance for INESSS organizational and 
ethical considerations or for NICE end of life criteria etc., - One icon that lists 
the availability or not of risk sharing agreements. These 2 elements are 
essential if we want to compare R&R accurately” 
 
Figure 7.9: Agency respondents preferred formats for the Regulatory and 
Reimbursement Atlas (n=5) 
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Pharmaceutical industry 
 
PART IV - Availability of the HTA Process Maps for Pharmaceutical companies 
 
The industry study questionnaire was distributed to eight pharmaceutical companies 
and six completed questionnaires were received (75% response rate) from responders 
based in the USA (n=4) and Europe (n=2). The roles of the responders varied from 
senior Executive Director to Research Associate. The companies were selected due 
to their membership of the Centre for Innovation in Regulatory Science’s (CIRS) HTA 
program where the process maps have been previously presented. Therefore, only 
one of the six respondents had not seen the process maps prior to completion of the 
questionnaire.  
 
Pharmaceutical industry respondents were also asked if they had used six named 
information sources to collect information for R&R systems:  
 Agency websites 
 ISPOR Roadmaps 
 Regulatory and Reimbursement Atlas 
 Internal reference source 
 Thomson Reuters Cortellis™  
 Consultants 
The most popular information sources utilised by industry respondents was agency 
websites and consultants with five of the six respondents indicating that they have 
used both. Four respondents indicated that they have used ISPOR Roadmaps, 
Regulatory and Reimbursement Atlas and an internal reference source. The least 
used was Thomson Reuters Cortellis™, which was only used by one industry 
respondent (Figure 7.10). Industry respondents were also asked to rank four factors 
of regulatory and reimbursement information sources. The most important factor for 
industry was up-to-date information and was ranked first by all six of the industry 
respondents. User-friendly, Standardised format and Link to sources were all ranked 
either second, third or fourth by at least one respondent and thus scored very closely 
for second, third and fourth position. Overall, the second most important ranked factor 
was link to sources, the third most important factor was standardised format and the 
least important was user-friendly (Figure 7.11).  
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Figure 7.10: Sources used by pharmaceutical industry to collect information 
for regulatory and reimbursement systems (n=6) 
 
 
 
Figure 7.11: Information source factors ranked by industry (n=6)  
(From 1 being most important to 4 as least important) 
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Industry respondents also indicated how, in their personal experience, they believed 
the six named information sources complied with the four previously ranked factors 
(Figure 7.12 to 7.13). Agency websites were one of the most used information sources, 
but industry respondents also assigned the most negative scores to agency websites 
(Figures 7.10 and 7.12). However, agency websites also scored highest for the 
number of industry respondents at the top ranked factor (up-to-date information) 
Figure 7.11). The Regulatory and Reimbursement Atlas received the greatest quantity 
of ‘yes’ scores of all named information sources for up-to-date information, link to 
sources, user friendly and standardised format (Figure 7.12). ISPOR Road maps were 
assigned two ‘no’ scores for providing up-to-date information, which was also the 
information source factor ranked top priority by all six industry respondents (Figure 
7.12 and 7.13). 
 
Figure 7.12: Factors exhibited by agency websites, ISPOR Roadmaps and 
Regulatory and Reimbursement Atlas according to industry respondents 
 
 
 
PART V - Availability of the HTA process maps for pharmaceutical 
companies 
 
The industry respondents indicated how much they agreed or disagreed with ten 
statements for how the systematic process maps can provide value as an educational 
0
1
2
3
4
Y
e
s
S
o
m
e
ti
m
e
N
o
D
o
n
't
 k
n
o
w
Y
e
s
S
o
m
e
ti
m
e
N
o
D
o
n
't
 k
n
o
w
Y
e
s
S
o
m
e
ti
m
e
N
o
D
o
n
't
 k
n
o
w
Y
e
s
S
o
m
e
ti
m
e
N
o
D
o
n
't
 k
n
o
w
Up-to-date
information
User-friendly Standardised
format
Link to sources
In
d
u
s
tr
y
 r
e
s
p
o
n
d
e
n
ts
Source factors
Agency Websites 
Regulatory and 
Reimbursement Atlas ISPOR Roadmaps 
 
 
220 
 
and comparative tool  (Figure 7.14). These ten statements are the same statements 
included in the first section of the agency study questionnaire.  
 
Figure 7.13: Factors exhibited by Regulatory and Reimbursement Atlas, 
Consultants and Internal reference sources according to industry respondents 
 
 
 
Nine of the ten statements were assigned ‘Strongly agree’ or ‘Agree’ by all industry 
respondents. The two most positively scored statements refer to information provided 
by the systematic mapping methodology: 
 It is of value to know how the sponsor interacts with agencies within the R&R 
system 
 It is of value to know how agencies interact with each other within the R&R 
system 
The next most popular statement was scored three ‘Strongly agree’ and three ‘Agree’: 
 The 7 core functions aid comparability between R&R systems 
Only one industry responder scored one of the ten statements negatively:  
 The uniform methodology enables quick visual comparison between R&R 
systems 
However, three other industry respondents also selected ‘Strongly agree’ and two 
selected ‘Agree’ for this statement.  
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Figure 7.14: Value of systematic HTA process mapping methodology according to industry respondents (n=6) 
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In response to a question asking why companies would choose to use the process 
maps (Regulatory and Reimbursement Atlas) over other information sources, three of 
the six respondents provided comments that were all positive attributes of the process 
maps: 
 “Uniform methodology” 
 “Clarity and ease of use” 
 “The graphical representation of the Atlas would be a good choice for 
discussions with internal colleagues and external audiences to provide a 
common point of discussion” 
 
 PART VI - How the process maps could impact company strategy 
The industry representatives scored seven statements for how the process maps 
(Regulatory and Reimbursement Atlas) could impact company strategy (Figure 7.15). 
Two of the seven statements were all scored as ‘Strongly agree’ or ‘Agree’ with only 
one responder indicating ‘no opinion’: 
 I see the value of the process maps as a reference source to understand new 
R&R systems 
 I see the value of the process maps as a reference source to update knowledge 
of R&R systems 
All industry respondents, except one, also answered ‘Strongly agree’ or ‘Agree’ for the 
following two real-life applications of the Regulatory and Reimbursement Atlas: 
 I see the value of the process maps as a presentation aid 
 I see the value of the process maps as a training tool to introduce employees 
to new R&R systems 
The most negatively scored statement with only one positive score was: 
 Tool to support research projects to aid market access strategies 
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Figure 7.15: Potential impact of HTA process maps on company strategy 
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The industry questionnaire included the same list of 20 countries to be ranked (high, 
medium or low) as the agency questionnaire. Unlike the agency results, only three 
countries scored ‘high’ from all respondents: Germany, France and the USA. The 
majority of industry responders were also mainly based in the USA (n=4) and two 
responders from Europe (Switzerland and the UK). However, most of the responders 
(n=4) also held very senior positions (Director or higher) with a global role, one 
responder had a global management role and another was a research associate. 
Industry respondents also scored countries without HTA agencies higher than the 
agency responses (e.g. Japan and China) (Figure 7.16).  The two lowest priority 
countries were Latvia and Luxembourg with one ‘Medium’ and five ‘Low’ scores. 
 
Figure 7.16: Importance of countries by industry respondents 
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PART VII – How the process maps may inform decision-making for 
pharmaceutical companies 
Seven statements for ways the process maps could influence company decision-
making were included in the industry study. Industry scored the answers using a five 
point Likert scale (Figure 7.17). The two most positively answered statements were all 
scored ‘Strongly agree’ or ‘Agree’ by respondents:  
 I see the value of the process maps influencing decision-making for Acquiring 
better knowledge of R&R system market access requirements 
 I see the value of the process maps influencing decision-making for Identifying 
which R&R systems are similar/dissimilar  
 
The following statements were assigned four positive scores by industry respondents: 
 I see the value of the process maps influencing decision-making for determining 
which agencies drive access 
 I see the value of the process maps influencing decision-making for determining 
which agencies drive price 
Overall, the scores were mostly positive for all statements except one:  
 I see the value of the process maps influencing decision-making for determining 
which parts of your organisation should be involved 
This statement was negatively scored by three industry respondents but two other 
industry respondents scored the statement positively. 
Industry respondents also selected the website format as their preferred method of 
accessing the process maps from four different formats: website, interactive PDF, iPad 
application® and Android® application. The second most popular method was by 
interactive PDF (Figure 7.18). 
Industry respondents provided the following comments in response to the industry 
study questionnaire: 
 “As probably every large pharma company we have dedicated market access 
teams in the countries which I would approach on specific questions. Thus, I 
see most value in the comparison of systems and the training component.” 
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Figure 7.17: Process maps potential to inform company decision-making 
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Figure 7.18: Industry respondents preferred format for accessing Regulatory 
and Reimbursement Atlas (n=6) 
 
 
 
 “The Atlas is a helpful tool to gain first insights into a P&R system and its 
actors” 
The comments from industry respondents support the use of the systematic process 
maps as an educational and training tool for providing insights into reimbursement 
systems and also as a comparative tool. 
 
DISCUSSION 
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response from agency representatives was largely positive despite that 2 of the 5 
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questionnaire. One of the most encouraging results is the agency representatives 
score for the Regulatory and Reimbursement Atlas (compilation of systematic process 
maps) for how well, in their opinion, they believe the Regulatory and Reimbursement 
Atlas provides up-to-date information, links to sources, has a standardised format and 
is user-friendly.  Agency websites were the most selected source to be utilised by 
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Part II of the agency questionnaire provided more encouraging results for the process 
maps. Ten positive statements that related to the value of the process maps did not 
receive a single disagree of strongly disagree answer. The questionnaire results 
strongly support the use of the process maps as an educational tool with the following 
statements achieving all positive opinion scores:  
 Process maps are easy to understand for a person with no prior knowledge of 
R&R systems 
 Process maps are easy to understand for a person with some prior knowledge 
of R&R systems 
 The process maps are valuable for a person who wishes to expand their 
knowledge of R&R systems to include new jurisdictions  
 The 7 core functions (Regulatory, Market Access, HTA, pricing, recommender, 
decision-maker and provider) identify important roles within the R&R system 
 The 6 HTA key icons (Scientific advice, Therapeutic value, Economic value, 
Reimbursement rate, Public consultation and Coverage with evidence 
development) identify valuable aspects of HTA activities 
 The 7 core functions  aid comparability between R&R systems 
 The 6 HTA key icons aid comparability between R&R systems 
 The uniform methodology enables quick visual comparison between R&R 
systems 
 I see the value of the process maps as a training tool to introduce employees 
to new R&R systems 
 I see the value of the process maps as a reference source to understand new 
R&R systems 
 I see the value of the process maps as a source to identify how other R&R 
systems and HTA processes compare 
 
The following statements all received positive opinion scores to support the utilisation 
of the process maps as a communication tool: 
 I see the value of the process maps as a presentation aid  
 I see the value of the process maps as a source to identify how other R&R 
systems and HTA processes compare to your own practices 
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 I see the value of the process maps as demonstrating your agencies role in the 
R&R system to stakeholders 
 
The visual representation of the system could aid communication from HTA agencies 
to patients, citizens and other stakeholders. Using the comparability functions of the 
process maps to compare how roles between different regulatory and reimbursement 
systems compare to internal practices could be useful to support comparisons with 
peers and internal audits.   
The Industry study also provides support for the Regulatory and Reimbursement Atlas. 
Similarly to the HTA agency responses, the agency websites were the most utilised 
source but the Regulatory and Reimbursement Atlas (process maps) received the 
highest scores for compliance across all four information source factors. The 
responses support the utilisation of the process maps as an educational tool. A 
comment from an industry representative supports the application of the tool as an 
educational support for introducing and obtaining an overview of regulatory and 
reimbursement systems: 
 
“The Regulatory and Reimbursement Atlas is a helpful tool to gain first insights into a 
P&R system and its actors” 
 
Another free text answer from an industry representative acknowledges the value of 
utilising the process maps as a communication tool: 
“The graphical representation of the Atlas would be a good choice for discussions with 
internal colleagues and external audiences to provide a common point of discussion”   
The main questions that received different answers from industry and agency 
respondents were the ranking of jurisdictions by level of importance (Figure 7.19). 
However, this is to be expected as industry and agencies have different priorities and 
will view jurisdictions from different perspectives. Important jurisdictions to most 
pharmaceutical industry representatives will be the larger or rapidly growing markets. 
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Figure 7.19: Ten highest ranked countries by importance for HTA agency and pharmaceutical industry respondents 
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However, a HTA agency is more likely to view jurisdictions with an established HTA 
organisation that is internationally active as these countries can provide opportunities 
for shared learning or comparison. Overall the agency and industry study 
questionnaires have both yielded a majority of positive responses from both the 
multiple-choice questions and free text answers, for example: 
 
“Great job. I think this work fills an important gap in the resources and tools available 
for industry, HTA bodies, payers and academics... the methodology and 
standardised format is quite sophisticated yet simple and user-friendly.” 
 
SUMMARY 
 This study achieved a response rate of 75% for the industry and 50% for the 
HTA agencies. The industry received a better response rate, but five of the five 
respondents were based in English speaking nations. Language may have 
been a barrier for lower agency response rate.  
 
 Overall, agency and industry responses were positive.  
 
 Both Industry and agency responses support the utilisation of the HTA process 
maps as an educational tool. 
 
 Industry and agency respondents both agreed with statements to support the 
use of the Regulatory and Reimbursement Atlas (Process maps) as a 
communication tool. 
 
 The main disparities between the agency and industry responses were from 
ranking of jurisdictions/markets by importance. As industry and agencies have 
different priorities, they would therefore view jurisdictions from different 
perspectives. 
 
 Both industry and agency respondents favoured the website format for 
accessing the systematic process maps (Regulatory and Reimbursement 
Atlas). 
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CHAPTER 8 
 
 
 
 
 
General Discussion 
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INTRODUCTION 
Background 
The process required for providing patients’ access to new medicines has become 
more complex with the increased uptake of Health Technology Assessment (HTA) to 
inform coverage decisions. HTA is commonly referred to as the ‘fourth hurdle’ as it 
assesses the clinical effectiveness of a new health technology following the regulatory 
assessment for safety, efficacy and quality with the fifth hurdle as affordability. The 
establishment of the European Medicines Agency (EMA) in 1995 standardised the 
procedure for gaining market access for new medicines across Europe, but now the 
pharmaceutical industry is required to submit multiple applications to individual 
European countries for reimbursement. The methodologies and processes used to 
conduct HTA can vary from country to country and also between regions when 
decision-making is decentralised. Thus, the pharmaceutical industry must learn to 
navigate a market that resembles an ever changing patchwork of HTA agencies as 
HTA methodologies and processes continue to evolve. Manufacturers often submit 
applications first to markets where they are likely to achieve a higher price, as many 
European countries will review prices achieved in other European markets to guide 
pricing. This can result in patient access inequalities throughout Europe, as patients 
in countries that tend to pay higher prices are more likely to have earlier access and 
patients in countries that are unable or not willing to provide coverage at a price 
obtained in other European countries may be denied access. The time taken to 
prepare multiple submissions is also detrimental to the pharmaceutical industry as it 
reduces the time left on the patent to recover research and development costs and 
generate a profit. In order to move forward to a more harmonised HTA environment 
within Europe, it is first necessary to understand the current varying HTA practices 
and how these may impact coverage decisions. 
This study was designed to evaluate a range of HTA agencies with different processes 
and positions within both national and regional healthcare systems. The relationship 
between HTA agencies, regulatory authorities and coverage decision-making bodies 
was also considered to be important to enable an understanding of current healthcare 
pathways, identify areas of potential overlap and evaluate the impact of HTA 
recommendations. Different methods for HTA were also compared to understand the 
prevalence and impact for the varying approaches for considering clinical and cost-
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effectiveness. Several objectives were met to achieve the study aim namely, to review 
Health Technology Assessment agencies and their relationship to regulatory 
authorities and other decision-makers and to identify common appraisal practices with 
respect to economic and therapeutic evaluation.  
First, a novel classification tool was developed to enable groupings of HTA agencies 
that share certain characteristics, but without implying any indication of rank between 
groupings. Being objective is an important feature of the classification tool because 
the mandates of HTA agencies can vary greatly. The relationship between the 
classification tool groupings and HTA recommendations for nine European national 
HTA agencies (Belgium, England, France, Germany, Ireland, Italy, the Netherlands, 
Scotland and Sweden) were subsequently evaluated to identify trends to meet the 
second objective. Thirdly, HTA recommendations and rationale were also compared 
for four HTA agencies (Australia, Canada, England and Scotland) with broadly similar 
approaches to identify causes for discordant HTA recommendations. The Canadian 
HTA environment was further evaluated as a case study to investigate the impact of 
non-mandatory coverage recommendations from a centralised HTA agency for 
multiple payers. Finally, representatives from HTA agencies and the pharmaceutical 
industry were studied to identify how the regulatory, HTA and reimbursement process 
maps can provide value in practice. Achieving these objectives provides evidence to 
debate the potential development of a pan-European HTA agency and whether 
lessons can be learned from current HTA agencies that have sought to provide HTA 
evidence and/or coverage recommendations for multiple heterogeneous regions.  
 
Comparative studies 
HTA recommendations from HTA agencies across Australasia, Europe and North 
America have been compared to evaluate agreement, identify trends and understand 
the rationale behind discordant HTA recommendations. This adds to the existing body 
of knowledge by expanding on previous work and supports the identification of trends 
over an extended period of time. This study has also investigated the rationale 
underpinning discordant HTA recommendations issued by national HTA agencies 
from Australia, Canada, England and Scotland, which all share a common welfare 
state origin, similar approaches for cost-effectiveness evaluations, similar GDP and 
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inclusion of an independent expert committee. This expands upon previous studies 
that have evaluated HTA recommendations to determine agreement between country 
pairs and compared rationale for discordant recommendations. However, even when 
reviewing the proportion of recommendation types issued by the four countries there 
are considerable disparities, which does not support the conclusion by Lexchin and 
Mintzes (2008) that there is no difference between the proportions of 
recommendations.  A study by Spinner et al. (2013) evaluated the clinical evidence 
reviewed for nine case studies and concluded that differences in recommendations 
can be attributed to differences in clinical evidence. However, the results from this 
study indicate that the situation is much more complex and that even where similar 
evidence has been considered, different HTA recommendations were issued. For 
example, the concerns that led to negative recommendations by one agency were 
often considered by another agency which issued a positive recommendation. For 
example, ranibizumab injection (Lucentis) to treat macular oedema, secondary to 
retinal vein occlusion secondary to Branch Retinal Vein Occlusion (BRVO) and Central 
Retinal Vein Occlusion (CRVO), was issued a negative recommendation by the 
Australian HTA agency due to high cost and uncertainties regarding its cost-
effectiveness. The same comparators were submitted to all four agencies, but the 
PBAC believed that a more appropriate comparator which reflected clinical practice 
(bevacizumab) should have been included in the submission, despite not having 
marketing authorisation for the indication under review. NICE also noted that they 
believed bevacizumab was an appropriate comparator, but accepted that data were 
not available for bevacizumab and issued a positive recommendation. These results 
are supportive of the conclusions by Clement et al. (2009) who argued that differences 
in listing decisions were more likely to be due to differences in willingness to accept 
risk. Interestingly, the case studies also provided examples where all four agencies 
have expressed concerns over safety for new medicines which had already been 
granted regulatory approval. Therefore the regulatory authorities for Australia, Canada 
and Europe had already assessed the safety, efficacy and quality of the new medicine 
and deemed the benefits to be acceptable in regards to the relative risks. In one 
example, prasugrel to treat coronary syndromes, achieved positive recommendations 
from Australia, England and Scotland. However, the Canadian national HTA agency 
issued a negative listing recommendation primarily due to concerns over the 
transferability of the clinical trials to the Canadian context, but also as a result of 
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concerns over increased adverse events.  Therefore, the consideration of safety by 
both regulatory authorities and HTA agencies indicates an area of overlap and 
potential duplication of work. This could point towards the value of a closer 
collaboration and work-sharing between regulatory authorities and HTA agencies as 
provided in the joint scientific advice piloted by the EMA and European HTA agencies.  
The comparisons of nine European HTA agencies (Belgium, England, France, 
Germany, Ireland, Italy, the Netherlands, Scotland and Sweden) build upon previous 
studies such as Nicod and Kanavos (2012) and Bending et al. (2012). Nicod and 
Kanavos (2012) evaluated HTA recommendations from Australia, Canada, England, 
Scotland and Sweden with a particular focus on therapeutic areas and concluded that 
these can result in significant differences. The results from this study also grouped 
HTA recommendations by therapeutic area, but only the group of medicines to treat 
malignant disease contained a reasonable number of products for comparison. The 
agreement calculated between HTA recommendations for medicines to treat 
malignant disease issued by country pairs was considerably lower than the level of 
agreement calculated for all therapeutic areas combined. Therefore, these results 
support the findings of Nicod and Kanavos (2012) as they also suggest that there are 
differences between therapeutic areas, but this study has included a cohort of more 
recent medicines that were evaluated across a larger selection of European HTA 
agencies. Bending et al. (2012) compared the processes and recommendations of two 
national HTA agencies (France and Scotland) to identify differences between agencies 
that include or exclude cost-effectiveness evaluations for reimbursement 
recommendations for new medicines. However, there are many factors that can cause 
discordant HTA recommendations and comparing only two agencies has limited value. 
Therefore the comparisons of HTA recommendations from nine European HTA 
agencies is more likely to identify potential correlation of factors that impact 
reimbursement recommendations. The calculations for agreement between country 
pairs indicated that HTA agencies, classified by the System process taxonomy, may 
correlate with concordant HTA recommendations. This is a novel result and a valuable 
outcome of the development of the classification tool. Interestingly, the results 
produced from using the classification tool to group HTA agencies/organisations from 
33 European jurisdictions by archetypes did not demonstrate any correlation with 
geographical location or welfare state design. Therefore, this indicates that using 
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location to select groups of countries for collaborations which require similar processes 
may not provide optimum results. A more practical approach would be to identify 
factors more closely related to current HTA processes for work sharing collaborations, 
but this should not suggest that they will also issue concordant recommendations. No 
correlation was identified between the HTA process taxonomic set and the HTA 
recommendations issued by nine European national HTA agencies. It is also often 
said that “if you have seen one HTA system, you have seen one HTA system” 
(O’Donnell et al., 2009). Even countries with generally similar aspects to their 
healthcare system, their ability to pay, and approaches for cost-effectiveness 
evaluations can issue discordant HTA recommendations. 
The archetype groups from the classification tool cover a broad range of approaches 
for HTA and reimbursement systems, including countries that do not conduct their own 
HTA. Therefore, it is likely that these archetypes could categorise approaches for HTA 
that have been established in countries outside Europe. This could provide value for 
the recently established regional networks such as: HTAsiaLink and RedETSA 
(HTAsiaLink, 2015b; Lemgruber, 2013). One of the initial goals of RedETSA is to map 
out the current HTA environment across member countries. The classification tool and 
HTA process maps could potentially support the initial mapping stages and provide an 
educational tool for increasing awareness of newly established HTA agencies. The 
HTA process maps could also update knowledge of various reimbursement systems 
for professionals, academics and provide value as a communication tool for patients, 
citizens and students to support initiatives for transparency and awareness. This could 
be particularly useful for patient groups to educate new members. The process maps 
could also accompany more in-depth profiles when more detail is required such as 
guidelines for manufacturer’s submissions. The classification tools can also be used 
by HTA agencies to identify other agencies that share similarities, which could be 
valuable for identifying potential collaborators, but also for choosing appropriate 
comparators if an agency wishes to undertake benchmarking activities. As the HTA 
agency, and/or the healthcare system evolves it is possible it will change its archetype 
and taxonomic groupings. If the changes in classification are recorded over time, this 
could enable the trajectory of HTA agencies to be tracked and also identify potential 
trends, which may indicate that the global HTA environment is naturally converging 
towards an optimal approach for HTA. However, it should also be noted that these 
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HTA archetypes and taxonomic groups have been developed as an academic 
research project and the potential obstacles for collaboration are likely to be more 
complex in the real world.  
 
LESSONS FROM CANADA 
The Canadian HTA environment was evaluated by comparing HTA recommendations 
(excluding oncology medicines) from the national centralised Canadian HTA agency, 
the Common Drug Review (CDR) with listing decisions from four provinces (Alberta, 
British Columbia, Ontario and Quebec). The Canadian HTA environment is of 
particular interest because it has the potential to provide learnings for future HTA 
harmonisation in Europe. The CDR is not the only HTA agency that was established 
to standardise multiple regions. The National Institute for Health and Care Excellence 
(NICE) was created to reduce patient access inequalities to new medicines across 
England and Wales. Increased standardisation is achieved by NICE through 
mandatory positive recommendations, in addition to other roles such as the generation 
of clinical guidance. The Canadian HTA environment is unique, as it includes a 
centralised HTA agency that provides non-mandatory listing recommendations 
accompanied with comprehensive clinical and economic dossiers that are sent to 18 
participating provincial, territorial and federal drug plans.  Each drug plan is 
responsible for determining the final listing decision and utilises the CDR dossiers by 
considering the evidence in the local context. Manufacturers are still required to submit 
an application to the regional drug plans, which also provides an opportunity to provide 
local context specific data within the submission. These factors indicate the CDR as a 
potential model for future harmonisation of the European HTA environment as the 
CDR participating drug plans are heterogeneous and could represent European 
countries.  
Evidence was generated in this study through surveys, semi-structured interviews and 
data collected from the public domain to provide insights into the CDR, the impact of 
non-mandatory HTA recommendations on regional decision-makers and to expand on 
existing research. Comparisons of CDR HTA recommendations and provincial listing 
decisions from four provinces (Alberta, British Columbia, Ontario and Quebec) 
enabled the calculation of concordance between the CDR and the four provinces. This 
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provided valuable information to the existing body of knowledge, as the most recently 
published comparative studies had conflicting conclusions regarding the impact of the 
CDR. Attaran et al. (2011) concluded that for some provinces the impact of the CDR 
was no better than random chance, yet Gamble et al. (2011) reviewed new medicines 
from a similar period and the results demonstrated moderate to substantial correlation. 
The study conducted by Attaran et al. (2011) did not review all medicines from 
inception of the CDR, instead they selected the first 25 and last 25 recommendations 
from 2003 to late 2008. The results from this study supported the results from Gamble 
et al. (2011), which reviewed the full set of CDR recommendations from inception up 
to 2009 and indicated greater alignment. This suggests the impact of the CDR is 
leading to more harmonised provincial recommendations across Canada.  
 
The results from the semi-structured interviews with payer/HTA agency 
representatives and decision-makers added weight to the results as these opinions 
strongly supported the work of the CDR and described upcoming measures that 
demonstrated increasing reliance on the CDR process. For example, British Columbia 
will no longer consider medicines for regional review if issued a ‘do not recommend’ 
by the CDR, but will still consider all other CDR recommendation types (including ‘do 
not list at the submitted price’) for the regional review for considering the 
manufacturers submission and CDR evidence in the local context. Therefore, the 
results of this study provide evidence to indicate that the non-mandatory CDR 
recommendations impact regional decision-making and that the CDR is increasing 
harmonisation across participating plans. This could be due to the CDR continuing to 
develop the evidence dossiers and HTA recommendations to become increasingly 
suited to participating payers’ needs, but could also be a result of payers’ becoming 
more reliant on the CDR. Ultimately, the CDR provides an example of a working model 
for a centralised HTA agency that could improve harmonisation for a range of 
heterogeneous regions while maintaining the flexibility for each region to determine 
the final coverage decision. 
Previous studies have also discussed the potential for a pan-European HTA agency 
and a few of these have drawn comparisons with the Canadian HTA environment and 
the potential harmonisation of European HTA. However, these were published more 
than a decade ago and do not reflect current developments in Canada and Europe 
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(McDaid, 2003; Lehoux et al., 2004). McDaid (2003) suggested the establishment of 
a European equivalent for the Canadian Co-ordinating office of Health Technology 
Assessment (CCOHTA) the European Co-ordinating office of Health Technology 
Assessment (ECOHTA) could either prepare assessments and disseminate evidence 
to participating agencies or analyse reports generated by individual European HTA 
agencies. Twelve years have passed since the publication of the study by McDaid 
(2003) and CCOHTA has now evolved into the Canadian Agency for Drugs and 
Technologies in Health (CADTH) and now operates the CDR and the pan-Canadian 
Oncology Drug Review (pCODR). The CDR and pCODR both provide listing 
recommendations for participating drug plans. Therefore, the introduction of ECOHTA 
could be controversial in Europe if it was expected to develop into a European Agency 
for Drugs and Technologies in Health that would provide pan-European HTA 
recommendations. Initially the national Canadian HTA agency CCOHTA (now 
CADTH) could not agree whether to issue a listing recommendation with the nationally 
conducted HTA’s as it is the responsibility of provincial governments to determine 
reimbursement (Lehoux et al., 2004). The proposal for EUnetHTA explicitly states that 
EUnetHTA is not intended to be a European HTA agency and should never issue 
reimbursement recommendations. While there are similarities between the challenges 
faced by heterogeneous Canadian provincial payers and great variation between 
European countries, there are more similarities to the Canadian HTA environment and 
this study agrees with the EUnetHTA proposal in regards to a European HTA agency 
not to issue HTA reimbursement recommendation (European Network for Health 
Technology Assessment (EUnetHTA), 2008). 
Lehoux et al. (2004) reviewed six Canadian HTA agencies (one national and five 
regional) and discussed challenges with streamlining manufacturer’s submissions. 
The results from this study indicate that this is less of an issue now for provincial 
payers as the CDR has helped to streamline the submission process. Manufacturers 
are still required to submit applications at the provincial level, but the feedback from 
the semi-structured interviews indicated that the CDR submission is very similar to 
previous provincial submission requirements and that the additional information 
required for the provincial submission is specific for reviewing the medicine in the local 
context. Lehoux et al. (2004) also discussed a paradox between the importance of 
contextualising findings for increased impact and the argument that if HTA agencies 
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consider the same evidence with the same methodology then they should reach a 
similar conclusion. The development of the CDR provides a compromise for this 
paradox as all participating public drug plans now receive the same evidence dossiers 
and therefore do not need to conduct a full HTA assessment across multiple provinces 
that could choose to utilise multiple methodologies. However, the provincial payers 
retain their positions as decision-makers and that enables the final decision to also 
consider the local context. Other issues for consideration raised by Lehoux et al. 
(2004) included the need to improve awareness of HTA to increase impact for 
informing policy and practice. Ultimately Lehoux et al. (2004) recommended the 
establishment of collectives of HTA agencies, which would enable shared resources 
and research. The establishment of the CDR in Canada has demonstrated a 
successful working model for sharing HTA evidence as a result of a centralised review, 
which provides a more efficient use of resources. The rationale underpinning the 
establishment of EUnetHTA has similarities with the rationale for the creation of the 
CDR as both aim to reduce duplication of work, use HTA resources more efficiently 
and provide access to robust scientific evidence. The disparities between medicines 
coverage across Canadian provinces was a key concern that led to the development 
of the CDR. Similarly, patient access to new medicines varies across Europe and 
EUnetHTA aims to support cross-border application of tools and methodologies for 
HTA.  
PAN-EUROPEAN HTA  
Drummond (2003) argued that the creation of a European HTA agency is a possibility 
but three key challenges will need to be harmonised first: economic evaluation 
guidelines; decision-making processes and societal willingness-to-pay for health 
technologies. He suggested that the harmonisation of economic guidelines would be 
the easiest of the three challenges, but even with common European guidelines the 
differences between country policies may require tailored reports to enable inclusion 
or exclusion of data, such as productivity costs. Harmonising societal willingness-to-
pay is arguably the most challenging factor. Even if there was a single price for Europe, 
there would still be differences in the local costs for healthcare that may be required 
to deliver or monitor the medicine, which would affect the cost-effectiveness of the 
product. Overall, Drummond (2003) suggests the likelihood of all three achieving 
harmonisation in the near future is very low.  
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An abridged European HTA agency could be a feasible compromise in the near future, 
rather than waiting for the European Healthcare environment to align HTA 
methodologies and societal willingness-to-pay to be standardised. The abridged 
European agency would actually be a collection of European HTA agencies working 
in collaboration. This could be called the European Health Technology Assessment 
Collaborations (EHTAC) and would work in collaboration with the EMA to provide 
parallel scientific advice and generate evidence for the rapid REA report to supplement 
the EMA’s EPARs (Figure 8.1, step 1). It is proposed that European agencies with 
existing similarities could form collaborative groups to share HTA assessment 
evidence that is suitable to meet their common needs (Figure 8.1, step 2). For 
example, rather than having a single European guideline for economic evaluation, 
there could be several guidelines that are each accepted by a group of HTA agencies 
and these groups would collaborate to generate the evidence. This would enable HTA 
agencies to acquire the benefits of shared resources and the pharmaceutical industry 
would also benefit if they had significantly fewer economic-evaluation guidelines to 
meet. In addition to coordinating multiple collaborations, EHTAC could also have a 
central role in generating Relative Effectiveness Assessment (REA) using the 
EUNETHTA adapted and piloted core model for rapid REA process. The rapid REA 
process only requires safety and effectiveness data available at the time of launch. 
Ascroft and Pichler (2014) have argued in favour of the rapid REA process over the 
full core model as, at least for the pilot stage, the former would be more realistic for 
industry and HTA agencies resources to conduct for every medicine evaluated by the 
EMA.    
Eventually, it is feasible that a truly pan-European HTA agency could evolve from 
EHTAC as multiple HTA agencies with varying practices will have already aligned 
within their collaborative groups. The pan-European HTA agency would then be 
established to complete the second and final phase of the progressive alignment 
approach by harmonising the HTA processes and methodologies utilised by the 
collaborative groups. This would enable a pan-European HTA agency to generate 
evidence at the European level, which could be provided in dossiers to participating 
countries to be considered in the local context. The pan-European agency could be 
independent from the regulatory authority, similar to the Canadian HTA environment, 
or it could be established as part of the EMA (Figure 8.2). There are already examples 
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of agencies that conduct regulatory and HTA functions at the national level in Europe 
such as the Italian Medicines Agency (AIFA). The EMA has already collaborated with 
EUnetHTA to improve the EPARs to become more supportive of HTA needs (Berntgen 
et al., 2014) and conducted pilots for joint EMA and HTA scientific advice (European 
Medicines Agency (EMA), 2015b). The EMA-HTA would utilise the EUnetHTA Core 
Model to produce evidence dossiers for participants and would also implement the 15 
Key Principles as proposed by Drummond et al. (2008). These would provide the 
backbone of the EMA-HTA as the EUnetHTA Core Model and Key Principles are 
already generally well respected in the field. Overall, the EMA-HTA would provide 
many practical benefits such as the sharing of resources, reducing duplication of work 
and sharing data. Kendall et al. (2009) has proposed the establishment of NICE in the 
USA by incorporating the HTA body within the Food and Drug Administration (FDA) 
which would enable the HTA body to share resources with the regulatory authority. 
A pan-European HTA agency is a controversial topic and it could be argued that it is 
not possible to harmonise HTA across Europe as countries are too different and the 
political, social and economic aspects of HTA cannot be aligned. However, the 
Canadian HTA environment provides a working model for a centralised HTA agency 
that enables regions to include evidence generated at the national level that has been 
considered in the local context. It should also be noted that prior to the establishment 
of the EMA there were many that doubted the possibility of a single European 
regulatory authority due to varying approaches across Europe. However, the EMA was 
established in 1995 and has now been successfully providing marketing authorisation 
for medicines across Europe for more than twenty years.  
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Figure 8.1: Progressive alignment phase 1  
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Figure 8.2: Progressive alignment phase 2   
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STUDY LIMITATIONS 
 The data collection for most of this research was limited to the public domain and 
grey literature searches, such as government, academic or industry literature that is 
not formally published.  Where possible, HTA agencies were contacted directly to 
confirm the information collected in the public domain and to complete surveys and 
semi-structured interviews to provide further insights and opinions. However, not all 
of the HTA agencies/organisations were able to provide feedback for the process 
maps. 
 
 The HTA agencies and organisations within the healthcare systems evaluated in this 
study produced websites with varying degrees of transparency. This emphasised 
the need for additional steps to validate data collected from the public domain but 
also provided insights for how different agencies comply with one of the 15 Key 
Principles for HTA (Drummond et al., 2008).  
 
 Some agency websites only published information in their national language, which 
was a limitation for the primary researcher when no English version was available. 
To reduce this limitation, an online translation tool was utilised and, when possible, 
a second researcher with the relevant language skills conducted an audit of the 
translated data.   
 
 A small sample of provincial payer and agency representatives (n=7) were 
interviewed to evaluate the impact of the national Canadian HTA agency 
recommendations (chapter 6). This sample was limited due to the very small 
population size of Canadian provincial payers, the number of provinces with 
potential contacts identified to invite to interview,, interviewer time and travel costs. 
These seven interviewees were sought from the four largest provinces, which also 
represented the provinces with the most divergent decisions.  However, it would 
have been preferable to have at least one representative interviewed from all 18 
participating plans of the Common Drug Review and Quebec.  
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 The primary researcher conducted all semi-structured interviews for this study for 
consistency (Chapter 6). However the primary researcher only had limited 
interviewing experience prior to this study which can affect the quality and depth of 
the answers provided by the interviewees. To reduce this limitation, the interview 
guide was reviewed by researchers with experience conducting interviews and two 
pilot interviews were conducted prior to the commencement of the full study. 
 
 The selection criteria for identifying participants for the questionnaire to understand 
value of the HTA process maps (chapter 7), was primarily determined by 
membership of a not-for-profit organisation that provides a neutral, professional 
forum. This selection criteria provided contact with representatives from HTA 
agencies and the pharmaceutical industry, but also increased the likelihood that 
responders would be familiar with the HTA process maps and would therefore be 
able to provide more informed answers. However, this could also introduce bias into 
the study as the research had been presented at previous meetings of the not-for-
profit organisation that was attended by some of the responders. This study has 
successfully piloted the questionnaire with a range of senior stakeholder 
representatives and has indicated an overall positive response for the process 
maps. However, a larger study could be conducted with a broader selection criteria 
and inclusion of a wider range of stakeholders (e.g. academics, clinicians, patients 
and researchers) to reduce bias and understand the potential value of the process 
maps for a more diverse audience.    
 
RECOMMENDATIONS 
 It is recommended that HTA agencies regularly update their websites to ensure they 
clearly outline current practices. Publishing information in English would also support 
international studies.  
 
 The maps generated from this research could be used by agencies to support 
patient and public engagement as well as being an educational and reference tool 
for pharmaceutical industry employees, researchers and professionals working 
within the field of HTA.                           
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 HTA agencies should consider using the objective classification tool and record the 
archetype group that reflects their current practices and re-evaluate and record their 
archetype groupings when their processes change. This would enable comparisons 
over time that could track the trajectory of HTA agencies as they evolve.  
 
FUTURE WORK 
 Results produced from this research suggests that provincial payers are becoming 
more aligned with CDR recommendations.  Combining these results with feedback 
from interviews with payer representatives and decision-makers, strongly suggests 
that the CDR recommendations increasingly impact regional decisions despite being 
non-mandatory. Future research could build on this study by asking provincial 
payers if and why they think the results demonstrate an increase in agreement. 
 
 Future adaptions to the HTA classification tool would benefit from input from a range 
of stakeholders that are part of the process for new medicines obtaining 
reimbursement such as: regulatory authorities, HTA agencies, manufacturers and 
patient groups.  
 
 The research conducted for comparing CDR recommendations with regional 
coverage decisions should be repeated when a sizeable cohort of new CDR 
recommendations have been issued and compared with all provincial payers. This 
will enable comparisons to be drawn before and after implementation of the pan-
Canadian Pharmaceutical Alliance (PCPA). The introduction of the PCPA may 
produce greater harmonisation between the CDR provinces and a comparative 
study of provincial HTA recommendations prior and post introduction of the PCPA 
could provide some interesting insights for the impact of the PCPA.  
 
 The archetype groups and two taxonomic sets (System process taxonomy and ‘HTA 
process taxonomy’) were developed and tested on 33 European jurisdictions with a 
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wide range of processes and healthcare systems. Therefore, it would be of value to 
determine whether this tool can be applied to a range of reimbursement systems 
and HTA agencies beyond Europe.  
 
 The archetype groups could be refined to include an option for pricing controls. This 
would enable the classification tool to capture the variations in countries that do not 
use HTA, but use a form of pricing controls to regulate the reimbursement of new 
medicines. 
 
 This study has focused on HTA for new medicines, but the HTA process mapping 
methodology and classification tool could be applied to HTA processes for the 
reimbursement of medical devices.  
 
 The malignant disease case study has highlighted areas where further research 
could provide interesting insights. Due to the small number of medicines allocated 
to other therapeutic area categories, this study was unable to fully evaluate the 
impact of therapeutic areas on HTA recommendations. A larger study that collected 
data over a longer period of time could produce a sufficient dataset to evaluate more 
therapeutic areas.  
 
 
CONCLUSION 
The establishment of a pan-European regulatory authority was initially controversial but 
the EMA has since transformed the European regulatory environment from a patchwork 
of multiple regulatory authorities with individual submission requirements for marketing 
authorisation to a single streamlined process. Overall, this has produced a more 
harmonised and efficient European regulatory environment while also maintaining 
national regulatory authorities in order to conduct activities that are specific for each 
member nation. However, the uptake of formal HTA processes has now created an 
additional level of complexity that essentially undermines the harmonisation and 
efficiencies achieved by the establishment of the EMA as multiple submissions with 
different evidence requirements are now necessary to gain access to individual 
European markets. Projects such as EUnetHTA have produced vital research that will 
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support the creation of a more harmonised and efficient European HTA environment. 
The publication of the 15 Key Principles for HTA support the implementation of more 
robust and accountable approaches to HTA throughout the world (Drummond et al., 
2008).  
 
The progressive alignment approach that has been developed throughout this research 
builds on the important work by EUnetHTA funded by the European Commission and 
various multi-stakeholder initiatives such as parallel regulatory authority and HTA 
scientific advice, to suggest a model for achieving a more harmonised HTA 
environment. This progressive alignment approach is novel as it enables the benefits of 
harmonisation to be achieved prior to the establishment of a single pan-European HTA 
agency which may not happen in the near future. Instead, collaborations can be 
achieved by grouping HTA agencies that already have similar approaches to HTA so 
harmonisation can be achieved within various groups first. Sharing evidence would 
reduce duplication of work and be particularly beneficial for HTA agencies or 
organisations with fewer resources, but would also increase the efficiency for all 
collaborating agencies. The collaborations could eventually result in the European HTA 
environment only requiring a few different guidelines for economic evaluation in the near 
future. This would reduce the resources required by industry for completing submissions 
and could also speed up the time to submission. Therefore, the development of a novel 
classification tool, comparisons of HTA recommendations from very different and also 
generally similar HTA agencies and the evaluation of the Canadian HTA environment 
have ultimately led to the development of the ground-breaking progressive alignment 
approach which supports the ongoing efforts to create a more efficient European HTA 
environment.       
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Information sources for agencies included in the HTA Process Maps 
Country Acronym Full name Link 
Australia TGA Therapeutic Goods Administration http://www.tga.gov.au 
DUSC Drug Utilisation Sub-committee http://www.pbs.gov.au/info/industry/listing/participants/drug-utilisation-
subcommittee 
PBAC Pharmaceutical Benefits Advisory 
Committee 
http://www.health.gov.au/internet/main/publishing.nsf/Content/Pharmaceutical+
Benefits+Advisory+Committee-1 
ESC  Economics Sub-Committee http://www.pbs.gov.au/info/industry/listing/participants/economics-
subcommittee-esc 
 Minister for Health and Ageing http://www.health.gov.au/ 
PBS Pharmaceutical Benefits Scheme http://www.pbs.gov.au 
Austria BASG/AGES Austrian Federal Office for Safety in 
Health Care    
http://www.basg.at 
BMG The Federal Ministry of Health http://www.bmg.gv.at/  
HVB Federation of Austrian Social Insurance 
Institutions 
www.hauptverband.at  
PK Price Committee http://bmg.gv.at/home/Schwerpunkte/Medizin/Arzneimittel/Arzneimittelpreise/E
U-Durchschnittspreise_laut_ASVG  
HEK Drugs Evaluation Commission http://www.hauptverband.at/portal27/portal/hvbportal/channel_content/cmsWind
ow?action=2&p_menuid=65987&p_tabid=5  
UHK Independent Medicinal Products 
Commission 
http://bmg.gv.at/home/Schwerpunkte/Medizin/Arzneimittel/Beiraete_und_Komm
issionen/Unabhaengige_Heilmittelkommission  
Belgium AFMPS/FAGG Federal Agency for Medicines and 
Health Products 
http://www.fagg-afmps.be 
CTG/CRM Medicine reimbursement commission http://www.inami.fgov.be/fr/inami/organes/Pages/commission-remboursement-
médicaments.aspx 
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KCE Belgian Health Care Knowledge Centre https://kce.fgov.be/  
FPSE Federal Public Service Economy http://economie.fgov.be/en/  
FPSSS Federal Public Service Social Security http://socialsecurity.fgov.be/  
RIZIV/INAMI National Institute for Sickness and 
Invalidity Insurance 
http://www.inami.be  
Bulgaria BDA Bulgarian Drug Agency http://en.bda.bg/  
MOH Ministry of Health http://www.mh.government.bg  
PC Price Committee http://www.mh.government.bg/Articles.aspx?lang=bg-BG&pageid=383  
PDL Positive drug list committee http://www.mh.government.bg/Articles.aspx?lang=bg-BG&pageid=384  
TC Transparency committee http://www.mh.government.bg/Articles.aspx?lang=bg-BG&pageid=413  
NHIF National Health Insurance Fund http://www.en.nhif.bg/  
Canada 
 
Health Canada http://www.hc-sc.gc.ca/index-eng.php 
CADTH Canadian Agency for Drugs and 
Technologies in Health 
http://www.cadth.ca/ 
 
CDR Common Drug Review https://www.cadth.ca/cdr 
CDEC Canadian Drug Expert Committee https://www.cadth.ca/canadian-drug-expert-committee-cdec 
PMPRB Patented Medicine Price Review Board http://www.pmprb-cepmb.gc.ca/home 
ECDET Expert committee on Drugs Evaluation 
and Therapeutics 
http://www.health.alberta.ca/about/advisory-bodies.html 
 Alberta Health http://www.health.alberta.ca 
 
 British Columbia Ministry of Health  http://www.gov.bc.ca/health/ 
INESSS National Institute for Excellence in 
Health and Social Services 
www.inesss.qc.ca 
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CSEMI Scientific Committee to evaluate drugs 
for registration   
http://www.inesss.qc.ca/index.php?id=27&L=1 
RGAM Basic prescription drug insurance plan  http://www.ramq.gouv.qc.ca/fr/citoyens/assurance-
medicaments/Pages/description.aspx 
RAMQ Quebec Health Insurance Plan  http://www.ramq.gouv.qc.ca 
Cyprus  Drug Council http://www.moh.gov.cy/moh/phs/phs.nsf/dmlcouncilmed_gr/dmlcouncilmed_gr?
OpenDocument  
 Drug Price Control Committee http://www.moh.gov.cy/moh/phs/phs.nsf/dmlcomminspect_gr/dmlcomminspect_
gr?OpenDocument  
 Drug committee http://www.moh.gov.cy/moh/phs/phs.nsf/dmlphcomm_gr/dmlphcomm_gr?Open
Document 
HIO Health Insurance Organization http://www.hio.org.cy/en/index_en.htm  
MOH Ministry of Health http://www.moh.gov.cy 
Czech 
Republic 
SUKL The State Institute for Drug Control http://www.sukl.eu/  
 General Health Insurance http://www.vzp.cz 
MOH Ministry of Health http://www.mzcr.cz 
Denmark DHMA The Danish Medicines Agency http://laegemiddelstyrelsen.dk  
MTN The Reimbursement committee http://laegemiddelstyrelsen.dk/en/topics/statistics,-prices-and-
reimbursement/reimbursement-of-medicines/the-reimbursement-
committee.aspx  
IRF Institute for Rational Pharmacotherapy http://laegemiddelstyrelsen.dk/en/service-menu/about-us/institute-for-rational-
pharmacotherapy 
DACEHTA The Danish Centre for Health 
Technology Assessment  
http://www.sst.dk/English/DACEHTA.aspx  
Estonia SAM State Agency of Medicines http://www.sam.ee 
EHIF Estonia Health Insurance Fund http://www.haigekassa.ee/eng  
SM Ministry of Social Affairs http://www.sm.ee/eng/pages/index.html  
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Finland FIMEA Finnish Medicines Agency http://www.sam.ee 
KELA Social Insurance Institution of Finland http://www.fimea.fi 
HILA The Finnish Pharmaceuticals Pricing 
Board 
http://www.stm.fi/en/ministry/boards/pharmaboard/frontpagel  
STM Ministry of Social Affairs and Health  http://www.stm.fi/ 
France ANSM French Agency for the Safety of 
Medicines and Health Products 
http://www.ansm.sante.fr/ 
HAS French National Authority for Health http://www.has-sante.fr  
UNCAM National Union of Health Insurance 
Funds 
http://www.ameli.fr 
CEPS The Economic Committee on Health 
Care Products 
http://www.sante.gouv.fr/comite-economique-des-produits-de-sante-ceps.html 
N/A Social Security System http://www.securite-sociale.fr/ 
Germany BfArM  Federal Institute for Drugs and Medical 
Devices 
http://www.bfarm.de 
PEI Federal Institute for Vaccines and  
Biomedicines 
http://www.pei.de  
G-BA Federal Joint Committee http://www.g-ba.de  
IQWIG  Institute for Quality and Efficiency in 
Health Care 
https://http://www.iqwig.de  
GKV  Federal Association of the Statutory 
Health Insurances 
https://http://www.gkv-spitzenverband.de  
Greece EOF National Organisation for Medicines  http://www.eof.gr  
YYKA Ministry of Health and Social Solidarity http://www.yyka.gov.gr/  
GGKA General Secretariat of Social Security http://ggka.citron.gr  
Hungry OGYI National Institute of Pharmacy http://www.ogyi.hu  
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ESKI National Institute for Strategic Health 
Research 
http://www.eski.hu 
OEP The National Health Fund http://www.oep.hu  
Iceland IMA Iceland Medicine Agency  http://www.imca.is/  
IMPRC Icelandic Medicine Pricing and 
Reimbursement Committee  
http://www.lgn.is/?pageid=62  
TR  The Social Insurance Administration  http://www.tr.is  
Ireland IMB Irish Medicines Board. http://www.imb.ie/  
NCPE The National Centre for 
Pharmacoeconomics 
http://www.ncpe.ie  
HSE The Health Service Executive http://www.hse.ie/eng/  
HSE PCRS  Primary Care Reimbursement Service  http://www.hse.ie/eng/staff/PCRS/About_PCRS/  
Italy AIFA Italian Medicines Agency http://www.agenziafarmaco.gov.it  
CPR Price and Reimbursement Committee http://www.agenziafarmaco.gov.it/en/content/committees  
CTS Technical Scientific Committee http://www.agenziafarmaco.gov.it/en/content/committees  
ASLs  Local Health Unites  http://www.salute.gov.it/infoSalute/atlanteHome.jsp?menu=atlante  
Latvia VZA State Agency for Medicine http://www.vza.gov.lv  
CHE The Centre of Health Economics http://vec.gov.lv/  
VNC Health Payment Centre http://www.vnc.gov.lv  
Liechtenstei
n 
 Department of Medicine  http://www.llv.li/amtsstellen/llv-ag-heilmittel-2/llv-ag-arzneimittel-2/llv-ag-
arzneimittel-kontrollstelle_fuer_arzneimittel.htm  
 Department of Health and Accident 
Insurance  
http://www.llv.li/amtsstellen/llv-ag-versicherung/llv-ag-versicherung-
krankenversicherung_neu/llv-ag-versicherung-krankenversicherung-
krankenkassen.htm  
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OKP Compulsory  Health Insurance  http://www.llv.li/amtsstellen/llv-avw-krankenversicherung-
kurzvorstellung.htm?nav=teaser&imainpos=46728&lpid=3789  
Lithuania VVKT State Medicine Control Agency http://www.vvkt.lt  
VLK State Patient Fund http://www.vlk.lt  
MOH Ministry of Health  http://www.sam.lt/  
Luxembourg MOH Ministry of Health http://www.ms.public.lu  
 Ministry of Social Security http://www.mss.public.lu  
CNS  National Health Fund http://www.cns.lu/  
Malta MA  Medicine Authority http://medicinesauthority.gov.mt/aboutus.htm  
MOH Ministry of Health, the Elderly and 
Community care 
https://ehealth.gov.mt  
HPSS Healthcare Procurement and Supplies 
Services  
http://sahha.gov.mt/pages.aspx?page=200  
Netherland CBG/MEB  Medicines Evaluation Board http://www.cbg-meb.nl/  
CFH  Board for Pharmaceutical Aid http://www.cvz.nl/zorgpakket/cfhagenda/commissie/commissie.html  
ZIN  The National Health Institute http://www.zorginstituutnederland.nl/  
VWS  Ministry of Health, Welfare and Sport http://www.minvws.nl  
GVS  The pharmaceutical reimbursement 
system 
http://www.farmatec.nl/geneesmiddelen/prijzenenlimieten/vergoedingssysteem/  
Norway NoMA  Norwegian Medicines Agency http://www.legemiddelverket.no  
HOD Ministry of Health and Care Service http://www.regjeringen.no/en/dep/hod.html  
Poland URPL Office for Registration of  Medicinal 
Products, Medical Devices and Biocidal 
Products 
http://en.urpl.gov.pl/  
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AHTAPol Health Technology Assessment Agency 
in Poland  
http://www.aotm.gov.pl  
MZ Ministry of Health  http://www.mz.gov.pl  
NFZ National Health Fund http://www.nfz.gov.pl  
Portugal INFARMED National Authority of Medicines and 
Health Products  
http://www.infarmed.pt/portal/page/portal/INFARMED  
DGAE General Directorate of Economic 
Activities  
http://www.dgae.min-economia.pt/ 
 MOH Ministry of Health http://www.min-saude.pt  
Romania ANMDM National Medicines and Medical 
Devices Agency 
http://www.anm.ro  
 Transparency Commission http://www.ms.gov.ro/?pag=10&id=2870  
 MOH Ministry of Health http://www.ms.gov.ro  
Slovakia SUKL State Institute for Drug Control  http://www.sukl.sk  
 N/A Categorisation committee http://www.health.gov.sk/?statuty-6  
SLOVAHTA Slovak Agency for Health Technology 
Assessment  
http://www.farmako-ekonomika.sk/images/stories/slovahta/vizia/Slovahta-
vizia.pdf  
VsZP General Health Insurance  http://www.vszp.sk  
MOH Ministry of Health  http://www.health.gov.sk  
Slovenia JAZMP  Agency for Medicinal Products and 
Medical Devices of the Republic of 
Slovenia 
www.jazmp.si 
ZZZS Slovenia Health Insurance Institute  http://www.zzzs.si  
Spain AEMPS Spanish Medicines Agency http://www.aemps.gob.es  
ISCIII The Institute of Health Carlos III  http://www.isciii.es  
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CIPM Inter-ministerial Commission on 
Medicines Prices 
http://www.msc.es/profesionales/farmacia/financiacion/home.htm  
DGFPS General Directorate of Pharmacy and 
Health Products 
http://www.msc.es/profesionales/farmacia/organizacion.htm  
Sweden MPA Medical Products Agency http://www.lakemedelsverket.se/english/  
SBU Swedish Council on Technology 
Assessment in Health Care 
http://www.sbu.se  
TLV/LFN Pharmaceutical Benefits Board http://www.tlv.se/  
Switzerland  Swissmedic http://www.swissmedic.ch  
BAG/ FOPH  Federal Office of Public Health http://www.bag.admin.ch  
UK    MHRA Medicines and Healthcare products 
Regulatory Agency  
http://www.mhra.gov.uk 
  NICE National Institute for Health and Clinical 
Excellence 
http://www.nice.org.uk/ 
  NIHR National Institute for Health Research http://www.nihr.ac.uk 
  PPRS Pharmaceutical Price Regulation 
Scheme 
https://www.gov.uk/government/publications/pharmaceutical-price-regulation-
scheme-2014 
SMC Scottish Medicines Consortium http://www.scottishmedicines.org.uk/Home 
PASAG 
Patient Access Scheme Assessment 
Group 
https://www.scottishmedicines.org.uk/Submission_Process/Submission_guidan
ce_and_forms/Patient-Access-Schemes 
AWMSG Scotland Regional Health Board http://www.gov.scot/Topics/Health/NHS-Workforce/NHS-Boards 
 
All Wales Medicines Strategy Group http://www.wales.nhs.uk/sites3/home.cfm?orgid=371 
LHB New Medicine Group http://www.wales.nhs.uk/sites3/page.cfm?orgid=371&pid=25692 
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Process map for Australia 
Version: December 2014 
 
 
Australian Government 
Department of Health
4
TGA
Therapeutic Goods 
Administration
PBS
Pharmaceutical Benefits Scheme
Minister of Health
DUSC
Drug Utilization 
Sub-Committee
HTA
ESC
Economics Sub-Committee
HTA
PBAC
Pharmaceutical Benefits 
Advisory Committee
HTA
1
2
3
Sponsor
EV
Recommender
Regulator
Market 
Authorisation
Decision Maker
Price Authority
Provider
1 1
TV 0SA TV CED
EV
EV
Agency 
(Committee) 
Function Key activity 
TGA 
The Therapeutic 
Goods 
Administration 
Regulator 
The regulatory agency for medical drugs and devices. The key 
activities of the TGA include pre-market evaluation, licensing of 
manufacture and post-marketing monitoring.   
Market 
Authorisation 
While the TGA recommends registration, the final decision is made 
by the delegate of the Minister of Health. 
PBAC 
Pharmaceutical 
Benefits 
Advisory 
Committee 
HTA 
PBAC assesses the comparable clinical and cost effectiveness of 
pharmaceuticals and vaccines for the purpose of determining 
eligibility for public subsidy.  
Recommender 
PBAC makes recommendations for listing on the PBS that are non-
binding and require Ministerial approval. However 
recommendations not to list are binding. 
DUSC 
Drug Utilisation 
Sub-Committee 
HTA 
The DUSC is a sub-committee of that estimates projected usage 
and forecasts the financial cost of new medicines (i.e. budget 
impact). 
ESC  
Economics  
Sub-Committee 
HTA 
The ESC is a sub-committee of PBAC. The ESC reviews and 
interprets economic analyses in submissions to PBAC and advises 
PBAC on cost-effectiveness. 
Minister of 
Health 
Price Authority 
As currently, the Minister (or delegate) considers pricing matters 
subsequent to PBAC meetings, following the introduction of a new 
streamlined process for listing medicines on the PBS in 1 April 2014. 
A key component of this measure was the cessation of the 
operations of the Pharmaceutical Benefits Pricing Authority (PBPA). 
The Minister’s decision must be based on consultation with the 
sponsor and advice from the PBAC. 
Decision Maker 
For pharmaceuticals with a projected annual cost of less that 
AUD$10 million, the Minister of Health (or a delegate) is the 
decision maker for listing new drugs onto the PBS. For 
pharmaceuticals with an estimated value of greater than AUD$10 
million, the decision is required to be made at Cabinet level. 
PBS 
Pharmaceutical 
Benefits 
Scheme 
Provider 
The national government subsidies the cost of medicines listed 
under the PBS. An exception is vaccines which are subsidised under 
the National Immunisation Programme (NIP). 
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Process map for Austria 
Version: January 2012 
 
 
Agency 
(Committee) 
Function Key activity 
BASG/AGES 
Austrian Federal 
Office for Safety 
in Health Care 
Regulator 
BASG is the regulatory authority for medicinal products and 
medical devices. The key activities of BASG include providing 
scientific advice, admission of clinical trial, inspections, 
market authorisation of medicinal products and market 
surveillance for medicinal products and medical devices. 
Market 
Authorisation 
BASG is responsible for granting marketing authorisations for 
pharmaceuticals. 
PK 
Pricing 
Committee 
Recommender 
The Committee collects price notifications from companies 
to calculate the EU average price. The result of assessment is 
sent to BMG to support price setting. 
BMG 
The Federal 
Ministry of 
Health 
Price Authority 
The manufacture price of pharmaceuticals is set at the level 
of EU Average Price. The Ministry sets the EU Average Price 
for reimbursable drugs under the advice from Pricing 
Committee.  
HEK 
Pharmaceutical 
Evaluation 
Board 
HTA 
HEK studies the therapeutic benefits of the products with 
respect to pharmacological, medical therapeutic, and health 
economic value. 
Recommender 
HEK is a group of 20 experts nominated by several Austrian 
public bodies, including social health insurance 
representatives to provide advice on the reimbursement 
decision.  
HVB  
Federation of 
Austrian Social 
Insurance 
Institutions 
Decision Maker 
Decisions on reimbursement status are made by HVB on the 
basis of recommendations of the Pharmaceutical Evaluation 
Board. 
Provider 
HVB is the umbrella organization for 21 sick funds in Austria. 
The HVB is responsible for reimbursement of 
pharmaceuticals  
UHK 
Independent 
Medicinal 
Products 
Commission 
Decision Maker 
An appeal against the negative decision made by HVB can be 
made to UHK, the Independent Medicinal Products 
Commission. The UHK has the function of an appeal court. All 
committee members are independent experts nominated by 
public bodies in Austria. The UHK is responsible for 
monitoring HEK and HVB. 
4
EU CommissionEMA
European Medicines Agency
1a
BASG/AGES
Austrian Federal Office 
for Safety in Health Care
Sponsor
2
1b
Regulator
Market 
Authorisation
Regulator
BMG
The Federal 
Ministry of Health
Decision Maker
Price Authority Recommender
PK
Pricing Committee
The Federal Ministry of Health 
Provider
HVB
Federation of Austrian 
Social Insurance Institutions
3
HTA
TV EV
Recommender
HEK
Drugs Evaluation Commission
UHK
Independent Medicinal 
Products Commission
Recommender
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Process map for Belgium 
Version: May 2014 
 
 
 
 
EMA
European Medicines Agency
1a
AFMPS / FAGG
Federal Agency for Medicines 
and Health Products
FPSE
Federal Public Service Economy
CTG /CRM
Medicines Reimbursement 
Commission
( under RIZIV/INAMI)
Sponsor
FPS
Federal Public Service
2a
2b
HTA
d1b
Regulator
Regulator
Price Authority
Recommender
EU Commission
KCE
Belgian Health Care 
Knowledge Centre
DRC
Drug Reimbursement 
Committee
FPSSS
Federal Public Service Social 
Security
EV
RIZIV / INAMI
National Institute for Sickness 
and Invalidity Insurance
Market 
Authorisation
Decision Maker
Provider
TVTV EV $
TV CED
CED
Agency (Committee) Function Key activity 
AFMPS / FAGG 
Federal Agency for 
Medicines and Health 
Products 
Regulator 
The regulatory agency for medical drugs and devices. The 
key activities of AFMPS include evaluation, approval and 
control of requests for clinical trials for medicines, market 
authorisation and post-market surveillance. 
Market 
Authorisation 
AFMPS/FAGG grants market authorisation based on 
efficacy, safety and quality. The market authorisation 
holder of medicines approved by EMA must inform the 
AFMPS/FAGG about the date the medicine will be 
marketed. 
CTG /CRM 
(hosted under INAMI) 
Medicines 
Reimbursement 
Commission  
Recommender CRM provides recommendation on reimbursement status 
and reimbursement price to the FPSSS. 
HTA 
The sponsor submits the reimbursement application to 
CTG/CRM at the same time as the pricing application is made 
to FPSE. 
Legal criteria affecting the drug reimbursement decisions 
include: (Added) therapeutic value, medical and social 
need, budget impact, price and efficacy. 
KCE  
Belgian Health Care 
Knowledge Centre 
HTA 
The KCE is an independent organization that provides 
studies and reports to advise policy-makers on health care 
decisions. 
KCE conducts studies that support the political decision 
making on healthcare. The KCE is not itself involved in 
making decisions and not in their implementation.  
FPSSS 
Federal Public Service 
Social Security 
Decision 
maker 
FPS Social Security (FPSSS) is responsible for assigning 
reimbursement to pharmaceuticals. 
Reimbursable drugs are classified into seven 
reimbursement categories on the basis of its therapeutic 
value. 
FPSE  
Federal Public Service 
Economy 
Price 
Authority 
The FPSE is responsible for pricing. The FPSE sets maximum 
price of reimbursable prescription-only drugs. For non-
reimbursed medicines, the pricing is free but the FPSE must 
be notified. 
RIZIV / INAMI 
National Institute for 
Sickness and Invalidity 
Insurance 
Provider 
RIZIV /INAMI is the public social security institution that 
organises and financially manages healthcare insurance in 
Belgium. 
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Process map for Bulgaria 
Version: October 2011 
 
 
4
EU CommissionEMA
European Medicines Agency
1a
BDA
Bulgarian Drug Agency
2
1b
Regulator
Market 
Authorisation
Regulator
PC
Price Committee for 
medicinal products
Price Authority
Ministry of Health
Provider
NHIF
National Health 
Insurance  Fund
3
HTA
TV EV
PDL
Positive Drug List 
Committee
TC
Transparency Committee
Decision Maker
Decision Maker
Sponsor
$
Agency 
(Committee) 
Function Key activity 
BDA 
Bulgaria Drug 
Agency 
Regulator 
The BDA is the regulatory authority under 
administrative supervision of the Ministry of Health. 
The BDA coordinates its activity with the regional 
inspectorates for the prevention and control of public 
health. 
Market 
Authorisation 
The BDA issues authorisations for medicinal products 
and carries out assessment of the quality, efficacy, and 
safety of medicinal products in relation with their 
marketing authorisations. 
PC 
Price Committee 
for medicinal 
products  
Price 
Authority 
The Price Committee is established at the Ministry of 
Health to regulate the prices of medicinal products 
dispensed on medical prescription and registers the 
prices of medicinal products dispensed without 
medical prescription. 
PDL 
Positive Drug List 
Committee 
 
Decision 
Maker 
The Positive Drug List Committee reviews and makes 
decisions on applications for inclusion, change, or 
exclusion of medicinal products from the Positive Drug 
List of the Republic of Bulgaria. 
HTA 
The committee evaluates the therapeutic benefit of 
medicinal products, conducts economic evaluation for 
additional therapeutic benefits, and the social and 
economic burden. 
Transparency 
Committee 
Decision 
Maker 
The Transparency Committee is a body which may 
appeal the decisions of the Pricing Commission and 
Positive List Committee. 
NHIF 
National Health 
Insurance Fund 
Provider 
The funding of healthcare for insured citizens is 
provided by the National Health Insurance Fund 
(NHIF). The NIHF is an independent public institution 
separated from the structure of the social healthcare 
system and has its own bodies of management.  
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Process map for Canada (National Common Drug Review) 
Version: March 2014 
  
Health Canada
CADTH
Canadian Agency for Drugs and 
Technologies in Health
PMPRB
Patented Medicines Price 
Review Board
Sponsor
1
3
2
Price Authority
Regulator
Market 
Authorisation
Recommender
SA EVTV
PAG
Provincial advisory Group
Participating publicly funded 
federal, provincial and 
territorial  public drug plans 
(n=16)*
Decision Maker (x 16)
Provider (x16)
Re ommender
Patient  advocacy groups
PAG
Provincial advisory Group
Recommender
CDEC
Canadian Drug Experts 
Committee
CDR 
Common Drug Review 
4
Agency (Committee) Function Key activity 
Health Canada 
Regulator 
Therapeutic Products Directorate (TPD) regulates drugs and 
medical devices for human use. Biologics and Genetic 
Therapies Directorate (BGTD) regulate biologics and 
radiopharmaceuticals. 
Market 
Authorisation 
The Notice of Compliance is signed by the Director General in 
TPD/BGTD as the approval documents for market 
authorisation. The NOC and a Drug Notification Form is sent to 
manufacture. 
CADTH 
Canadian Agency for 
Drugs and 
Technologies in 
Health 
HTA The Common Drug Review (CDR) is part CADTH, an 
independent agency that assesses drugs and health 
technologies. The sponsor’s initial submission is sent, with 
information from an independent literature search and patient 
input, to the CDR for clinical and pharmacoeconomic review.  
Recommender 
The Common Drug Review evaluates the efficacy and 
pharmacoeconomic data of drug, and considers comments 
from the CDEC and the participating provincial and territorial 
public drug programs to provide recommendations for 
reimbursement to the provincial and territorial public plans. 
CDEC 
Canadian Drug 
Experts Committee 
Recommender 
The CDEC is an appointed independent body comprised of 
physicians, pharmacists and professionals that makes 
recommendations on drug reimbursement as part of common 
drug review process for participating provincial and territorial 
public drug plans.  
Patient Advocacy 
groups  
Recommender 
CADTH notifies and receives patient input from advocacy 
groups to send to the CDR clinical and pharmacoeconomic 
reviewers. 
PMPRB 
Patented Medicines 
Price Review Board 
Price Authority The PMPRB regulates the price of patented drug products. 
Participating public 
drug plans  
Decision maker 
The participating federal, provincial and territorial public drug 
plans receive a final reimbursement recommendation from 
CDEC to help guide their final reimbursement decision within 
the terms of their mandate. 
Provider 
The participating federal, provincial and territorial public drug 
plans provide access to the health technology, according to 
their respective provincial or territorial final reimbursement 
decision, to patients who meet their defined eligibility criteria.  
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Process map for Canada (Alberta) 
Version: September 2013 
 
 
Health Canada
CADTH
Canadian Agency for Drugs and 
Technologies in Health
PMPRB
Patented Medicines Price 
Review Board
Sponsor
1
3
2
Price Authority
Regulator
Market 
Authorisation
Recommender
SA EVTV
PAG
Provincial advisory GroupRecommender
Patient  advocacy groups
PAG
Provincial advisory GroupRecommender
CDEC
Canadian Drug Experts 
Committee
CDR 
Common Drug Review 
4
ECDET
Expert committee on drugs 
evaluation and therapeutics 
Minister of Health & 
Wellness 
Decision Maker
Provider
Alberta  Health 
Alberta Department of 
Health & Wellness 
Recommender
Agency (Committee) Function Key activity 
Health Canada 
Regulator 
Therapeutic Products Directorate (TPD) regulates drugs 
and medical devices for human use. Biologics and Genetic 
Therapies Directorate (BGTD) regulate biologics and 
radiopharmaceuticals. 
Market 
Authorisation 
The Notice of Compliance is signed by the Director 
General in TPD/BGTD as the approval documents for 
market authorisation. The NOC and a Drug Notification 
Form is sent to manufacture. 
CADTH 
Canadian Agency for 
Drugs and 
Technologies in 
Health 
HTA The Canadian Agency for Drugs and Technologies in 
Health (CADTH) is an independent agency that assesses 
drugs and health technologies. 
Recommender 
The Common Drug Review (CDR), which is run through the 
CADTH, evaluates the efficacy and pharmacoeconomic 
data of drug, and makes recommendations on 
reimbursement to the provinces. 
CDEC 
Canadian Drug 
Experts Committee 
Recommender 
The CDEC is an appointed independent body comprised of 
physicians, pharmacists and professionals that makes 
recommendations on drug reimbursement as part of 
common drug review process for participating provincial 
and territorial public drug plans.  
Patient Advocacy 
groups  
Recommender 
The common drug review retrieves patient input to send 
to clinical and pharmacoeconomic reviewers. 
PMPRB 
Patented Medicines 
Price Review Board 
Price Authority 
The PMPRB is an independent quasi-judicial body with a 
mandate to regulate the prices charged for patented drug 
products and report pharmaceuticals trends for sales of 
drugs and R&D spending by patentees.  
Alberta Health 
Decision maker 
Minister of Health for Alberta reviews the 
recommendations from ECDET to determine eligibility for 
reimbursement 
Provider  
Alberta Health provides financial assistance to eligible 
residents to purchase approved prescription 
pharmaceuticals.  
ECDET 
Expert Committee on 
Drug Evaluation and 
Therapeutics 
Recommender 
The ECDET evaluates the clinical and economic value of 
pharmaceuticals that do not fall within the Common Drug 
Review Mandate, and provides formulary listing 
recommendations. 
 
290 
 
Process map for Canada (British Columbia) 
Version: March 2013 
 
  
Health Canada
CADTH
Canadian Agency for Drugs and 
Technologies in Health
PMPRB
Patented Medicines Price 
Review Board
Sponsor
1
3
2
Price Authority
Regulator
Market 
Authorisation
Recommender
SA EVTV
PAG
Provincial advisory Group
Recommender
Patient  advocacy groups
PAG
Provincial advisory Group
Recommender
CDEC
Canadian Drug Experts 
CommitteeCDR 
Common Drug Review 
4
Ministry of Health
Decision Maker 
Provider 
Pharmacare Programs 
British Columbia Ministry of 
Health
Recommender
DBC
Drug Benefit Council
Agency 
(Committee) 
Function Key activity 
Health Canada 
Regulator 
Therapeutic Products Directorate (TPD) regulates drugs and 
medical devices for human use. Biologics and Genetic 
Therapies Directorate (BGTD) regulate biologics and 
radiopharmaceuticals. 
Market 
Authorisation 
The Notice of Compliance is signed by the Director General 
in TPD/BGTD as the approval documents for market 
authorisation. The NOC and a Drug Notification Form is sent 
to manufacture. 
CADTH 
Canadian Agency 
for Drugs and 
Technologies in 
Health 
HTA The Canadian Agency for Drugs and Technologies in Health 
(CADTH) is an independent agency that assesses drugs and 
health technologies. 
Recommender 
The Common Drug Review (CDR), which is run through the 
CADTH, evaluates the efficacy and pharmacoeconomic data 
of drug, and makes recommendations on reimbursement to 
the provinces. 
CDEC 
Canadian Drug 
Experts Committee 
Recommender 
The CDEC is an appointed independent body comprised of 
physicians, pharmacists and professionals that makes 
recommendations on drug reimbursement as part of 
common drug review process for participating provincial 
and territorial public drug plans.  
Patient Advocacy 
groups  
Recommender 
The common drug review retrieves patient input to send to 
clinical and pharmacoeconomic reviewers. 
British Columbia 
Ministry of Health 
Decision maker 
The British Columbia Ministry of Health considers the 
recommendations from  the Drug Benefit Council to 
determine eligibility for reimbursement by  the British 
Columbia Pharmacare plans, 
Provider  
British Columbia Pharmacare provides financial assistance 
to eligible residents to purchase recommended medicines.  
DBC 
Drug Benefit Council 
Recommender 
The DBC reviews the CDR evidence, final recommendation 
and patient input from the ‘Your Voice’ website to 
determine a listing recommendation. 
PMPRB 
Patented 
Medicines Price 
Review Board 
Price Authority 
The PMPRB is an independent quasi-judicial body with a 
mandate to regulate the prices charged for patented drug 
products and report pharmaceuticals trends for sales of 
drugs and R&D spending by patentees.  
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Process map for Canada (Ontario) 
Version: March 2013  
Agency 
(Committee) Function Key activity 
Health Canada 
Regulator 
Therapeutic Products Directorate (TPD) regulates drugs and medical 
devices for human use. Biologics and Genetic Therapies Directorate 
(BGTD) regulate biologics and radiopharmaceuticals. 
Market 
Authorisation 
The Notice of Compliance is signed by the Director General in 
TPD/BGTD as the approval documents for market authorisation. The 
NOC and a Drug Notification Form is sent to manufacture. 
CADTH 
Canadian Agency 
for Drugs and 
Technologies in 
Health 
HTA The Canadian Agency for Drugs and Technologies in Health (CADTH) 
is an independent agency that assesses drugs and health 
technologies. 
Recommender 
The Common Drug Review (CDR), which is run through the CADTH, 
evaluates the efficacy and pharmacoeconomic data of drug, and 
makes recommendations on reimbursement to the provinces. 
CDEC 
Canadian Drug 
Experts 
Committee 
Recommender 
The CDEC is an appointed independent body comprised of physicians, 
pharmacists and professionals that makes recommendations on drug 
reimbursement as part of common drug review process for 
participating provincial and territorial public drug plans.  
Patient Advocacy 
groups  Recommender 
The common drug review retrieves patient input to send to clinical 
and pharmacoeconomic reviewers. 
PMPRB 
Patented 
Medicines Price 
Review Board 
Price Authority 
The PMPRB is an independent quasi-judicial body with a mandate to 
regulate the prices charged for patented drug products and report 
pharmaceuticals trends for sales of drugs and R&D spending by 
patentees.  
CED 
Committee to 
evaluate Drugs 
Recommender  
The CED is an independent advisory group of healthcare professionals 
with experience in drug therapy and drug use evaluation.  The CED 
provides listing recommendations to the Executive Officer for the 
Ontario Ministry of Health and Long Term Care.  
Ontario Ministry 
of Health and 
Long Term Care 
Decision 
maker 
The Executive officer for Ontario Ministry of Health and Long Term 
Care reviews the recommendations from the CDR and CED to 
determine eligibility for reimbursement 
Provider  Ontario Drug Benefit programs provide financial assistance to eligible 
residents to purchase approved prescription pharmaceuticals.  
Health Canada
CADTH
Canadian Agency for Drugs and 
Technologies in Health
PMPRB
Patented Medicines Price 
Review Board
Sponsor
1
3
2
Price Authority
Regulator
Market 
Authorisation
Recommender
SA EVTV
PAG
Provincial advisory GroupRecommender
Patient  advocacy groups
PAG
Provincial advisory GroupRecommender
CDEC
Canadian Drug Experts 
Committee
CDR 
Common Drug Review 
4
Executive Officer
Decision Maker 
Provider 
Ontario Drug Benefit 
Program 
CED
Committee to Evaluate Drugs
Recommender
Ontario Ministry of Health
& Long Term Care
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Process map for Canada (Quebec) 
 Version: September 2013 
 
 
   
Agency (Committee) Function Key activity 
Health Canada 
Regulator 
Therapeutic Products Directorate (TPD) regulates drugs and 
medical devices for human use. Biologics and Genetic 
Therapies Directorate (BGTD) regulate biologics and 
radiopharmaceuticals. 
Market 
Authorisation 
The Notice of Compliance is signed by the Director General in 
TPD/BGTD as the approval documents for market 
authorisation. The NOC and a Drug Notification Form is sent to 
manufacture. 
INESSS 
Institut national 
d’excellence en santé 
et en services sociaux  
HTA From January 2011 the INESSS succeeded the Council of the 
drug and the Agency for Health Technology Assessment and 
Intervention Methods in Health (AETMIS). INESSS will evaluate 
the therapeutic and economic value of pharmaceuticals, 
technologies and health interventions. 
Recommender 
The institute provides a clinical and economical evaluation of a 
pharmaceutical, technology or health intervention to help aid 
the reimbursement decision.  
CSEMI 
Scientific Committee 
to Evaluate Drugs for 
Registration 
Recommender 
The CSEMI is usually formed of external experts (Physicians, 
pharmacists and health economists) who provide a 
reimbursement recommendation by voting according to the 
criteria in the INESSS Act.  
Groups and 
associations of health 
professionals and 
citizens 
Recommender 
INESSS invites groups and associations of health professionals 
and citizens to provide comments and observations of the 
evaluation plan to CSEMI 
MOH 
Quebec Minister of 
Health 
Decision 
maker 
The Quebec Minister of Health will decided whether the health 
technology is eligible for coverage by the regional  health 
insurance plan / Régie de l'assurance maladie du Québec 
(RAMQ).  
RGAM 
le régime général 
d'assurance 
médicaments  
Payer 
The RGAM is a list of medicines covered by the basic 
prescription drug insurance plan. Drug Formulary for 
Institutions lists medications eligible for use in Quebec health 
institutions to be covered by the RAMQ 
PMPRB 
Patented Medicines 
Price Review Board 
Price Authority 
The PMPRB regulates the price of patented drug products. 
Non-patented medicines do not need to have the price 
reviewed by PMPRB. 
Health Canada
PMPRB
Patented Medicines Price 
Review Board
Sponsor
1
2
3
Price Authority
Regulator
Market 
Authorisation
Recommender
EVTV
RGAM
Basic prescription drug 
insurance plan
Provider 
PAG
Provincial advisory GroupRecommender
Groups and associations 
of health professionals 
and citizens 
CSEMI 
Scientific Committee to 
evaluate drugs for listing  
INESSS
Institut national d’excellence 
en santé et en services sociaux 
Decision Maker 
Minister of Health
RAMQ
Régie de l'assurance maladie 
du Québec
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Process map for Cyprus 
Version: February 2012 
 
 
 
EU CommissionEMA
European Medicines Agency
1a
Drug Council
Department of 
Pharmaceutical Services
Sponsor
2
1b
Regulator
Market 
Authorisation
Regulator
Ministry of 
Health
Decision Maker
Price Authority
HIO
Healthcare Insurance 
Organization
Drug Committee
Department of 
Pharmaceutical Service
Recommender
HTA
$EV
Ministry of Health 
Provider
Recommender
Drug Price Control 
Committee
Department of 
Pharmaceutical Service
TV
Agency 
(Committee) 
Function Key activity 
Drug Council  
Department of 
Pharmaceutical 
Services of the MoH 
Regulator 
The regulatory body for medical drugs and devices. The 
key activities of the Department of Pharmaceutical 
Service include licensing of medicines, licensing of 
manufacture and wholesales, pharmacovigilance, and the 
pricing of medicines. 
Market 
Authorisation 
The Department of Pharmaceutical Services of the MoH 
is in charge of issuing market authorisation to new 
medicines based on their quality, safety and efficacy. The 
result of evaluation will also be used to support the 
coverage decision-making. 
Drug Committee 
Department of 
Pharmaceutical 
Service of the MoH 
HTA 
The assessment conducted by drug committee is based 
on the Evidence Based Medicine method. An economic 
evaluation is also conducted in relation to the financial 
capabilities required by the annual growth rate of the 
budget for medicines. 
Recommender 
The Drug Committee is responsible for evaluating 
submissions for new drug to be listed on the national 
formulary. The result of assessment is sent to the MOH 
to facilitate decision-making. 
Drug Price Control 
Committee 
Department of 
Pharmaceutical 
Service of the MoH 
Recommender 
The Price committee is responsible for advising the MOH 
on all matters relating to drug price. 
MoH 
Ministry of Health 
Price Authority 
In the public system pharmaceuticals are purchased 
through tendering operated by the Department of 
Pharmaceutical Services of the MoH. The MoH makes 
decision on purchase of substances from different 
tenders. 
MoH 
Minister of Health 
Decision Maker 
The MoH makes decisions on drug reimbursement based 
on the advice from Drug Council and Drug Committee. 
HIO 
Health Insurance 
Organization  
Provider 
Healthcare service is covered by health insurance, which 
is managed by Health Insurance Organisation. The HIO is 
operated by representatives of the government. 
Pharmaceuticals listed on the National Formulary can be 
reimbursed under the public system at 100% or 50%.   
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Process map for Czech Republic 
Version: October 2011 
 
 
 
 
 
Sponsor
EU CommissionEMA
European Medicines Agency
1a
2
1b
Market 
Authorisation
Provider
Regulator
MZ
Ministry of Health
VsZP
General Health Insurance
SUKL
State Institute 
for Drug Control
Regulator
Decision Maker
Price Authority
HTA
TV EV $
Agency 
(Committee) 
Function Key activity 
SUKL 
The State 
Institute for 
Drug Control 
Regulator 
The SUKL is an administration body established 
under direct control of the Ministry of Health to 
ensure high-quality, effective and safe human 
pharmaceuticals are available in the Czech 
Republic. 
Market 
Authorisation 
The SUKL assesses the drug applications with 
regards to their quality, efficacy, and safety and 
grants the market authorisations. 
HTA 
The SUKL conducts assessment of new medicines 
for the assignment of reimbursement. The 
principles for evaluation include: efficacy and 
safety, cost-effectiveness, budget impact and 
therapeutic assessment. 
Price Authority 
SUKL decides on the maximum prices of 
pharmaceuticals. Separate pricing application and 
reimbursement application are made to SUKL. 
Decision 
Maker 
The SUKL is responsible for the regulation of drug 
prices and reimbursement. The decision-making 
process involves individual administrative 
proceedings. 
 VsZP 
General Health 
Insurance 
 
Provider 
There are nine sick funds that are responsible for 
the reimbursement of pharmaceuticals. The VsZP is 
the biggest sick fund and is one of the basic pillars 
of the Czech health care system. 
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Process map for Denmark 
Version: June 2014 
 
  
Agency 
(Committee) 
Function Key activity 
DHMA  
The Danish 
Health and 
Medicines 
Authority 
Regulator 
The DHMA is a government agency that operates under the 
Ministry of the Interior and Health to ensure effective and 
safe healthcare products use in Denmark. 
Market 
Authorisation 
The Licensing Division in DHMA is responsible for granting 
market authorisation to human and veterinary medicinal 
products based on their efficacy, safety and quality.   
 
HTA 
The DHMA assesses the therapeutic value and cost-
effectiveness of reimbursable drugs. 
Price authority 
The DHMA fixes the reimbursement prices based on a co-
payment rate for pharmaceuticals. There is free pricing for all 
pharmaceuticals at the manufacturer and wholesale price 
level.  
Decision maker 
The DHMA decides if a drug will be included on the positive 
list for general reimbursement. Applications for individual 
reimbursement can also be made directly to the DHMA.  
MTN 
The 
Reimbursement 
committee 
HTA 
The MTN is an independent committee, comprised of a 
maximum seven people, that assesses the safety and added 
therapeutic value of pharmaceuticals. 
Recommender 
The MTN advises the DHMA on both general reimbursement 
and individual reimbursement of new drugs. 
IRF 
Institute for 
Rational 
Pharmacothera
py 
HTA 
The IRF is responsible for promoting the most rational use of 
medicinal products with respect to both pharmacological and 
economics aspects. 
Recommender 
The IRF conducts its own pharmacoeconomic evaluation and 
provides advice and guidance to the DHMA. 
DACEHTA  
the Danish 
Centre for 
Health 
Technology 
Assessment  
HTA 
DACEHTA is an HTA body within the National Board of Health 
that aims to improve quality, standards and value for money 
in the Danish health service. 
Recommender 
DACEHTA collaborates with health authorities at regional 
level to evaluate pharmaceutical products. 
Five regional 
councils 
Provider 
Five regions act as a third-party payer for the coverage of 
reimbursable drugs at regional level. At local level the 
municipalities have supplementary reimbursement system 
based on social indications. 
EU CommissionEMA
European Medicines Agency
1a
DHMA
Danish Medicines Agency
HTA
Sponsor
MTN
Reimbursement Committee
The Ministry of the
Interior and Health
2
The five regions/
Regional Councils
HTA
HTA
IRF
Institute for Rational 
Pharmacotherapy
DACEHTA
Danish Centre for Health 
Technology Assessment
HTA
1b
Price Authority
Regulator
Market 
Authorisation
Recommender
Decision Maker
Provider
Regulator
Recommender
Recommender
TVTV EV CED
TV EV
TV
TVSA TV EV $ CED
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EMA
European Medicines Agency
1a
MHRA
Medicines and Healthcare 
Products Regulatory Agency
Sponsor
Department of Health
d1b
Regulator
Regulator
EU Commission
NIHR
National Institute for 
Health Research
ERG (one of nine)
Evidence Review Group
EVTV
Market 
Authorisation
PPRS
Pharmaceutical Price 
Regulation Scheme
NICE
National Institute for Health 
and Care Excellence
Centre for Health 
Technology Evaluation
Price Authority
NHS England and 
Clinical 
Commissioning 
Groups (CCGs)
Decision Maker
Provider 
2
4
3 Appraisal Committee
Recommender
5
TVSA CED
Agency 
(Committee) 
Function Key activity 
MHRA 
Medicines and 
Healthcare 
products 
Regulatory 
Agency  
Regulator 
The MHRA is a government agency that regulates medicines on the 
basis of safety, quality and efficacy. 
Market 
Authorisation 
The MHRA authorises marketing licence for new drugs.  
NICE 
National 
Institute for 
Health and Care 
Excellence 
 
HTA 
NICE provides pharmacoeconomic guidance, sets quality standards 
and manages a national medicinal products database.  The recent 
change of NICE’s name represents the broadening of its remit to 
improve social care guidelines. 
Decision maker 
NICE carries out cost-effectiveness evaluations for new 
pharmaceuticals that are submitted for inclusion in national 
formulary. In June 2013, the scope of NICE assessment was broadened 
to include a medicine’s value to patients and society. 
NIHR 
National 
Institute for 
Health Research 
HTA 
The NIHR is a government body that coordinates and funds research 
for the National Health Service (England). The NIHR supports 
individuals, facilities and research projects. 
NHS  
England and 
Clinical 
Commissioning 
Groups (CCGs) 
Provider 
NHS is a government independent body whose main role is to improve 
health outcomes in England. From April 2013, Strategic Health 
Authorities (SHAs) and Primary Care Trusts (PCTs) were replaced by 
NHS England and Clinical commissioning Groups (CCGs).  
NHS England provides leadership for the NHS, authorises 211 CCGs 
and devolves responsibility to 27 Local Area Teams (LATs) to 
commission primary care. Ten of the LATs are leads for specialised 
commissioning.   
CCG’s are responsible for the allocation of the drug budget and 
managing prescribing for their jurisdiction. 
PPRS 
Pharmaceutical 
Price Regulation 
Scheme 
Price Authority 
The PPRS regulates the price indirectly by controlling the profit of the 
pharmaceutical companies.  From 2014, the new PPRS scheme will 
ensure the NHS bill for branded medicines will remain flat over the 
following two years and will increase by less than 2% in each of the 
subsequent three years.  
Appraisal 
Committee 
Recommender 
The Appraisal Committee is an independent standing advisory 
committee of NICE.  It makes a judgement on whether or not the 
technology should be recommended for use within the NHS. 
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Agency 
(Committee) 
Function Key activity 
SAM 
State Agency of 
Medicines 
Regulator 
The main responsibility of SAM is the protection 
and promotion of public and animal health, 
through the supervision of medicines for human 
and veterinary use. 
Market Authorisation 
SAM is established under the Ministry of Social 
Affairs which is responsible for issuing market 
authorisations. 
HTA 
The application for drug reimbursement is 
submitted to SAM. The criteria of evaluation by 
SAM include safety, effectiveness and alternative 
treatment. 
EHIF 
Estonian Health 
Insurance Fund 
HTA 
The EHIF evaluates the applications from financial 
and budgetary standpoints. 
Provider 
The EHIF is responsible for the reimbursement of 
pharmaceuticals. 
Committee for 
Medicinal Product  
Recommender 
After applications evaluated by SAM and EHIF, the 
opinions are forwarded to the Committee for 
Medicinal Product.  The SM makes decisions based 
on recommendations from the Committee for 
Medicinal Product. 
SM 
Ministry of Social 
Affairs 
HTA 
The SM evaluates the applications based on the 
criteria of pharmacoeconomic analysis, 
comparative treatment, price development and 
budgetary restrictions. 
Decision Maker 
The SM is responsible for making decision on 
reimbursement, based on the advice from the 
Committee for Medicinal Products. 
Price Authority  
The SM makes decision on the manufacturer price 
base the decision on reimbursement, sometimes 
the pricing procedure is incorporated into the 
reimbursement procedure. 
EMA
European Medicines Agency
1a
Sponsor
2
EU Commission
Market 
Authorisation
Regulator
1b
SAM
State Agency of Medicines
Regulator
Committee for 
Medicinal Product
Recommender
EHIF
Estonian Health Insurance Fund
HTA
EV
Decision Maker
Price Authority
SM
Ministry of Social Affairs
HTA
TV EV
$
$
SAM
State Agency of Medicines
HTA
TV
3 Provider
EHIF
Estonian Health Insurance Fund
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Process map for Finland  
Version: June 2012  
Agency 
(Committee) 
Function Key activity 
FIMEA 
Finnish Medicines 
Agency 
Regulator 
The FIMEA is the national authority operated under the 
Ministry of Social Affairs and Health. The FIMEA 
promotes the health and safety of the population by 
regulating pharmaceuticals. 
Market Authorisation 
The FIMEA assesses the quality, safety and efficacy of 
drug applications and grants market authorisation to new 
medicines. 
The Expert Group  
of HILA  
Recommender 
This expert group represents medical, pharmacological, 
health economics and social insurance expertise. The 
expert group provides advice to the HILA for drug 
reimbursement. 
HILA 
The Finnish 
Pharmaceuticals 
Pricing Board 
HTA 
The criteria of the HILA evaluation include therapeutic 
value, cost-effectiveness, benefits gained and costs of 
special reimbursement status. 
Price Authority  
The HILA decides the wholesale prices of medicinal 
products based on the opinions from the Social Insurance 
Institution (KELA) and from the expert group if necessary. 
Decision Maker 
The HILA acquires an opinion from its expert group and 
makes the final decision on drug reimbursement. 
KELA 
Social Insurance 
Institution of 
Finland 
Recommender 
The HILA will consult with the opinion from KELA during 
coverage decision-making process. 
Provider 
The KELA provides a National Health Insurance scheme 
that covers part of the cost of a range of health services 
Sponsor
EU CommissionEMA
European Medicines Agency
1a
FIMEA
Finnish Medicines  Agency
HILA
The Finnish Pharmaceuticals 
Pricing Board
The Expert Group 
of HILA
STM
Ministry of Social Affairs and Health
2
KELA
Social Insurance Institution 
of Finland
$EVTV
HTA
d1b
Regulator
Market 
Authorisation
Regulator
Price Authority Recommender
Decision Maker Provider
Recommender
 
299 
 
 
Process map for France 
Version: July 2014 
 
  
Agency (Committee) Function Key activity 
ANSM 
French Agency for the 
Safety of Medicines and 
Health Products  
Regulator 
The ANSM has replaced AFSSAPS as the government agency 
responsible for regulating health products intended for 
human consumption. 
The key activities of ANSM also include implementation of 
regulations for trials, manufacturing, import, export, 
wholesale distribution, storage, marketing and advertising.   
Market 
Authorisation 
The ANSM is responsible for granting market authorisation 
as well as post-market surveillance. 
HAS 
French National 
Authority for Health 
HTA The Transparency Committee evaluates pharmaceuticals 
with regards to their medical benefit (SMR) and their 
innovation rate (ASMR). 
Recommender 
The Transparency Committee forwards its recommendation 
simultaneously to both CEPS for pricing decision and to 
UNCAM for fixing reimbursement rate. The HAS may also 
provide its own advice. 
UNCAM 
National Union of 
Health Insurance Funds 
HTA The UNCAM evaluate the medical benefit of pharmaceuticals 
under recommendations from the Transparency Committee. 
Decision maker 
The UNCAM makes decision on reimbursement rate based 
on the evaluation made by the Transparency Committee and 
the pricing decision of the CEPS. 
The UNCAM fixes the reimbursement rate of 
pharmaceuticals within the rate limit defined by decree. 
CEPS 
The Economic 
Committee on Health 
Care Products 
Price Authority 
The CEPS is a regulatory body that fix prices of drugs and 
rates of single-use medical devices that are covered by 
compulsory health insurance.  
CEPS fixes price after negotiation pharmaceutical companies, 
the price will relate to the ASMR rating provided by HAS. 
Social Security system 
National Health 
Insurance Adoption 
committee 
Provider 
The Social Security system manages and controls the 
national health insurance. 
Sponsor
Regulator
ANSM
French Agency for the safety of 
Medicines and Health Products 
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
Ministry of Health
HAS
The French National 
Authority for Health
Transparency 
Committee
Social Security 
system
National Health Insurance 
Adoption committee
Provider
HTA
UNCAM
National Union of Health 
Insurance Funds
Price Authority
1a
CEPS
The Economic Committee on 
Health Care Products
Decision Maker
Minister of Health
1b
TV CED
$
2a
2b
Recommender
Recommender
SA
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Agency 
(Committee) 
Function Key activity 
BfArM  
Federal Institute 
for Drugs and 
Medical Devices 
Regulator 
The BfArM is the federal agency operated under the 
Ministry of Health that regulates drugs and medical 
devices for human use. 
Market 
Authorisation 
The BfArM is responsible for market authorisation of 
pharmaceuticals, registration of medical devices and 
post-marketing surveillance. 
PEI 
Federal Institute 
for Vaccines and  
Biomedicines 
Regulator 
The PEI is the federal agency operated under the 
Ministry of Health that is responsible for regulating 
biological products, including vaccines, antibodies, 
blood/blood products, tissues and medicines for gene 
therapy. 
Market 
Authorisation 
The PEI is responsible for market authorisation of 
vaccines and biomedicines. 
G-BA 
Federal Joint 
Committee 
HTA 
The G-BA is responsible for evaluating and then 
categorising reimbursable pharmaceuticals. The G-BA 
performs a rapid assessment to evaluate the additional 
benefit in relation to an appropriate comparator for 
new drugs; the appropriate comparator is set by G-BA. 
The outcome of the assessment will be used to 
determine the final price.  
Decision maker 
The G-BA makes decisions on reimbursement eligibility 
of new pharmaceuticals based on their additional 
medical benefit compared to designated comparator 
IQWIG  
Institute for 
Quality and 
Efficiency in 
Health Care 
 
 
HTA 
The IQWIG is an independent federal organization for 
evaluation of the medical benefit of new 
pharmaceuticals. 
IQWIG conducts benefit assessment commissioned by 
G-BA. 
Recommender 
The IQWIG will recommend new pharmaceuticals 
depending on its assessments of their benefits. 
Sponsor
PEI
Federal Institute for Vaccines 
and  Biomedicines
Regulator
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator1a
Regulator
BfArM
Federal Institute for Drugs and
Medical Devices
GKV-Spitzenverband
Federal Association of the 
Statutory Health Insurances
Price Authority
G-BA
Federal Joint Committee
Decision Maker
CRM
Medicines Reimbursement 
Commission
$
IQWIG
Institute for Quality and 
Efficiency in Health Care
Recommender
HTA
TV
Ministry of Health
SHI
Statutory Health Insurance 
Provider
3
1b
TV
2
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Agency (Committee) Function Key activity 
EOF 
National Organisation 
for Medicines 
Regulator 
The EOF is the national agency responsible for 
regulation of pharmaceuticals. The EOF is operated 
under the Ministry of Health and Social Solidarity. 
Market 
Authorisation 
The EOF is responsible for evaluation and approval of 
safe, effective medicinal products. 
Department of Pricing 
of Medicinal Products 
Recommender 
The Department of Pricing of Medicinal Products and 
the Committee of Pricing of Medicinal Products will 
review the pricing application and provide advice to 
the Ministry of Health and Social Solidarity for 
pricing. 
Committee of Pricing 
of Medicinal Products 
YYKA 
Ministry of Health and 
Social Solidarity 
Price Authority 
The Ministry of Health and Social Solidarity is the 
competent authority for drug pricing. The Ministry 
sets the wholesale, hospital and retail prices of 
medicines. 
EOF 
Special Committee 
Recommender 
The special committee is appointed by EOF to set up 
a list of reimbursable medicinal products. The 
recommendation is sent to Minister for decision-
making. 
Minister of Labour 
and Social Security 
Decision Maker 
The Minister of Labour and Social Security and 
Minister of Health and Social Solidarity make a 
common decision to approve the list of reimbursable 
medicinal products suggested by the special 
committee. 
Minister of Health and 
Social Solidarity 
GGKA 
General Secretariat of 
Social Security 
Provider 
The GGKA is the umbrella organization for 40 
occupation-based sickness funds in Greece. The 
GGKA is responsible for the reimbursement of 
pharmaceuticals. 
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Regulator
EOF
National Organisation 
for Medicines
Sponsor
2
GGKA
General Secretariat
of Social Security
Provider
YYKA
Ministry of Health and 
Social Solidarity
Price Authority
1b
Recommender
Department of Pricing of 
Medicinal Products 
Recommender
Committee of 
Pricing of Medicinal Products
Ministry of 
Health and Social Solidarity
Decision Maker
Ministry of  
Labour and Social Security
Decision Maker
EOF
Special Committee 
Recommender
 
302 
 
Process map for Hungary 
Version: November 2011 
 
 
  
Sponsor
Regulator
OGYI
National Institute of Pharmacy
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
Ministry of Health
OEP
The National Health Fund 
Provider
HTA
ESKI
National Institute for 
Strategic Health Research
Price Authority
1a
Decision Maker
1b
2
Recommender
OHTA
The Office of Health 
Technology Assessment
TAC
Technology Appraisal Committee
Recommender
OEP
The National Health Fund
Department of 
Pharmaceuticals
TV EV
$TV EV
Agency 
(Committee) 
Function Key activity 
OGYI 
National 
Institute of 
Pharmacy 
Regulator 
The OGYI is the regulatory agency responsible for marketing 
authorization and supervision of manufacturing, wholesale 
trade and retail trade of medicinal products and devices in 
Hungary. 
Market 
Authorisation 
The OGYI grants market authorisation to medicinal products 
based on their efficacy, safety and quality. 
OHTA (under 
ESKI) 
The Office of 
Health 
Technology 
Assessment 
HTA 
The Office of Health Technology Assessment (OHTA) is an 
independent institute within ESKI. The OHTA conducts 
pharmacoeconomic analysis and evaluates the efficacy and 
effectiveness of medicinal products. 
Recommender 
The drug reimbursement application is submitted to the 
Department of Pharmaceutical in the OEP for registration. 
Afterwards, the OHTA makes critical appraisal based on the 
submitted dossier, the outcome is then forwarded to the 
TAC. 
TAC 
Technology 
Appraisal 
Committee 
HTA 
The TAC assesses the reimbursement application regarding 
the efficacy and cost-effectiveness information, burden of 
the disease and budget impact. 
Recommender 
The TAC conducts drug evaluation based on the appraisal 
from OHTA. The TAC provides recommendation to the OEP 
for reimbursement decision.  
OEP 
The National 
Health Fund 
Decision Maker 
The Department of Pharmaceuticals in OEP makes decision 
on the drug reimbursement under advice from TAC. 
Price Authority 
The market authorisation holder negotiates the price with 
the OEP for reimbursable drugs.  The pricing process is 
integrated in the reimbursement procedure. 
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Agency 
(Committee) 
Function Key activity 
IMA 
Iceland 
Medicine 
Agency 
Regulator 
The IMA is the regulatory agency under the 
Ministry of Health and Social Securities. The 
main responsibilities of IMA are assessment, 
inspection and market authorisation of 
medicinal products. 
Market 
Authorisation 
The IMA grants market authorisation to 
medicinal products based on their quality, 
safety and efficacy. 
IMPRC 
Icelandic 
Medicine 
Pricing and 
Reimbursement 
Committee 
Price Authority  
The IMPRC makes decision on the wholesale 
price of pharmaceuticals. 
HTA 
The IMPRC assesses drugs regarding their 
safety, therapeutic value and evaluates 
pharmacoeconomic data and budget impact. 
Decision Maker 
The IMPRC grants reimbursement approvals 
to pharmaceuticals. The reimbursement rate 
will be set by the Ministry of Health. 
Minister of 
Health 
Decision Maker 
The Ministry of Health sets the National 
Reimbursement Code for reimbursable drugs 
based on the ATC code. The reimbursement 
rate of drugs is dependent on the category of 
the Reimbursement Code. 
TR 
The Social 
Insurance 
Administration 
Provider 
The Social Insurance Administration is a 
governmental service institution that manages 
the Icelandic Health Insurance. 
IMA 
Iceland 
Medicine 
Agency 
Regulator 
The IMA is the regulatory agency under the 
Ministry of Health and Social Securities. The 
main responsibilities of IMA are assessment, 
inspection and market authorisation of 
medicinal products. 
Sponsor
Regulator
IMA
Iceland Medicine Agency
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
Ministry of Health and 
Social Security
Price Authority
1a
Decision Maker
1b
2
HTA
Ministry of 
Health
IMPRC
Icelandic Medicine Pricing and 
Reimbursement Committee
TV EV
Decision Maker Provider
TR
The Social Insurance 
Administration
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Agency (Committee) Function Key activity 
IMB 
Irish Medicine Board 
Regulator 
The IMB is the regulatory agency under the Department of 
Health and Children responsible for the regulation of 
medicine, medical devices and healthcare products. 
Market 
Authorisation 
The IMB evaluates and grants market authorisation to new 
medicines to ensure the quality, safety and efficacy of 
medicines available in Ireland. 
NCPE 
The National Centre 
for 
Pharmacoeconomics 
HTA 
The reimbursement application is sent to the Health 
Service Executive (HSE). The NCPE reviews the cost-
effectiveness and budget impact of the new medicines for 
the HSE. 
HSE 
The Health Service 
Executive 
Price 
Authority  
The HSE sets the wholesale price of new medicines.  
Decision 
Maker 
The HSE makes decisions on the reimbursement of 
pharmaceuticals based on the pharmacoeconomic 
evaluations by NCPE. 
HSE PCRS 
Primary Care 
Reimbursement 
Service 
Provider 
The Primary Care Reimbursement Service makes payment 
for healthcare service and provides the reimbursement of 
pharmaceutical products on behalf of HSE. 
Sponsor
Regulator
IMB
Ireland Medicine  Board
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
Department of Health and Children
Price Authority
1a
1b
2
HSE
The Health Service Executive
Provider
HSE PCRS
Primary Care 
Reimbursement Service
NCPE
The National Centre for 
Pharmacoeconomics
Recommender
HTA
TV EV $
Decision Maker
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Agency 
(Committee) 
Function Key activity 
AIFA  
Italian Medicine 
Agency 
Regulator 
The AIFA is the national authority responsible for 
the drug regulation in Italy. The key activities of 
AIFA include registration of medicinal products, 
post-marketing surveillance, pricing and 
reimbursement of medicines. 
Market 
Authorisation 
The technical scientific committee (CTS) of the 
AIFA evaluates pharmaceuticals regarding their 
quality, safety and efficacy, the AIFA grants the 
market authorisation to the new drugs based on 
the assessment by CTS. 
CTS (within AIFA) 
Technical 
Scientific 
Committee 
HTA  
The CTS assess the therapeutic benefit and the 
level of innovation of new medicinal products. 
Recommender 
The CTS provide classification of the new medicinal 
products for reimbursement according to 
homogeneous therapeutic category. 
CPR (within AIFA) 
Price and 
Reimbursement 
Committee 
Price Authority  
The CPR negotiates price of reimbursable drugs 
with manufacture. The criteria for pricing include 
therapeutic value assessment by CTS, innovation 
level, cost-effectiveness, budget impact, price and 
consumption data in other European countries. 
AIFA  
Italian Medicine 
Agency 
Decision Maker 
The AIFA makes decision on the price and 
reimbursement status of new medicinal products. 
The decision is officially published in a decree. 
Regional 
Governments & 
Health 
Department  
(×20) 
Decision Maker 
Twenty regions implement the coverage decision 
by the AIFA according to their own resources. The 
regionalisation results in variance in level of co-
payment across the country. 
ASLs 
Local Health 
Unites (×195) 
Provider 
The healthcare provision is organized and 
managed by ASL at local level. 
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Sponsor
Ministry of Health
2
1b
Regional Governments 
& Health Departments
(n=20)
Decision Maker (x 20)
ASLs
Local Health Unites 
Provider (× 195)
Regulator
AIFA
Italian Medicines Agency
CTS
Technical Scientific 
Committee
TV
Recommender
AIFA
Italian Medicines Agency
CPR
Price and Reimbursement
Committee
EV $
Price Authority
AIFA
Italian Medicines Agency
AIFA
Italian Medicines Agency
Decision Maker
CED
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Agency 
(Committee) 
Function Key activity 
VZA 
State Agency 
for Medicine  
Regulator 
The VZA is the Regulatory Authority under the Ministry of Health 
to ensure availability of efficient, safe and qualitative medicines 
for the Latvian population. 
Market 
Authorisation 
The VZA grants market authorisations for new medicines based 
on their efficacy, safety and quality. 
CHE 
Centre of 
Health 
Economics 
HTA 
The CHE is the state institution operated under the Ministry of 
Health to ensure the most effective use of the state budget in 
providing health care services. The CHE evaluates 
pharmaceuticals regarding the therapeutic value, the cost-
effectiveness data, the burden of the disease and the budget 
impact. 
Decision 
Maker 
The CHE makes decisions on the reimbursement of 
pharmaceuticals based on the therapeutic and financial 
assessment.  
Price 
Authority  
The CHE makes decision on the price for reimbursable 
pharmaceuticals.  
VNC 
Health 
Payment 
Centre 
Provider 
The VNC is operated under the Ministry of Health to administrate 
the state budgetary funds for health care and provide health care 
services. 
Sponsor
EU CommissionEMA
European Medicines Agency
1a
VZA
State Agency for Medicine
CHE
The Centre of Health Economics
2
VNC
Health Payment Centre
$EVTV
HTA
d1b
Regulator
Market 
Authorisation
Regulator
Price Authority
Decision Maker
Provider
Ministry of Health
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Agency 
(Committee) 
Function Key activity 
Department of 
Medicine  
Regulator 
The Department of medicine is a regulatory body 
operated under the Office of Public Health. The main 
responsibility of the Department includes 
inspections, market authorisations and market 
surveillance of pharmaceutical products 
Market 
Authorisation 
The Department is responsible for granting market 
authorisation to new medicines based on their 
quality, safety and efficacy.  
Based on the Agreement between the Governments 
of Austria and Liechtenstein, medicines approved in 
Austria will be recognized automatically in 
Liechtenstein. 
Medicines approved by Swissmedic (in Switzerland) 
that contain new active substances will be 
recognized in Liechtenstein after 12 months. 
Switzerland 
Federal Office 
of Public Health  
Price Authority 
The pricing for medicines in Liechtenstein is 
proposed according to the price set by the Federal 
Office of Public Health in Switzerland. 
Department of 
Health and 
Accident 
Insurance  
Decision Maker 
The Department of Health and Accident Insurance 
decides whether to adopt the drug price set in 
Switzerland and the reimbursement status of the 
medicines. 
OKP  
Compulsory  
Health 
Insurance  
Provider 
OKP provides the payment and coverage for 
healthcare service in Liechtenstein. 
  
Department of 
Medicine
Sponsor
Provider
2
OKP
Compulsory  Health Insurance
Switzerland
Federal Office of Public Health 
Price Authority
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
1b
Regulator
Department of 
Health and 
Accident Insurance
Decision Maker
The Office of Public Health
Austria
Austrian Agency for 
Health and Food Safety
Switzerland
Swissmedic
Market 
Authorisation
Market 
Authorisation
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Agency 
(Committee) 
Function Key activity 
VVKT 
State Medicine 
Control Agency  
Regulator 
The VVKT is operated under the Ministry of Health, its 
responsibilities include granting marketing 
authorisation, classifying pharmaceuticals, 
pharmacovigilance, inspections and distribution of 
pharmaceuticals. 
Market 
Authorisation 
The VVKT protects public health through the 
evaluation and supervision of medicines for human 
use. The market authorisation is issued based on the 
assessment of efficacy, safety and quality of medicinal 
products. 
Reimbursement 
Committee 
HTA 
The drug reimbursement application is sent to the 
Department of Pharmacy, after registration the 
application is forwarded to the Reimbursement 
Committee for assessment. The Committee evaluates 
the therapeutic value, cost-effectiveness, safety and 
budget impact. 
Recommender 
The Reimbursement Committee makes 
recommendations on the drug reimbursement based 
on its evaluation; the result is sent to the Ministry of 
Health. 
Ministry of 
Health 
Decision 
Maker 
The Ministry of Health is responsible for organizing 
the Reimbursement Committee to evaluate the 
reimbursement application. The Ministry of Health 
makes the final decision based on the assessment 
from the Committee. 
Price Authority  
The Department of Pharmacy under the Ministry of 
Health sets the price for reimbursable medicines. The 
pricing application is made separately to the 
department after the reimbursement approval.  
VLK 
State Patient 
Fund 
Provider 
The VLK provides coverage for health care under the 
supervision of the Ministry of Health. 
3
Sponsor
EU CommissionEMA
European Medicines Agency
1a
VVKT
State Medicine Control Agency
Ministry of Health
2
VLK
State Patient Fund
d1b
Regulator
Market 
Authorisation
Regulator
Price Authority
Decision MakerProvider
Ministry of Health
Reimbursement 
Committee
HTA
EVTV $
Recommender
Department of 
Pharmacy
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Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Sponsor
2
1b
Regulator
Ministry of Health
Division of pharmacy
and medicine
Price Authority
Ministry of Social 
Security
CNS
National Health Fund
Provider Decision Maker
HTA
TV EV
Agency 
(Committee) 
Function Key activity 
Ministry of Health 
Division of 
Pharmacy and 
Medicines  
Regulator 
The Ministry of Health is in charge of health policy and 
legislation, the Division of Pharmacy and Medicines 
within the Ministry of Health is responsible for the 
authorisation of pharmaceuticals, post-marketing 
surveillance and the supervision of the practice of 
professional pharmacists. 
Market 
Authorisation 
The Division of Pharmacy and Medicines assesses drug 
applications regarding their efficacy, safety and quality. 
Based on the positive outcome of the assessment, the 
Ministry of Health issues market authorisation for 
medicinal products. 
Ministry of Social 
Security 
Price 
Authority  
The Ministry of Social Security fixes the pharmacy retail 
price of pharmaceuticals. 
HTA 
The market authorisation holder submits drug 
applications to Ministry of Social Security for inclusion 
on the positive list. The key criteria of assessment are 
the therapeutic value of the medicine, cost-
effectiveness and patient need.  
Decision 
Maker 
The Ministry of Social Security makes decision on the 
inclusion of medicinal products on the positive list. 
CNS 
National Health 
Fund 
Provider 
 Reimbursement provided by the CNS is calculated 
based on the cheapest price of generic drugs 
containing the same active ingredients. Patients are 
eligible to accept the branded or generic formulations. 
However, they will be responsible for any extra 
medication costs that are not covered by the CNS. 
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Agency 
(Committee) 
Function Key activity 
MA 
Medicine 
Authority 
Regulator 
The MA is the regulatory agency for national public health. 
The main activities of the MA include the regulation of the 
safety, quality and efficacy of medicinal products in the 
Maltese market, post market surveillance and monitoring of 
advertisements for medicinal products. 
Market 
Authorisation 
The MA is responsible for issuing market authorisation and 
classification of pharmaceuticals. 
DTC 
Drug and 
Therapeutic 
Committee 
Recommender 
The DTC provides recommendations to the MOH for the 
inclusion of medicinal products in the national formulary. 
MOH 
Ministry of 
Health, the Elderly 
and Community 
Care 
HTA 
The MOH assesses medicinal products regarding their 
efficacy, safety, cost and cost-effectiveness and their 
allocation of resources. 
Decision 
Maker 
The MOH makes decisions on the inclusion of medicinal 
products in the national formulary with advice from the DTC.  
HPSS 
Healthcare 
Procurement and 
Supplies Services 
Price 
Authority 
The HPSS is set up within the MOH for the procurement of 
pharmaceuticals. The HPSS makes decisions on the price of 
pharmaceuticals in the NHS system via tendering. 
NHS 
National Health 
Insurance 
Provider 
The NHS provides full reimbursements for pharmaceuticals 
listed on the national formulary. 
 
  
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Regulator
MA
Medicine Authority
CFH
Board for Pharmaceutical Aid
HPSS
Healthcare Procurement and 
Supplies Services 
Sponsor
2
3
NHS
The pharmaceutical 
reimbursement system
ProviderPrice Authority
DTC
Drugs and Therapeutic 
Committee
Recommender
HTA
MOH
Ministry of Health, the Elderly 
and Community care
TV
1b
Ministry of Health, the Elderly 
and Community Care
Decision Maker
EV
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Agency 
(Committee) 
Function Key activity 
CBG/MEB 
Medicines 
Evaluation 
Board 
Regulator 
The CBG/MEB is part of Ministry of Health, Welfare and Sport 
that regulates medicinal products for human use.  
Market 
Authorisation 
The CBG/MEB is responsible for market authorisation of 
pharmaceuticals, registration of medical devices and 
monitoring the safety of medicines. 
WAR 
Scientific 
Advisory Board 
HTA The WAR assesses the therapeutic value for new 
pharmaceuticals based on efficacy, effectiveness and their 
applicability. 
Recommender 
The WAR performs assessment on pharmaceuticals to advice 
ZIN. 
The WAR decides whether the new drugs are therapeutically 
interchangeable (to be included in the reference price 
system) or not interchangeable (no reimbursement limit) 
based on its assessment. 
ZIN 
The National 
Health Care 
Institute  
 
 
HTA 
On 1 April 2014, the CVZ, as a result of a task expansion in the 
areas of Quality and Innovation, changed its name to National 
Health Care Institute (ZIN) 
The National Health Care Institute performs 
pharmacoeconomic assessment for new pharmaceuticals and 
provides advice on reimbursement to VWS. 
Recommender 
The National Health Care Institute provides recommendations 
to the VWS for reimbursement decisions. 
VWS  
Ministry of 
Health, 
Welfare and 
Sport 
HTA 
The VWS assesses the reimbursement applications based on 
recommendations from CFH. The reimbursement decision will 
be based on an assessment of cost-effectiveness and budget 
impact. 
Decision maker 
The VWS makes decisions on the reimbursement category 
and reference reimbursement price. 
GVS  
The 
pharmaceutical 
reimbursement 
system 
Provider 
The GVS a system for claiming the drug reimbursement.  
The coverage by the drug reimbursement system is based on 
the classification of drugs into groups of interchangeable 
drugs 
 
Sponsor
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Regulator
CBG
Medicines Evaluation
Board
CFH
Board for Pharmaceutical Aid
VWS
Ministry of Health,
Welfare and Sport
Decision Maker
HTA
Ministry of Health,
Welfare and Sport
2
3
Recommender
GVS
The pharmaceutical 
reimbursement system
Provider
Price Authority
ZIN
The National Health Care 
Institute 
Recommender
HTA
HTA
WAR
Scientific Advisory Board
EV
EVTV $ CED
1b
TVSA TV
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Agency 
(Committee) 
Function Key activity 
NoMA 
Norwegian 
Medicines 
Agency  
Regulator 
The NoMA is the national agency that regulates drugs and 
medical devices. The key activities of NoMA include: 
supervision of clinical trials, supervision of manufacture and 
distribution of pharmaceuticals, authorisation and post 
marketing control of pharmaceuticals. 
Market 
Authorisation 
The NoMA is responsible for granting market authorisations 
for pharmaceuticals and the registration of medical devices. 
 It ensures cost-efficient, effective and rational use of 
medicines. 
HTA 
The NoMA assesses both the therapeutic value and the cost-
effectiveness of drugs. 
Price Authority 
The NoMA makes decisions on the maximum price based on 
international price comparisons and determines the 
reimbursement price of drugs that are covered by the 
National Insurance Scheme (NIS). 
Decision maker 
The NoMA makes decisions on reimbursement if the annual 
budget impact is less than 5 million Norwegian Krone (NOK) 
by the fifth year of approval. 
HOD 
Ministry of 
Health and Care 
Service 
HTA 
The HOD evaluates the drug reimbursement application. It 
acts under advice from The National Council for Health Care 
Priorities. 
Decision maker 
The HOD makes decision on reimbursement if the annual 
budget impact is more than five million Norwegian Krone 
(NOK) by the fifth year of approval.  
National 
Advisory 
Committee for 
Drug 
Reimbursement 
Recommender 
The National Advisory Committee for Drug Reimbursement is 
an external committee that advises the NoMA on the 
decision of drug reimbursement. It provides advice regarding 
verification of documentation, severity of disease and clinical 
criteria. 
The National 
Council for 
Health Care 
Priorities 
Recommender 
The National Council for Health Care Priorities provides 
recommendations to the HOD on decisions of drug 
reimbursement. 
NIS 
The national 
insurance 
scheme 
Provider The NIS reimburses the cost of drugs. 
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Regulator
NoMA
Norwegian Medicines agency
CFH
Board for Pharmaceutical Aid
HOD
Ministry of Health and Care Service
Decision Maker
HTA
Sponsor
Ministry of Health and 
Care Services
2
The National Council for 
Health Care Priorities
Price Authority
National Advisory  
Committee for 
Drug Reimbursement
Recommender
HTA
Decision Maker
TV EV $
TV EV $
Provider
NIS
The National Insurance Scheme
Recommender
21b
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Agency (Committee) Function Key activity 
URPL  
Office for 
Registration 
of  Medicinal 
Products, Medical 
Devices and 
Biocidal Products  
Regulator 
The URPL is a government administrative authority 
under the Ministry of Health (MZ). The URPL is 
responsible for authorisation, classification and 
pharmacovigilance of pharmaceutical products. 
Market 
Authorisation 
The URPL grants market authorisations for medicinal 
products, medical devices and biocidal products. 
AHTAPol  
Health Technology 
Assessment Agency 
in Poland  
HTA 
AHTAPol assesses drug applications based on the 
therapeutic value, pharmacoeconomics studies and 
financial consequences to the healthcare system. 
Recommender 
AHTAPol serves as an advisory body to support the MZ 
in the decision making process. 
Consultative 
Council  
Recommender 
The Consultative Council is an advisory, independent 
body with 10 highly qualified members appointed by 
the Minister of Health. The HTA appraisal is prepared 
by the Consultative Council and the President of 
AHTAPol. 
MZ  
Ministry of Health  
Price 
Authority  
The MZ decides on the price for reimbursed drugs. The 
price is set through a negotiation with the Drug 
Management Team. 
Decision 
Maker 
The Minister of Health makes the final decision for 
drug pricing and reimbursement. The Minister is not 
obliged to follow the recommendation from AHTAPol. 
NFZ  
National Health 
Fund 
(16 regional 
branches) 
Provider 
The NFZ was set up under the control of MZ and 
organized in 16 regional branches. The NFZ provides 
coverage for the healthcare service. 
Sponsor
EU CommissionEMA
European Medicines Agency
1a
URPL
Office for Registration 
of Medicinal Products, Medical 
Devices and Biocidal Products
Ministry of Health
Economic 
Commission
2b
NFZ
National Health Fund
( n = 16 Regional branch)
d1b
Regulator
Market 
Authorisation
Regulator
Price Authority
Provider
AHTAPol
Health Technology Assessment 
Agency in Poland
Recommender
EVTV
HTA
2a
$
Ministry of Health
Decision Maker
ATAPol
Consultative Council/
Transparency Committee
Ministry of Health
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Agency (Committee) Function Key activity 
INFARMED 
National Authority 
of Medicines and 
Health Products 
Regulator 
The INFARMED is the regulatory agency in Portugal. The key 
activities of INFARMED include evaluation, market 
authorisation, regulation and control of medicinal products, 
medical devices and cosmetics. 
Price 
Authority 
The INFARMED is the authority responsible for price approval 
of medicinal products, having replaced DGAE in August 2012. 
INFARMED establishes the maximum price for the medicinal 
product and the application is then forwarded to the DGAE 
for auditing. 
Market 
Authorisation 
The INFARMED issues market authorisation to new drugs 
based on its quality, efficacy and safety. 
HTA 
The INFARMED assesses medicinal products regarding its 
therapeutic value and economic advantages. 
Recommender 
The INFARMED provides its recommendation to the Minister 
of Health for a formal decision. Upon the positive decision 
from the Minister of Health, the INFARMED issues an official 
approval letter for reimbursement to the manufacturer. 
DGAE 
General Directorate 
of Economic 
Activities 
Recommender 
The DGAE is the former public entity responsible for pricing. 
The DGAE will continue to be consulted, by issuing non-
binding secondary opinion to INFARMED. 
Minister of Health 
Decision 
Maker 
Based on a positive outcome of assessment by INFARMED, 
the Minister of Health makes the decision on reimbursement 
approval. 
SNS 
National Health 
Insurance 
Provider 
The costs of reimbursable drugs are covered by the SNS. 
There are four reimbursement levels (90%, 69%, 37%, 15%) 
based on the therapeutic value of the medicinal products. 
  
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Sponsor
Ministry of Health
2
1b
Provider 
Regulator
INFARMED
National Authority of Medicines 
and Health Products
DGAE
General Directorate of 
Economic Activities 
SNS
National Health Service
HTA
$
INFARMED
National Authority of Medicines 
and Health Products
SA TV
Recommender
EV
Price Authority
SNS
National Health Service
Ministry of Health 
Decision Maker
Recommender
CED
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Agency 
(Committee) 
Function Key activity 
ANMDM 
National 
Medicines and 
Medical 
Devices Agency 
Regulator 
The ANMDM is the regulatory agency operated 
under the Ministry of Health. The key activities of the 
ANMDM include the evaluation, authorisation and 
surveillance of medicinal products.  
Market 
Authorisation 
The ANMDM grants market authorisation to high 
quality, safe and effective medicinal products for 
human use. 
Ministry of 
Health 
Price 
Authority  
The Directorate for Strategies and Medicine Policy 
under the Ministry of Health sets price for 
prescription only medicines. 
HTA  
The reimbursement procedure is set by the Ministry 
of Health. The Therapeutic Strategy Commission 
assesses product applications for inclusion in the 
reimbursement list. The effectiveness, efficacy and 
safety of products are evaluated; no pharmaco-
economic analysis is required. 
Recommender 
The reimbursement list proposed by the Therapeutic 
Strategy Commission is sent to the Transparency 
Commission. The Transparency Commission 
endorses the list and forwards it to the Minister of 
Health. 
Decision 
Maker 
The Minister of Health signs the final list of 
reimbursement products. The Ministry is the 
decision maker that sets the reimbursement rate and 
reimbursement price for pharmaceuticals. 
CNAS 
National Health 
Insurance Fund 
Provider 
The CNAS is the umbrella organisation of regional 
and nationwide sickness funds. The CNAS provides 
coverage for reimbursable medicines. 
 
  
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Regulator
ANMDM
National Medicines and 
Medical Devices Agency 
Sponsor
Ministry of Health
Transparency 
Commission
2
3
Price Authority
1b
Provider 
CNAS
National Health Insurance Fund
Recommender
Decision Maker
Therapeutic Strategy 
Commission
TVTV $
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Agency 
(Committee) 
Function Key activity 
MHRA 
Medicines and 
Healthcare 
products 
Regulatory Agency  
Regulator 
The MHRA is a government agency that regulates 
medicines on the basis of safety, quality and 
efficacy. 
Market 
Authorisation 
The MHRA authorises marketing licences for new 
drugs.  
SMC 
Scottish Medicines 
Consortium 
HTA The Scottish Medicines Consortium was 
established to assess all new medicines for use in 
Scotland. The SMC assess the efficacy, comparative 
safety and cost-effectiveness of new drugs. 
Decision maker 
The Scottish Medicines Consortium (SMC) makes 
final decision to advise to NHS Boards and their 
Area Drug and Therapeutics Committees (ADTCs) 
across Scotland whether they are cost effective for 
use in Scotland.  
NDC 
New Drug 
Committee 
Recommender 
Applications submitted to SMC will be reviewed by 
the New Drug Committee (NDC) first; the NDC will 
provide a draft advice to companies. Companies 
will have a chance to respond to the advice before 
submit the application to the SMC for final 
decision. 
PASAG 
Patient Access 
Scheme 
Assessment Group 
Recommender 
The Patient Access Scheme (PAS) is a scheme 
proposed by a pharmaceutical company in order to 
improve the cost-effectiveness of a medicine. The 
application for PAS will be reviewed by the Patient 
Access Scheme Assessment Group.  
PPRS 
Pharmaceutical 
Price Regulation 
Scheme 
Price Authority 
The PPRS regulates the price indirectly by 
controlling the profit of the pharmaceutical 
companies.   
RHB  (×14) 
Regional Health 
Board 
Decision maker 
Each Health Board has an Area Drugs and 
Therapeutic Committee (AD&TC) which advise on 
the use of medicines within their geographical 
location. The ADTC and Health Board provide 
decisions for the provision of drug based on the 
SMC recommendation. 
Provider 
The 14 Health Boards in Scotland are responsible 
for the provision of health care to their area. 
EMA
European Medicines Agency
1a
MHRA
Medicines and Healthcare 
Products Regulatory Agency
Sponsor
Department of Health
d1b
Regulator
Regulator
EU Commission
Market 
Authorisation
HTA
RHB (n = 14)
Regional Health Board 
Formulatory
Decision Maker
Provider (×14)
2a
Recommender
3
TV
SMC
Scottish Medicines Consortium
TV EV
PPRS
Pharmaceutical Price 
Regulation Scheme
Price Authority
Decision Maker
PASAG
Patient  Access  Scheme 
Assessment Group2b
NDC
New Drug Committee
RHB 
Area Drugs and Therapeutic 
Committee 
Recommender
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Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Sponsor
2
1b
Regulator
SUKL
State Institute for Drug Control
MOH
Department of Categorisation 
and Price Policy
Price Authority
HTA
EV
Categorisation 
Committee
SNS
National Health Service
Decision Maker
Provider 
VsZP
General Health Insurance
TV
Recommender
3 Ministry of Health
Ministry of Health
SLOVAHTA 
Slovak Agency for Health 
Technology Assessment
Recommender
Agency 
(Committee) 
Function Key activity 
SUKL 
State Institute 
for Drug Control 
Regulator 
The SUKL is operated under the Ministry of Health. The 
SUKL is responsible for the authorisation and 
classification of pharmaceuticals, as well as for the 
vigilance and the examination of market players in the 
pharmaceutical system. 
Market 
Authorisation 
The SUKL issues market authorisation to new medicines 
based on their efficacy, safety and quality. 
MOH 
Department of 
Categorisation 
and Price Policy 
Price Authority The MOH sets the retail price for reimbursable drugs. 
MOH 
Categorisation 
Committee 
HTA 
The Categorisation Committee is set up under the 
Ministry of Health to assess drug applications for 
reimbursement. The Committee evaluates the 
therapeutic benefit and economic data of products. 
Recommender 
The Committee provides recommendation to the 
Minister of Health based on its medical and economical 
assessment. 
Minister of 
Health 
Decision Maker 
The Minister of Health makes decisions on the inclusion 
of drugs in the reimbursement list and on 
reimbursement rates. 
SLOVAHTA 
Slovak Agency 
for Health 
Technology 
Assessment 
HTA 
The SLOVAHTA is a not-for-profit organization that 
carries out activities to provide information on health 
technologies. It is not involved in official procedure of 
pricing and reimbursement. 
VsZP 
General Health 
Insurance 
Provider 
The VsZP provides coverage of the cost for reimbursable 
pharmaceuticals. 
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Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Sponsor
2
1b
Regulator
Price Authority
HTA
Reimbursement 
Committee
SNS
National Health Service
Decision Maker
Provider 
TV
Recommender
3
ZZZS
Slovenia Health Insurance 
Institute
Ministry of Health
JAZMP
Agency for Medicinal Products 
and Medical Devices of the 
Republic of Slovenia
Recommender
Health Council
$
JAZMP
Agency for Medicinal Products 
and Medical Devices of the 
Republic of Slovenia
Agency 
(Committee) 
Function Key activity 
JAZMP 
Agency for 
Medicinal 
Products and 
Medical Devices 
of the Republic 
of Slovenia 
Regulator 
The JAZMP is operated under the Ministry of Health 
to implement national policies and legislation for 
medicines, medical devices, blood, tissues and cells with 
the aim of protecting public health. 
Market 
Authorisation 
The JAZMP is responsible for marketing authorisation, 
registration and classification of pharmaceuticals based 
on the assessment of their efficacy, safety and quality. 
JAZMP 
Agency for 
Medicinal 
Products and 
Medical Devices 
of the Republic 
of Slovenia 
Price Authority 
The JAZMP sets up statutory pricing at the wholesale 
level for pharmaceuticals. The pricing decision is sent to 
Slovenia Health Insurance Institute (ZZZS) for 
reimbursement evaluation. If the price exceeds the limit 
set by the Slovenia Health Insurance Institute, the drug 
cannot be reimbursed. 
ZZZS 
Slovenia Health 
Insurance 
Institute 
Reimbursement 
Committee 
HTA 
The Reimbursement Committee is set up under the ZZZS 
to evaluate the drugs applications for reimbursement. 
The Committee assesses the efficacy and indications of 
each drug. 
Recommender The Committee advises the ZZZS on drug reimbursement. 
Health Council Recommender 
The Health Council is the highest coordination expert 
body that advises the Ministry of Health on important 
health issues. The Health Council may provide advice to 
the Reimbursement Committee on drug reimbursement. 
ZZZS 
Slovenia Health 
Insurance 
Institute 
Decision Maker 
The ZZZS makes decision on the reimbursement of 
pharmaceuticals regarding the reimbursement category, 
the reimbursement rates and the reimbursement price. 
Provider 
The ZZZS aims to provide efficient distribution of public 
funds for national health care. 
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Agency 
(Committee) 
Function Key activity 
AEMPS 
Spanish 
Medicines Agency 
Regulator 
The AEMPS, as the regulatory agency under the Ministry of Health, 
Social Policy and Equality, is responsible for the evaluation, market 
authorisation, inspection and post-market surveillance of 
pharmaceuticals.  
Within AEMPS, GCPT (Therapeutic. Positioning Coordination 
Group), in coordination with DGFPS and the Autonomous Health 
Authorities, prepares a national therapeutic positioning report 
(IPT), in which the comparative efficacy and safety of a drug are 
evaluated. The report is used as the basis of reimbursement 
decisions.  
Market 
Authorisation 
The AEMPS issues market authorisations for medicinal products 
and assigns the national code. 
DGFPS 
General 
Directorate of 
Pharmacy and 
Health Products 
HTA 
The DGFPS initiates the pricing and reimbursement procedure with 
the manufacturer. The DGFPS evaluates the drugs regarding their 
therapeutic value and efficacy, the degree of innovation of the 
drug and severity of the disease. The likely price of the drug and 
budget impact is also considered during the assessment. 
Decision 
Maker 
The DGFPS makes decisions on the inclusion of medicinal products 
into the national health care reimbursement system. 
AETS 
Agency of Health 
Technology 
Assessment 
HTA 
The AETS is set up within the Institute of Health Carlos III to provide 
guidance and facilitate the decision making process for 
reimbursement. The assessment of AETS is initiated by requests 
from government. 
CIPM 
Inter-ministerial 
Commission on 
Medicines Prices 
Price 
Authority 
The CIPM sets the price for reimbursable pharmaceuticals. 
Autonomous 
Health Authorities 
(n=17) 
Decision 
Maker 
The regional governments implement the coverage and 
reimbursement decisions at local level based on their health care 
budgets. The regional governments compile local formularies. 
Provider 
The provision of medicinal products is controlled by local 
formularies and reimbursement is covered by the national health 
care system. 
Sponsor
EU CommissionEMA
European Medicines Agency
1a
AEMPS
Spanish Medicines Agency
DGFPS
General Directorate of 
Pharmacy and Health Products
2 $EVTV
HTA
d1b
Regulator
Market 
Authorisation
Regulator
Decision Maker
ISCIII
The Institute of Health Carlos III
Recommender
EVTV
AETS
Agency for Health 
Technology Assessment
CIPM
Inter-ministerial Commission on 
Medicines Prices
Price Authority
Autonomous Health 
Authorities (n=17)
Provider (x 17)
Decision Maker (x 17)
Ministry of Health,
Social Policy and Equality
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Agency 
(Committee) 
Function Key activity 
MPA/NAM 
Medical 
Products 
Agency 
Regulator 
The MPA/NAM is the Swedish national authority 
responsible for regulation and surveillance of the 
development, manufacture and marketing of drugs and 
other medicinal products. 
The MPA/NAM is responsible for granting market 
authorisation for medicines and the registration of 
medical devices. 
Marketing authorisation of medicines is granted or 
rejected by the General Director of the MPA/NAM based 
on their quality, safety and efficacy. 
SBU 
Swedish Council 
on Technology 
Assessment in 
Health Care 
HTA 
The SBU is a national institute responsible for conducting 
pharmaco-economic appraisals. The SBU provides 
support for the scientific assessment report and decision 
making in health care. However, the SBU is not officially 
involved in the pricing and reimbursement decision. 
TLV/LFN 
Dental and 
Pharmaceutical 
Benefits  
Agency 
HTA 
The TLV/LFN assesses the therapeutic value and cost 
effectiveness of new pharmaceuticals. The TLV/LFN may 
consult the MPA/NAM for advice. 
Decision 
maker 
The TLV/LFN is a government agency that makes decision 
on drug price and reimbursement. 
Reimbursement decisions made by the TLV/LFN are at 
national level and are adopted at the local level by the 
county councils. 
Price 
Authority 
The TLV/LFN approves the wholesale price for drugs 
requiring reimbursement. 
21 County 
Councils 
Provider 
The provision of health care is determined by the 21 
county councils. The cost of drugs is reimbursed through 
each single county council with a fixed state subsidy. 
  
Sponsor
Regional County Councils 
(n = 21)
Provider (x 21)
Decision Maker (x 21)
Market 
Authorisation
EU CommissionEMA
European Medicines Agency
Regulator
1a
Regulator
MPA / NAM
Medicinal Products Agency
TLV  (LFN)
Dental and Pharmaceutical 
Benefits  Agency
Ministry of Health and 
Social Affairs
SBU
Swedish Council on Technology 
Assessment in Health Care
HTA
EVTV CE
2
3
Price Authority
PBB
Pharmaceutical Benefits 
Board
$
SA EVTV CED
Decision Maker
1b
 
321 
 
 
Process map for Switzerland 
Version: January 2012 
 
Agency 
(Committee) 
Function Key activity 
Swissmedic 
Regulator 
Swissmedic is affiliated with the Federal Department of 
Home Affairs to regulate medicine and medical devices and 
is independent in its organisation and management. The key 
activities of Swissmedic include: licensing medicines, 
granting authorizations to manufacture and distribute 
wholesale, inspecting facilities and monitoring medicines 
and medical devices already on the market. 
Market 
Authorisation 
Swissmedic is responsible for pre-market evaluation, 
granting market authorisation and post-market monitoring. 
FDC 
Federal Drug 
Commission 
HTA 
THE FOPH has commissioned the FDC to evaluate new drugs. 
The FDC evaluates the effectiveness of drugs based on 
Swissmedic’s assessment. The FDC classifies new drugs 
within 5 categories according to their level of innovation. 
Recommender 
The FDC advises the Federal Office of Public Health on the 
inclusion of pharmaceuticals in the Specialities List (SL). 
BAG/OFSP  
FOPH 
Federal 
Office of 
Public Health  
Decision 
maker 
The OFSP regulates both the inclusion of pharmaceuticals in 
the Specialities List (SL) and the pricing of reimbursed 
pharmaceuticals. 
The criteria of reimbursable drugs are efficacy and cost-
effectiveness. 
Price 
Authority 
The OFSP sets the maximum price for all drugs in the 
Specialities List (SL). 
 
 
 
 
 
 
Sponsor
Swissmedic
1
Provider
FOPH
Federal Office of Public Health 
BAG/OFSP 
Bundesamt für Gesundheit
Office Fédéral de la Santé 
Publique
2
Healthcare Insurance
Specialities List (SL)
Regulator
FDC
Federal drug commission
Price Authority
Recommender
Market 
Authorisation
HTA
Federal Department of 
Home Affairs
Decision Maker
TVTV EV
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Agency 
(Committee) 
Function Key activity 
MHRA 
Medicines and 
Healthcare 
products 
Regulatory 
Agency  
Regulator 
The MHRA is a government agency that regulates medicines 
on the basis of safety, quality and efficacy. 
Market 
Authorisation 
The MHRA authorises marketing licences for new drugs.  
AWMSG 
All Wales 
Medicines 
Strategy Group  
HTA The AWMSG appraises new medicines for which no NICE 
guidance is expected for at least 12 months from the date of 
submission. 
Decision maker 
The AWMSG meets in public to assess the evidence for a new 
drug application and considers the advice from the New 
Medicine Group, considering the broader health context 
of Wales and the broader budgetary impact of the 
treatment, to provide a recommendation to the Minister. 
The Welsh 
Medicines 
Partnership 
Recommender 
Evidence for evaluation is collected from medicines 
companies and public sources, clinical experts and patient 
organisations. The evidence is collated and evaluated by an 
expert secretariat at the Welsh Medicines Partnership.  
New Medicine 
Group 
Recommender 
The NMG makes an initial recommendation to the AWMSG 
on the use of the medicine, based on its cost-effectiveness 
and potential benefits in the Welsh context.  
Minister of Health Decision maker 
The Minister for Health and Social Services makes decision 
on the coverage of medicines by NHS Wales following advice 
from two sources: the National Institute for Health and 
Clinical Excellence (NICE) and the All Wales Medicines 
Strategy Group (AWMSG). 
PPRS 
Pharmaceutical 
Price Regulation 
Scheme 
Price Authority 
The PPRS ensures the NHS has access to good quality 
branded medicines at reasonable prices.  
The PPRS regulates the price indirectly by controlling the 
profit of the pharmaceutical companies. The scheme will be 
replaced by value-based pricing for branded drugs in 2014. 
LHB   (×7) 
Local Health 
Board 
Provider 
The 7 Local Health Boards in Wales are responsible for the 
provision of health care to their area. 
EMA
European Medicines Agency
1a
MHRA
Medicines and Healthcare 
Products Regulatory Agency
Sponsor
Department of Health
d1b
Regulator
Regulator
EU Commission
The Welsh Medicines 
Partnership
Market 
Authorisation
Minister of Health
HTA
LHB (n = 7)
Local Health Board
Decision Maker
Provider (× 7)
2a
New Medicine Group
Recommender
3
TV CED
AWMSG
All Wales Medicines Strategy 
Group
TV EV
Recommender
PPRS
Pharmaceutical Price 
Regulation Scheme
Price Authority
Decision MakerNICE
National Institute for Health and 
Clinical Excellence
Decision Maker
2b
